{"cd4f4c515f225e4d441f8d593090fe7333b8dc87": [["INTRODUCTIONBeyond direct effects of the COVID-19 on populations in every country, the pandemic had and will continue to have indirect effects on morbidity and mortality, through changes in patient and clinician behaviour, and health system reorganisation.", [["patient", "ORGANISM", 190, 197], ["patient", "SPECIES", 190, 197], ["the COVID", "TREATMENT", 37, 46]]], ["1 In order to plan and adapt responses to this and future public health threats, therefore, there is a need to understand the indirect effects of the pandemic on non-communicable diseases for both disease burden and health service provision.", [["non-communicable diseases", "DISEASE", 162, 187], ["non-communicable diseases", "PROBLEM", 162, 187], ["both disease burden", "PROBLEM", 192, 211]]], ["2 Cardiovascular diseases (CVDs) are the largest cause of morbidity and mortality in the UK and globally.", [["Cardiovascular", "ANATOMY", 2, 16], ["Cardiovascular diseases", "DISEASE", 2, 25], ["CVDs", "DISEASE", 27, 31], ["Cardiovascular diseases (CVDs)", "PROBLEM", 2, 32], ["morbidity", "PROBLEM", 58, 67], ["Cardiovascular", "ANATOMY", 2, 16], ["diseases", "OBSERVATION", 17, 25], ["largest", "OBSERVATION_MODIFIER", 41, 48], ["morbidity", "OBSERVATION", 58, 67]]], ["3 4 Moreover, prior CVD is a major risk factor for complications and mortality associated with COVID-19.", [["CVD", "DISEASE", 20, 23], ["COVID-19", "CHEMICAL", 95, 103], ["COVID-19", "CHEMICAL", 95, 103], ["complications", "PROBLEM", 51, 64], ["COVID", "TEST", 95, 100]]], ["5 6 Government guidance has advised individuals with CVD to pay particular attention to physical isolation measures.", [["CVD", "DISEASE", 53, 56], ["physical isolation measures", "TREATMENT", 88, 115]]], ["7 Concerns have been raised about provision of care during the pandemic for these diseases, from prevention to treatment, and are supported by data from multiple countries showing reduced service activity.", [["these diseases", "PROBLEM", 76, 90], ["treatment", "TREATMENT", 111, 120]]], ["8 9 In the UK, studies have reported reductions in activity across CVDs.", [["CVDs", "DISEASE", 67, 71], ["studies", "TEST", 15, 22], ["activity across CVDs", "PROBLEM", 51, 71], ["reductions", "OBSERVATION_MODIFIER", 37, 47]]], ["10 11 Moreover, official national statistics show an excess of non-COVID-19 and CVD deaths, 12 13 as well as a reduction in emergency department (ED) attendances for cardiac presentations.", [["cardiac", "ANATOMY", 166, 173], ["CVD", "DISEASE", 80, 83], ["deaths", "DISEASE", 84, 90], ["cardiac", "ORGAN", 166, 173], ["non-COVID", "TEST", 63, 72], ["CVD deaths", "PROBLEM", 80, 90], ["cardiac", "ANATOMY", 166, 173]]], ["14 There are multiple disease-specific national audits for CVD, in addition to routine primary and secondary care data.", [["CVD", "DISEASE", 59, 62], ["multiple disease", "PROBLEM", 13, 29], ["CVD", "PROBLEM", 59, 62], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["disease", "OBSERVATION", 22, 29]]], ["15 For audit, quality improvement, surveillance and to inform policy responses, it is necessary to determine changes in service delivery that occurred during the pandemic.", [["surveillance", "TEST", 35, 47], ["delivery", "TREATMENT", 128, 136]]], ["Transparent, public-facing, near realtime information has been shown to be of value to patients, the public, researchers, clinicians and policymakers alike during the pandemic.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["1 16 For presentation, diagnosis and treatment of CVD, we aimed to: (1) develop a protocol for national surveillance of CVD hospital services during the COVID-19 pandemic; (2) present pilot data from a preliminary cohort of hospitals; and (3) Healthcare delivery, economics and global health design and implement a simple tool for monitoring and visualising trends in CVD hospital services in the UK.Study design and data sourcesWe conducted a retrospective hospital-based analysis of presentations, diagnoses and treatments or procedures for selected CVDs in hospitals across the UK before and during the COVID-19 epidemic.", [["CVD", "DISEASE", 50, 53], ["CVD", "DISEASE", 120, 123], ["CVD", "DISEASE", 368, 371], ["CVDs", "DISEASE", 552, 556], ["treatment", "TREATMENT", 37, 46], ["CVD", "PROBLEM", 50, 53], ["a protocol", "TREATMENT", 80, 90], ["the COVID", "TEST", 149, 158], ["Healthcare delivery", "TREATMENT", 243, 262], ["Study design", "TEST", 400, 412], ["treatments", "TREATMENT", 514, 524], ["procedures", "TREATMENT", 528, 538], ["the COVID", "TEST", 602, 611], ["epidemic", "PROBLEM", 615, 623]]], ["The protocol was developed by a group of seven cardiovascular clinicians with relevant clinical, epidemiological and health data science expertise and agreed with members of the CVD-COVID-UK collaboration, supported by the British Heart Foundation (BHF) Data Science Centre.", [["cardiovascular", "ANATOMY", 47, 61], ["CVD", "DISEASE", 178, 181], ["The protocol", "TREATMENT", 0, 12], ["Heart", "ANATOMY", 231, 236]]], ["We requested aggregate data, with no individual level or linked data, including inpatient admissions and ED visits, both overall and for specified cardiovascular diagnoses and procedures or treatments, and we provided guidance on which International Classification of Diseases, 10th Revision (ICD-10), Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) or equivalent codes to use.", [["cardiovascular", "ANATOMY", 147, 161], ["procedures", "TREATMENT", 176, 186], ["treatments", "TREATMENT", 190, 200], ["Diseases", "PROBLEM", 268, 276], ["10th Revision (ICD", "TREATMENT", 278, 296], ["Procedures version", "TEST", 380, 398], ["OPCS", "TEST", 402, 406]]], ["We selected six disease areas to gain an overview of CVD service provision in a short timescale: \u25ba Acute coronary syndrome (ACS). \u25ba Heart failure. \u25ba Stroke and transient ischaemic attack. \u25ba Venous thromboembolism. \u25ba Peripheral arterial disease (PAD). \u25ba Aortic aneurysm.Data collectionOnline supplemental table 1 shows the data request sent to hospitals for weekly counts of relevant ED categories, hospital admission diagnoses and hospital treatments/procedures covering the period 28 October 2019-10 May 2020, designed to show activity in three phases: pre-COVID-19 pandemic to the first UK confirmed case of COVID-19 (31 January 2020), between the first COVID-19 case but prelockdown on 23 March 2020 and postlockdown.", [["coronary", "ANATOMY", 105, 113], ["Heart", "ANATOMY", 132, 137], ["Venous", "ANATOMY", 190, 196], ["Peripheral arterial", "ANATOMY", 216, 235], ["Aortic aneurysm", "ANATOMY", 253, 268], ["CVD", "DISEASE", 53, 56], ["Acute coronary syndrome", "DISEASE", 99, 122], ["ACS", "DISEASE", 124, 127], ["Heart failure", "DISEASE", 132, 145], ["Stroke", "DISEASE", 149, 155], ["transient ischaemic attack", "DISEASE", 160, 186], ["Venous thromboembolism", "DISEASE", 190, 212], ["Peripheral arterial disease", "DISEASE", 216, 243], ["PAD", "DISEASE", 245, 248], ["Aortic aneurysm", "DISEASE", 253, 268], ["coronary", "MULTI-TISSUE_STRUCTURE", 105, 113], ["Heart", "ORGAN", 132, 137], ["Venous", "ORGANISM_SUBSTANCE", 190, 196], ["Peripheral arterial", "MULTI-TISSUE_STRUCTURE", 216, 235], ["Aortic aneurysm", "PATHOLOGICAL_FORMATION", 253, 268], ["six disease areas", "PROBLEM", 12, 29], ["Acute coronary syndrome", "PROBLEM", 99, 122], ["Heart failure", "PROBLEM", 132, 145], ["Stroke", "PROBLEM", 149, 155], ["transient ischaemic attack", "PROBLEM", 160, 186], ["Venous thromboembolism", "PROBLEM", 190, 212], ["Peripheral arterial disease (PAD)", "PROBLEM", 216, 249], ["Aortic aneurysm", "PROBLEM", 253, 268], ["Data collection", "TEST", 269, 284], ["hospital treatments", "TREATMENT", 431, 450], ["COVID", "TEST", 610, 615], ["Acute", "OBSERVATION_MODIFIER", 99, 104], ["coronary", "ANATOMY", 105, 113], ["syndrome", "OBSERVATION", 114, 122], ["failure", "OBSERVATION", 138, 145], ["transient", "OBSERVATION_MODIFIER", 160, 169], ["ischaemic attack", "OBSERVATION", 170, 186], ["thromboembolism", "OBSERVATION", 197, 212], ["arterial", "ANATOMY", 227, 235], ["disease", "OBSERVATION", 236, 243], ["Aortic", "ANATOMY", 253, 259], ["aneurysm", "OBSERVATION", 260, 268]]], ["All participating hospitals had local information governance approval.Data collectionSince our principal aim was to capture change in activity over time within each hospital rather than to make direct comparisons between hospitals, we incorporated a degree of flexibility in the way each data item was defined.", [["Data collection", "TEST", 70, 85]]], ["For example, one hospital, which did not have timely access to ICD codes for ACS, was able to provide counts using a data capture tool embedded into the patient record that identifies all patients with ACS at the point of cardiac troponin testing.", [["cardiac", "ANATOMY", 222, 229], ["ACS", "DISEASE", 77, 80], ["ACS", "DISEASE", 202, 205], ["patient", "ORGANISM", 153, 160], ["patients", "ORGANISM", 188, 196], ["troponin", "GENE_OR_GENE_PRODUCT", 230, 238], ["patient", "SPECIES", 153, 160], ["patients", "SPECIES", 188, 196], ["ACS", "PROBLEM", 77, 80], ["ACS", "PROBLEM", 202, 205], ["cardiac troponin testing", "TEST", 222, 246], ["cardiac", "ANATOMY", 222, 229]]], ["18 Where available, as measures of total acute activity, we requested counts of all ED attendances, all hospital admissions and all COVID-19 hospital admissions.Data collectionIn addition, given known seasonal fluctuations in hospital services, we requested data on the same items from the same calendar weeks (or months) in the previous year (2018-2019) for comparison.", [["total acute activity", "PROBLEM", 35, 55], ["Data collection", "TEST", 161, 176], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["activity", "OBSERVATION_MODIFIER", 47, 55]]], ["We recognised that not all disease areas or treatments and procedures would be relevant to or available from every participating hospital, and so invited hospitals to contribute whichever data items they were able to.Data analysisThe study period was divided into three phases based on complete weeks (Monday-Sunday) of data: (1) before the first case of SARS-CoV2 in the UK (28 October 2019-2 February 2020 (14 weeks)); (2) between the first case and start of lockdown in the UK (3 February 2020-22 March 2020 (7 weeks)); and (3) during lockdown (23 March 2020-10 May 2020 (7 weeks)).Data analysisWe used the aggregate data to compare the weekly counts within each hospital and across all hospitals combined, estimating associated 95% CIs using the Poisson exact method.", [["SARS", "DISEASE", 355, 359], ["all disease areas", "PROBLEM", 23, 40], ["treatments", "TREATMENT", 44, 54], ["procedures", "TREATMENT", 59, 69], ["Data analysis", "TEST", 217, 230], ["The study period", "TEST", 230, 246], ["SARS", "PROBLEM", 355, 359]]], ["In addition, we calculated percentage change from the corresponding week in the previous year (2018-2019), together with 95% CIs using the Wilson score interval, in the three phases described above.", [["percentage", "OBSERVATION_MODIFIER", 27, 37], ["change", "OBSERVATION_MODIFIER", 38, 44]]], ["We also calculated the percentage reduction in total hospital admissions and ED attendances around Christmas and New Year in 2019-2020 by comparing the period 16 December 2019-12 January 2020 to the immediately preceding period 18 November-15 December 2019, using the same approach with equivalent weeks to calculate the percentage reduction around Christmas and New Year in 2018-2019.", [["the percentage reduction", "TREATMENT", 317, 341], ["percentage", "OBSERVATION_MODIFIER", 23, 33], ["reduction", "OBSERVATION_MODIFIER", 34, 43]]], ["Such rolling means enable clearer visualisation of trends for data items with low numbers and high variability.", [["data items", "TEST", 62, 72], ["low numbers", "PROBLEM", 78, 89], ["high variability", "OBSERVATION", 94, 110]]], ["Where data providers suppressed values less than 5, we converted these to the value of 2.5 for analytic purposes.", [["analytic purposes", "TEST", 95, 112]]], ["To demonstrate relative change of hospital activities between phases, we also calculated relative reduction (RR) in weekly counts compared with the first phase (before the first UK case of COVID-19).", [["RR", "TEST", 109, 111], ["COVID", "TEST", 189, 194], ["relative", "OBSERVATION_MODIFIER", 15, 23], ["change", "OBSERVATION_MODIFIER", 24, 30], ["reduction", "OBSERVATION_MODIFIER", 98, 107]]], ["We performed all statistical procedures in R (V.4.0.0).", [["all statistical procedures", "TEST", 13, 39]]], ["Relevant code is available at https:// github. com/ HDRUK/ 4C-Initiative.Interactive data visualisation tool and patient and public involvementAs understanding trends and patterns in hospital activity should inform policymakers and other stakeholders in the planning of services as the UK eases out of lockdown, we developed an interactive online tool to enable dynamic visualisation of the data.", [["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120]]], ["It will enable periodic (eg, monthly) updates of data from contributing hospitals to monitor trends over time and facilitate incorporation of data from other UK hospitals and comparisons between hospitals (http://www. hospitalactivity. com).", [["hospitalactivity", "DISEASE", 218, 234], ["hospitalactivity", "PROBLEM", 218, 234]]], ["There was no formal patient and public involvement.Overall hospital activityOf 21 hospitals (or groups of regionally connected hospitals) contacted, 17 agreed to participate.", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["no", "UNCERTAINTY", 10, 12]]], ["Of these, nine hospitals distributed across England and Scotland, providing cardiovascular services to an estimated population of up to 10 million people, contributed data in time for the analyses reported here.", [["cardiovascular", "ANATOMY", 76, 90], ["cardiovascular", "ANATOMICAL_SYSTEM", 76, 90], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["the analyses", "TEST", 184, 196]]], ["There were 676 and 5182 COVID-19 related admissions from eight hospitals for the second and third phases (after the first UK case of COVID-19 until lockdown commenced and from the start of lockdown onwards), respectively.Overall hospital activityAcross all hospitals, total admissions before the first case of COVID-19 were very similar to the corresponding period in 2018-2019, including the expected dip in admissions of around 12% during the Christmas period in December 2018 and 2019 (online supplemental table 2).", [["COVID", "TEST", 24, 29], ["COVID", "TEST", 133, 138], ["COVID", "TEST", 310, 315]]], ["After lockdown, admissions decreased by 57.9% (95% CI 57.1% to 58.6%) compared with the previous year (table 1 and figure 1) .Overall hospital activityOverall ED attendances showed a similar pattern, with a small 3.4% (3.2%-3.5%) increase compared with the previous year before the first case, a more modest winter reduction of around 8% (online supplemental table 2), a marked 52.9% (52.2%-53.5%) reduction after lockdown and evidence of some recovery back towards pre-COVID-19 levels of activity from mid-April 2020.", [["CI", "TEST", 51, 53], ["lockdown", "TREATMENT", 414, 422], ["pre-COVID", "TEST", 466, 475], ["mid-April", "TREATMENT", 503, 512], ["small", "OBSERVATION_MODIFIER", 207, 212]]], ["The reduction in hospital admissions was substantially larger than the number of admissions for COVID-19 (figure 1).", [["COVID-19", "CHEMICAL", 96, 104], ["COVID", "TEST", 96, 101], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["larger", "OBSERVATION_MODIFIER", 55, 61]]], ["However, while there was some recovery in ED attendances from mid-April 2020 in all hospitals that provided data, hospital admissions had only started to return towards usual levels in some, but not all, hospitals by early May (figure 2).Cardiac, cerebrovascular and other vascular conditionsCompared with the previous year, hospital statistics on cardiac, cerebrovascular and other vascular conditions dropped by between 31% and 88% after lockdown (table 1) .", [["Cardiac", "ANATOMY", 238, 245], ["cerebrovascular", "ANATOMY", 247, 262], ["vascular", "ANATOMY", 273, 281], ["cardiac", "ANATOMY", 348, 355], ["cerebrovascular", "ANATOMY", 357, 372], ["vascular", "ANATOMY", 383, 391], ["Cardiac, cerebrovascular and other vascular conditions", "DISEASE", 238, 292], ["cardiac, cerebrovascular and other vascular conditions", "DISEASE", 348, 402], ["Cardiac", "MULTI-TISSUE_STRUCTURE", 238, 245], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 247, 262], ["vascular", "MULTI-TISSUE_STRUCTURE", 273, 281], ["cardiac", "ORGAN", 348, 355], ["vascular", "MULTI-TISSUE_STRUCTURE", 383, 391], ["Cardiac, cerebrovascular and other vascular conditions", "PROBLEM", 238, 292], ["other vascular conditions", "TEST", 377, 402], ["recovery", "OBSERVATION_MODIFIER", 30, 38], ["cerebrovascular", "OBSERVATION", 247, 262], ["vascular", "ANATOMY", 273, 281], ["conditions", "OBSERVATION", 282, 292], ["cerebrovascular", "ANATOMY", 357, 372], ["vascular", "ANATOMY", 383, 391]]], ["Some recovery from mid-April 2020 was evident in ED attendances for these conditions and for cardiac procedures (primarily driven by PCI) (figure 2, figure 3 and www. hospitalactivity. com).", [["cardiac", "ANATOMY", 93, 100], ["hospitalactivity", "DISEASE", 167, 183], ["cardiac", "ORGAN", 93, 100], ["mid-April", "TREATMENT", 19, 28], ["cardiac procedures", "TREATMENT", 93, 111], ["hospitalactivity", "PROBLEM", 167, 183]]], ["The greatest proportional reductions (65% or more) were in coronary artery bypass graft surgery, carotid endarterectomy, aortic aneurysm repair and procedures for PAD (table 1) .Comparison with the pre-COVID-19 periodCompared with the period before the first COVID-19 case, activity declined across diseases and specialties between the first case and lockdown (total ED attendances RR 0.94, 0.93-0.95; total hospital admissions RR 0.96, 0.95-0.97) and, more markedly, after lockdown (total ED attendances RR 0.63, 0.62-0.64; total hospital admissions RR 0.59, 0.57-0.60).", [["coronary artery", "ANATOMY", 59, 74], ["carotid", "ANATOMY", 97, 104], ["aortic aneurysm", "ANATOMY", 121, 136], ["aortic aneurysm", "DISEASE", 121, 136], ["PAD", "DISEASE", 163, 166], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 59, 74], ["graft", "TISSUE", 82, 87], ["carotid", "MULTI-TISSUE_STRUCTURE", 97, 104], ["aortic aneurysm", "MULTI-TISSUE_STRUCTURE", 121, 136], ["pre-COVID-19", "DNA", 198, 210], ["The greatest proportional reductions", "TREATMENT", 0, 36], ["coronary artery bypass graft surgery", "TREATMENT", 59, 95], ["carotid endarterectomy", "TREATMENT", 97, 119], ["aortic aneurysm repair", "TREATMENT", 121, 143], ["procedures", "TREATMENT", 148, 158], ["PAD", "TEST", 163, 166], ["the pre-COVID", "TEST", 194, 207], ["RR", "TEST", 382, 384], ["RR", "TEST", 428, 430], ["RR", "TEST", 505, 507], ["RR", "TEST", 551, 553], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["proportional", "OBSERVATION_MODIFIER", 13, 25], ["reductions", "OBSERVATION_MODIFIER", 26, 36], ["coronary artery", "ANATOMY", 59, 74], ["bypass graft", "OBSERVATION", 75, 87], ["carotid", "ANATOMY", 97, 104], ["endarterectomy", "OBSERVATION", 105, 119], ["aortic", "ANATOMY", 121, 127], ["aneurysm", "OBSERVATION", 128, 136]]], ["Reductions in coronary artery bypass grafts, carotid endarterectomy, peripheral arterial procedures and aortic aneurysm repairs were the most prominent (RRs 0.23-0.49) (figure 4).", [["coronary artery", "ANATOMY", 14, 29], ["grafts", "ANATOMY", 37, 43], ["carotid", "ANATOMY", 45, 52], ["peripheral arterial", "ANATOMY", 69, 88], ["aortic aneurysm", "ANATOMY", 104, 119], ["aortic aneurysm", "DISEASE", 104, 119], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 14, 29], ["grafts", "TISSUE", 37, 43], ["carotid", "MULTI-TISSUE_STRUCTURE", 45, 52], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 69, 88], ["aortic aneurysm", "MULTI-TISSUE_STRUCTURE", 104, 119], ["coronary artery bypass grafts", "TREATMENT", 14, 43], ["carotid endarterectomy", "TREATMENT", 45, 67], ["peripheral arterial procedures", "TREATMENT", 69, 99], ["aortic aneurysm repairs", "TREATMENT", 104, 127], ["RRs", "TEST", 153, 156], ["coronary artery", "ANATOMY", 14, 29], ["bypass grafts", "OBSERVATION", 30, 43], ["carotid", "ANATOMY", 45, 52], ["endarterectomy", "OBSERVATION", 53, 67], ["peripheral", "ANATOMY_MODIFIER", 69, 79], ["arterial", "ANATOMY", 80, 88], ["aortic", "ANATOMY", 104, 110], ["aneurysm", "OBSERVATION", 111, 119], ["most", "OBSERVATION_MODIFIER", 137, 141], ["prominent", "OBSERVATION_MODIFIER", 142, 151]]], ["All hospitals had reduced activities after lockdown but with variation between hospitals in the extent of reduction for different diseases and treatments (online supplemental figure 1 ).Summary of findingsThree main findings have emerged from this rapid assimilation of UK hospital routine health data.", [["different diseases", "PROBLEM", 120, 138], ["treatments (online supplemental figure", "TREATMENT", 143, 181]]], ["First, the current data have shown in detail the pattern of sharp reductions in activity across CVDs, across services and across hospitals, during the initial wave of the pandemic.", [["CVDs", "DISEASE", 96, 100], ["sharp reductions in activity across CVDs", "PROBLEM", 60, 100], ["the pandemic", "PROBLEM", 167, 179], ["sharp", "OBSERVATION_MODIFIER", 60, 65], ["reductions", "OBSERVATION_MODIFIER", 66, 76], ["activity", "OBSERVATION_MODIFIER", 80, 88], ["pandemic", "OBSERVATION", 171, 179]]], ["Second, the results have demonstratedHealthcare delivery, economics and global healththat changes in hospital services started to occur prior to lockdown, with some-but not all-moving towards pre-COVID-19 activity levels by early May 2020.", [["Healthcare delivery", "TREATMENT", 37, 56], ["global healththat changes", "PROBLEM", 72, 97], ["pre-COVID", "TEST", 192, 201]]], ["Third, the visualisation tool developed for this analysis has illustrated how aggregate data can be collected from hospitals and presented rapidly.Healthcare delivery, economics and global healthOur results indicate the reduction in overall admissions was substantially larger than the increase in COVID-19 related admissions across all hospitals that provided information on both.", [["the visualisation tool", "TEST", 7, 29], ["this analysis", "TEST", 44, 57], ["Healthcare delivery", "TREATMENT", 147, 166], ["COVID", "TEST", 298, 303], ["reduction", "OBSERVATION_MODIFIER", 220, 229], ["larger", "OBSERVATION_MODIFIER", 270, 276]]], ["Adapting hospital services to address the pandemic has been more complex than simply accommodating an increase in hospital admissions.", [["increase", "OBSERVATION_MODIFIER", 102, 110]]], ["Hospitals had to create additional critical care capacity by repurposing operating theatres and staff, therefore, cancelling elective surgical procedures.", [["elective surgical procedures", "TREATMENT", 125, 153]]], ["Hospitalwide measures have also been required to minimise spread of infection.", [["infection", "DISEASE", 68, 77], ["Hospitalwide measures", "TREATMENT", 0, 21], ["infection", "PROBLEM", 68, 77], ["infection", "OBSERVATION", 68, 77]]], ["These adaptations necessitated reductions in overall activity.", [["reductions", "OBSERVATION_MODIFIER", 31, 41], ["overall activity", "OBSERVATION", 45, 61]]], ["These service adaptations were justifiable, but the marked reduction in overall hospital admissions compared with the numbers due to COVID-19 raises the possibility of overall health service overcompensation.", [["COVID", "TEST", 133, 138], ["marked", "OBSERVATION_MODIFIER", 52, 58], ["reduction", "OBSERVATION_MODIFIER", 59, 68]]], ["The observed reduction in hospital activity will undoubtedly lead to adverse, indirect, long-term impacts on care and incidence of non-COVID-19 diseases.", [["non-COVID-19 diseases", "PROBLEM", 131, 152], ["reduction", "OBSERVATION_MODIFIER", 13, 22]]], ["Understanding patient and professional behaviours and service organisational factors contributing to the observed response across different parts of the health service should help in planning appropriate service adaptation for potential further surge of COVID-19 or future emergencies.Healthcare delivery, economics and global healthThe present data showed a dramatic and consistent decline in overall admissions and ED attendances from ~2 weeks before lockdown.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["COVID", "TREATMENT", 254, 259], ["Healthcare delivery", "TREATMENT", 285, 304], ["dramatic", "OBSERVATION_MODIFIER", 359, 367], ["decline", "OBSERVATION_MODIFIER", 383, 390]]], ["This may reflect changes in behaviour of clinicians, hospital management and the public, which occurred prior to lockdown.", [["hospital management", "TREATMENT", 53, 72], ["may reflect", "UNCERTAINTY", 5, 16]]], ["It is possible that disease incidence of both cardiovascular and non-cardiovascular conditions decreased, which needs to be investigated.", [["cardiovascular", "ANATOMY", 46, 60], ["cardiovascular", "ANATOMICAL_SYSTEM", 46, 60], ["disease incidence of both cardiovascular and non-cardiovascular conditions", "PROBLEM", 20, 94], ["possible", "UNCERTAINTY", 6, 14], ["disease", "OBSERVATION", 20, 27], ["both", "ANATOMY_MODIFIER", 41, 45], ["cardiovascular", "ANATOMY", 46, 60]]], ["There was evidence of recovery in ED attendances and in admissions in some hospitals from around mid-April 2020, although, as of 10 May 2020, activity generally remained below that of the previous year.", [["evidence of", "UNCERTAINTY", 10, 21], ["recovery", "OBSERVATION_MODIFIER", 22, 30]]], ["We also observed marked reductions in CVD-specific ED attendances, admissions and hospital procedures and treatments, although with some recovery in ED attendances and percutaneous coronary interventions (PCI) from mid-April 2020.Figure 3% change compared with the previous year in ED attendance, hospital admissions and procedures/treatments for cardiac, cerebrovascular and other vascular conditions.", [["percutaneous", "ANATOMY", 168, 180], ["coronary", "ANATOMY", 181, 189], ["cardiac", "ANATOMY", 347, 354], ["cerebrovascular", "ANATOMY", 356, 371], ["vascular", "ANATOMY", 382, 390], ["CVD", "DISEASE", 38, 41], ["cardiac, cerebrovascular and other vascular conditions", "DISEASE", 347, 401], ["coronary", "MULTI-TISSUE_STRUCTURE", 181, 189], ["cardiac", "MULTI-TISSUE_STRUCTURE", 347, 354], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 356, 371], ["vascular", "MULTI-TISSUE_STRUCTURE", 382, 390], ["treatments", "TREATMENT", 106, 116], ["percutaneous coronary interventions", "TREATMENT", 168, 203], ["PCI", "TREATMENT", 205, 208], ["procedures/treatments", "TREATMENT", 321, 342], ["cardiac, cerebrovascular and other vascular conditions", "PROBLEM", 347, 401], ["marked", "OBSERVATION_MODIFIER", 17, 23], ["reductions", "OBSERVATION_MODIFIER", 24, 34], ["coronary", "ANATOMY", 181, 189], ["cardiac", "ANATOMY", 347, 354], ["cerebrovascular", "OBSERVATION", 356, 371], ["vascular", "ANATOMY", 382, 390]]], ["Cardiac ED attendances are those with an ED diagnosis code for cardiac conditions; cardiac admissions include those with acute coronary syndrome or heart failure; cardiac procedures/treatments include percutaneous coronary intervention, cardiac pacemaker or resynchronisation and coronary artery bypass graft; cerebrovascular ED attendances are those with an ED diagnosis code for cerebrovascular conditions; cerebrovascular admissions include those with acute stroke (ischaemic, intracerebral haemorrhage or subarachnoid haemorrhage) or transient ischaemic attack; cerebrovascular procedures/treatments include stroke thrombolysis, thrombectomy, carotid endarterectomy/stenting or cerebral aneurysm coiling; other vascular ED attendances are those with an ED diagnosis code for other vascular conditions; other vascular admissions include those with aortic aneurysms, DVT, PE or peripheral arterial disease; other vascular procedures include aortic aneurysm repair, limb revascularisation, bypass or amputation and peripheral angioplasty.", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 63, 70], ["cardiac", "ANATOMY", 83, 90], ["coronary", "ANATOMY", 127, 135], ["heart", "ANATOMY", 148, 153], ["cardiac", "ANATOMY", 163, 170], ["percutaneous", "ANATOMY", 201, 213], ["coronary", "ANATOMY", 214, 222], ["cardiac", "ANATOMY", 237, 244], ["coronary artery", "ANATOMY", 280, 295], ["cerebrovascular", "ANATOMY", 310, 325], ["cerebrovascular", "ANATOMY", 381, 396], ["cerebrovascular", "ANATOMY", 409, 424], ["intracerebral", "ANATOMY", 480, 493], ["subarachnoid", "ANATOMY", 509, 521], ["cerebrovascular", "ANATOMY", 566, 581], ["carotid", "ANATOMY", 647, 654], ["cerebral aneurysm", "ANATOMY", 682, 699], ["vascular", "ANATOMY", 715, 723], ["vascular", "ANATOMY", 785, 793], ["vascular", "ANATOMY", 812, 820], ["aortic", "ANATOMY", 851, 857], ["peripheral arterial", "ANATOMY", 880, 899], ["vascular", "ANATOMY", 915, 923], ["aortic aneurysm", "ANATOMY", 943, 958], ["limb", "ANATOMY", 967, 971], ["cardiac conditions", "DISEASE", 63, 81], ["acute coronary syndrome", "DISEASE", 121, 144], ["heart failure", "DISEASE", 148, 161], ["cerebrovascular conditions", "DISEASE", 381, 407], ["acute stroke", "DISEASE", 455, 467], ["ischaemic, intracerebral haemorrhage", "DISEASE", 469, 505], ["subarachnoid haemorrhage", "DISEASE", 509, 533], ["transient ischaemic attack", "DISEASE", 538, 564], ["stroke", "DISEASE", 612, 618], ["cerebral aneurysm coiling", "DISEASE", 682, 707], ["aortic aneurysms", "DISEASE", 851, 867], ["DVT", "DISEASE", 869, 872], ["PE", "DISEASE", 874, 876], ["peripheral arterial disease", "DISEASE", 880, 907], ["aortic aneurysm", "DISEASE", 943, 958], ["heart", "ORGAN", 148, 153], ["coronary", "MULTI-TISSUE_STRUCTURE", 214, 222], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 280, 295], ["carotid", "MULTI-TISSUE_STRUCTURE", 647, 654], ["vascular", "MULTI-TISSUE_STRUCTURE", 715, 723], ["vascular", "MULTI-TISSUE_STRUCTURE", 785, 793], ["vascular", "MULTI-TISSUE_STRUCTURE", 812, 820], ["aortic", "MULTI-TISSUE_STRUCTURE", 851, 857], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 880, 899], ["vascular", "MULTI-TISSUE_STRUCTURE", 915, 923], ["aortic", "MULTI-TISSUE_STRUCTURE", 943, 949], ["limb", "ORGANISM_SUBDIVISION", 967, 971], ["cardiac conditions", "PROBLEM", 63, 81], ["acute coronary syndrome", "PROBLEM", 121, 144], ["heart failure", "PROBLEM", 148, 161], ["cardiac procedures", "TREATMENT", 163, 181], ["treatments", "TREATMENT", 182, 192], ["percutaneous coronary intervention", "TREATMENT", 201, 235], ["cardiac pacemaker", "TREATMENT", 237, 254], ["resynchronisation", "TREATMENT", 258, 275], ["coronary artery bypass graft", "TREATMENT", 280, 308], ["cerebrovascular conditions", "PROBLEM", 381, 407], ["acute stroke", "PROBLEM", 455, 467], ["ischaemic, intracerebral haemorrhage", "PROBLEM", 469, 505], ["subarachnoid haemorrhage", "PROBLEM", 509, 533], ["transient ischaemic attack", "PROBLEM", 538, 564], ["cerebrovascular procedures/treatments", "TREATMENT", 566, 603], ["stroke thrombolysis", "TREATMENT", 612, 631], ["thrombectomy", "TREATMENT", 633, 645], ["carotid endarterectomy", "TREATMENT", 647, 669], ["stenting", "TREATMENT", 670, 678], ["cerebral aneurysm coiling", "TREATMENT", 682, 707], ["other vascular conditions", "PROBLEM", 779, 804], ["aortic aneurysms", "PROBLEM", 851, 867], ["DVT", "PROBLEM", 869, 872], ["PE", "PROBLEM", 874, 876], ["peripheral arterial disease", "PROBLEM", 880, 907], ["other vascular procedures", "TREATMENT", 909, 934], ["aortic aneurysm repair", "TREATMENT", 943, 965], ["limb revascularisation", "TREATMENT", 967, 989], ["bypass", "TREATMENT", 991, 997], ["amputation", "TREATMENT", 1001, 1011], ["peripheral angioplasty", "TREATMENT", 1016, 1038], ["coronary", "ANATOMY", 127, 135], ["syndrome", "OBSERVATION", 136, 144], ["heart", "ANATOMY", 148, 153], ["failure", "OBSERVATION", 154, 161], ["cardiac", "ANATOMY", 237, 244], ["pacemaker", "OBSERVATION", 245, 254], ["resynchronisation", "OBSERVATION", 258, 275], ["coronary artery", "ANATOMY", 280, 295], ["bypass graft", "OBSERVATION", 296, 308], ["cerebrovascular", "ANATOMY", 310, 325], ["acute", "OBSERVATION_MODIFIER", 455, 460], ["stroke", "OBSERVATION", 461, 467], ["ischaemic", "OBSERVATION_MODIFIER", 469, 478], ["intracerebral", "ANATOMY", 480, 493], ["haemorrhage", "OBSERVATION", 494, 505], ["subarachnoid", "ANATOMY", 509, 521], ["haemorrhage", "OBSERVATION", 522, 533], ["transient", "OBSERVATION_MODIFIER", 538, 547], ["ischaemic", "OBSERVATION_MODIFIER", 548, 557], ["thrombectomy", "OBSERVATION", 633, 645], ["carotid", "ANATOMY", 647, 654], ["endarterectomy", "OBSERVATION", 655, 669], ["stenting", "OBSERVATION", 670, 678], ["cerebral", "ANATOMY", 682, 690], ["aneurysm", "OBSERVATION", 691, 699], ["vascular", "ANATOMY", 715, 723], ["vascular", "ANATOMY", 785, 793], ["vascular", "ANATOMY", 812, 820], ["aortic", "ANATOMY", 851, 857], ["aneurysms", "OBSERVATION", 858, 867], ["DVT", "OBSERVATION", 869, 872], ["PE", "OBSERVATION", 874, 876], ["peripheral", "ANATOMY_MODIFIER", 880, 890], ["arterial", "ANATOMY", 891, 899], ["disease", "OBSERVATION", 900, 907], ["vascular", "ANATOMY", 915, 923], ["aortic", "ANATOMY", 943, 949], ["aneurysm", "OBSERVATION", 950, 958], ["limb", "ANATOMY", 967, 971], ["revascularisation", "OBSERVATION", 972, 989], ["bypass", "OBSERVATION", 991, 997], ["amputation", "OBSERVATION", 1001, 1011], ["peripheral", "OBSERVATION_MODIFIER", 1016, 1026], ["angioplasty", "OBSERVATION", 1027, 1038]]], ["Horizontal brown line indicates 0%; vertical green dotted line indicates first confirmed COVID-19 case on 31 January 2020; vertical purple dotted line indicates lockdown date on 23 March 2020.", [["brown line", "ANATOMY", 11, 21], ["brown line", "CELL", 11, 21], ["vertical green dotted line", "CELL_LINE", 36, 62], ["Horizontal brown line", "TREATMENT", 0, 21], ["vertical green dotted line", "PROBLEM", 36, 62], ["COVID", "TEST", 89, 94], ["vertical purple dotted line", "TREATMENT", 123, 150], ["brown line", "OBSERVATION", 11, 21]]], ["DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism.Healthcare delivery, economics and global healthWe assessed relative change in activity both through percentage change compared with the previous year and through relative reduction compared with before the first UK COVID-19 case.", [["deep vein", "ANATOMY", 5, 14], ["pulmonary", "ANATOMY", 57, 66], ["DVT", "DISEASE", 0, 3], ["deep vein thrombosis", "DISEASE", 5, 25], ["PE", "DISEASE", 53, 55], ["pulmonary embolism", "DISEASE", 57, 75], ["vein", "MULTI-TISSUE_STRUCTURE", 10, 14], ["pulmonary", "ORGAN", 57, 66], ["DVT", "PROBLEM", 0, 3], ["deep vein thrombosis", "PROBLEM", 5, 25], ["PE", "PROBLEM", 53, 55], ["pulmonary embolism", "PROBLEM", 57, 75], ["Healthcare delivery", "TREATMENT", 76, 95], ["relative change in activity both through percentage change", "PROBLEM", 136, 194], ["deep", "ANATOMY_MODIFIER", 5, 9], ["vein", "ANATOMY", 10, 14], ["thrombosis", "OBSERVATION", 15, 25], ["PE", "OBSERVATION", 53, 55], ["pulmonary", "ANATOMY", 57, 66], ["embolism", "OBSERVATION", 67, 75], ["change", "OBSERVATION_MODIFIER", 145, 151]]], ["These two approaches yielded consistent results, suggesting that the observed reductions related mainly to the COVID-19 pandemic rather than to expected variations (eg, the known declining rates in carotid endarterectomy 20 or seasonal fluctuations).", [["carotid", "ANATOMY", 198, 205], ["carotid", "MULTI-TISSUE_STRUCTURE", 198, 205], ["the observed reductions", "PROBLEM", 65, 88], ["the COVID", "TEST", 107, 116], ["carotid endarterectomy", "TREATMENT", 198, 220], ["carotid", "ANATOMY", 198, 205], ["endarterectomy", "OBSERVATION", 206, 220]]], ["Reductions in procedures for CVDs and PAD were particularly dramatic, with no evidence of recovery by early May.", [["CVDs", "DISEASE", 29, 33], ["PAD", "DISEASE", 38, 41], ["procedures", "TREATMENT", 14, 24], ["CVDs", "PROBLEM", 29, 33], ["PAD", "TREATMENT", 38, 41], ["PAD", "ANATOMY", 38, 41], ["no evidence of", "UNCERTAINTY", 75, 89]]], ["The number of coronary artery bypass surgery (CABG) was more than halved during the pandemic with a less marked reduction in PCI ( figure 4 and table 1 ).", [["coronary artery", "ANATOMY", 14, 29], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 14, 29], ["coronary artery bypass surgery", "TREATMENT", 14, 44], ["CABG", "TREATMENT", 46, 50], ["a less marked reduction in PCI", "TREATMENT", 98, 128], ["coronary artery", "ANATOMY", 14, 29], ["bypass", "OBSERVATION", 30, 36], ["marked", "OBSERVATION_MODIFIER", 105, 111], ["reduction", "OBSERVATION_MODIFIER", 112, 121]]], ["While we did not collect data to explore the reasons for this disparity between modes of coronary revascularisation, several factors may be relevant.", [["coronary", "ANATOMY", 89, 97], ["coronary", "MULTI-TISSUE_STRUCTURE", 89, 97], ["coronary revascularisation", "TREATMENT", 89, 115], ["coronary", "ANATOMY", 89, 97], ["revascularisation", "OBSERVATION", 98, 115]]], ["The repurposing of cardiac surgical and anaesthetic resources during the pandemic will underpin the reduction in cardiac surgical procedures.", [["cardiac", "ANATOMY", 19, 26], ["cardiac", "ANATOMY", 113, 120], ["cardiac", "ORGAN", 19, 26], ["cardiac", "ORGAN", 113, 120], ["cardiac surgical", "TREATMENT", 19, 35], ["anaesthetic resources", "TREATMENT", 40, 61], ["the reduction", "TREATMENT", 96, 109], ["cardiac surgical procedures", "TREATMENT", 113, 140], ["cardiac", "ANATOMY", 19, 26], ["surgical", "OBSERVATION", 27, 35], ["reduction", "OBSERVATION_MODIFIER", 100, 109], ["cardiac", "ANATOMY", 113, 120], ["surgical procedures", "OBSERVATION", 121, 140]]], ["Furthermore, some patients who had been referred or accepted for CABG were redirected in some hospitals to be treated instead by PCI, which does not require anaesthetic support.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["CABG", "TREATMENT", 65, 69], ["PCI", "TREATMENT", 129, 132], ["anaesthetic support", "TREATMENT", 157, 176]]], ["Guidelines from the UK's Vascular Society early in the pandemic suggested increasing the size threshold for elective surgical intervention for abdominal aortic aneurysms and the avoidance of carotid endarterectomy.", [["abdominal aortic", "ANATOMY", 143, 159], ["carotid", "ANATOMY", 191, 198], ["abdominal aortic aneurysms", "DISEASE", 143, 169], ["abdominal aortic", "MULTI-TISSUE_STRUCTURE", 143, 159], ["carotid", "MULTI-TISSUE_STRUCTURE", 191, 198], ["elective surgical intervention", "TREATMENT", 108, 138], ["abdominal aortic aneurysms", "PROBLEM", 143, 169], ["carotid endarterectomy", "TREATMENT", 191, 213], ["Vascular", "ANATOMY", 25, 33], ["size", "OBSERVATION_MODIFIER", 89, 93], ["abdominal aortic", "ANATOMY", 143, 159], ["aneurysms", "OBSERVATION", 160, 169], ["carotid", "ANATOMY", 191, 198], ["endarterectomy", "OBSERVATION", 199, 213]]], ["21 This advice will have contributed to the dramatic decline in aortic aneurysm repairs and carotid endarterectomies.", [["aortic aneurysm", "ANATOMY", 64, 79], ["carotid", "ANATOMY", 92, 99], ["aortic aneurysm", "DISEASE", 64, 79], ["aortic aneurysm", "MULTI-TISSUE_STRUCTURE", 64, 79], ["carotid endarterectomies", "MULTI-TISSUE_STRUCTURE", 92, 116], ["the dramatic decline", "PROBLEM", 40, 60], ["aortic aneurysm repairs", "TREATMENT", 64, 87], ["carotid endarterectomies", "TREATMENT", 92, 116], ["dramatic", "OBSERVATION_MODIFIER", 44, 52], ["decline", "OBSERVATION_MODIFIER", 53, 60], ["aortic", "ANATOMY", 64, 70], ["aneurysm", "OBSERVATION", 71, 79], ["carotid", "ANATOMY", 92, 99], ["endarterectomies", "OBSERVATION", 100, 116]]], ["These diseasespecific and service-specific data enable monitoring of service activity as well as estimates to inform on the indirect effects of the pandemic on morbidity, mortality and health economic measures.", [["morbidity", "TREATMENT", 160, 169], ["mortality", "TREATMENT", 171, 180], ["health economic measures", "TREATMENT", 185, 209]]], ["Furthermore, we have developed an online tool to facilitate the inclusion of additional hospitals and incorporate data updates for ongoing monitoring of trends in hospital activity as lockdown restrictions ease across the UK in the coming weeks and months.", [["ongoing monitoring", "TEST", 131, 149]]], ["These data and our tool provide surveillance of overall and cardiovascular hospital activities and could inform which services for which diseases require particular attention at system level and at hospital level.", [["cardiovascular", "ANATOMY", 60, 74], ["These data", "TEST", 0, 10]]], ["This framework could be used in other non-COVID-19 diseases, for example, cancer and respiratory disease, where national efforts are already underway (eg, those led by the Health Data Research UK cancer and respiratory research hubs, DATACAN and BREATHE, respectively).", [["cancer", "ANATOMY", 74, 80], ["respiratory", "ANATOMY", 85, 96], ["cancer", "ANATOMY", 196, 202], ["cancer", "DISEASE", 74, 80], ["respiratory disease", "DISEASE", 85, 104], ["cancer", "DISEASE", 196, 202], ["cancer", "CANCER", 74, 80], ["cancer", "CANCER", 196, 202], ["cancer", "PROBLEM", 74, 80], ["respiratory disease", "PROBLEM", 85, 104], ["respiratory research hubs", "TREATMENT", 207, 232], ["cancer", "OBSERVATION", 74, 80], ["respiratory disease", "OBSERVATION", 85, 104]]], ["22 23 These types of data need to be integrated across disease-specific domains in order to tackle the complex nature of the indirect effects of the pandemic as well as the prominent role of multimorbidity in the risk of COVID-19 severity and mortality.", [["the pandemic", "PROBLEM", 145, 157], ["multimorbidity", "PROBLEM", 191, 205], ["COVID", "TEST", 221, 226], ["prominent", "OBSERVATION_MODIFIER", 173, 182], ["multimorbidity", "OBSERVATION", 191, 205]]], ["Such data are not currently part of routine pandemic or emergency preparedness, 24 but the scale of the indirect effects across the UK and worldwide suggests that this situation needs to change.Figure 4Relative reductions in hospital activities during the COVID-19 pandemic.", [["the COVID", "TEST", 252, 261], ["pandemic", "PROBLEM", 265, 273], ["reductions", "OBSERVATION_MODIFIER", 211, 221]]], ["Relative reduction (RR) comparing phase 2 (between first case and lockdown) and phase 3 (after lockdown) to phase 1 (before first case).", [["RR", "TEST", 20, 22], ["reduction", "OBSERVATION_MODIFIER", 9, 18]]], ["ACS, acute coronary syndrome; CABG, coronary artery bypass graft; DVT, deep vein thrombosis; ED, emergency department; PCI, percutaneous coronary interventions; PE, pulmonary embolus; TIA, transient ischaemic attack.Comparison with other dataNational mortality data from the UK and other countries also demonstrate the direct and indirect impacts of the pandemic, showing peaks in COVID-19 deaths, non-COVID-19 deaths and CVD deaths.", [["coronary", "ANATOMY", 11, 19], ["coronary artery", "ANATOMY", 36, 51], ["deep vein", "ANATOMY", 71, 80], ["percutaneous", "ANATOMY", 124, 136], ["coronary", "ANATOMY", 137, 145], ["pulmonary", "ANATOMY", 165, 174], ["ACS", "DISEASE", 0, 3], ["acute coronary syndrome", "DISEASE", 5, 28], ["DVT", "DISEASE", 66, 69], ["deep vein thrombosis", "DISEASE", 71, 91], ["PE", "DISEASE", 161, 163], ["pulmonary embolus", "DISEASE", 165, 182], ["TIA", "DISEASE", 184, 187], ["transient ischaemic attack", "DISEASE", 189, 215], ["deaths", "DISEASE", 390, 396], ["deaths", "DISEASE", 411, 417], ["CVD", "DISEASE", 422, 425], ["deaths", "DISEASE", 426, 432], ["coronary", "MULTI-TISSUE_STRUCTURE", 11, 19], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 36, 51], ["vein", "MULTI-TISSUE_STRUCTURE", 76, 80], ["coronary", "MULTI-TISSUE_STRUCTURE", 137, 145], ["pulmonary", "ORGAN", 165, 174], ["ACS", "PROBLEM", 0, 3], ["acute coronary syndrome", "PROBLEM", 5, 28], ["CABG", "TREATMENT", 30, 34], ["coronary artery bypass graft", "TREATMENT", 36, 64], ["DVT", "PROBLEM", 66, 69], ["deep vein thrombosis", "PROBLEM", 71, 91], ["PCI", "TREATMENT", 119, 122], ["percutaneous coronary interventions", "TREATMENT", 124, 159], ["PE", "PROBLEM", 161, 163], ["pulmonary embolus", "PROBLEM", 165, 182], ["TIA", "PROBLEM", 184, 187], ["transient ischaemic attack", "PROBLEM", 189, 215], ["the pandemic", "PROBLEM", 350, 362], ["COVID", "TEST", 381, 386], ["non-COVID", "TEST", 398, 407], ["CVD deaths", "PROBLEM", 422, 432], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["coronary", "ANATOMY", 11, 19], ["syndrome", "OBSERVATION", 20, 28], ["CABG", "OBSERVATION", 30, 34], ["coronary artery", "ANATOMY", 36, 51], ["bypass graft", "OBSERVATION", 52, 64], ["DVT", "OBSERVATION", 66, 69], ["deep", "ANATOMY_MODIFIER", 71, 75], ["vein", "ANATOMY", 76, 80], ["thrombosis", "OBSERVATION", 81, 91], ["coronary", "ANATOMY", 137, 145], ["PE", "OBSERVATION", 161, 163], ["pulmonary", "ANATOMY", 165, 174], ["embolus", "OBSERVATION", 175, 182], ["transient", "OBSERVATION_MODIFIER", 189, 198], ["ischaemic attack", "OBSERVATION", 199, 215], ["peaks", "OBSERVATION_MODIFIER", 372, 377]]], ["25 26 Other studies have also reported similar reductions in hospital activity overall, for CVDs and for other conditions (eg, cancer) during the COVID-19 pandemic, both in the UK and many other countries.", [["cancer", "ANATOMY", 127, 133], ["CVDs", "DISEASE", 92, 96], ["cancer", "DISEASE", 127, 133], ["cancer", "CANCER", 127, 133], ["Other studies", "TEST", 6, 19], ["CVDs", "PROBLEM", 92, 96], ["other conditions (eg, cancer", "PROBLEM", 105, 133], ["reductions", "OBSERVATION_MODIFIER", 47, 57], ["cancer", "OBSERVATION", 127, 133]]], ["9 27-29 Our results on procedures and treatments for CVDs are consistent with the estimated cancellation rate of over 70% for elective operations based on projections from the initial response to the pandemic.", [["CVDs", "DISEASE", 53, 57], ["procedures", "TEST", 23, 33], ["treatments", "TREATMENT", 38, 48], ["CVDs", "PROBLEM", 53, 57], ["the estimated cancellation rate", "TEST", 78, 109], ["elective operations", "TREATMENT", 126, 145], ["the pandemic", "PROBLEM", 196, 208], ["consistent with", "UNCERTAINTY", 62, 77]]], ["29 Where reported, recovery of activity has generally been slow; for example, in hospitals in China, CVD activity remained below pre-COVID-19 levels for 2-3 months, even after easing lockdown.", [["CVD", "DISEASE", 101, 104], ["CVD activity", "PROBLEM", 101, 113], ["pre-COVID", "TEST", 129, 138]]], ["10 To our knowledge, the present report is the first UK study to have recorded overall and cardiovascular hospital activity over a long enough period since lockdown to show the beginning of recovery in some measures and is the only study we are aware of to provide analyses of these via an online tool designed to include data from additional hospitals and regular updates over the months ahead.Strengths and limitationsThe simple, aggregate nature of our data request enabled a large proportion of the hospitals contacted to provide data in a short timeframe.", [["cardiovascular", "ANATOMY", 91, 105], ["simple", "OBSERVATION_MODIFIER", 424, 430]]], ["This has made possible the notion of a regularly updated online tool that can incorporate and display near real-time data from an increasing number of hospitals across the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 172, 174], ["increasing", "OBSERVATION_MODIFIER", 130, 140]]], ["However, the aggregate nature of the data means that the influence of individual-level factors such as age, socioeconomic status, ethnicity and comorbidities cannot be explored.", [["individual-level factors", "PROBLEM", 70, 94], ["comorbidities", "PROBLEM", 144, 157]]], ["Furthermore, our current data request combines data on the primary and other (secondary) reasons for hospital admission and does not subdivide admissions or procedures according to elective (planned) and emergency (unplanned) activity.", [["procedures", "TREATMENT", 157, 167]]], ["Future modifications of our data collection procedures could enable separate analysis of elective and emergency procedures.", [["our data collection procedures", "TEST", 24, 54], ["elective and emergency procedures", "TREATMENT", 89, 122]]], ["While data averaged across the previous 5 years may provide a more stable comparator and has been used to assess excess mortality from national mortality data, such data would mask longer term trends in some activities (eg, reductions in carotid endarterectomies and aortic aneurysm repairs and increasing numbers of procedures for PAD), 30 hospitals may have found it more challenging to provide these data, and changes in hospital catchment areas and service arrangements would be more likely to have occurred over a longer period.ConclusionIn conclusion, we have shown the value of simple aggregate data for monitoring changes in general and disease-specific hospital activity during the course of the COVID-19 pandemic in the UK and the potential for further development of an online tool to enable ongoing monitoring.", [["carotid", "ANATOMY", 238, 245], ["aortic aneurysm", "ANATOMY", 267, 282], ["aneurysm", "DISEASE", 274, 282], ["PAD", "DISEASE", 332, 335], ["carotid endarterectomies", "MULTI-TISSUE_STRUCTURE", 238, 262], ["aortic aneurysm", "MULTI-TISSUE_STRUCTURE", 267, 282], ["carotid endarterectomies", "TREATMENT", 238, 262], ["aortic aneurysm repairs", "TREATMENT", 267, 290], ["PAD", "TEST", 332, 335], ["these data", "TEST", 397, 407], ["monitoring changes", "TEST", 611, 629], ["the COVID", "TEST", 701, 710], ["ongoing monitoring", "TEST", 803, 821], ["carotid", "ANATOMY", 238, 245], ["endarterectomies", "OBSERVATION", 246, 262], ["aortic", "ANATOMY", 267, 273], ["aneurysm", "OBSERVATION", 274, 282]]]], "bddd75ff4f00e94ce274299c608c3500d227b90f": [["IntroductionRespiratory Syncytial Virus (RSV), a negative strand RNA virus in the Pneumoviridae family, is the most important cause of respiratory tract infection during infancy, causing annual winter outbreaks in the US [1] [2] [3] [4] [5] [6] .", [["respiratory tract", "ANATOMY", 135, 152], ["IntroductionRespiratory Syncytial Virus", "DISEASE", 0, 39], ["respiratory tract infection", "DISEASE", 135, 162], ["[1] [2] [3] [4] [5] [6]", "CHEMICAL", 221, 244], ["IntroductionRespiratory Syncytial Virus", "ORGANISM", 0, 39], ["RSV", "ORGANISM", 41, 44], ["respiratory tract", "ORGANISM_SUBDIVISION", 135, 152], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 221, 244], ["RSV", "SPECIES", 41, 44], ["IntroductionRespiratory Syncytial Virus (RSV)", "PROBLEM", 0, 45], ["a negative strand RNA virus", "PROBLEM", 47, 74], ["respiratory tract infection", "PROBLEM", 135, 162], ["Syncytial Virus", "OBSERVATION", 24, 39], ["respiratory tract", "ANATOMY", 135, 152], ["infection", "OBSERVATION", 153, 162]]], ["In the US approximately half of the 4 million newborns are infected during their first winter with 1-3% hospitalized and an additional 4-7% and 10-16% seen in emergency departments or physician offices, respectively, for RSV infections 7 .", [["RSV infections", "DISEASE", 221, 235], ["newborns", "ORGANISM", 46, 54], ["RSV", "ORGANISM", 221, 224], ["RSV", "SPECIES", 221, 224], ["RSV infections", "PROBLEM", 221, 235], ["infected", "OBSERVATION", 59, 67], ["infections", "OBSERVATION", 225, 235]]], ["Mortality is uncommon in the US (~50 deaths annually); however, in developing countries it is estimated that annually RSV causes 118 thousand deaths, 6 million cases of severe acute lower respiratory illness and 3 million hospitalizations in children under 5 years of age 8, 9 .", [["deaths", "DISEASE", 37, 43], ["RSV", "DISEASE", 118, 121], ["deaths", "DISEASE", 142, 148], ["lower respiratory illness", "DISEASE", 182, 207], ["RSV", "ORGANISM", 118, 121], ["children", "ORGANISM", 242, 250], ["children", "SPECIES", 242, 250], ["RSV", "SPECIES", 118, 121], ["severe acute lower respiratory illness", "PROBLEM", 169, 207], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["lower", "ANATOMY_MODIFIER", 182, 187], ["respiratory", "ANATOMY", 188, 199], ["illness", "OBSERVATION", 200, 207]]], ["Currently there is no available vaccine for RSV in infants, although several candidate vaccines are in clinical trials.IntroductionLong established major risk factors for severe illness include prematurity, bronchopulmonary dysplasia, cyanotic heart disease, neuromuscular disease, and immune compromise 4, 10 .", [["bronchopulmonary dysplasia", "ANATOMY", 207, 233], ["heart", "ANATOMY", 244, 249], ["neuromuscular", "ANATOMY", 259, 272], ["RSV", "DISEASE", 44, 47], ["illness", "DISEASE", 178, 185], ["prematurity", "DISEASE", 194, 205], ["bronchopulmonary dysplasia", "DISEASE", 207, 233], ["cyanotic heart disease", "DISEASE", 235, 257], ["neuromuscular disease", "DISEASE", 259, 280], ["RSV", "ORGANISM", 44, 47], ["infants", "ORGANISM", 51, 58], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 207, 233], ["heart", "ORGAN", 244, 249], ["infants", "SPECIES", 51, 58], ["RSV", "SPECIES", 44, 47], ["available vaccine", "TREATMENT", 22, 39], ["RSV", "PROBLEM", 44, 47], ["several candidate vaccines", "TREATMENT", 69, 95], ["severe illness", "PROBLEM", 171, 185], ["prematurity", "PROBLEM", 194, 205], ["bronchopulmonary dysplasia", "PROBLEM", 207, 233], ["cyanotic heart disease", "PROBLEM", 235, 257], ["neuromuscular disease", "PROBLEM", 259, 280], ["immune compromise", "PROBLEM", 286, 303], ["no available", "UNCERTAINTY", 19, 31], ["prematurity", "OBSERVATION", 194, 205], ["bronchopulmonary", "ANATOMY", 207, 223], ["dysplasia", "OBSERVATION", 224, 233], ["cyanotic", "OBSERVATION_MODIFIER", 235, 243], ["heart", "ANATOMY", 244, 249], ["disease", "OBSERVATION", 250, 257], ["neuromuscular disease", "OBSERVATION", 259, 280], ["immune compromise", "OBSERVATION", 286, 303]]], ["However, approximately 70% of hospitalized infants in the US have no overt risk factors for severe illness.", [["infants", "ORGANISM", 43, 50], ["infants", "SPECIES", 43, 50], ["overt risk factors", "PROBLEM", 69, 87], ["severe illness", "PROBLEM", 92, 106], ["no", "UNCERTAINTY", 66, 68], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["illness", "OBSERVATION", 99, 106]]], ["Although young age at infection, environmental influences such as tobacco smoke exposure, viral load and strain, low levels of maternally derived RSV-neutralizing antibody, as well as a multitude of genetic host factors have been associated with severe disease in some but not all studies 4,11-22 .", [["infection", "DISEASE", 22, 31], ["smoke", "CHEMICAL", 74, 79], ["tobacco", "ORGANISM", 66, 73], ["RSV", "ORGANISM", 146, 149], ["RSV-neutralizing antibody", "PROTEIN", 146, 171], ["tobacco", "SPECIES", 66, 73], ["RSV", "SPECIES", 146, 149], ["infection", "PROBLEM", 22, 31], ["viral load and strain", "PROBLEM", 90, 111], ["low levels of maternally derived RSV-neutralizing antibody", "PROBLEM", 113, 171], ["severe disease", "PROBLEM", 246, 260], ["all studies", "TEST", 277, 288], ["infection", "OBSERVATION", 22, 31], ["viral load", "OBSERVATION", 90, 100], ["neutralizing antibody", "OBSERVATION", 150, 171], ["severe", "OBSERVATION_MODIFIER", 246, 252], ["disease", "OBSERVATION", 253, 260]]], ["Recently, the presence of Haemophilus influenzae and Streptococcus pneumoniae in the nasal microbiota during RSV infection has been associated with greater severity [23] [24] [25] .IntroductionFinally, and importantly, the infant's immune response to RSV is thought to be a major driver of disease pathogenesis, especially during primary infection 26, 27 .", [["nasal microbiota", "ANATOMY", 85, 101], ["Haemophilus influenzae", "DISEASE", 26, 48], ["RSV infection", "DISEASE", 109, 122], ["RSV", "DISEASE", 251, 254], ["primary infection", "DISEASE", 330, 347], ["Haemophilus influenzae", "ORGANISM", 26, 48], ["Streptococcus pneumoniae", "ORGANISM", 53, 77], ["nasal microbiota", "MULTI-TISSUE_STRUCTURE", 85, 101], ["RSV", "ORGANISM", 109, 112], ["infant", "ORGANISM", 223, 229], ["RSV", "ORGANISM", 251, 254], ["Haemophilus influenzae", "SPECIES", 26, 48], ["Streptococcus pneumoniae", "SPECIES", 53, 77], ["infant", "SPECIES", 223, 229], ["Haemophilus influenzae", "SPECIES", 26, 48], ["Streptococcus pneumoniae", "SPECIES", 53, 77], ["RSV", "SPECIES", 109, 112], ["RSV", "SPECIES", 251, 254], ["Haemophilus influenzae", "PROBLEM", 26, 48], ["Streptococcus pneumoniae", "PROBLEM", 53, 77], ["the nasal microbiota", "PROBLEM", 81, 101], ["RSV infection", "PROBLEM", 109, 122], ["RSV", "PROBLEM", 251, 254], ["disease pathogenesis", "PROBLEM", 290, 310], ["primary infection", "PROBLEM", 330, 347], ["Haemophilus", "OBSERVATION_MODIFIER", 26, 37], ["influenzae", "OBSERVATION", 38, 48], ["Streptococcus pneumoniae", "OBSERVATION", 53, 77], ["nasal microbiota", "ANATOMY", 85, 101], ["RSV infection", "OBSERVATION", 109, 122], ["disease", "OBSERVATION", 290, 297]]], ["Several studies in infants suggest that Th2 biased responses and Th17 responses during primary infection may contribute to a more inflammatory and severe outcome [28] [29] [30] .", [["primary infection", "DISEASE", 87, 104], ["infants", "ORGANISM", 19, 26], ["Th2", "GENE_OR_GENE_PRODUCT", 40, 43], ["infants", "SPECIES", 19, 26], ["Several studies", "TEST", 0, 15], ["primary infection", "PROBLEM", 87, 104], ["a more inflammatory and severe outcome", "PROBLEM", 123, 161], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142]]], ["Innate immune responses by immune cells, such as neutrophils, and respiratory epithelial cells are also likely to play pivotal roles in both eliminating virus replication as well as enhancing or moderating the inflammatory response 31, 32 .IntroductionThe AsPIRES (Assessing and Predicting Infant RSV Effects and Severity) study is a comprehensive study designed to identify factors associated with disease severity in full term healthy infants less than 10 months of age undergoing primary RSV infection.", [["immune cells", "ANATOMY", 27, 39], ["neutrophils", "ANATOMY", 49, 60], ["respiratory epithelial cells", "ANATOMY", 66, 94], ["RSV infection", "DISEASE", 491, 504], ["immune cells", "CELL", 27, 39], ["neutrophils", "CELL", 49, 60], ["respiratory epithelial cells", "CELL", 66, 94], ["infants", "ORGANISM", 437, 444], ["RSV", "ORGANISM", 491, 494], ["immune cells", "CELL_TYPE", 27, 39], ["neutrophils", "CELL_TYPE", 49, 60], ["respiratory epithelial cells", "CELL_TYPE", 66, 94], ["infants", "SPECIES", 437, 444], ["RSV", "SPECIES", 297, 300], ["RSV", "SPECIES", 491, 494], ["immune cells", "PROBLEM", 27, 39], ["neutrophils", "TEST", 49, 60], ["respiratory epithelial cells", "PROBLEM", 66, 94], ["a comprehensive study", "TEST", 332, 353], ["disease severity", "PROBLEM", 399, 415], ["primary RSV infection", "PROBLEM", 483, 504], ["immune cells", "OBSERVATION", 27, 39], ["respiratory epithelial cells", "OBSERVATION", 66, 94], ["virus", "OBSERVATION", 153, 158], ["inflammatory", "OBSERVATION_MODIFIER", 210, 222], ["RSV infection", "OBSERVATION", 491, 504]]], ["In this report we analyze gene expression of nasal respiratory epithelial cells, in addition to the influence of respiratory microbiota, in relation to illness severity during primary RSV infection.", [["nasal respiratory epithelial cells", "ANATOMY", 45, 79], ["respiratory", "ANATOMY", 113, 124], ["illness", "DISEASE", 152, 159], ["primary RSV infection", "DISEASE", 176, 197], ["nasal respiratory epithelial cells", "CELL", 45, 79], ["RSV", "ORGANISM", 184, 187], ["nasal respiratory epithelial cells", "CELL_TYPE", 45, 79], ["RSV", "SPECIES", 184, 187], ["nasal respiratory epithelial cells", "PROBLEM", 45, 79], ["respiratory microbiota", "PROBLEM", 113, 135], ["illness severity", "PROBLEM", 152, 168], ["primary RSV infection", "PROBLEM", 176, 197], ["nasal", "ANATOMY", 45, 50], ["respiratory epithelial cells", "OBSERVATION", 51, 79], ["respiratory microbiota", "OBSERVATION", 113, 135], ["RSV infection", "OBSERVATION", 184, 197]]], ["In addition, we describe the development of an in vitro model of RSV infection to explore the relationship between interferon activity, airway cell gene expression and productive RSV infection.RSV infected infants were identified and enrolled into the Assessing Predictors of InfantRSV Effects and Severity (AsPIRES) study during three winter (2013-14, 2014-15, and 2015-16) in Rochester NY as previously described 33, 34 .", [["airway cell", "ANATOMY", 136, 147], ["RSV infection", "DISEASE", 65, 78], ["RSV infection", "DISEASE", 179, 192], ["RSV infected", "DISEASE", 193, 205], ["RSV", "ORGANISM", 65, 68], ["interferon", "GENE_OR_GENE_PRODUCT", 115, 125], ["airway cell", "CELL", 136, 147], ["RSV", "ORGANISM", 179, 182], ["RSV", "ORGANISM", 193, 196], ["infants", "ORGANISM", 206, 213], ["interferon", "PROTEIN", 115, 125], ["RSV", "SPECIES", 193, 196], ["infants", "SPECIES", 206, 213], ["RSV", "SPECIES", 65, 68], ["RSV", "SPECIES", 179, 182], ["RSV", "SPECIES", 193, 196], ["RSV infection", "PROBLEM", 65, 78], ["interferon activity", "TREATMENT", 115, 134], ["airway cell gene expression", "TREATMENT", 136, 163], ["productive RSV infection", "PROBLEM", 168, 192], ["RSV infected infants", "PROBLEM", 193, 213], ["Severity (AsPIRES) study", "TEST", 298, 322], ["RSV infection", "OBSERVATION", 65, 78], ["interferon activity", "OBSERVATION", 115, 134], ["airway cell", "OBSERVATION", 136, 147], ["productive", "OBSERVATION_MODIFIER", 168, 178], ["RSV infection", "OBSERVATION", 179, 192]]], ["All infants were less than 10 months of age at the time of primary RSV infection and came from one of three cohorts;RSV infected infants were identified and enrolled into the Assessing Predictors of Infant(1) infants prospectively enrolled at birth and followed for development of RSV infection, (2) infants enrolled upon hospitalization with RSV infection, and (3) infants identified with RSV in emergency rooms or physician offices managed as outpatients.", [["RSV infection", "DISEASE", 67, 80], ["RSV infected", "DISEASE", 116, 128], ["RSV infection", "DISEASE", 281, 294], ["RSV infection", "DISEASE", 343, 356], ["RSV", "DISEASE", 390, 393], ["infants", "ORGANISM", 4, 11], ["RSV", "ORGANISM", 67, 70], ["RSV", "ORGANISM", 116, 119], ["infants", "ORGANISM", 129, 136], ["infants", "ORGANISM", 209, 216], ["RSV", "ORGANISM", 281, 284], ["infants", "ORGANISM", 300, 307], ["RSV", "ORGANISM", 343, 346], ["infants", "ORGANISM", 366, 373], ["RSV", "ORGANISM", 390, 393], ["infants", "SPECIES", 4, 11], ["infants", "SPECIES", 129, 136], ["infants", "SPECIES", 209, 216], ["infants", "SPECIES", 300, 307], ["infants", "SPECIES", 366, 373], ["RSV", "SPECIES", 67, 70], ["RSV", "SPECIES", 116, 119], ["RSV", "SPECIES", 281, 284], ["RSV", "SPECIES", 343, 346], ["RSV", "SPECIES", 390, 393], ["primary RSV infection", "PROBLEM", 59, 80], ["RSV infected infants", "PROBLEM", 116, 136], ["RSV infection", "PROBLEM", 281, 294], ["RSV infection", "PROBLEM", 343, 356], ["RSV infection", "OBSERVATION", 67, 80], ["RSV", "OBSERVATION_MODIFIER", 281, 284], ["infection", "OBSERVATION", 285, 294], ["infection", "OBSERVATION", 347, 356]]], ["All subjects were previously healthy full-term infants (gestational age \u2265 36 weeks) born after May 1 of the previous spring.", [["infants", "ORGANISM", 47, 54], ["infants", "SPECIES", 47, 54]]], ["Infants hospitalized only for apnea were excluded as well as those with any known high-risk conditions.", [["apnea", "DISEASE", 30, 35], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["apnea", "PROBLEM", 30, 35]]], ["The Research Subject Review Board of the University of Rochester and Rochester General Hospital approved the study and all parents provided written informed consent.Study Protocol and ProceduresRSV infection was identified by reverse transcription polymerase chain reaction (RT-PCR) on nasal swabs.", [["nasal swabs", "ANATOMY", 286, 297], ["infection", "DISEASE", 198, 207], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 286, 297], ["the study", "TEST", 105, 114], ["Study Protocol", "TEST", 165, 179], ["ProceduresRSV infection", "PROBLEM", 184, 207], ["reverse transcription polymerase chain reaction", "PROBLEM", 226, 273], ["RT-PCR", "TEST", 275, 281], ["nasal swabs", "TREATMENT", 286, 297], ["infection", "OBSERVATION", 198, 207], ["nasal", "ANATOMY", 286, 291]]], ["Following confirmation of RSV infection all study subjects underwent a standard evaluation at three time points.", [["RSV infection", "DISEASE", 26, 39], ["RSV", "ORGANISM", 26, 29], ["RSV", "SPECIES", 26, 29], ["RSV infection", "PROBLEM", 26, 39], ["a standard evaluation", "TEST", 69, 90], ["RSV", "ANATOMY", 26, 29], ["infection", "OBSERVATION", 30, 39]]], ["The first illness visit occurred within 24 hours of RSV diagnosis, a second visit 12-16 days after illness onset, and final visit on illness day 25-32.", [["illness", "DISEASE", 10, 17], ["illness", "DISEASE", 99, 106], ["illness", "DISEASE", 133, 140], ["RSV", "ORGANISM", 52, 55], ["RSV", "SPECIES", 52, 55]]], ["At the first and third visits a nasal swab was collected from one nostril for analysis of respiratory microbiota, followed by collection of nasal epithelial cells from the contralateral nostril as previously described 35 .", [["nasal swab", "ANATOMY", 32, 42], ["nostril", "ANATOMY", 66, 73], ["respiratory", "ANATOMY", 90, 101], ["nasal epithelial cells", "ANATOMY", 140, 162], ["nostril", "ANATOMY", 186, 193], ["nasal swab", "ORGANISM_SUBSTANCE", 32, 42], ["nostril", "ORGAN", 66, 73], ["nasal epithelial cells", "CELL", 140, 162], ["nostril", "ORGAN", 186, 193], ["nasal epithelial cells", "CELL_TYPE", 140, 162], ["a nasal swab", "TEST", 30, 42], ["respiratory microbiota", "PROBLEM", 90, 112], ["nasal epithelial cells from the contralateral nostril", "PROBLEM", 140, 193], ["nasal", "ANATOMY", 32, 37], ["respiratory microbiota", "ANATOMY", 90, 112], ["nasal", "ANATOMY", 140, 145], ["epithelial cells", "OBSERVATION", 146, 162], ["contralateral", "ANATOMY_MODIFIER", 172, 185], ["nostril", "ANATOMY", 186, 193]]], ["Briefly, after washing the nares with 5 ml of sterile saline to remove mucus and cellular debris the mid turbinate was brushed for 5 seconds with a flocked swab (Copan, FLOQSwabs\u2122 catalog # 525CS01, Copan, Murrieta, CA) to remove respiratory epithelial cells.", [["nares", "ANATOMY", 27, 32], ["mucus", "ANATOMY", 71, 76], ["cellular", "ANATOMY", 81, 89], ["mid turbinate", "ANATOMY", 101, 114], ["respiratory epithelial cells", "ANATOMY", 230, 258], ["nares", "ORGANISM_SUBDIVISION", 27, 32], ["saline", "SIMPLE_CHEMICAL", 54, 60], ["mucus", "ORGANISM_SUBSTANCE", 71, 76], ["cellular debris", "TISSUE", 81, 96], ["turbinate", "ORGAN", 105, 114], ["respiratory epithelial cells", "CELL", 230, 258], ["respiratory epithelial cells", "CELL_TYPE", 230, 258], ["washing the nares", "TREATMENT", 15, 32], ["sterile saline", "TREATMENT", 46, 60], ["mucus and cellular debris the mid turbinate", "PROBLEM", 71, 114], ["a flocked swab", "TREATMENT", 146, 160], ["Copan", "TREATMENT", 162, 167], ["Copan", "TREATMENT", 199, 204], ["Murrieta", "TREATMENT", 206, 214], ["respiratory epithelial cells", "PROBLEM", 230, 258], ["nares", "ANATOMY", 27, 32], ["cellular debris", "OBSERVATION", 81, 96], ["mid", "ANATOMY_MODIFIER", 101, 104], ["turbinate", "ANATOMY", 105, 114], ["respiratory epithelial cells", "OBSERVATION", 230, 258]]], ["The swab was immediately placed in 2 ml of RNA protect and maintained at 4 o C until the cells were recovered by filtration and homogenized in RNA lysis buffer, as described 35 .Statistical Analysis of Clinical DataDescriptive characteristics of the study cohort were reported in Table 1Defining Illness SeverityThe severity of the clinical illness in these patients was defined by a global respiratory severity score (GRSS) 33 .", [["swab", "ANATOMY", 4, 8], ["cells", "ANATOMY", 89, 94], ["respiratory", "ANATOMY", 391, 402], ["illness", "DISEASE", 341, 348], ["swab", "ORGANISM_SUBSTANCE", 4, 8], ["cells", "CELL", 89, 94], ["patients", "ORGANISM", 358, 366], ["patients", "SPECIES", 358, 366], ["The swab", "TREATMENT", 0, 8], ["RNA protect", "TREATMENT", 43, 54], ["RNA lysis buffer", "TREATMENT", 143, 159], ["the study", "TEST", 246, 255], ["the clinical illness", "PROBLEM", 328, 348], ["a global respiratory severity score", "TEST", 382, 417], ["RNA lysis", "OBSERVATION", 143, 152]]], ["Briefly, a Global Respiratory Severity Score (GRSS) was defined by a weighted combination of 9 clinical measures including general appearance, presence of rales, wheezing, cyanosis, retractions, lethargy, poor air movement, maximal age-adjusted respiratory rate, and worst room air oxygen saturation.", [["respiratory", "ANATOMY", 245, 256], ["wheezing", "DISEASE", 162, 170], ["cyanosis", "DISEASE", 172, 180], ["retractions", "DISEASE", 182, 193], ["lethargy", "DISEASE", 195, 203], ["oxygen", "CHEMICAL", 282, 288], ["oxygen", "CHEMICAL", 282, 288], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["a Global Respiratory Severity Score", "PROBLEM", 9, 44], ["rales", "PROBLEM", 155, 160], ["wheezing", "PROBLEM", 162, 170], ["cyanosis", "PROBLEM", 172, 180], ["retractions", "PROBLEM", 182, 193], ["lethargy", "PROBLEM", 195, 203], ["poor air movement", "PROBLEM", 205, 222], ["adjusted respiratory rate", "PROBLEM", 236, 261], ["worst room air oxygen saturation", "PROBLEM", 267, 299], ["rales", "OBSERVATION", 155, 160], ["wheezing", "OBSERVATION", 162, 170], ["cyanosis", "OBSERVATION", 172, 180], ["retractions", "OBSERVATION", 182, 193], ["air movement", "OBSERVATION", 210, 222], ["respiratory rate", "OBSERVATION", 245, 261], ["oxygen saturation", "OBSERVATION", 282, 299]]], ["The GRSS is defined on a continuous scale from 0-10, and is highly correlated with need for hospitalization.", [["GRSS", "DNA", 4, 8], ["a continuous scale", "TEST", 23, 41]]], ["For some secondary analyses, severe illness was dichotomously defined as GRSS>3.5.Library Preparation and SequencingThe RNA was isolated and assessed for quality and quantity (average yield 275 ng per sample).", [["illness", "DISEASE", 36, 43], ["some secondary analyses", "PROBLEM", 4, 27], ["severe illness", "PROBLEM", 29, 43], ["GRSS", "TEST", 73, 77], ["Library Preparation", "TREATMENT", 82, 101], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["illness", "OBSERVATION", 36, 43]]], ["1 ng of total RNA was amplified using the SMARter Ultra Low amplification kit (Clontech, Mountain, CA) with PCR amplification to generate sufficient cDNA for library construction.", [["cDNA", "DNA", 149, 153], ["total RNA", "TREATMENT", 8, 17], ["the SMARter Ultra Low amplification kit", "TREATMENT", 38, 77], ["Mountain, CA)", "TREATMENT", 89, 102], ["PCR amplification", "TREATMENT", 108, 125], ["library construction", "TREATMENT", 158, 178]]], ["Amplified cDNA quantification was determined with the Qubit Flourometer (Life Technologies, Grand Island, NY) and quality was assessed using the Agilent Bioanalyzer 2100 (Santa Clara, CA).", [["Amplified cDNA quantification", "TEST", 0, 29]]], ["Library construction was performed using NexteraXT library kit (Illumina, San Diego, CA) with 1 ng of input amplified cDNA per manufacturer's recommendations.", [["Library construction", "TREATMENT", 0, 20]]], ["Nextera libraries were quantified with the Qubit Flourometer (Life Technologies, Grand Island, NY) and quality was assessed using the Agilent Tape Station (Santa Clara, CA).", [["Nextera libraries", "TREATMENT", 0, 17], ["the Agilent Tape Station", "TREATMENT", 130, 154]]], ["Libraries were sequenced on the Illumina HiSeq2500 (Illumina, San Diego, CA) to generate 20 million 1X100-bp single end reads per sample 35 .Read Mapping, Data Normalization and FilteringSequences were aligned by STAR against human genome version of GRCh38 and normalized to FPKM.", [["human", "ORGANISM", 226, 231], ["GRCh38", "GENE_OR_GENE_PRODUCT", 250, 256], ["Illumina HiSeq2500", "DNA", 32, 50], ["GRCh38", "DNA", 250, 256], ["FPKM", "DNA", 275, 279], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["Libraries", "TREATMENT", 0, 9], ["Read Mapping", "TEST", 141, 153], ["FilteringSequences", "TEST", 178, 196]]], ["We used the following non-specific filtering strategy to remove genes with low expression values indistinguishable from background signal.", [["non-specific filtering strategy", "TREATMENT", 22, 53], ["low expression values", "PROBLEM", 75, 96], ["low expression", "OBSERVATION_MODIFIER", 75, 89]]], ["First, we compute , the 95% sample quantile of the expression level of the th gene, for all genes.", [["th gene", "DNA", 75, 82]]], ["After this filtering step, a total of 13,819 genes were selected for further analyses.", [["13,819 genes", "DNA", 38, 50], ["further analyses", "TEST", 69, 85]]], ["After removing fifteen samples with total number of mapped reads less than 5 million and ten samples with low average correlation with other samples, 175 samples were selected for further analyses.Read Mapping, Data Normalization and FilteringObjective metrics for data from these samples suggested a high degree of quality (Supplemental Figure 1) , similar to what we have previously published 35 .Read Mapping, Data Normalization and FilteringDue to the fact that our study spanned three years, all samples were processed as six library batches.", [["samples", "ANATOMY", 23, 30], ["samples", "ANATOMY", 93, 100], ["samples", "ANATOMY", 154, 161], ["samples", "ANATOMY", 501, 508], ["samples", "CANCER", 154, 161], ["other samples", "TEST", 135, 148], ["further analyses", "TEST", 180, 196], ["Read Mapping", "TEST", 197, 209], ["FilteringObjective metrics", "TEST", 234, 260], ["these samples", "TEST", 275, 288], ["Read Mapping", "TEST", 399, 411], ["our study", "TEST", 466, 475], ["high degree", "OBSERVATION_MODIFIER", 301, 312], ["library batches", "OBSERVATION", 531, 546]]], ["We noticed that there are significant batch effects in the total number of mapped reads of these 175 samples.", [["samples", "ANATOMY", 101, 108], ["significant batch effects", "PROBLEM", 26, 51], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["batch effects", "OBSERVATION", 38, 51]]], ["In addition, using an analysis of variance (ANOVA) We also removed 131 genes for which their expression was winsorized in more than half of the samples (n>53).", [["samples", "ANATOMY", 144, 151], ["an analysis", "TEST", 19, 30], ["131 genes", "OBSERVATION_MODIFIER", 67, 76]]], ["In summary, a total of 13,688 gene expression profiles passed the quality control procedure and were selected for further investigations.Gene Significance AnalysesBoth univariate and multivariate gene significance analyses were conducted by using the R package LIMMA 37 with a robust M-estimator 38Detection of Pathogenic Virus and Bacteria (TLDA)Initial diagnosis of RSV infection was confirmed by RT-PCR as described 11 .", [["RSV infection", "DISEASE", 368, 381], ["RSV", "ORGANISM", 368, 371], ["RSV", "SPECIES", 368, 371], ["the quality control procedure", "TREATMENT", 62, 91], ["further investigations", "TEST", 114, 136], ["multivariate gene significance analyses", "TEST", 183, 222], ["Pathogenic Virus", "PROBLEM", 311, 327], ["Bacteria", "PROBLEM", 332, 340], ["RSV infection", "PROBLEM", 368, 381], ["RT-PCR", "TEST", 399, 405], ["RSV infection", "OBSERVATION", 368, 381]]], ["TaqMan\u00aeDetection of Pathogenic Virus and Bacteria (TLDA)Array Card (TAC) technology was used to detect other common respiratory pathogens in the initial nasal swab as well as Hemophilus influenzae and Streptococcus pneumoniae, as previously described [40] [41] [42] 35, 40 .", [["nasal swab", "ANATOMY", 153, 163], ["Hemophilus influenzae", "DISEASE", 175, 196], ["nasal swab", "ORGAN", 153, 163], ["Hemophilus influenzae", "ORGANISM", 175, 196], ["Streptococcus pneumoniae", "ORGANISM", 201, 225], ["Hemophilus influenzae", "SPECIES", 175, 196], ["Streptococcus pneumoniae", "SPECIES", 201, 225], ["Hemophilus influenzae", "SPECIES", 175, 196], ["Streptococcus pneumoniae", "SPECIES", 201, 225], ["Pathogenic Virus", "PROBLEM", 20, 36], ["Bacteria", "PROBLEM", 41, 49], ["Card (TAC) technology", "TREATMENT", 62, 83], ["other common respiratory pathogens", "PROBLEM", 103, 137], ["the initial nasal swab", "TEST", 141, 163], ["Hemophilus influenzae", "PROBLEM", 175, 196], ["Streptococcus pneumoniae", "PROBLEM", 201, 225], ["Pathogenic Virus", "OBSERVATION", 20, 36], ["nasal", "ANATOMY", 153, 158], ["Streptococcus pneumoniae", "OBSERVATION", 201, 225]]], ["Detection of the human RNase P (RNP3) gene was a positive control to confirm the presence of cellular material.Microbiome AnalysisAirway microbiota analysis from infants was performed essentially as previously described 35Transcriptome and Microbiome Integration Analyses:We limited analyses to those 83 subjects for which both transcriptome and microbiome samples were available, and who were not on antibiotics.", [["cellular", "ANATOMY", 93, 101], ["samples", "ANATOMY", 357, 364], ["human", "ORGANISM", 17, 22], ["RNase P", "GENE_OR_GENE_PRODUCT", 23, 30], ["RNP3", "GENE_OR_GENE_PRODUCT", 32, 36], ["cellular material", "CELLULAR_COMPONENT", 93, 110], ["infants", "ORGANISM", 162, 169], ["human RNase P (RNP3) gene", "DNA", 17, 42], ["human", "SPECIES", 17, 22], ["infants", "SPECIES", 162, 169], ["human", "SPECIES", 17, 22], ["the human RNase P (RNP3) gene", "TREATMENT", 13, 42], ["a positive control", "TREATMENT", 47, 65], ["cellular material", "PROBLEM", 93, 110], ["Microbiome AnalysisAirway microbiota analysis", "TEST", 111, 156], ["antibiotics", "TREATMENT", 401, 412], ["cellular material", "OBSERVATION", 93, 110]]], ["Data were available for a total of 471 operational taxonomic units (OTUsNasal Fluid Cytokine Determination Multiplex AssayNasal wash samples were tested for cytokines and chemokines using R&D SystemsFunctional ClassificationGenes identified as differentially expressed were subsequently used for canonical pathway identification and upstream regulator analysis using Ingenuity Pathway Analysis (IPA; http://analysis.ingenuity.com/pa/); ontology and phenotype functional enrichment analysis using ToppGene Suite (https://toppgene.cchmc.org/); cell-type enrichment identification using CTen (http://www.influenza-Functional Classificationx.org/~jshoemaker/cten/advanced_example.php).Gene Expression ValidationQuantitative real-time polymerase chain reaction (qPCR) was performed using aliquots of RNA samples obtained for sequencing. cDNA was generated from approximately 250 ng RNA using the iScript cDNA Synthesis Kit (BioRad, Hercules, CA) according to manufacturer's recommendations.", [["cell", "ANATOMY", 542, 546], ["samples", "ANATOMY", 799, 806], ["cell", "CELL", 542, 546], ["cytokines", "PROTEIN", 157, 166], ["chemokines", "PROTEIN", 171, 181], ["CTen", "DNA", 584, 588], ["cDNA", "DNA", 832, 836], ["OTUsNasal Fluid Cytokine Determination", "TREATMENT", 68, 106], ["AssayNasal wash samples", "TEST", 117, 140], ["cytokines", "TREATMENT", 157, 166], ["chemokines", "TREATMENT", 171, 181], ["canonical pathway identification", "TEST", 296, 328], ["upstream regulator analysis", "TEST", 333, 360], ["RNA samples", "TEST", 795, 806], ["sequencing", "TEST", 820, 830], ["cDNA", "TEST", 832, 836], ["the iScript cDNA Synthesis Kit", "TREATMENT", 887, 917]]], ["PCR was performed using gene-specific primer sets Gene expression levels were calculated relative to PPIA (cyclophilin A) using the ddCT method.Development of in vitro RSV infection model using respiratory epithelial cellsPediatric/Infant Human Lung Epithelial (PHLE) cells were generated from transplant donor quality lung from the LungMAP program as we recently described 45Subject DemographicsWe sought to understand target organ resident cell responses during primary RSV infection in the first year of life in infants displaying the full spectrum of illness severity.Subject DemographicsWe implemented our recently described nasal cell sampling procedure 35, 47 to measure infant airway transcriptional responses.", [["respiratory epithelial cells", "ANATOMY", 194, 222], ["Lung Epithelial (PHLE) cells", "ANATOMY", 245, 273], ["lung", "ANATOMY", 319, 323], ["organ", "ANATOMY", 427, 432], ["cell", "ANATOMY", 442, 446], ["nasal cell", "ANATOMY", 630, 640], ["airway", "ANATOMY", 685, 691], ["RSV infection", "DISEASE", 168, 181], ["RSV infection", "DISEASE", 472, 485], ["illness", "DISEASE", 555, 562], ["PPIA", "GENE_OR_GENE_PRODUCT", 101, 105], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 107, 120], ["RSV", "ORGANISM", 168, 171], ["respiratory epithelial cells", "CELL", 194, 222], ["Human", "ORGANISM", 239, 244], ["Lung Epithelial (PHLE) cells", "CELL", 245, 273], ["lung", "ORGAN", 319, 323], ["organ resident cell", "CELL", 427, 446], ["RSV", "ORGANISM", 472, 475], ["infants", "ORGANISM", 515, 522], ["nasal cell", "CELL", 630, 640], ["airway", "MULTI-TISSUE_STRUCTURE", 685, 691], ["PPIA", "PROTEIN", 101, 105], ["cyclophilin A", "PROTEIN", 107, 120], ["respiratory epithelial cells", "CELL_TYPE", 194, 222], ["Infant Human Lung Epithelial (PHLE) cells", "CELL_LINE", 232, 273], ["Human", "SPECIES", 239, 244], ["infants", "SPECIES", 515, 522], ["RSV", "SPECIES", 168, 171], ["RSV", "SPECIES", 472, 475], ["PCR", "TEST", 0, 3], ["Gene expression levels", "TEST", 50, 72], ["PPIA (cyclophilin A", "TREATMENT", 101, 120], ["the ddCT method", "TREATMENT", 128, 143], ["vitro RSV infection", "PROBLEM", 162, 181], ["respiratory epithelial cells", "PROBLEM", 194, 222], ["Pediatric/Infant Human Lung Epithelial (PHLE) cells", "TEST", 222, 273], ["primary RSV infection", "PROBLEM", 464, 485], ["illness severity", "PROBLEM", 555, 571], ["nasal cell sampling procedure", "TREATMENT", 630, 659], ["RSV infection", "OBSERVATION", 168, 181], ["respiratory epithelial cells", "OBSERVATION", 194, 222], ["Lung", "ANATOMY", 245, 249], ["Epithelial", "ANATOMY_MODIFIER", 250, 260], ["lung", "ANATOMY", 319, 323], ["RSV infection", "OBSERVATION", 472, 485], ["nasal cell", "ANATOMY", 630, 640], ["airway", "ANATOMY", 685, 691]]], ["Of the 139 RSV infected infants enrolled in the AsPIRES study, 106 had satisfactory nasal samples and gene expression results for analysis.", [["nasal samples", "ANATOMY", 84, 97], ["RSV infected", "DISEASE", 11, 23], ["RSV", "ORGANISM", 11, 14], ["infants", "ORGANISM", 24, 31], ["nasal samples", "CANCER", 84, 97], ["infants", "SPECIES", 24, 31], ["RSV", "SPECIES", 11, 14], ["the AsPIRES study", "TEST", 44, 61], ["analysis", "TEST", 130, 138]]], ["Demographic data of these 106 infants are described in Table 1 .", [["infants", "ORGANISM", 30, 37], ["infants", "SPECIES", 30, 37]]], ["Infants ranged from 0.5 to 9.4 months of age (mean age 3.3 months) and were equally distributed by gender.", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7]]], ["Sixty-three (59%) were hospitalized during the infection while the other 43 were managed as outpatients.Subject DemographicsSubjects were assigned a continuous Global Respiratory Severity Score (GRSS) as previously described 33 .", [["infection", "DISEASE", 47, 56], ["the infection", "PROBLEM", 43, 56], ["a continuous Global Respiratory Severity Score", "PROBLEM", 147, 193], ["infection", "OBSERVATION", 47, 56]]], ["There was no association between severity (defined as being hospitalized or by GRSS) and RSV strain, family-reported environmental tobacco smoke exposure, or the presence of other viral pathogens or bacterial colonization based on a positive RT-PCR (Table 1) .Airway Transcriptional Correlates of Disease SeverityTranscriptome analysis of airway samples collected from subjects during the acute phase of their RSV infection included the assessment of 13,688 genes following standard QC-based sample and gene filtering 28, 35 .", [["Airway", "ANATOMY", 260, 266], ["airway samples", "ANATOMY", 339, 353], ["sample", "ANATOMY", 492, 498], ["smoke", "CHEMICAL", 139, 144], ["RSV infection", "DISEASE", 410, 423], ["RSV", "ORGANISM", 89, 92], ["tobacco", "ORGANISM", 131, 138], ["Airway", "MULTI-TISSUE_STRUCTURE", 260, 266], ["airway samples", "CANCER", 339, 353], ["RSV", "ORGANISM", 410, 413], ["13,688 genes", "DNA", 451, 463], ["QC", "DNA", 483, 485], ["RSV", "SPECIES", 89, 92], ["tobacco", "SPECIES", 131, 138], ["RSV", "SPECIES", 410, 413], ["RSV strain", "PROBLEM", 89, 99], ["other viral pathogens", "PROBLEM", 174, 195], ["bacterial colonization", "PROBLEM", 199, 221], ["Disease Severity", "PROBLEM", 297, 313], ["airway samples", "TEST", 339, 353], ["their RSV infection", "PROBLEM", 404, 423], ["the assessment", "TEST", 433, 447], ["gene filtering", "TEST", 503, 517], ["no association between", "UNCERTAINTY", 10, 32], ["bacterial colonization", "OBSERVATION", 199, 221], ["airway", "ANATOMY", 339, 345], ["RSV infection", "OBSERVATION", 410, 423]]], ["As we previously described, gene expression data from this procedure is enriched in canonical (e.g., CDH1, EPCAM) andAirway Transcriptional Correlates of Disease Severityupper airway-specific (e.g., BPIFs, MUCs) marker genes, with lower levels of expression for leukocyte markers (Supplemental Figure 2) .", [["airway", "ANATOMY", 176, 182], ["leukocyte", "ANATOMY", 262, 271], ["CDH1", "GENE_OR_GENE_PRODUCT", 101, 105], ["EPCAM", "GENE_OR_GENE_PRODUCT", 107, 112], ["BPIFs", "GENE_OR_GENE_PRODUCT", 199, 204], ["MUCs", "GENE_OR_GENE_PRODUCT", 206, 210], ["leukocyte", "CELL", 262, 271], ["CDH1", "DNA", 101, 105], ["EPCAM", "DNA", 107, 112], ["Disease Severityupper airway-specific (e.g., BPIFs, MUCs) marker genes", "DNA", 154, 224], ["leukocyte markers", "PROTEIN", 262, 279], ["this procedure", "TREATMENT", 54, 68], ["Disease Severityupper airway", "PROBLEM", 154, 182], ["specific (e.g., BPIFs, MUCs) marker genes", "PROBLEM", 183, 224], ["leukocyte markers", "TEST", 262, 279], ["Airway", "ANATOMY", 117, 123], ["airway", "ANATOMY", 176, 182]]], ["Univariate analysis indicated that many variables were not associated with substantial differences in gene expression after appropriate adjustments for multiple testing ( Table 2) .", [["Univariate analysis", "TEST", 0, 19], ["multiple testing", "TEST", 152, 168]]], ["As previously reported 35 Gene expression displayed an interesting association with clinical severity.", [["clinical severity", "PROBLEM", 84, 101]]], ["No gene was marginally identified as significantly associated with severity (after adjustment for multiple testing adjustment), when severity was defined dichotomously as mild and severe.", [["multiple testing adjustment", "TREATMENT", 98, 125], ["mild and severe", "PROBLEM", 171, 186], ["mild", "OBSERVATION_MODIFIER", 171, 175], ["severe", "OBSERVATION_MODIFIER", 180, 186]]], ["When severity was defined continuously by GRSS, 142 genes were significantly associated with GRSS.", [["GRSS", "DNA", 42, 46]]], ["In order to better define gene expression changes independently associated with GRSS, we completed a multivariate analysis including sex, race, bacterial colonization and time since onset of clinical symptoms in the model.", [["gene expression changes", "PROBLEM", 26, 49], ["a multivariate analysis", "TEST", 99, 122], ["bacterial colonization", "PROBLEM", 144, 166], ["clinical symptoms in the model", "PROBLEM", 191, 221]]], ["This analysis identified 252 genes significantly associated with disease severity (Supplemental Figure 3) .", [["This analysis", "TEST", 0, 13], ["disease severity", "PROBLEM", 65, 81]]], ["In this multivariate model, 728 genes were associated with time since illness onset and 135 genes were associated with the presence of any bacterial pathogen (Table 2) .Airway Transcriptional Correlates of Disease SeverityGenes significantly associated with severity, in both the univariate (data not shown) and multivariate models were rich in chemokines, cytokines and interleukin-related molecules (Supplemental Figure 4) .", [["Airway", "ANATOMY", 169, 175], ["illness", "DISEASE", 70, 77], ["Airway", "MULTI-TISSUE_STRUCTURE", 169, 175], ["interleukin-related molecules", "GENE_OR_GENE_PRODUCT", 371, 400], ["chemokines", "PROTEIN", 345, 355], ["cytokines", "PROTEIN", 357, 366], ["interleukin-related molecules", "PROTEIN", 371, 400], ["illness onset", "PROBLEM", 70, 83], ["any bacterial pathogen", "PROBLEM", 135, 157], ["Disease SeverityGenes", "PROBLEM", 206, 227], ["severity", "PROBLEM", 258, 266], ["multivariate models", "PROBLEM", 312, 331], ["cytokines and interleukin-related molecules", "TREATMENT", 357, 400], ["Disease", "OBSERVATION", 206, 213]]], ["Ontological analysis of this gene set identified multiple biological functions related to viral infection (Fig. 1A) , confirming the validity of the approach and the data.", [["viral infection", "DISEASE", 90, 105], ["Ontological analysis", "TEST", 0, 20], ["multiple biological functions", "PROBLEM", 49, 78], ["viral infection", "PROBLEM", 90, 105], ["the data", "TEST", 162, 170], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["infection", "OBSERVATION", 96, 105]]], ["Interestingly, this analysis suggested that gene expression biomarkers of severity are associated with pneumonia (Fig. 1B) .", [["pneumonia", "DISEASE", 103, 112], ["this analysis", "TEST", 15, 28], ["gene expression biomarkers of severity", "PROBLEM", 44, 82], ["pneumonia", "PROBLEM", 103, 112], ["pneumonia", "OBSERVATION", 103, 112]]], ["This observation, consistent with the lower respiratory track pathogenesis of severe RSV infections, also supports the utility of upper airway transcriptome as a surrogate for identifying relevant disease mechanisms in the lung.", [["upper airway", "ANATOMY", 130, 142], ["lung", "ANATOMY", 223, 227], ["RSV infections", "DISEASE", 85, 99], ["RSV", "ORGANISM", 85, 88], ["upper airway", "MULTI-TISSUE_STRUCTURE", 130, 142], ["lung", "ORGAN", 223, 227], ["RSV", "SPECIES", 85, 88], ["This observation", "TEST", 0, 16], ["the lower respiratory track pathogenesis", "PROBLEM", 34, 74], ["severe RSV infections", "PROBLEM", 78, 99], ["upper airway transcriptome", "PROBLEM", 130, 156], ["relevant disease mechanisms in the lung", "PROBLEM", 188, 227], ["consistent with", "UNCERTAINTY", 18, 33], ["lower", "OBSERVATION_MODIFIER", 38, 43], ["respiratory track", "OBSERVATION", 44, 61], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["RSV infections", "OBSERVATION", 85, 99], ["upper", "ANATOMY_MODIFIER", 130, 135], ["airway", "ANATOMY", 136, 142], ["disease", "OBSERVATION", 197, 204], ["lung", "ANATOMY", 223, 227]]], ["We also assessed cell signatures in these severity associated gene expression biomarkers.", [["cell", "ANATOMY", 17, 21], ["cell", "CELL", 17, 21], ["cell signatures", "TEST", 17, 32]]], ["Unlike the epithelial predominant signature of the healthy asymptomatic infant 35 , severe clinical responses to RSV infection were associated with signatures of multiple blood and inflammatory cells, as well as smooth muscle (Fig. 1C) .", [["epithelial", "ANATOMY", 11, 21], ["blood", "ANATOMY", 171, 176], ["inflammatory cells", "ANATOMY", 181, 199], ["smooth muscle", "ANATOMY", 212, 225], ["RSV infection", "DISEASE", 113, 126], ["epithelial", "CELL", 11, 21], ["RSV", "ORGANISM", 113, 116], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["inflammatory cells", "CELL", 181, 199], ["smooth muscle", "TISSUE", 212, 225], ["inflammatory cells", "CELL_TYPE", 181, 199], ["infant", "SPECIES", 72, 78], ["RSV", "SPECIES", 113, 116], ["severe clinical responses", "PROBLEM", 84, 109], ["RSV infection", "PROBLEM", 113, 126], ["multiple blood and inflammatory cells", "PROBLEM", 162, 199], ["epithelial", "ANATOMY_MODIFIER", 11, 21], ["RSV infection", "OBSERVATION", 113, 126], ["inflammatory cells", "OBSERVATION", 181, 199], ["smooth muscle", "ANATOMY", 212, 225], ["Fig", "OBSERVATION_MODIFIER", 227, 230]]], ["The most predominant cell signatures were those related to CD14+Airway Transcriptional Correlates of Disease Severityand CD33+ myeloid lineages.", [["cell", "ANATOMY", 21, 25], ["myeloid", "ANATOMY", 127, 134], ["cell", "CELL", 21, 25], ["CD14", "GENE_OR_GENE_PRODUCT", 59, 63], ["CD33", "GENE_OR_GENE_PRODUCT", 121, 125], ["CD14", "PROTEIN", 59, 63], ["CD33", "PROTEIN", 121, 125], ["myeloid lineages", "CELL_TYPE", 127, 143], ["CD14", "TEST", 59, 63], ["Disease", "PROBLEM", 101, 108], ["myeloid lineages", "PROBLEM", 127, 143], ["most predominant", "OBSERVATION_MODIFIER", 4, 20], ["cell signatures", "OBSERVATION", 21, 36], ["Airway", "ANATOMY", 64, 70], ["myeloid lineages", "OBSERVATION", 127, 143]]], ["Pathway analysis confirmed increases in expression of myeloid cell-related genes in severe cases, and also strongly implicated IL17-related responses (Fig. 1D) .Airway Transcriptional Correlates of Disease SeverityWe validated severity-associated gene expression changes at the transcriptional level by qPCR of RNA samples from the same 106 subjects (Supplemental Table 1 ).", [["myeloid cell", "ANATOMY", 54, 66], ["Airway", "ANATOMY", 161, 167], ["samples", "ANATOMY", 315, 322], ["myeloid cell", "CELL", 54, 66], ["IL17", "GENE_OR_GENE_PRODUCT", 127, 131], ["Airway", "MULTI-TISSUE_STRUCTURE", 161, 167], ["myeloid cell-related genes", "DNA", 54, 80], ["IL17", "PROTEIN", 127, 131], ["Pathway analysis", "TEST", 0, 16], ["myeloid cell", "PROBLEM", 54, 66], ["related genes in severe cases", "PROBLEM", 67, 96], ["Disease", "PROBLEM", 198, 205], ["gene expression changes", "PROBLEM", 247, 270], ["RNA samples", "TEST", 311, 322], ["increases", "OBSERVATION_MODIFIER", 27, 36], ["myeloid cell", "OBSERVATION", 54, 66], ["severe", "OBSERVATION_MODIFIER", 84, 90]]], ["We also performed multi-plex ELISA analysis, using nasal washes obtained immediately prior to nasal brush sample collection, to confirm the biological impact of these transcriptional changes.", [["nasal", "ANATOMY", 51, 56], ["nasal brush sample", "ANATOMY", 94, 112], ["multi-plex ELISA analysis", "TEST", 18, 43], ["nasal washes", "TREATMENT", 51, 63], ["nasal brush sample collection", "TEST", 94, 123], ["transcriptional changes", "OBSERVATION", 167, 190]]], ["As shown in Figure 1E , we validated significant differences in the level of multiple inflammatory biomarkers associated with severity (eg, CXCL1, CXCL2, IL6), and non-significant differences in others (eg, IL16). influenzae (Supplemental Figure 5) , was the only OTU significantly associated with severity following adjustment for multiple testing in this cohort (Supplemental Table 2 ).Effects of Airway Microbiota on Severity BiomarkersAs can be seen in Figure 2A, Given the substantial impact of the presence of bacterial pathogens on airway gene expression in asymptomatic 35 and symptomatic subjects (Table 2) , and the singular association of H. influenzae with severity, we sought to identify severity-associated gene expression independent of the impact of H. influenzae.", [["airway", "ANATOMY", 539, 545], ["influenzae", "DISEASE", 214, 224], ["H. influenzae", "DISEASE", 650, 663], ["CXCL1", "GENE_OR_GENE_PRODUCT", 140, 145], ["CXCL2", "GENE_OR_GENE_PRODUCT", 147, 152], ["IL6", "GENE_OR_GENE_PRODUCT", 154, 157], ["IL16", "GENE_OR_GENE_PRODUCT", 207, 211], ["airway", "MULTI-TISSUE_STRUCTURE", 539, 545], ["H. influenzae", "ORGANISM", 650, 663], ["H. influenzae", "ORGANISM", 766, 779], ["CXCL1", "PROTEIN", 140, 145], ["CXCL2", "PROTEIN", 147, 152], ["IL6", "PROTEIN", 154, 157], ["IL16", "PROTEIN", 207, 211], ["influenzae", "SPECIES", 214, 224], ["H. influenzae", "SPECIES", 650, 663], ["H. influenzae", "SPECIES", 766, 779], ["influenzae", "SPECIES", 214, 224], ["H. influenzae", "SPECIES", 650, 663], ["H. influenzae", "SPECIES", 766, 779], ["multiple inflammatory biomarkers", "PROBLEM", 77, 109], ["CXCL1", "TEST", 140, 145], ["non-significant differences in others", "PROBLEM", 164, 201], ["influenzae", "PROBLEM", 214, 224], ["multiple testing", "TEST", 332, 348], ["this cohort (Supplemental Table", "TREATMENT", 352, 383], ["bacterial pathogens", "PROBLEM", 516, 535], ["H. influenzae", "PROBLEM", 650, 663], ["severity", "PROBLEM", 669, 677], ["H. influenzae", "PROBLEM", 766, 779], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["inflammatory", "OBSERVATION", 86, 98], ["non-significant", "OBSERVATION_MODIFIER", 164, 179], ["differences", "OBSERVATION_MODIFIER", 180, 191], ["Airway", "ANATOMY", 399, 405], ["bacterial", "OBSERVATION_MODIFIER", 516, 525], ["pathogens", "OBSERVATION", 526, 535], ["airway", "ANATOMY", 539, 545]]], ["We performed multivariate analysis, similar to as described above, but including the relative abundance of H. influenzae in the model.", [["H. influenzae", "ORGANISM", 107, 120], ["H. influenzae", "SPECIES", 107, 120], ["H. influenzae", "SPECIES", 107, 120], ["multivariate analysis", "TEST", 13, 34], ["H. influenzae", "PROBLEM", 107, 120], ["influenzae", "OBSERVATION", 110, 120]]], ["We identified 643 genes significantly associated with GRSS independent of the presence of H. influenzae and visit age.", [["H. influenzae", "ORGANISM", 90, 103], ["H. influenzae", "SPECIES", 90, 103], ["H. influenzae", "SPECIES", 90, 103], ["H. influenzae", "PROBLEM", 90, 103]]], ["Analysis of this gene set revealed many genes, pathways (Supplemental Figures 6-8 ) and cell types that were identified in our analysis not including H. influenzae.", [["cell", "ANATOMY", 88, 92], ["cell", "CELL", 88, 92], ["H. influenzae", "ORGANISM", 150, 163], ["H. influenzae", "SPECIES", 150, 163], ["H. influenzae", "SPECIES", 150, 163], ["this gene set", "TEST", 12, 25], ["Supplemental Figures", "TEST", 57, 77], ["cell types", "PROBLEM", 88, 98], ["our analysis", "TEST", 123, 135], ["H. influenzae", "PROBLEM", 150, 163]]], ["However, ontological analysis of this gene set identified a greater association with bacterial infection (Fig. 2B) .Effects of Airway Microbiota on Severity BiomarkersAdditionally, when including H. influenzae, we note that cell type signatures are attenuated for myeloid lineages and inflated for both CD4+ and CD8+ lymphocyte lineages (Fig. 2C) .", [["cell", "ANATOMY", 224, 228], ["myeloid lineages", "ANATOMY", 264, 280], ["CD4+", "ANATOMY", 303, 307], ["CD8+ lymphocyte", "ANATOMY", 312, 327], ["bacterial infection", "DISEASE", 85, 104], ["H. influenzae", "ORGANISM", 196, 209], ["cell", "CELL", 224, 228], ["myeloid lineages", "CELL", 264, 280], ["CD4", "GENE_OR_GENE_PRODUCT", 303, 306], ["CD8", "GENE_OR_GENE_PRODUCT", 312, 315], ["myeloid lineages", "CELL_TYPE", 264, 280], ["CD4", "PROTEIN", 303, 306], ["CD8+ lymphocyte lineages", "CELL_TYPE", 312, 336], ["H. influenzae", "SPECIES", 196, 209], ["H. influenzae", "SPECIES", 196, 209], ["ontological analysis", "TEST", 9, 29], ["bacterial infection", "PROBLEM", 85, 104], ["Severity Biomarkers", "TEST", 148, 167], ["H. influenzae", "PROBLEM", 196, 209], ["cell type signatures", "TEST", 224, 244], ["myeloid lineages", "PROBLEM", 264, 280], ["both CD4", "TEST", 298, 306], ["CD8", "TEST", 312, 315], ["greater", "OBSERVATION_MODIFIER", 60, 67], ["bacterial", "OBSERVATION_MODIFIER", 85, 94], ["infection", "OBSERVATION", 95, 104], ["Airway", "ANATOMY", 127, 133], ["myeloid lineages", "OBSERVATION", 264, 280], ["lymphocyte lineages", "OBSERVATION", 317, 336]]], ["These data suggest that H. influenzae influences the clinical severity of RSV infection in infants by modifying the immune system and nature of the inflammatory response.Effects of Timing on Severity BiomarkersAs indicated above, the samples were collected at a single time during the acute phase of infection following the onset of clinical symptoms, and this timing appeared to have a major impact on gene expression ( Table 2 and Supplemental Figures 9-12) .", [["immune system", "ANATOMY", 116, 129], ["samples", "ANATOMY", 234, 241], ["H. influenzae", "DISEASE", 24, 37], ["RSV infection", "DISEASE", 74, 87], ["infection", "DISEASE", 300, 309], ["H. influenzae", "ORGANISM", 24, 37], ["RSV", "ORGANISM", 74, 77], ["infants", "ORGANISM", 91, 98], ["H. influenzae", "SPECIES", 24, 37], ["infants", "SPECIES", 91, 98], ["H. influenzae", "SPECIES", 24, 37], ["RSV", "SPECIES", 74, 77], ["These data", "TEST", 0, 10], ["H. influenzae", "PROBLEM", 24, 37], ["RSV infection", "PROBLEM", 74, 87], ["the inflammatory response", "PROBLEM", 144, 169], ["Severity Biomarkers", "TEST", 191, 210], ["the samples", "TEST", 230, 241], ["infection", "PROBLEM", 300, 309], ["clinical symptoms", "PROBLEM", 333, 350], ["Supplemental Figures", "TEST", 433, 453], ["RSV", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 78, 87], ["inflammatory response", "OBSERVATION", 148, 169], ["infection", "OBSERVATION", 300, 309]]], ["We further interrogated gene expression biomarkers for this timing to better understand the nature of airway response to infection, and how they may relate to clinical disease severity.Effects of Timing on Severity BiomarkersInterestingly, pathway analysis ( Fig. 3A) indicated there was a strong signal of increasing EIF2 and mTOR signaling, and alterations in mitochondrial and oxidative phosphorylation activity, over time.", [["airway", "ANATOMY", 102, 108], ["mitochondrial", "ANATOMY", 362, 375], ["infection", "DISEASE", 121, 130], ["airway", "MULTI-TISSUE_STRUCTURE", 102, 108], ["EIF2", "GENE_OR_GENE_PRODUCT", 318, 322], ["mTOR", "GENE_OR_GENE_PRODUCT", 327, 331], ["mitochondrial", "CELLULAR_COMPONENT", 362, 375], ["EIF2", "PROTEIN", 318, 322], ["mTOR", "PROTEIN", 327, 331], ["infection", "PROBLEM", 121, 130], ["clinical disease severity", "PROBLEM", 159, 184], ["Severity Biomarkers", "TEST", 206, 225], ["pathway analysis", "TEST", 240, 256], ["increasing EIF2 and mTOR signaling", "PROBLEM", 307, 341], ["alterations in mitochondrial and oxidative phosphorylation activity", "PROBLEM", 347, 414], ["airway", "ANATOMY", 102, 108], ["infection", "OBSERVATION", 121, 130], ["increasing", "OBSERVATION_MODIFIER", 307, 317], ["EIF2", "OBSERVATION", 318, 322], ["mTOR signaling", "OBSERVATION", 327, 341], ["oxidative phosphorylation activity", "OBSERVATION", 380, 414]]], ["Less surprisingly, there was also an indication of diminishing innate interferon signaling over time.", [["interferon", "GENE_OR_GENE_PRODUCT", 70, 80], ["interferon", "PROTEIN", 70, 80], ["diminishing innate interferon signaling", "PROBLEM", 51, 90], ["indication of", "UNCERTAINTY", 37, 50], ["diminishing", "OBSERVATION_MODIFIER", 51, 62], ["innate interferon", "OBSERVATION", 63, 80]]], ["The genes contributing to this signature included multiple intracellular IFN signaling molecules (MX1, IFIT1, STAT2), but not the ligands or receptors themselves.", [["intracellular", "ANATOMY", 59, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 72], ["MX1", "GENE_OR_GENE_PRODUCT", 98, 101], ["IFIT1", "GENE_OR_GENE_PRODUCT", 103, 108], ["STAT2", "GENE_OR_GENE_PRODUCT", 110, 115], ["intracellular IFN signaling molecules", "PROTEIN", 59, 96], ["MX1", "PROTEIN", 98, 101], ["IFIT1", "PROTEIN", 103, 108], ["STAT2", "PROTEIN", 110, 115], ["this signature", "PROBLEM", 26, 40], ["multiple intracellular IFN signaling molecules", "PROBLEM", 50, 96]]], ["We performed exploratory analysis of these IFN pathway-related genes to better understand their expression patterns in our subjects.Effects of Timing on Severity BiomarkersThis revealed a surprising dichotomy between severe and non-severe subjects in expression of the IFN pathway genes identified in our analysis (Fig. 3B ).", [["IFN", "GENE_OR_GENE_PRODUCT", 43, 46], ["IFN", "GENE_OR_GENE_PRODUCT", 269, 272], ["IFN", "PROTEIN", 43, 46], ["IFN pathway genes", "DNA", 269, 286], ["exploratory analysis", "TEST", 13, 33], ["these IFN pathway", "TREATMENT", 37, 54], ["Severity Biomarkers", "TEST", 153, 172], ["a surprising dichotomy between severe and non-severe subjects", "PROBLEM", 186, 247], ["the IFN pathway genes", "PROBLEM", 265, 286], ["our analysis", "TEST", 301, 313], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["non-severe", "OBSERVATION_MODIFIER", 228, 238]]], ["An association with severity was likely not identified in our prior analysis, as significant increases in expression noted in non-severe subjects were only noted during the first 3-4 days following the onset of clinical symptoms, whereas little to no evidence for interferon signaling was noted in any subjects at later time points. qPCR validation of many of these genes supported a complex relationship between gene expression, clinical severity and the ontogeny of illness (Supplemental Table 3 ).Effects of Timing on Severity BiomarkersAn analysis of potential regulators for this gene expression response implicated both type 3 (IFNL1; p<10 \u221235 ) and type 1 (IFNA2; p<10 \u221230 ) ligands, as well as the canonical interferon-associated transcription factors IRF-3, -7 and -5 (p<10 \u221215 ).", [["illness", "DISEASE", 468, 475], ["interferon", "GENE_OR_GENE_PRODUCT", 264, 274], ["type 3", "GENE_OR_GENE_PRODUCT", 626, 632], ["IFNL1", "GENE_OR_GENE_PRODUCT", 634, 639], ["type 1", "GENE_OR_GENE_PRODUCT", 656, 662], ["IFNA2", "GENE_OR_GENE_PRODUCT", 664, 669], ["IRF-3", "GENE_OR_GENE_PRODUCT", 760, 765], ["-7", "GENE_OR_GENE_PRODUCT", 767, 769], ["-5", "GENE_OR_GENE_PRODUCT", 774, 776], ["p<10 \u221215", "GENE_OR_GENE_PRODUCT", 778, 786], ["interferon", "PROTEIN", 264, 274], ["canonical interferon-associated transcription factors", "PROTEIN", 706, 759], ["IRF-3, -7 and -5", "PROTEIN", 760, 776], ["p<10 \u221215", "PROTEIN", 778, 786], ["severity", "PROBLEM", 20, 28], ["our prior analysis", "TEST", 58, 76], ["non-severe subjects", "PROBLEM", 126, 145], ["clinical symptoms", "PROBLEM", 211, 228], ["interferon signaling", "PROBLEM", 264, 284], ["qPCR validation", "TEST", 333, 348], ["this gene expression response", "PROBLEM", 580, 609], ["IFNA2", "TEST", 664, 669], ["ligands", "TEST", 682, 689], ["the canonical interferon", "TREATMENT", 702, 726], ["IRF", "TEST", 760, 763], ["likely not", "UNCERTAINTY", 33, 43], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["increases", "OBSERVATION_MODIFIER", 93, 102], ["no evidence for", "UNCERTAINTY", 248, 263], ["interferon", "OBSERVATION", 264, 274], ["interferon", "OBSERVATION", 716, 726]]], ["Due to the low level of expression for many IFN ligand and receptor genes in most subjects, we removed them from our analytical data set, as part of our procedures to avoid false discovery and increase statistical power.", [["IFN ligand", "GENE_OR_GENE_PRODUCT", 44, 54], ["IFN ligand", "PROTEIN", 44, 54], ["many IFN ligand", "TREATMENT", 39, 54], ["our analytical data", "TEST", 113, 132], ["our procedures", "TREATMENT", 149, 163], ["false discovery", "PROBLEM", 173, 188]]], ["We performed a post-hoc analysis of IFN ligand expression and found evidence for high levels of expression for both type 1 and 3 ligands (particularly IFNB1, IFNL1, IFNL2, IFNL3) in non-severe subjects, but not severe subjects (Fig. 3C) .", [["IFN ligand", "GENE_OR_GENE_PRODUCT", 36, 46], ["type 1", "GENE_OR_GENE_PRODUCT", 116, 122], ["3", "GENE_OR_GENE_PRODUCT", 127, 128], ["IFNB1", "GENE_OR_GENE_PRODUCT", 151, 156], ["IFNL1", "GENE_OR_GENE_PRODUCT", 158, 163], ["IFNL2", "GENE_OR_GENE_PRODUCT", 165, 170], ["IFNL3", "GENE_OR_GENE_PRODUCT", 172, 177], ["IFN ligand", "PROTEIN", 36, 46], ["IFNB1", "PROTEIN", 151, 156], ["IFNL1", "PROTEIN", 158, 163], ["IFNL2", "PROTEIN", 165, 170], ["IFNL3", "PROTEIN", 172, 177], ["a post-hoc analysis", "TEST", 13, 32], ["IFN ligand expression", "TEST", 36, 57], ["high levels of expression", "PROBLEM", 81, 106], ["both type 1 and 3 ligands", "PROBLEM", 111, 136], ["IFNB1", "TEST", 151, 156], ["non-severe subjects", "PROBLEM", 182, 201]]], ["We used multiplex ELISA of nasal washings to measure airway IFN ligand production during the first few days following onset of clinical symptoms.", [["nasal", "ANATOMY", 27, 32], ["airway", "ANATOMY", 53, 59], ["airway", "MULTI-TISSUE_STRUCTURE", 53, 59], ["IFN", "PROTEIN", 60, 63], ["nasal washings", "TREATMENT", 27, 41], ["airway IFN ligand production", "TREATMENT", 53, 81], ["clinical symptoms", "PROBLEM", 127, 144], ["airway", "ANATOMY", 53, 59]]], ["We confirmed higher levels of IFNB and IFNL in non-severe subjects (Fig. 3D) .", [["IFNB", "GENE_OR_GENE_PRODUCT", 30, 34], ["IFNL", "GENE_OR_GENE_PRODUCT", 39, 43], ["IFNB", "PROTEIN", 30, 34], ["IFNL", "PROTEIN", 39, 43], ["higher levels of IFNB", "PROBLEM", 13, 34], ["IFNL in non-severe subjects", "PROBLEM", 39, 66], ["higher levels", "OBSERVATION_MODIFIER", 13, 26]]], ["These data suggest that interferon signaling responses and/or interferon production, within the first few days of infection, contributes to establishing clinical severity in RSV infected infants.Interferon Signaling Controls RSV Infection In VitroWhile interferon production is known to be a ubiquitous host response to suppress viral infection, its role in mediating the severity of RSV illness in infants is unclear, as the virus actively suppresses this host protection mechanism via the RSV NS1 and NS2 gene products 49 .", [["infection", "DISEASE", 114, 123], ["RSV infected", "DISEASE", 174, 186], ["viral infection", "DISEASE", 329, 344], ["RSV illness", "DISEASE", 384, 395], ["interferon", "GENE_OR_GENE_PRODUCT", 24, 34], ["interferon", "GENE_OR_GENE_PRODUCT", 62, 72], ["RSV", "ORGANISM", 174, 177], ["infants", "ORGANISM", 187, 194], ["Interferon", "GENE_OR_GENE_PRODUCT", 195, 205], ["RSV", "ORGANISM", 225, 228], ["VitroWhile interferon", "GENE_OR_GENE_PRODUCT", 242, 263], ["RSV", "ORGANISM", 384, 387], ["infants", "ORGANISM", 399, 406], ["RSV", "ORGANISM", 491, 494], ["NS1", "GENE_OR_GENE_PRODUCT", 495, 498], ["interferon", "PROTEIN", 24, 34], ["interferon", "PROTEIN", 62, 72], ["interferon", "PROTEIN", 253, 263], ["RSV NS1 and NS2 gene products 49", "PROTEIN", 491, 523], ["infants", "SPECIES", 187, 194], ["infants", "SPECIES", 399, 406], ["RSV", "SPECIES", 174, 177], ["RSV", "SPECIES", 225, 228], ["RSV", "SPECIES", 384, 387], ["RSV", "SPECIES", 491, 494], ["These data", "TEST", 0, 10], ["interferon signaling responses", "PROBLEM", 24, 54], ["interferon production", "PROBLEM", 62, 83], ["infection", "PROBLEM", 114, 123], ["clinical severity in RSV infected infants", "PROBLEM", 153, 194], ["Interferon", "TREATMENT", 195, 205], ["RSV Infection", "PROBLEM", 225, 238], ["VitroWhile interferon production", "TREATMENT", 242, 274], ["viral infection", "PROBLEM", 329, 344], ["RSV illness", "PROBLEM", 384, 395], ["the virus", "PROBLEM", 422, 431], ["the RSV NS1", "TREATMENT", 487, 498], ["NS2 gene products", "TREATMENT", 503, 520], ["interferon", "OBSERVATION", 24, 34], ["infection", "OBSERVATION", 114, 123], ["RSV infected", "OBSERVATION", 174, 186], ["RSV Infection", "OBSERVATION", 225, 238], ["RSV", "OBSERVATION", 384, 387]]], ["Further, since our data are from the upper respiratory system, they may not accurately reflect the importance of this pathway in the lower airway as a disease mechanism contributing to clinical severity.", [["lower airway", "ANATOMY", 133, 145], ["upper respiratory", "ORGANISM_SUBDIVISION", 37, 54], ["system", "ANATOMICAL_SYSTEM", 55, 61], ["lower airway", "ORGANISM_SUBDIVISION", 133, 145], ["our data", "TEST", 15, 23], ["a disease mechanism", "PROBLEM", 149, 168], ["clinical severity", "PROBLEM", 185, 202], ["upper", "ANATOMY_MODIFIER", 37, 42], ["respiratory system", "ANATOMY", 43, 61], ["may not accurately reflect", "UNCERTAINTY", 68, 94], ["lower", "ANATOMY_MODIFIER", 133, 138], ["airway", "ANATOMY", 139, 145], ["disease", "OBSERVATION", 151, 158]]], ["We tested for the induction of expression of our severity associated biomarkers in PHLEs.", [["PHLEs", "CANCER", 83, 88], ["our severity associated biomarkers in PHLEs", "PROBLEM", 45, 88]]], ["Not surprisingly, as we are only modeling a portion of the in vivo responses to infection, we found that some but not all genes were regulated.Interferon Signaling Controls RSV Infection In VitroWe were able to demonstrate RSV infection-related increases in the expression of CCL7, IL6 and MMP19 at the RNA level.Interferon Signaling Controls RSV Infection In VitroWe tested the effects of gain-and loss-of-function manipulation of IFN activity during RSV infection of PHLE cells ( Fig 4B) .", [["PHLE cells", "ANATOMY", 469, 479], ["infection", "DISEASE", 80, 89], ["infection", "DISEASE", 227, 236], ["RSV infection", "DISEASE", 452, 465], ["Interferon", "GENE_OR_GENE_PRODUCT", 143, 153], ["RSV", "ORGANISM", 173, 176], ["RSV", "ORGANISM", 223, 226], ["CCL7", "GENE_OR_GENE_PRODUCT", 276, 280], ["IL6", "GENE_OR_GENE_PRODUCT", 282, 285], ["MMP19", "GENE_OR_GENE_PRODUCT", 290, 295], ["Interferon", "GENE_OR_GENE_PRODUCT", 313, 323], ["RSV", "ORGANISM", 343, 346], ["IFN", "GENE_OR_GENE_PRODUCT", 432, 435], ["RSV", "ORGANISM", 452, 455], ["PHLE cells", "CELL", 469, 479], ["Fig 4B", "CELL", 482, 488], ["CCL7", "PROTEIN", 276, 280], ["IL6", "PROTEIN", 282, 285], ["MMP19", "PROTEIN", 290, 295], ["IFN", "PROTEIN", 432, 435], ["PHLE cells", "CELL_LINE", 469, 479], ["RSV", "SPECIES", 173, 176], ["RSV", "SPECIES", 223, 226], ["RSV", "SPECIES", 343, 346], ["RSV", "SPECIES", 452, 455], ["infection", "PROBLEM", 80, 89], ["Interferon", "TREATMENT", 143, 153], ["RSV Infection", "PROBLEM", 173, 186], ["RSV infection", "PROBLEM", 223, 236], ["CCL7", "TEST", 276, 280], ["IL6", "TEST", 282, 285], ["MMP19", "TEST", 290, 295], ["Interferon", "TREATMENT", 313, 323], ["RSV Infection", "PROBLEM", 343, 356], ["IFN activity", "PROBLEM", 432, 444], ["RSV infection of PHLE cells", "PROBLEM", 452, 479], ["infection", "OBSERVATION", 80, 89], ["RSV Infection", "OBSERVATION", 173, 186], ["RSV", "OBSERVATION_MODIFIER", 223, 226], ["infection", "OBSERVATION", 227, 236], ["increases", "OBSERVATION_MODIFIER", 245, 254], ["RSV Infection", "OBSERVATION", 343, 356]]], ["As expected, pretreatment of PHLE cells with type I (Figure 4B , C) and type III (Supplemental Figure 13 Figure 14) .", [["PHLE cells", "ANATOMY", 29, 39], ["PHLE cells", "CELL", 29, 39], ["PHLE cells", "CELL_LINE", 29, 39], ["PHLE cells", "PROBLEM", 29, 39], ["type I (Figure 4B", "PROBLEM", 45, 62]]], ["Critically, but not surprisingly, RUX potentiated viral infection but did not block IFN ligand production (Fig. 4C) .", [["RUX", "CHEMICAL", 34, 37], ["viral infection", "DISEASE", 50, 65], ["RUX", "CHEMICAL", 34, 37], ["RUX", "SIMPLE_CHEMICAL", 34, 37], ["IFN ligand", "GENE_OR_GENE_PRODUCT", 84, 94], ["IFN", "PROTEIN", 84, 87], ["viral infection", "PROBLEM", 50, 65], ["block IFN ligand production", "PROBLEM", 78, 105], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infection", "OBSERVATION", 56, 65]]], ["These data indicate IFN signaling is necessary and sufficient to suppress the expression of correlates of RSVinfected infant clinical severity in primary cultures of pediatric lung epithelial cells.DiscussionOur studies address a critical knowledge gap in our understanding of the mechanisms involved in infant respiratory disease, in that we rarely have had the opportunity to comprehensively interrogate resident cell responses in the target organ.", [["primary cultures", "ANATOMY", 146, 162], ["lung epithelial cells", "ANATOMY", 176, 197], ["respiratory", "ANATOMY", 311, 322], ["cell", "ANATOMY", 415, 419], ["organ", "ANATOMY", 444, 449], ["respiratory disease", "DISEASE", 311, 330], ["IFN", "GENE_OR_GENE_PRODUCT", 20, 23], ["lung epithelial cells", "CELL", 176, 197], ["cell", "CELL", 415, 419], ["organ", "ORGAN", 444, 449], ["IFN", "PROTEIN", 20, 23], ["pediatric lung epithelial cells", "CELL_TYPE", 166, 197], ["infant", "SPECIES", 304, 310], ["These data", "TEST", 0, 10], ["IFN signaling", "PROBLEM", 20, 33], ["RSVinfected infant clinical severity", "PROBLEM", 106, 142], ["primary cultures", "TEST", 146, 162], ["pediatric lung epithelial cells", "PROBLEM", 166, 197], ["DiscussionOur studies", "TEST", 198, 219], ["infant respiratory disease", "PROBLEM", 304, 330], ["lung", "ANATOMY", 176, 180], ["epithelial cells", "OBSERVATION", 181, 197], ["respiratory disease", "OBSERVATION", 311, 330]]], ["We applied our recently developed methods that facilitate comprehensive molecular analysis of the airways, amenable to any infant subject, whether clinically well 35 or during illness 47 .", [["airways", "ANATOMY", 98, 105], ["illness", "DISEASE", 176, 183], ["airways", "MULTI-TISSUE_STRUCTURE", 98, 105], ["methods", "TREATMENT", 34, 41], ["comprehensive molecular analysis", "TEST", 58, 90], ["airways", "ANATOMY", 98, 105]]], ["As applied here to infant subjects during the acute phase of RSV illness, our data supports the utility of this biospecimen as a reasonable surrogate for pathophysiological responses occurring in the lower airway (Fig. 1 ).", [["biospecimen", "ANATOMY", 112, 123], ["lower airway", "ANATOMY", 200, 212], ["RSV illness", "DISEASE", 61, 72], ["RSV", "ORGANISM", 61, 64], ["lower airway", "ORGANISM_SUBDIVISION", 200, 212], ["infant", "SPECIES", 19, 25], ["RSV", "SPECIES", 61, 64], ["RSV illness", "PROBLEM", 61, 72], ["this biospecimen", "TEST", 107, 123], ["pathophysiological responses", "PROBLEM", 154, 182], ["RSV", "OBSERVATION", 61, 64], ["lower", "ANATOMY_MODIFIER", 200, 205], ["airway", "ANATOMY", 206, 212]]], ["In addition, they provide novel insight into disease-related responses related to the severity of clinical symptoms (Fig. 1) , the presence of co-occurring microbes (Fig. 2 ) and the timeline of clinical symptoms (Fig. 3) .DiscussionWe also leveraged a novel, physiological When identifying gene expression correlates of severity in this population, we were not surprised to identify many chemokines that are reflective of a more robust inflammatory response (Fig. 1) .", [["chemokines", "PROTEIN", 389, 399], ["clinical symptoms", "PROBLEM", 98, 115], ["clinical symptoms", "PROBLEM", 195, 212], ["severity", "PROBLEM", 321, 329], ["a more robust inflammatory response", "PROBLEM", 423, 458], ["robust", "OBSERVATION_MODIFIER", 430, 436], ["inflammatory", "OBSERVATION", 437, 449]]], ["Somewhat more insightful is the ontological analysis that implicates robust changes in IL17 signaling in severe patients, when compared to those with milder forms of illness, specifically in the airway.", [["airway", "ANATOMY", 195, 201], ["illness", "DISEASE", 166, 173], ["IL17", "GENE_OR_GENE_PRODUCT", 87, 91], ["patients", "ORGANISM", 112, 120], ["airway", "MULTI-TISSUE_STRUCTURE", 195, 201], ["IL17", "PROTEIN", 87, 91], ["patients", "SPECIES", 112, 120], ["the ontological analysis", "TEST", 28, 52], ["robust changes in IL17 signaling", "PROBLEM", 69, 101], ["illness", "PROBLEM", 166, 173], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["illness", "OBSERVATION", 166, 173], ["airway", "ANATOMY", 195, 201]]], ["Likewise, the data implicate airway changes in IL-1, -8, and 10 signaling, and alterations in matrix metalloproteinase activity.", [["airway", "ANATOMY", 29, 35], ["airway", "MULTI-TISSUE_STRUCTURE", 29, 35], ["IL-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["-8", "GENE_OR_GENE_PRODUCT", 53, 55], ["10", "GENE_OR_GENE_PRODUCT", 61, 63], ["matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 94, 118], ["matrix metalloproteinase", "PROTEIN", 94, 118], ["the data", "TEST", 10, 18], ["airway changes in IL", "PROBLEM", 29, 49], ["alterations in matrix metalloproteinase activity", "PROBLEM", 79, 127], ["airway", "ANATOMY", 29, 35]]], ["Of additional novel insight, our data suggests the nature of the inflammatory response in the airway differs in infants with severe RSV-associated illness.", [["airway", "ANATOMY", 94, 100], ["RSV-associated illness", "DISEASE", 132, 154], ["airway", "MULTI-TISSUE_STRUCTURE", 94, 100], ["infants", "ORGANISM", 112, 119], ["RSV", "ORGANISM", 132, 135], ["infants", "SPECIES", 112, 119], ["RSV", "SPECIES", 132, 135], ["our data", "TEST", 29, 37], ["the inflammatory response", "PROBLEM", 61, 86], ["severe RSV", "PROBLEM", 125, 135], ["associated illness", "PROBLEM", 136, 154], ["inflammatory", "OBSERVATION", 65, 77], ["airway", "ANATOMY", 94, 100], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["RSV", "OBSERVATION", 132, 135], ["illness", "OBSERVATION", 147, 154]]], ["In particular, our data indicates an enrichment in CD14+ and CD133+ myeloid cells.", [["CD14+", "ANATOMY", 51, 56], ["CD133+ myeloid cells", "ANATOMY", 61, 81], ["CD14", "GENE_OR_GENE_PRODUCT", 51, 55], ["CD133", "GENE_OR_GENE_PRODUCT", 61, 66], ["CD14", "PROTEIN", 51, 55], ["CD133", "PROTEIN", 61, 66], ["myeloid cells", "CELL_TYPE", 68, 81], ["our data", "TEST", 15, 23], ["CD14", "TEST", 51, 55], ["myeloid cells", "PROBLEM", 68, 81], ["enrichment", "OBSERVATION", 37, 47], ["myeloid cells", "OBSERVATION", 68, 81]]], ["These observations warrant further investigation to test them for potential mechanistic roles.DiscussionWe were interested in understanding the role of the airway microbiota in defining clinical responses to RSV in infants.", [["airway", "ANATOMY", 156, 162], ["RSV", "DISEASE", 208, 211], ["airway microbiota", "MULTI-TISSUE_STRUCTURE", 156, 173], ["RSV", "ORGANISM", 208, 211], ["infants", "ORGANISM", 215, 222], ["infants", "SPECIES", 215, 222], ["RSV", "SPECIES", 208, 211], ["further investigation", "TEST", 27, 48], ["airway", "ANATOMY", 156, 162]]], ["We failed to find a strong association between the presence/absence of microbial pathogens and severity.", [["microbial pathogens and severity", "PROBLEM", 71, 103], ["microbial", "OBSERVATION_MODIFIER", 71, 80], ["pathogens", "OBSERVATION", 81, 90]]], ["However, we confirmed a report published during our studies indicating a higher burden of H. influenzae in infants with severe clinical symptoms requiring hospitalization (Fig. 2) .", [["H. influenzae", "DISEASE", 90, 103], ["H. influenzae", "ORGANISM", 90, 103], ["infants", "ORGANISM", 107, 114], ["H. influenzae", "SPECIES", 90, 103], ["infants", "SPECIES", 107, 114], ["H. influenzae", "SPECIES", 90, 103], ["our studies", "TEST", 48, 59], ["H. influenzae", "PROBLEM", 90, 103], ["severe clinical symptoms", "PROBLEM", 120, 144], ["influenzae", "OBSERVATION", 93, 103]]], ["Although other taxa were associated with airway gene expression, we were somewhat surprised to find no otherDiscussionOTUs were significantly associated with severity.", [["airway", "ANATOMY", 41, 47], ["airway", "MULTI-TISSUE_STRUCTURE", 41, 47], ["airway gene expression", "PROBLEM", 41, 63], ["otherDiscussionOTUs", "PROBLEM", 103, 122], ["severity", "PROBLEM", 158, 166]]], ["It is worth knowing, 16S ribosomal RNA sequencing was not able to identify S. pneumoniae at the species level.", [["ribosomal", "ANATOMY", 25, 34], ["ribosomal", "CELLULAR_COMPONENT", 25, 34], ["S. pneumoniae", "ORGANISM", 75, 88], ["S. pneumoniae", "SPECIES", 75, 88], ["S. pneumoniae", "SPECIES", 75, 88], ["16S ribosomal RNA sequencing", "TEST", 21, 49], ["S. pneumoniae", "PROBLEM", 75, 88], ["pneumoniae", "OBSERVATION", 78, 88]]], ["Given our prior studies revealing a large impact of the microbiota upon gene expression in the airway, we studied the inter-relationships between the airway microbiome, airway gene expression and clinical severity.", [["airway", "ANATOMY", 95, 101], ["airway", "ANATOMY", 150, 156], ["airway", "ANATOMY", 169, 175], ["airway", "MULTI-TISSUE_STRUCTURE", 95, 101], ["airway microbiome", "MULTI-TISSUE_STRUCTURE", 150, 167], ["airway", "MULTI-TISSUE_STRUCTURE", 169, 175], ["our prior studies", "TEST", 6, 23], ["gene expression in the airway", "PROBLEM", 72, 101], ["large", "OBSERVATION_MODIFIER", 36, 41], ["impact", "OBSERVATION_MODIFIER", 42, 48], ["gene expression", "OBSERVATION", 72, 87], ["airway", "ANATOMY", 95, 101], ["airway", "ANATOMY", 150, 156], ["airway", "ANATOMY", 169, 175]]], ["In general, these analyses confirmed that the existence of known pathogens, particularly bacteria, are strongly associated with gene expression in asymptomatic 35, 47 and symptomatic 47 infants.", [["infants", "ORGANISM", 186, 193], ["infants", "SPECIES", 186, 193], ["these analyses", "TEST", 12, 26], ["known pathogens", "PROBLEM", 59, 74], ["bacteria", "PROBLEM", 89, 97], ["pathogens", "OBSERVATION", 65, 74]]], ["We considered the specific effect of the microbiota/H. flu on the relationship between gene expression and RSV severity.", [["H. flu", "ORGANISM", 52, 58], ["RSV", "ORGANISM", 107, 110], ["H. flu", "SPECIES", 52, 58], ["H. flu", "SPECIES", 52, 58], ["RSV", "SPECIES", 107, 110], ["H. flu", "PROBLEM", 52, 58], ["RSV severity", "PROBLEM", 107, 119], ["RSV severity", "OBSERVATION", 107, 119]]], ["The results are consistent with H. flu altering the nature of the inflammatory response, from myeloid-predominant to CD4/8 T lymphocyte-predominant.", [["myeloid", "ANATOMY", 94, 101], ["CD4/8 T lymphocyte", "ANATOMY", 117, 135], ["H. flu", "ORGANISM", 32, 38], ["myeloid", "CELL", 94, 101], ["CD4", "GENE_OR_GENE_PRODUCT", 117, 120], ["CD4", "PROTEIN", 117, 120], ["T lymphocyte", "CELL_TYPE", 123, 135], ["H. flu", "SPECIES", 32, 38], ["H. flu", "PROBLEM", 32, 38], ["the inflammatory response", "PROBLEM", 62, 87], ["myeloid", "TEST", 94, 101], ["CD4", "TEST", 117, 120], ["consistent with", "UNCERTAINTY", 16, 31], ["flu", "OBSERVATION", 35, 38], ["inflammatory response", "OBSERVATION", 66, 87], ["myeloid", "ANATOMY", 94, 101], ["predominant", "OBSERVATION_MODIFIER", 136, 147]]], ["These data provide a currently untested hypothesis for a potential mechanism whereby H. influenzae contributes to severe responses at the molecular and cellular level, which is a focus of current investigation.DiscussionOur identification of distinct, time-dependent changes in IFN signaling when comparing severely affected versus non-severely affected infants is both novel and consistent with the fundamental biology of viral responses.", [["cellular", "ANATOMY", 152, 160], ["H. influenzae", "DISEASE", 85, 98], ["H. influenzae", "ORGANISM", 85, 98], ["cellular", "CELL", 152, 160], ["IFN", "GENE_OR_GENE_PRODUCT", 278, 281], ["infants", "ORGANISM", 354, 361], ["IFN", "PROTEIN", 278, 281], ["H. influenzae", "SPECIES", 85, 98], ["infants", "SPECIES", 354, 361], ["H. influenzae", "SPECIES", 85, 98], ["H. influenzae", "PROBLEM", 85, 98], ["severe responses", "PROBLEM", 114, 130], ["dependent changes in IFN signaling", "PROBLEM", 257, 291], ["severely affected versus non-severely affected infants", "PROBLEM", 307, 361], ["distinct", "OBSERVATION_MODIFIER", 242, 250], ["consistent with", "UNCERTAINTY", 380, 395]]], ["Perhaps this was not readily apparent in prior studies focusing on severely affected infants, as compared to non-infected infants, as they both show limited evidence for activation of this pathway.", [["infants", "ORGANISM", 85, 92], ["infants", "ORGANISM", 122, 129], ["infants", "SPECIES", 85, 92], ["infants", "SPECIES", 122, 129], ["prior studies", "TEST", 41, 54], ["severely affected infants", "PROBLEM", 67, 92], ["this pathway", "TREATMENT", 184, 196]]], ["In this way, our studies, focused upon clinical severity in a cohort where all were infected with RSV, provides opportunity for different insights.", [["RSV", "DISEASE", 98, 101], ["RSV", "ORGANISM", 98, 101], ["RSV", "SPECIES", 98, 101], ["our studies", "TEST", 13, 24], ["RSV", "PROBLEM", 98, 101], ["infected", "OBSERVATION", 84, 92]]], ["We also draw attention to the narrow time window in which differences in IFN between these groups is evident (Fig. 4) .", [["IFN", "GENE_OR_GENE_PRODUCT", 73, 76], ["IFN", "PROTEIN", 73, 76]]], ["Even in our own data, differences in expression do not reach the level of statistical significance without restricting our analyses to the first few days following the onset of clinical symptoms.DiscussionIn vitro, our data indicating that IFN is both necessary and sufficient to control RSV infection of mammalian cells is not particularly novel, but validates the hypothesis generated by our in vivo data.", [["cells", "ANATOMY", 315, 320], ["IFN", "CHEMICAL", 240, 243], ["infection", "DISEASE", 292, 301], ["IFN", "GENE_OR_GENE_PRODUCT", 240, 243], ["RSV", "ORGANISM", 288, 291], ["mammalian cells", "CELL", 305, 320], ["IFN", "PROTEIN", 240, 243], ["mammalian cells", "CELL_TYPE", 305, 320], ["RSV", "SPECIES", 288, 291], ["clinical symptoms", "PROBLEM", 177, 194], ["our data", "TEST", 215, 223], ["IFN", "PROBLEM", 240, 243], ["RSV infection of mammalian cells", "PROBLEM", 288, 320], ["mammalian cells", "OBSERVATION", 305, 320]]], ["However, we feel that it is important to demonstrate this mechanism is causal for infection in a truly physiological model of bona fide human pediatric lung epithelial cells.", [["lung epithelial cells", "ANATOMY", 152, 173], ["infection", "DISEASE", 82, 91], ["human", "ORGANISM", 136, 141], ["lung epithelial cells", "CELL", 152, 173], ["bona fide human pediatric lung epithelial cells", "CELL_TYPE", 126, 173], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["infection", "PROBLEM", 82, 91], ["infection", "OBSERVATION", 82, 91], ["lung", "ANATOMY", 152, 156], ["epithelial cells", "OBSERVATION", 157, 173]]], ["We suggest other severity-associated gene expression responses require, or result from, additional cell types (e.g., leukocytes), and likely to be modified by the microbial community.", [["cell", "ANATOMY", 99, 103], ["leukocytes", "ANATOMY", 117, 127], ["cell", "CELL", 99, 103], ["leukocytes", "CELL", 117, 127], ["leukocytes", "CELL_TYPE", 117, 127], ["gene expression responses", "PROBLEM", 37, 62], ["leukocytes", "TEST", 117, 127]]], ["Modeling these states and responses are one focus of future experimentation.DiscussionWe should emphasize that our primary observation is not that severity is associated with IFN ligand production, but with estimated levels of signaling activation in the airway.", [["airway", "ANATOMY", 255, 261], ["IFN ligand", "GENE_OR_GENE_PRODUCT", 175, 185], ["airway", "MULTI-TISSUE_STRUCTURE", 255, 261], ["IFN", "PROTEIN", 175, 178], ["IFN ligand production", "PROBLEM", 175, 196], ["signaling activation in the airway", "PROBLEM", 227, 261], ["airway", "ANATOMY", 255, 261]]], ["This distinction could be due to low levels of ligand production, even in infants with mild clinical symptoms.", [["infants", "ORGANISM", 74, 81], ["infants", "SPECIES", 74, 81], ["low levels of ligand production", "PROBLEM", 33, 64], ["mild clinical symptoms", "PROBLEM", 87, 109], ["low", "OBSERVATION_MODIFIER", 33, 36]]], ["However, we could show differences in IFN ligand expression at both the RNA and protein levels ( Fig. 1) , after our initial discovery phase of RNAseq data analysis.", [["IFN ligand", "GENE_OR_GENE_PRODUCT", 38, 48], ["IFN", "PROTEIN", 38, 41], ["differences in IFN ligand expression", "PROBLEM", 23, 59], ["protein levels", "TEST", 80, 94], ["RNAseq data analysis", "TEST", 144, 164]]], ["Conversely, the distinction could support the logical conclusion that downstream signaling is critical to the protective effects of viral-induced IFN production.DiscussionThis interpretation is supported by our in vitro data (Fig. 5 Both type I and type III IFN appear to be expressed in non-severe subjects during the acute phase of illness (Fig. 4) and can be induced by viral infection in vitro.DiscussionOur evaluation of human biospecimen-derived RNAseq data has utilized multiple analytical and statistical approaches, in an effort to thoroughly interrogate the in vivo responses they reflect.", [["illness", "DISEASE", 334, 341], ["viral infection", "DISEASE", 373, 388], ["IFN", "GENE_OR_GENE_PRODUCT", 146, 149], ["type III IFN", "GENE_OR_GENE_PRODUCT", 249, 261], ["human", "ORGANISM", 426, 431], ["IFN", "PROTEIN", 146, 149], ["type III IFN", "PROTEIN", 249, 261], ["human", "SPECIES", 426, 431], ["human", "SPECIES", 426, 431], ["viral-induced IFN production", "PROBLEM", 132, 160], ["viral infection in vitro", "PROBLEM", 373, 397], ["DiscussionOur evaluation", "TEST", 398, 422], ["human biospecimen", "TEST", 426, 443], ["viral", "OBSERVATION", 132, 137], ["viral", "OBSERVATION_MODIFIER", 373, 378], ["infection", "OBSERVATION", 379, 388]]], ["Critically, we have applied appropriately conservative corrections for multiple testing in each case.", [["appropriately conservative corrections", "TREATMENT", 28, 66], ["multiple testing", "TEST", 71, 87]]], ["We believe that use of each of these analytical approaches is justified, as they each provide distinct yet important insight.", [["these analytical approaches", "TREATMENT", 31, 58]]], ["Univariate analyses are used to estimate the direct associations between one covariate and individual genes.", [["Univariate analyses", "TEST", 0, 19]]], ["These analyses are easy to perform and interpret and do not suffer from potential collinearity issues among covariates.", [["potential collinearity issues", "PROBLEM", 72, 101]]], ["On the other hand, a multivariate model considers the influence of several covariates on gene expression simultaneously; therefore, the estimated association between the response variable and a given covariate is less likely to be affected by unmodeled interdependences.", [["unmodeled interdependences", "PROBLEM", 243, 269], ["less likely", "UNCERTAINTY", 213, 224]]], ["A more serious issue is the potential collinearity among the covariates, which may prevent modeling certain combinations of covariates and produce unstable estimates.", [["more serious", "OBSERVATION_MODIFIER", 2, 14]]], ["Therefore, we believe it is a practical strategy to first use univariate analyses to identify a subset of important covariates, and then use them to build a lean and robust multivariate model.DiscussionWe acknowledge this study is not without limitations.", [["univariate analyses", "TEST", 62, 81], ["a lean and robust multivariate model", "TREATMENT", 155, 191], ["this study", "TEST", 217, 227], ["not without", "UNCERTAINTY", 231, 242]]], ["We have focused our efforts in identifying gene expression responses that distinguish infants severely affected by RSV infection as compared to infants who are not severely ill and have not included noninfected controls.", [["RSV infection", "DISEASE", 115, 128], ["infants", "ORGANISM", 86, 93], ["RSV", "ORGANISM", 115, 118], ["infants", "ORGANISM", 144, 151], ["infants", "SPECIES", 86, 93], ["infants", "SPECIES", 144, 151], ["RSV", "SPECIES", 115, 118], ["RSV infection", "PROBLEM", 115, 128], ["severely ill", "PROBLEM", 164, 176], ["RSV", "OBSERVATION_MODIFIER", 115, 118], ["infection", "OBSERVATION", 119, 128]]], ["Other studies by our group (Storch and unpublished) suggest that responses to any viral infection can be identified but occur at a much smaller magnitude than those described here.", [["viral infection", "DISEASE", 82, 97], ["Other studies", "TEST", 0, 13], ["any viral infection", "PROBLEM", 78, 97], ["infection", "OBSERVATION", 88, 97]]], ["In some cases, we were able to show a mechanistic relationship between specific genes/pathway and the magnitude of viral infection (Fig. 5) .", [["viral infection", "DISEASE", 115, 130], ["viral infection", "PROBLEM", 115, 130], ["viral", "OBSERVATION_MODIFIER", 115, 120], ["infection", "OBSERVATION", 121, 130]]], ["However, this model also has limitations in that it currently isolates epithelial cell responses, while our data clearly suggests involvement of leukocytes and monocytes in vivo.", [["epithelial cell", "ANATOMY", 71, 86], ["leukocytes", "ANATOMY", 145, 155], ["monocytes", "ANATOMY", 160, 169], ["epithelial cell", "CELL", 71, 86], ["leukocytes", "CELL", 145, 155], ["monocytes", "CELL", 160, 169], ["leukocytes", "CELL_TYPE", 145, 155], ["monocytes", "CELL_TYPE", 160, 169], ["our data", "TEST", 104, 112], ["leukocytes", "PROBLEM", 145, 155], ["monocytes", "TEST", 160, 169], ["epithelial cell", "OBSERVATION", 71, 86], ["leukocytes", "OBSERVATION", 145, 155]]]], "c81478861107223687ef66663c19c7f890bd8e64": [["They suggest that suppression of angiotensin-converting enzyme-2 (ACE-2) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could impair the hydrolysis of des-Arg 9 -bradykinin and stimulate the bradykinin receptor type 1 (BKB1) pathway to induce leakage of fluid into the lungs.", [["fluid", "ANATOMY", 271, 276], ["lungs", "ANATOMY", 286, 291], ["angiotensin-converting enzyme-2 (ACE-2", "CHEMICAL", 33, 71], ["acute respiratory syndrome coronavirus", "DISEASE", 83, 121], ["des-Arg 9 -bradykinin", "CHEMICAL", 168, 189], ["bradykinin", "CHEMICAL", 208, 218], ["des-Arg 9 -bradykinin", "CHEMICAL", 168, 189], ["bradykinin", "CHEMICAL", 208, 218], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 33, 64], ["ACE-2", "GENE_OR_GENE_PRODUCT", 66, 71], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 76, 123], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 125, 135], ["des-Arg 9 -bradykinin", "SIMPLE_CHEMICAL", 168, 189], ["bradykinin receptor type 1", "GENE_OR_GENE_PRODUCT", 208, 234], ["BKB1", "GENE_OR_GENE_PRODUCT", 236, 240], ["fluid", "ORGANISM_SUBSTANCE", 271, 276], ["lungs", "ORGAN", 286, 291], ["angiotensin-converting enzyme-2", "PROTEIN", 33, 64], ["ACE-2", "PROTEIN", 66, 71], ["BKB1", "PROTEIN", 236, 240], ["severe acute respiratory syndrome coronavirus", "SPECIES", 76, 121], ["angiotensin", "TEST", 33, 44], ["ACE", "TEST", 66, 69], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 76, 121], ["SARS-CoV", "TEST", 125, 133], ["bradykinin", "TREATMENT", 179, 189], ["the bradykinin receptor type", "TREATMENT", 204, 232], ["leakage of fluid into the lungs", "PROBLEM", 260, 291], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory syndrome", "OBSERVATION", 89, 109], ["leakage", "OBSERVATION", 260, 267], ["fluid", "OBSERVATION", 271, 276], ["lungs", "ANATOMY", 286, 291]]], ["In support of their hypothesis, they stated that loss of ACE-2 in an animal model aggravated acid-induced pulmonary edema, and these effects are alleviated by administration of recombinant human ACE-2 Q 2 .", [["pulmonary", "ANATOMY", 106, 115], ["pulmonary edema", "DISEASE", 106, 121], ["ACE-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 106, 121], ["human", "ORGANISM", 189, 194], ["ACE-2 Q 2", "GENE_OR_GENE_PRODUCT", 195, 204], ["ACE-2", "PROTEIN", 57, 62], ["recombinant human ACE-2 Q 2", "PROTEIN", 177, 204], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["loss of ACE-2", "PROBLEM", 49, 62], ["an animal model aggravated acid-induced pulmonary edema", "PROBLEM", 66, 121], ["recombinant human ACE", "TREATMENT", 177, 198], ["aggravated", "OBSERVATION_MODIFIER", 82, 92], ["acid-induced", "OBSERVATION_MODIFIER", 93, 105], ["pulmonary", "ANATOMY", 106, 115], ["edema", "OBSERVATION", 116, 121]]], ["3 In addition, a report demonstrated that SARS-CoV infection downregulates the expression of ACE-2.", [["SARS", "DISEASE", 42, 46], ["infection", "DISEASE", 51, 60], ["SARS-CoV", "ORGANISM", 42, 50], ["ACE-2", "GENE_OR_GENE_PRODUCT", 93, 98], ["ACE", "PROTEIN", 93, 96], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["CoV infection", "PROBLEM", 47, 60], ["ACE", "TEST", 93, 96], ["CoV", "OBSERVATION_MODIFIER", 47, 50], ["infection", "OBSERVATION", 51, 60]]], ["4 However, other studies suggest that SARS-CoV-2 may upregulate the expression of ACE-2 in patients with coronavirus disease 2019 (COVID-19) or influenza pneumonia in alveolar epithelial cells, endothelial cells, and lymphocytes in perivascular tissue than in uninfected control autopsy lung.", [["alveolar epithelial cells", "ANATOMY", 167, 192], ["endothelial cells", "ANATOMY", 194, 211], ["lymphocytes", "ANATOMY", 217, 228], ["perivascular tissue", "ANATOMY", 232, 251], ["lung", "ANATOMY", 287, 291], ["SARS", "DISEASE", 38, 42], ["coronavirus disease", "DISEASE", 105, 124], ["influenza pneumonia", "DISEASE", 144, 163], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["ACE-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["patients", "ORGANISM", 91, 99], ["coronavirus", "ORGANISM", 105, 116], ["alveolar epithelial cells", "CELL", 167, 192], ["endothelial cells", "CELL", 194, 211], ["lymphocytes", "CELL", 217, 228], ["perivascular tissue", "TISSUE", 232, 251], ["lung", "ORGAN", 287, 291], ["ACE", "PROTEIN", 82, 85], ["alveolar epithelial cells", "CELL_TYPE", 167, 192], ["endothelial cells", "CELL_TYPE", 194, 211], ["lymphocytes", "CELL_TYPE", 217, 228], ["patients", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 38, 46], ["other studies", "TEST", 11, 24], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["ACE", "TEST", 82, 85], ["coronavirus disease", "PROBLEM", 105, 124], ["COVID", "TEST", 131, 136], ["influenza pneumonia in alveolar epithelial cells", "PROBLEM", 144, 192], ["endothelial cells", "PROBLEM", 194, 211], ["lymphocytes in perivascular tissue", "PROBLEM", 217, 251], ["coronavirus disease", "OBSERVATION", 105, 124], ["influenza", "OBSERVATION_MODIFIER", 144, 153], ["pneumonia", "OBSERVATION", 154, 163], ["alveolar", "ANATOMY_MODIFIER", 167, 175], ["epithelial cells", "ANATOMY", 176, 192], ["endothelial cells", "OBSERVATION", 194, 211], ["lymphocytes", "OBSERVATION", 217, 228], ["perivascular tissue", "ANATOMY", 232, 251], ["lung", "ANATOMY", 287, 291]]], ["5 Furthermore, single-cell RNA sequencing analysis revealed that secretory cells in the upper airway epithelium have higher ACE-2 expressions in COVID-19.", [["secretory cells", "ANATOMY", 65, 80], ["upper airway epithelium", "ANATOMY", 88, 111], ["secretory cells", "CELL", 65, 80], ["upper airway epithelium", "TISSUE", 88, 111], ["ACE-2", "GENE_OR_GENE_PRODUCT", 124, 129], ["secretory cells", "CELL_TYPE", 65, 80], ["ACE", "PROTEIN", 124, 127], ["single-cell RNA sequencing analysis", "TEST", 15, 50], ["secretory cells in the upper airway epithelium", "PROBLEM", 65, 111], ["higher ACE", "TEST", 117, 127], ["COVID", "TEST", 145, 150], ["secretory cells", "OBSERVATION", 65, 80], ["upper", "ANATOMY_MODIFIER", 88, 93], ["airway", "ANATOMY", 94, 100], ["epithelium", "ANATOMY_MODIFIER", 101, 111], ["higher", "OBSERVATION_MODIFIER", 117, 123]]], ["6 Thus, until the effect of SARS-CoV-2 on ACE-2 levels or functionality is thoroughly addressed in peer-reviewed publications, it is difficult to precisely determine the contributory role of ACE-2 in the bradykinin pathway during SARS-CoV-2 infection.CorrespondenceZwaveling bradykinin receptor type 2 (BKB2) could induce active fluid transfer through vascular pores (Fig 1 F1-4/C] , A).", [["fluid", "ANATOMY", 329, 334], ["vascular pores", "ANATOMY", 352, 366], ["bradykinin", "CHEMICAL", 204, 214], ["infection", "DISEASE", 241, 250], ["bradykinin", "CHEMICAL", 275, 285], ["bradykinin", "CHEMICAL", 275, 285], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["ACE-2", "GENE_OR_GENE_PRODUCT", 42, 47], ["ACE-2", "GENE_OR_GENE_PRODUCT", 191, 196], ["bradykinin", "GENE_OR_GENE_PRODUCT", 204, 214], ["SARS-CoV-2", "ORGANISM", 230, 240], ["Zwaveling bradykinin receptor type 2", "GENE_OR_GENE_PRODUCT", 265, 301], ["BKB2", "GENE_OR_GENE_PRODUCT", 303, 307], ["fluid", "ORGANISM_SUBSTANCE", 329, 334], ["vascular pores", "MULTI-TISSUE_STRUCTURE", 352, 366], ["ACE", "PROTEIN", 42, 45], ["ACE-2", "PROTEIN", 191, 196], ["BKB2", "PROTEIN", 303, 307], ["SARS-CoV", "SPECIES", 230, 238], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["ACE-2 levels", "TREATMENT", 42, 54], ["ACE", "TEST", 191, 194], ["the bradykinin pathway", "TREATMENT", 200, 222], ["SARS", "PROBLEM", 230, 234], ["CoV-2 infection", "PROBLEM", 235, 250], ["active fluid transfer", "TREATMENT", 322, 343], ["infection", "OBSERVATION", 241, 250], ["active", "OBSERVATION_MODIFIER", 322, 328], ["fluid", "OBSERVATION", 329, 334], ["vascular", "ANATOMY", 352, 360]]], ["Another explanation for extravascular fluid leakage into the lungs in COVID-19 is secretion of proinflammatory cytokines such as TNF and IL-6 during the cytokine storm (Fig 1, A) .", [["extravascular fluid", "ANATOMY", 24, 43], ["lungs", "ANATOMY", 61, 66], ["COVID-19", "CHEMICAL", 70, 78], ["extravascular fluid", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 43], ["lungs", "ORGAN", 61, 66], ["TNF", "GENE_OR_GENE_PRODUCT", 129, 132], ["IL-6", "GENE_OR_GENE_PRODUCT", 137, 141], ["proinflammatory cytokines", "PROTEIN", 95, 120], ["TNF", "PROTEIN", 129, 132], ["IL-6", "PROTEIN", 137, 141], ["cytokine", "PROTEIN", 153, 161], ["extravascular fluid leakage into the lungs", "PROBLEM", 24, 66], ["COVID", "TEST", 70, 75], ["proinflammatory cytokines", "PROBLEM", 95, 120], ["TNF and IL", "TREATMENT", 129, 139], ["explanation for", "UNCERTAINTY", 8, 23], ["extravascular", "OBSERVATION", 24, 37], ["fluid leakage", "OBSERVATION", 38, 51], ["lungs", "ANATOMY", 61, 66], ["proinflammatory cytokines", "OBSERVATION", 95, 120]]], ["7 We favor a third hypothesis, where excessive and prolonged secretion of type I and type III IFNs in the airways contributes to loss of lung epithelial barrier function during COVID-19 and other RNA virus infections (Fig 1, A) .", [["airways", "ANATOMY", 106, 113], ["lung epithelial barrier", "ANATOMY", 137, 160], ["infections", "DISEASE", 206, 216], ["type I", "GENE_OR_GENE_PRODUCT", 74, 80], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 85, 98], ["airways", "MULTI-TISSUE_STRUCTURE", 106, 113], ["lung epithelial barrier", "TISSUE", 137, 160], ["COVID-19", "GENE_OR_GENE_PRODUCT", 177, 185], ["type I and type III IFNs", "PROTEIN", 74, 98], ["a third hypothesis", "PROBLEM", 11, 29], ["type I and type III IFNs in the airways", "PROBLEM", 74, 113], ["loss of lung epithelial barrier function", "PROBLEM", 129, 169], ["COVID", "TEST", 177, 182], ["other RNA virus infections", "PROBLEM", 190, 216], ["airways", "ANATOMY", 106, 113], ["lung", "ANATOMY", 137, 141], ["epithelial", "ANATOMY_MODIFIER", 142, 152], ["barrier function", "OBSERVATION", 153, 169]]], ["8, 9 To test whether entry of SARS-CoV-2 through ACE-2 is sufficient to induce type III IFNs without need for viral replication, we engineered a replication-deficient SARS-CoV-2 spike-HIV-luc pseudotype virus.", [["SARS", "DISEASE", 30, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["ACE-2", "GENE_OR_GENE_PRODUCT", 49, 54], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 79, 92], ["SARS-CoV-2", "ORGANISM", 167, 177], ["HIV-luc pseudotype virus", "ORGANISM", 184, 208], ["ACE-2", "DNA", 49, 54], ["type III IFNs", "PROTEIN", 79, 92], ["HIV-luc pseudotype virus", "SPECIES", 184, 208], ["HIV-luc pseudotype virus", "SPECIES", 184, 208], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["ACE", "TEST", 49, 52], ["type III IFNs", "PROBLEM", 79, 92], ["viral replication", "TREATMENT", 110, 127], ["deficient SARS", "PROBLEM", 157, 171], ["CoV", "TEST", 172, 175], ["spike", "PROBLEM", 178, 183], ["HIV", "PROBLEM", 184, 187], ["luc pseudotype virus", "PROBLEM", 188, 208], ["luc pseudotype virus", "OBSERVATION", 188, 208]]], ["Infection of Caco-2 cells, which naturally express ACE-2, with this engineered virus was sufficient to increase the mRNA expression of IFN-l2 (Fig 1, B and C) , indicating that virus replication is not required for upregulating its expression.", [["Caco-2 cells", "ANATOMY", 13, 25], ["Caco-2 cells", "CELL", 13, 25], ["ACE-2", "GENE_OR_GENE_PRODUCT", 51, 56], ["IFN-l2", "GENE_OR_GENE_PRODUCT", 135, 141], ["Fig 1", "GENE_OR_GENE_PRODUCT", 143, 148], ["B", "GENE_OR_GENE_PRODUCT", 150, 151], ["C", "GENE_OR_GENE_PRODUCT", 156, 157], ["Caco-2 cells", "CELL_LINE", 13, 25], ["ACE", "PROTEIN", 51, 54], ["IFN", "PROTEIN", 135, 138], ["l2", "PROTEIN", 139, 141], ["Infection of Caco-2 cells", "PROBLEM", 0, 25], ["ACE", "TEST", 51, 54], ["this engineered virus", "PROBLEM", 63, 84], ["IFN", "TEST", 135, 138], ["Fig", "TEST", 143, 146], ["virus replication", "PROBLEM", 177, 194], ["Caco-2 cells", "ANATOMY_MODIFIER", 13, 25], ["virus", "OBSERVATION", 177, 182]]], ["Because IFN-l contributes to loss of lung epithelial barrier function, 8 we hypothesize that entry of SARS-CoV-2 via ACE-2 can stimulate secretion of IFN-l and induce leakage of fluid into the lungs (Fig 1, A) .CorrespondenceZwaveling et al's hypothesis is most intriguing and certainly plausible.", [["lung epithelial barrier", "ANATOMY", 37, 60], ["fluid", "ANATOMY", 178, 183], ["lungs", "ANATOMY", 193, 198], ["SARS", "DISEASE", 102, 106], ["IFN-l", "GENE_OR_GENE_PRODUCT", 8, 13], ["lung epithelial barrier", "TISSUE", 37, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 102, 112], ["ACE-2", "GENE_OR_GENE_PRODUCT", 117, 122], ["IFN-l", "GENE_OR_GENE_PRODUCT", 150, 155], ["fluid", "ORGANISM_SUBSTANCE", 178, 183], ["lungs", "ORGAN", 193, 198], ["IFN", "PROTEIN", 8, 11], ["ACE", "PROTEIN", 117, 120], ["IFN", "PROTEIN", 150, 153], ["IFN", "PROBLEM", 8, 11], ["loss of lung epithelial barrier function", "PROBLEM", 29, 69], ["SARS", "TEST", 102, 106], ["CoV", "TEST", 107, 110], ["ACE-2", "TREATMENT", 117, 122], ["IFN", "TEST", 150, 153], ["leakage of fluid into the lungs", "PROBLEM", 167, 198], ["CorrespondenceZwaveling et al's hypothesis", "PROBLEM", 211, 253], ["lung", "ANATOMY", 37, 41], ["epithelial", "ANATOMY_MODIFIER", 42, 52], ["barrier function", "OBSERVATION", 53, 69], ["leakage", "OBSERVATION", 167, 174], ["fluid", "OBSERVATION", 178, 183], ["lungs", "ANATOMY", 193, 198]]], ["However, as acknowledged by the authors, there is no direct evidence showing increased levels of bradykinin or des-Arg 9 -bradykinin in the patients with COVID-19 at this time.", [["bradykinin", "CHEMICAL", 97, 107], ["des-Arg 9 -bradykinin", "CHEMICAL", 111, 132], ["COVID-19", "CHEMICAL", 154, 162], ["bradykinin", "CHEMICAL", 97, 107], ["des-Arg 9 -bradykinin", "CHEMICAL", 111, 132], ["COVID-19", "CHEMICAL", 154, 162], ["bradykinin", "SIMPLE_CHEMICAL", 97, 107], ["des-Arg 9 -bradykinin", "SIMPLE_CHEMICAL", 111, 132], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["increased levels of bradykinin", "PROBLEM", 77, 107], ["bradykinin", "PROBLEM", 122, 132], ["COVID", "TEST", 154, 159], ["no direct evidence showing", "UNCERTAINTY", 50, 76]]], ["Here, we provide evidence that entry of SARS-CoV-2 through ACE-2 provides an adequate signal even without viral replication to stimulate IFN-l2 mRNA expression, a cytokine that can cause damage to the epithelial barrier.", [["epithelial barrier", "ANATOMY", 201, 219], ["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["ACE-2", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFN-l2", "GENE_OR_GENE_PRODUCT", 137, 143], ["epithelial barrier", "TISSUE", 201, 219], ["ACE-2", "DNA", 59, 64], ["IFN-l2 mRNA", "RNA", 137, 148], ["cytokine", "PROTEIN", 163, 171], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["viral replication", "TREATMENT", 106, 123], ["IFN", "TEST", 137, 140], ["damage", "PROBLEM", 187, 193], ["the epithelial barrier", "TREATMENT", 197, 219], ["epithelial", "ANATOMY_MODIFIER", 201, 211]]], ["Further investigations are required to test the hypotheses outlined in Figure 1 , A, which may induce leakage of fluid into the lungs in COVID-19, and identify the most important pathway(s).Q 9Koa Hosoki, MD, PhD a * Jason T. Kimata, PhD b * Abhijit Chakraborty, PhD a Sanjiv Sur, MD a", [["fluid", "ANATOMY", 113, 118], ["lungs", "ANATOMY", 128, 133], ["lungs", "ORGAN", 128, 133], ["Further investigations", "TEST", 0, 22], ["leakage of fluid into the lungs", "PROBLEM", 102, 133], ["leakage", "OBSERVATION", 102, 109], ["fluid", "OBSERVATION", 113, 118], ["lungs", "ANATOMY", 128, 133]]]], "1bd626c6e2bf333c14247fa3e4781bf8764caf3c": [["IntroductionThe COVID-19 pandemic has rapidly caused an enormous worldwide medical and socioeconomic impact since the first case emerged on November 16th 2019 [1] .", [["The COVID", "TREATMENT", 12, 21], ["enormous", "OBSERVATION_MODIFIER", 56, 64], ["worldwide", "OBSERVATION_MODIFIER", 65, 74]]], ["Although a self-limiting illness for most, the percentage of COVID-19 patients with hypoxaemic respiratory failure requiring ICU admission for mechanical ventilation translates into large numbers which may challenge healtcare provision.", [["respiratory", "ANATOMY", 95, 106], ["self-limiting illness", "DISEASE", 11, 32], ["respiratory failure", "DISEASE", 95, 114], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["a self-limiting illness", "PROBLEM", 9, 32], ["COVID", "TEST", 61, 66], ["hypoxaemic respiratory failure", "PROBLEM", 84, 114], ["mechanical ventilation", "TREATMENT", 143, 165], ["hypoxaemic", "OBSERVATION_MODIFIER", 84, 94], ["respiratory failure", "OBSERVATION", 95, 114], ["mechanical ventilation", "OBSERVATION", 143, 165]]], ["In Northern Italy, an exponential increase in COVID-19 admissions rapidly overwhelmed normal ICU capacity [2] and surge capacity had to be created quickly.", [["surge capacity", "PROBLEM", 114, 128], ["exponential", "OBSERVATION_MODIFIER", 22, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42]]], ["The exact reason for the sudden need for ICU surge capacity in Italy, and whether this will generalise to other countries, is unclear, but both demographic factors and healthcare system structure are likely to be important.", [["likely to be", "UNCERTAINTY", 200, 212]]], ["Whilst standard acute wards may be re-purposed easily, creating ICU capacity is constrained by the need for complex equipment and the delivery of highly specialised medical and nursing care.", [["complex equipment", "TREATMENT", 108, 125], ["nursing care", "TREATMENT", 177, 189], ["acute", "OBSERVATION_MODIFIER", 16, 21]]], ["Nevertheless, there are mechanisms by which ICU capacity could be increased in an emergency, including facilitating ICU discharge of recovering patients through liberating downstream beds by reducing elective work, by stopping elective work likely to require ICU admission, or by changing referral policies.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152]]], ["Furthermore, since ICUs in the UK typically undertake a high proportion of emergency work, much of which will continue despite the pandemic, and since occupancy is typically well above 80%, such strategies are likely to result in only a relatively modest increase in capacity.", [["the pandemic", "PROBLEM", 127, 139], ["a relatively modest increase in capacity", "PROBLEM", 235, 275], ["modest", "OBSERVATION_MODIFIER", 248, 254], ["increase", "OBSERVATION_MODIFIER", 255, 263]]], ["A greater increase in emergency physical capacity for mechanical ventilation could be achieved by opening new level 3 beds with additional equipment (e.g. operating theatre ventilators).", [["A greater increase in emergency physical capacity", "PROBLEM", 0, 49], ["mechanical ventilation", "TREATMENT", 54, 76], ["additional equipment", "TREATMENT", 128, 148], ["operating theatre ventilators", "TREATMENT", 155, 184], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["This requires significant changes to infrastructure, processes, or sta ng and is therefore logistically complex, expensive, and most importantly slow to implement.", [["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["The explosion of cases seen in Italy means that an early warning of need for surge capacity is likely to be required in other countries including England.IntroductionEpidemiological simulation has previously been successful in predicting the need for surge H1N1 ICU capacity in 2009 [4, 5] .", [["surge capacity", "PROBLEM", 77, 91]]], ["In recent days, a similar simulation model for COVID-19 has been described [6] , which suggests an overwhelming demand for critical care, with a peak occurring between May and early June 2020 and lasting 2 to 3 months depending on non-pharmacological intervention (NPI) assumptions.", [["COVID", "TEST", 47, 52], ["non-pharmacological intervention", "TREATMENT", 231, 263], ["overwhelming", "OBSERVATION", 99, 111]]], ["Such projected timescales are unlikely to be reliable and are unsuitable for real-time surveillance and early warning.", [["unlikely to be", "UNCERTAINTY", 30, 44]]], ["In this paper we use published COVID-19 diagnosis data for England to generate the earliest possible estimates of additional ICU demand due to infections in the coming days, based on cautious epidemiological data from the literature and under the assumption that the current increase in cases represents the exponential phase of an outbreak rather than a change in ascertainment.", [["infections", "DISEASE", 143, 153], ["infections", "PROBLEM", 143, 153], ["infections", "OBSERVATION", 143, 153], ["exponential", "OBSERVATION_MODIFIER", 308, 319], ["phase", "OBSERVATION_MODIFIER", 320, 325]]], ["We started to extract this data feed on 13/03/20 to give daily case data.", [["this data feed", "TREATMENT", 22, 36]]], ["Figure 2: Regional demographics and expected critical care demand per case of COVID-19, stratified by region and compared to ICU bed capacity per 100,000 people.", [["people", "SPECIES", 154, 160], ["COVID", "TEST", 78, 83]]], ["The numerical data can be seen in Table 1 .MethodsWe assumed that the daily incidence of COVID-19 can be modelled as an exponential growth (in line with what was observed in Italy [2] ).", [["COVID-19", "CHEMICAL", 89, 97], ["COVID-19", "CHEMICAL", 89, 97], ["The numerical data", "TEST", 0, 18], ["COVID", "TEST", 89, 94], ["growth", "OBSERVATION_MODIFIER", 132, 138]]], ["Therefore, we forecast the likely distributions of new COVID-19 diagnoses over the next 14 days by using an ordinary least squares fit to linearly extrapolate from the logarithm of the cumulative cases.", [["COVID", "DNA", 55, 60], ["new COVID-19 diagnoses", "PROBLEM", 51, 73], ["new", "OBSERVATION_MODIFIER", 51, 54]]], ["We di\u21b5erentiated the cumulative model to obtain a daily incidence model i.e. we multiply by the exponent ( d dx \u21e5 Ae Bx \u21e4 = BAe Bx ), which stabilises the exponent fitting (B).MethodsUsing early data from Verity et al. 2020 [9] (reproduced in Table 1 ), we estimated the ICU admission rate by standardising to the local population in each NHS commissioning region in England (see Figure 2 , obtained from the Clinical Commissioning Group population estimates for mid-2018 [10] ).", [["Bx", "PROTEIN", 117, 119], ["BAe Bx", "PROTEIN", 124, 130], ["Ae Bx", "TEST", 114, 119], ["BAe Bx", "TEST", 124, 130]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["19 Overall, Figure 4 shows predictions that will challenge ICU capacity in all areas, particularly in populous regions.", [["populous", "ANATOMY_MODIFIER", 102, 110]]], ["London and the Midlands will gain a number of COVID-19 patients equi-valent to 100% standard capacity within 14 days for slightly di\u21b5erent reasons.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["COVID", "TEST", 46, 51], ["slightly di\u21b5erent reasons", "PROBLEM", 121, 146]]], ["Whereas in the Midlands, due to an increased average age, a higher percentage of ICU admissions is predicted (see Table 1 ), which combined with a higher number of cases than other regions will lead to exhausted capacity.", [["exhausted capacity", "PROBLEM", 202, 220], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["average", "OBSERVATION_MODIFIER", 45, 52]]], ["As normal occupancy is often above 80%, even the additional minimum capacity due to COVID-19 of 20% in other regions will prove to be di cult to 5 .", [["COVID", "TEST", 84, 89], ["di cult", "TEST", 134, 141], ["normal", "OBSERVATION", 3, 9]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["The figure illustrates the large regional variation in projected ICU occupancy, with London and the Midlands reaching near 100% additional capacity due to COVID-19 within 14 days, whereas areas such as the South West and South East will only have approximately 20% of their beds occupied by COVID-19 patients.DiscussionIn this study we demonstrate how publicly available data can be rapidly combined to dynamic-6 .", [["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 300, 308], ["the large regional variation", "PROBLEM", 23, 51], ["COVID", "TEST", 155, 160], ["this study", "TEST", 322, 332], ["large", "OBSERVATION_MODIFIER", 27, 32], ["regional", "OBSERVATION_MODIFIER", 33, 41], ["variation", "OBSERVATION_MODIFIER", 42, 51], ["projected", "OBSERVATION_MODIFIER", 55, 64], ["ICU occupancy", "OBSERVATION", 65, 78]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["19.20039057 doi: medRxiv preprint ally model short-term ICU requirements in light of the emerging COVID-19 pandemic.", [["pandemic", "PROBLEM", 107, 115]]], ["Our data suggests that traditional ICU capacity could be rapidly consumed over a period of approximately 14 days from the time of modelling/writing, such figures hide substantial regional heterogeneity, with London and the Midlands demonstrating the most rapid growth.", [["Our data", "TEST", 0, 8], ["traditional ICU capacity", "PROBLEM", 23, 47], ["substantial regional heterogeneity", "PROBLEM", 167, 201], ["substantial", "OBSERVATION_MODIFIER", 167, 178], ["regional", "OBSERVATION_MODIFIER", 179, 187], ["heterogeneity", "OBSERVATION", 188, 201]]], ["Within the current acute stage of this pandemic, we hope our findings provide a framework to facilitate the rapid development and deployment of additional ICU surge capacity as was required within days of the Italian pandemic [2] .(which was not peer-reviewed)In the future, we feel that our methodological approach (use of emerging epidemic curve data, Monte Carlo simulation, and population standardisation), as well as our simultaneous deployment of an interactive and dynamically updated web-tool have merit in modelling and communicating any future dynamically emerging event.(which was not peer-reviewed)However, we do recognise that as with all models our is subject to significant assumptions and limitations.", [["additional ICU surge capacity", "TREATMENT", 144, 173], ["epidemic curve data", "TEST", 333, 352], ["acute", "OBSERVATION_MODIFIER", 19, 24]]], ["Both model and parameter uncertainties are inevitable, particularly when predicting the behaviour of a novel virus in a new population, and this may radically a\u21b5ect our forecasts.(which was not peer-reviewed)Nevertheless, we set out to provide the earliest possible data-driven forecast and therefore explicitly accept the limitations of the data that were available to us at the time.", [["a novel virus", "PROBLEM", 101, 114], ["the data", "TEST", 338, 346], ["parameter uncertainties", "OBSERVATION", 15, 38]]], ["With the small amount of available data, there are some specific limitations which need to be discussed.", [["small", "OBSERVATION_MODIFIER", 9, 14], ["amount", "OBSERVATION_MODIFIER", 15, 21]]], ["Our use of an updated, online resource we hope is a novel way of allowing interested parties to interact with the mathematical assumptions and formulate their own opinions.(which was not peer-reviewed)We have used PHE published data for case ascertainment.", [["PHE", "CHEMICAL", 214, 217]]], ["However, being as our explicit aim is to model the most severe cases, the e\u21b5ect of any ascertainment bias on our findings should be minimised due to the roll-out of routine testing for all critical care patients as part of the \"COVID Hospitalisation in England Surveillance System-CHESS\" [18] .", [["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["any ascertainment bias", "PROBLEM", 83, 105], ["routine testing", "TEST", 165, 180]]], ["Specifically, at the time of writing, test capacity for COVID-19(which was not peer-reviewed)in the UK has led to stringent requirements for testing with only cases requiring hospitalisation being routinely tested [16] .", [["test capacity", "TEST", 38, 51], ["COVID", "TEST", 56, 61], ["testing", "TEST", 141, 148]]], ["By incorporating a 'delay to ICU' parameter within our model, that can take on negative values (thus indicating a diagnosis after ICU admission), we hope to have replicated the anecdotal experience of clinicians in these early phases of the pandemic; that a substantial proportion of patients are being con- forecast numbers as these data inform our standardised estimates of ICU cases from within each population [9] .", [["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292]]], ["If the upturn in COVID-19 cases seen at the time of writing is largely driven by increased or altered ascertainment rather than a true rise in cases, 7 .", [["COVID", "TEST", 17, 22], ["a true rise in cases", "PROBLEM", 128, 148]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint .(which was not peer-reviewed)then this would render our model overly pessimistic.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["med", "ANATOMY", 99, 102]]], ["Nevertheless, this will always be a limitation of any early modelling [9] .(which was not peer-reviewed)Although we have resolved ICU admissions to the level of a commissioning region, this assumes that each region behaves as a homogeneously allocated 'pool' of ICU beds, which is not necessarily true because inter-hospital ICU-to-ICU transfers may not be feasible for both operational and clinical reasons.", [["ICU beds", "TREATMENT", 262, 270], ["not necessarily", "UNCERTAINTY", 281, 296]]], ["In this sense our predictions represent a 'best case' scenario and cannot be used for decision making at the level of an individual unit.(which was not peer-reviewed)Building on this theme, we forecast the percentage of COVID-19 bed requirements in isolation, figures which do not reflect competing ICU burden.", [["COVID-19 bed requirements", "TREATMENT", 220, 245]]], ["Since UK bed occupancy is typically greater than 80% and may frequently exceed 100% [7] , clearly not all beds can simply be re-allocated for COVID-19 patients.", [["UK", "GENE_OR_GENE_PRODUCT", 6, 8], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["greater", "OBSERVATION_MODIFIER", 36, 43]]], ["This may be especially true for specialist ICUs (e.g. neuroscience or cardiac) which may not be able to entirely reconfigure, or high-dependency beds which may not be able to provide mechanical ventilation routinely.", [["cardiac", "ANATOMY", 70, 77], ["cardiac", "ORGAN", 70, 77], ["high-dependency beds", "PROBLEM", 129, 149], ["mechanical ventilation", "TREATMENT", 183, 205]]], ["Furthermore, we assumed that all adult critical care bed spaces can be used for mechanically ventilated ICU patients, which operationally may not be possible for a variety of reasons including equipment and sta\u21b5 availability.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116]]], ["Thus, the precise percentage of additional COVID-19 patients that will actually exhaust routine capacity will vary from unit to unit, particularly in ICUs with a substantial postoperative elective surgical workload.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["a substantial postoperative elective surgical workload", "TREATMENT", 160, 214]]], ["Finally, front-line clinicians reviewing our results in these early days of the pandemic will highlight the disconnect between our estimated 'confirmed' cases and the substantial operational workload that is being created by treating all suspicious cases of respiratory failure as COVID-19 until proven otherwise.(which was not peer-reviewed)At the time of writing, the potential challenge that faces the health system (including intensive care) is essentially without precedent and has resulted in social and political interventions that have never been seen in peacetime.", [["respiratory", "ANATOMY", 258, 269], ["respiratory failure", "DISEASE", 258, 277], ["respiratory failure", "PROBLEM", 258, 277], ["COVID", "TEST", 281, 286], ["political interventions", "TREATMENT", 510, 533], ["respiratory failure", "OBSERVATION", 258, 277]]], ["We hope that regardless of the assumptions inherent within our model (which we feel are based on best available data) that the overarching message of the need for urgent surge capacity is timely.", [["urgent surge capacity", "TREATMENT", 163, 184]]], ["Finally, we hope that our transparency in releasing our code, model assumptions, and results in a dynamic web format embodies a new paradigm in rapidly developed and reviewed science that persists beyond the current pandemic.ConclusionsEarly warning of an impending need for ICU surge capacity is crucial if there is to be sufficient time to re-configure services.", [["ICU surge capacity", "TREATMENT", 275, 293], ["new", "OBSERVATION_MODIFIER", 128, 131]]], ["There remains a significant degree of uncertainty in the predictions due both to limitations of the reporting data and modelling assumptions.", [["the reporting data", "TEST", 96, 114], ["modelling assumptions", "TEST", 119, 140], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["degree", "OBSERVATION_MODIFIER", 28, 34], ["uncertainty", "OBSERVATION", 38, 49]]], ["This emphasises the need for the collection of real-time patient-facing local data by initiatives such as CHESS [18] and a dynamic approach to improving models as new data becomes available.ConclusionsDeclarations of interest statement None declared.Conclusions.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["a dynamic approach", "TREATMENT", 121, 139]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusions(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 196, 216], ["this preprint", "TREATMENT", 221, 234], ["med", "ANATOMY", 99, 102]]]], "74955d97332820eb7af2eb116ec62890c4b4b656": [["IntroductionCoronavirus disease 2019 is caused by severe acute respiratory syndrome (SARS) coronavirus (CoV)-2 [1] .", [["Coronavirus disease", "DISEASE", 12, 31], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 57, 102], ["coronavirus", "SPECIES", 91, 102], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 50, 102], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["severe acute respiratory syndrome (SARS) coronavirus (CoV)", "PROBLEM", 50, 108], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["The majority of individuals who contract SARS-CoV-2 have mild symptoms, however, a significant proportion develops respiratory failure due to pneumonia [1] .", [["respiratory", "ANATOMY", 115, 126], ["SARS", "DISEASE", 41, 45], ["respiratory failure", "DISEASE", 115, 134], ["pneumonia", "DISEASE", 142, 151], ["individuals", "ORGANISM", 16, 27], ["SARS-CoV-2", "ORGANISM", 41, 51], ["CoV", "TEST", 46, 49], ["mild symptoms", "PROBLEM", 57, 70], ["respiratory failure", "PROBLEM", 115, 134], ["pneumonia", "PROBLEM", 142, 151], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["symptoms", "OBSERVATION", 62, 70], ["respiratory failure", "OBSERVATION", 115, 134], ["pneumonia", "OBSERVATION", 142, 151]]], ["COVID-19 may also have extrapulmonary manifestations including coagulopathy and venous thromboembolism, which are associated with decreased survival [2] .", [["extrapulmonary", "ANATOMY", 23, 37], ["venous", "ANATOMY", 80, 86], ["coagulopathy", "DISEASE", 63, 75], ["venous thromboembolism", "DISEASE", 80, 102], ["venous", "MULTI-TISSUE_STRUCTURE", 80, 86], ["COVID", "TEST", 0, 5], ["extrapulmonary manifestations", "PROBLEM", 23, 52], ["coagulopathy", "PROBLEM", 63, 75], ["venous thromboembolism", "PROBLEM", 80, 102], ["extrapulmonary", "ANATOMY", 23, 37], ["coagulopathy", "OBSERVATION", 63, 75], ["venous", "ANATOMY", 80, 86], ["thromboembolism", "OBSERVATION", 87, 102]]], ["The mechanisms that activate coagulation in COVID-19 remain incompletely understood.IntroductionCoagulation is an intricate balance between clot promoting and dissolving processes in which vitamin K plays a well-known role.", [["clot", "ANATOMY", 140, 144], ["vitamin K", "CHEMICAL", 189, 198], ["COVID-19", "CHEMICAL", 44, 52], ["vitamin K", "CHEMICAL", 189, 198], ["COVID-19", "GENE_OR_GENE_PRODUCT", 44, 52], ["clot", "ORGANISM_SUBSTANCE", 140, 144], ["vitamin K", "SIMPLE_CHEMICAL", 189, 198], ["coagulation in COVID", "TEST", 29, 49], ["IntroductionCoagulation", "TREATMENT", 84, 107], ["clot promoting", "TREATMENT", 140, 154], ["vitamin K", "TREATMENT", 189, 198], ["clot", "OBSERVATION", 140, 144]]], ["Procoagulant factor II (FII; i.e. prothrombin) requires vitamin Kdependent carboxylation to fulfil its primary function.", [["vitamin Kdependent", "CHEMICAL", 56, 74], ["vitamin Kdependent", "CHEMICAL", 56, 74], ["Procoagulant factor II", "GENE_OR_GENE_PRODUCT", 0, 22], ["FII", "GENE_OR_GENE_PRODUCT", 24, 27], ["prothrombin", "GENE_OR_GENE_PRODUCT", 34, 45], ["vitamin Kdependent", "SIMPLE_CHEMICAL", 56, 74], ["Procoagulant factor II", "PROTEIN", 0, 22], ["FII", "PROTEIN", 24, 27], ["prothrombin", "PROTEIN", 34, 45], ["Procoagulant factor II (FII", "TREATMENT", 0, 27], ["prothrombin)", "TREATMENT", 34, 46], ["vitamin Kdependent carboxylation", "TREATMENT", 56, 88]]], ["Vitamin K is also cofactor of anticoagulant protein S. In contrast to FII, a significant proportion of protein S is extrahepatically synthesized in endothelial cells, which plays a local suppressive role against thrombosis [3] .", [["endothelial cells", "ANATOMY", 148, 165], ["Vitamin K", "CHEMICAL", 0, 9], ["thrombosis", "DISEASE", 212, 222], ["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "SIMPLE_CHEMICAL", 0, 9], ["FII", "GENE_OR_GENE_PRODUCT", 70, 73], ["protein S", "GENE_OR_GENE_PRODUCT", 103, 112], ["endothelial cells", "CELL", 148, 165], ["anticoagulant protein", "PROTEIN", 30, 51], ["FII", "PROTEIN", 70, 73], ["protein S", "PROTEIN", 103, 112], ["endothelial cells", "CELL_TYPE", 148, 165], ["Vitamin K", "TREATMENT", 0, 9], ["anticoagulant protein S.", "TREATMENT", 30, 54], ["protein S", "PROBLEM", 103, 112], ["extrahepatically synthesized in endothelial cells", "PROBLEM", 116, 165], ["thrombosis", "PROBLEM", 212, 222], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["protein S", "OBSERVATION", 103, 112], ["endothelial cells", "OBSERVATION", 148, 165]]], ["Vitamin K deficiency results in more severely compromised carboxylation of extrahepatic than of hepatic vitamin Kdependent proteins (figure 1) [4] .", [["extrahepatic", "ANATOMY", 75, 87], ["hepatic", "ANATOMY", 96, 103], ["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "CHEMICAL", 0, 9], ["vitamin Kdependent", "CHEMICAL", 104, 122], ["Vitamin K", "SIMPLE_CHEMICAL", 0, 9], ["extrahepatic", "ORGAN", 75, 87], ["hepatic vitamin Kdependent proteins", "PROTEIN", 96, 131], ["Vitamin K deficiency", "PROBLEM", 0, 20], ["hepatic vitamin Kdependent proteins", "TREATMENT", 96, 131], ["extrahepatic", "ANATOMY", 75, 87], ["hepatic", "ANATOMY", 96, 103]]], ["This can paradoxically lead to enhanced thrombogenicity in a state of low vitamin K [5] .IntroductionMatrix Gla protein (MGP) is also vitamin K-dependent but not involved in coagulation [6] .", [["vitamin K", "CHEMICAL", 74, 83], ["vitamin K-", "CHEMICAL", 134, 144], ["vitamin K", "CHEMICAL", 74, 83], ["vitamin K-", "CHEMICAL", 134, 144], ["vitamin K", "SIMPLE_CHEMICAL", 74, 83], ["Matrix Gla protein", "GENE_OR_GENE_PRODUCT", 101, 119], ["MGP", "GENE_OR_GENE_PRODUCT", 121, 124], ["vitamin K-", "GENE_OR_GENE_PRODUCT", 134, 144], ["Matrix Gla protein", "PROTEIN", 101, 119], ["MGP", "PROTEIN", 121, 124], ["enhanced thrombogenicity", "PROBLEM", 31, 55], ["low vitamin K", "TREATMENT", 70, 83], ["IntroductionMatrix Gla protein (MGP)", "TREATMENT", 89, 125], ["vitamin K-dependent", "PROBLEM", 134, 153], ["enhanced", "OBSERVATION_MODIFIER", 31, 39], ["thrombogenicity", "OBSERVATION", 40, 55]]], ["MGP is well-known as a calcification inhibitor in arterial walls [7] , but MGP's role in the pulmonary compartment seems to be comparable [8, 9] .", [["arterial walls", "ANATOMY", 50, 64], ["pulmonary compartment", "ANATOMY", 93, 114], ["calcification", "DISEASE", 23, 36], ["MGP", "GENE_OR_GENE_PRODUCT", 0, 3], ["arterial walls", "MULTI-TISSUE_STRUCTURE", 50, 64], ["MGP", "GENE_OR_GENE_PRODUCT", 75, 78], ["pulmonary compartment", "MULTI-TISSUE_STRUCTURE", 93, 114], ["MGP", "PROTEIN", 0, 3], ["MGP", "PROTEIN", 75, 78], ["a calcification inhibitor in arterial walls", "PROBLEM", 21, 64], ["MGP's role", "TEST", 75, 85], ["calcification", "OBSERVATION", 23, 36], ["arterial", "ANATOMY", 50, 58], ["walls", "ANATOMY_MODIFIER", 59, 64], ["pulmonary", "ANATOMY", 93, 102], ["compartment", "ANATOMY_MODIFIER", 103, 114]]], ["Elastic fibers are essential matrix components in lungs and have high calcium affinity [10] .", [["Elastic fibers", "ANATOMY", 0, 14], ["matrix components", "ANATOMY", 29, 46], ["lungs", "ANATOMY", 50, 55], ["calcium", "CHEMICAL", 70, 77], ["calcium", "CHEMICAL", 70, 77], ["Elastic fibers", "CELLULAR_COMPONENT", 0, 14], ["matrix components", "CELLULAR_COMPONENT", 29, 46], ["lungs", "ORGAN", 50, 55], ["calcium", "SIMPLE_CHEMICAL", 70, 77], ["Elastic fibers", "TREATMENT", 0, 14], ["essential matrix components in lungs", "PROBLEM", 19, 55], ["high calcium affinity", "PROBLEM", 65, 86], ["essential", "OBSERVATION_MODIFIER", 19, 28], ["matrix", "OBSERVATION_MODIFIER", 29, 35], ["components", "OBSERVATION_MODIFIER", 36, 46], ["lungs", "ANATOMY", 50, 55], ["high", "OBSERVATION_MODIFIER", 65, 69], ["calcium affinity", "OBSERVATION_MODIFIER", 70, 86]]], ["Degradation and mineralization of elastic fibers are interrelated processes [11, 12] .", [["elastic fibers", "ANATOMY", 34, 48], ["elastic fibers", "CELLULAR_COMPONENT", 34, 48], ["mineralization", "OBSERVATION_MODIFIER", 16, 30], ["elastic fibers", "OBSERVATION", 34, 48]]], ["Matrix metalloproteinases (MMPs) synthesis increases parallel with elastic fiber calcification [13] , and partially degraded elastic fibers become prone to mineralization [10] .", [["elastic fiber", "ANATOMY", 67, 80], ["elastic fibers", "ANATOMY", 125, 139], ["calcification", "DISEASE", 81, 94], ["Matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 0, 25], ["MMPs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Matrix metalloproteinases", "PROTEIN", 0, 25], ["MMPs", "PROTEIN", 27, 31], ["Matrix metalloproteinases (MMPs) synthesis", "TEST", 0, 42], ["elastic fiber calcification", "PROBLEM", 67, 94], ["elastic", "OBSERVATION_MODIFIER", 67, 74], ["fiber calcification", "OBSERVATION", 75, 94]]], ["Recent data show that a subset of MMP-producing macrophages is increased in severe SARS-CoV-2 pneumonia [14] .", [["macrophages", "ANATOMY", 48, 59], ["SARS", "DISEASE", 83, 87], ["pneumonia", "DISEASE", 94, 103], ["MMP", "GENE_OR_GENE_PRODUCT", 34, 37], ["macrophages", "CELL", 48, 59], ["SARS-CoV-2", "ORGANISM", 83, 93], ["MMP", "PROTEIN", 34, 37], ["macrophages", "CELL_TYPE", 48, 59], ["CoV-2", "SPECIES", 88, 93], ["Recent data", "TEST", 0, 11], ["MMP", "PROBLEM", 34, 37], ["macrophages", "PROBLEM", 48, 59], ["severe SARS", "PROBLEM", 76, 87], ["CoV-2 pneumonia", "PROBLEM", 88, 103], ["macrophages", "OBSERVATION", 48, 59], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["SARS", "OBSERVATION", 83, 87], ["pneumonia", "OBSERVATION", 94, 103]]], ["COVID-19 may theoretically be linked to both vitamin K deficiency and elastic fiber metabolism through a series of sequential pathologic steps (figure 2).IntroductionA c c e p t e d M a n u s c r i p t 5 Individuals with severe SARS-CoV-2 infections often have comorbidities that are associated with reduced vitamin K status, such as hypertension, diabetes, and cardiovascular diseases [1, 7] .", [["elastic fiber", "ANATOMY", 70, 83], ["cardiovascular", "ANATOMY", 362, 376], ["vitamin K", "CHEMICAL", 45, 54], ["SARS-CoV-2 infections", "DISEASE", 228, 249], ["vitamin K", "CHEMICAL", 308, 317], ["hypertension", "DISEASE", 334, 346], ["diabetes", "DISEASE", 348, 356], ["cardiovascular diseases", "DISEASE", 362, 385], ["vitamin K", "CHEMICAL", 45, 54], ["vitamin K", "CHEMICAL", 308, 317], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["vitamin K", "SIMPLE_CHEMICAL", 45, 54], ["elastic fiber", "MULTI-TISSUE_STRUCTURE", 70, 83], ["vitamin K", "SIMPLE_CHEMICAL", 308, 317], ["COVID", "TEST", 0, 5], ["vitamin K deficiency", "PROBLEM", 45, 65], ["elastic fiber metabolism", "TREATMENT", 70, 94], ["a n u s", "TEST", 184, 191], ["severe SARS", "PROBLEM", 221, 232], ["CoV", "PROBLEM", 233, 236], ["2 infections", "PROBLEM", 237, 249], ["comorbidities", "PROBLEM", 261, 274], ["reduced vitamin K status", "PROBLEM", 300, 324], ["hypertension", "PROBLEM", 334, 346], ["diabetes", "PROBLEM", 348, 356], ["cardiovascular diseases", "PROBLEM", 362, 385], ["fiber metabolism", "OBSERVATION", 78, 94], ["severe", "OBSERVATION_MODIFIER", 221, 227], ["SARS", "OBSERVATION", 228, 232], ["hypertension", "OBSERVATION", 334, 346], ["diabetes", "OBSERVATION", 348, 356], ["cardiovascular", "ANATOMY", 362, 376]]], ["The body uses vitamin K very efficiently, and storage capacity is low [15] .", [["body", "ANATOMY", 4, 8], ["vitamin K", "CHEMICAL", 14, 23], ["vitamin K", "CHEMICAL", 14, 23], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["vitamin K", "SIMPLE_CHEMICAL", 14, 23], ["vitamin K", "TREATMENT", 14, 23], ["storage capacity", "TEST", 46, 62]]], ["There are reasons to suspect that there is increased utilization of vitamin K for carboxylation of pulmonary MGP and coagulant factors during COVID-19 [16] .", [["pulmonary", "ANATOMY", 99, 108], ["vitamin K", "CHEMICAL", 68, 77], ["vitamin K", "CHEMICAL", 68, 77], ["COVID-19", "CHEMICAL", 142, 150], ["vitamin K", "SIMPLE_CHEMICAL", 68, 77], ["pulmonary", "ORGAN", 99, 108], ["MGP", "GENE_OR_GENE_PRODUCT", 109, 112], ["coagulant factors", "GENE_OR_GENE_PRODUCT", 117, 134], ["pulmonary MGP", "PROTEIN", 99, 112], ["coagulant factors", "PROTEIN", 117, 134], ["vitamin K", "TREATMENT", 68, 77], ["carboxylation of pulmonary MGP", "TREATMENT", 82, 112], ["coagulant factors", "TEST", 117, 134], ["COVID", "TEST", 142, 147], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["pulmonary", "ANATOMY", 99, 108]]], ["Vitamin K depletion may have devastating consequences in lungs [17] .IntroductionThe aim of this study was to evaluate whether a reduced vitamin K status plays a role in the pathogenesis of COVID-19 through interacting with both elastic fiber metabolism and the coagulation cascade, thereby linking pulmonary and coagulopathic disease manifestations.subjects hospitalized for COVID-19 in the Canisius-Wilhelmina Hospital between March 12 th andApril 15 th 2020 were included.", [["lungs", "ANATOMY", 57, 62], ["elastic fiber", "ANATOMY", 229, 242], ["pulmonary", "ANATOMY", 299, 308], ["Vitamin K", "CHEMICAL", 0, 9], ["vitamin K", "CHEMICAL", 137, 146], ["COVID-19", "CHEMICAL", 190, 198], ["Vitamin K", "CHEMICAL", 0, 9], ["vitamin K", "CHEMICAL", 137, 146], ["COVID-19", "CHEMICAL", 190, 198], ["Vitamin K", "SIMPLE_CHEMICAL", 0, 9], ["lungs", "ORGAN", 57, 62], ["vitamin K", "SIMPLE_CHEMICAL", 137, 146], ["COVID-19", "GENE_OR_GENE_PRODUCT", 190, 198], ["elastic fiber", "CELLULAR_COMPONENT", 229, 242], ["pulmonary", "ORGAN", 299, 308], ["Vitamin K depletion", "TREATMENT", 0, 19], ["devastating consequences in lungs", "PROBLEM", 29, 62], ["this study", "TEST", 92, 102], ["a reduced vitamin K status", "PROBLEM", 127, 153], ["COVID", "TEST", 190, 195], ["both elastic fiber metabolism", "TREATMENT", 224, 253], ["the coagulation cascade", "TEST", 258, 281], ["pulmonary and coagulopathic disease manifestations", "PROBLEM", 299, 349], ["lungs", "ANATOMY", 57, 62], ["elastic fiber metabolism", "OBSERVATION", 229, 253], ["pulmonary", "ANATOMY", 299, 308], ["coagulopathic disease", "OBSERVATION", 313, 334]]], ["SARS-CoV-2 infection was confirmed by Real Time polymerase chainreaction testing.", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["Real Time polymerase chainreaction testing", "TEST", 38, 80], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 11, 20]]], ["Patient data was extracted from hospital records, and vitamin K antagonist (VKA) usage was determined from pharmacy and anticoagulant clinic records.", [["vitamin K", "CHEMICAL", 54, 63], ["VKA", "CHEMICAL", 76, 79], ["vitamin K", "CHEMICAL", 54, 63], ["vitamin K antagonist", "SIMPLE_CHEMICAL", 54, 74], ["VKA", "SIMPLE_CHEMICAL", 76, 79], ["Patient", "SPECIES", 0, 7], ["vitamin K antagonist (VKA", "TREATMENT", 54, 79]]], ["The study was approved by the United Medical Research Ethics Committees of the Canisius-Wilhelmina Hospital (CWZ-nr.", [["The study", "TEST", 0, 9]]], ["027-2020; date of approval 12 th March 2020), which waived the need for written informed consent.subjects hospitalized for COVID-19 in the Canisius-Wilhelmina Hospital between March 12 th andPatients could opt-out after they were informed about the study.", [["Patients", "ORGANISM", 191, 199], ["Patients", "SPECIES", 191, 199], ["the study", "TEST", 245, 254]]], ["186 control subjects from a previously published COPD study were included in addition (www.controlled-trials.com, identifier ISRCTN86049077) [18] .", [["COPD", "DISEASE", 49, 53], ["a previously published COPD study", "PROBLEM", 26, 59]]], ["Two control subjects where the use of VKA was unknown were excluded from the analysis.subjects hospitalized for COVID-19 in the Canisius-Wilhelmina Hospital between March 12 th andPatients were followed-up until: 1) discharge from the hospital, 2) intubation and mechanical ventilation, or 3) death.", [["VKA", "CHEMICAL", 38, 41], ["death", "DISEASE", 293, 298], ["Patients", "ORGANISM", 180, 188], ["Patients", "SPECIES", 180, 188], ["VKA", "TREATMENT", 38, 41], ["the analysis", "TEST", 73, 85], ["intubation", "TREATMENT", 248, 258], ["mechanical ventilation", "TREATMENT", 263, 285], ["death", "PROBLEM", 293, 298]]], ["Outcome of COVID-19 patients was categorized as \"good\" if they were discharged from the hospital without the need for invasive ventilation, and \"poor\" if they either M a n u s c r i p t 6 required intubation and mechanical ventilation or died.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 11, 16], ["invasive ventilation", "TREATMENT", 118, 138], ["intubation", "TREATMENT", 197, 207], ["mechanical ventilation", "TREATMENT", 212, 234]]], ["During admission blood was sampled three times per week and EDTA plasma and serum were frozen at -80\u00b0C for retrospective analysis.Dp-ucMGPDirect quantification of blood vitamin K is not appropriate to assess vitamin K status due to differences in bioavailability and half-life time between the two naturally occurring forms (vitamin K1 and K2).", [["blood", "ANATOMY", 17, 22], ["plasma", "ANATOMY", 65, 71], ["serum", "ANATOMY", 76, 81], ["blood", "ANATOMY", 163, 168], ["vitamin K", "CHEMICAL", 169, 178], ["vitamin K", "CHEMICAL", 208, 217], ["vitamin K1", "CHEMICAL", 325, 335], ["EDTA", "CHEMICAL", 60, 64], ["vitamin K", "CHEMICAL", 169, 178], ["vitamin K", "CHEMICAL", 208, 217], ["vitamin K1 and K2", "CHEMICAL", 325, 342], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["EDTA", "ORGANISM_SUBSTANCE", 60, 64], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["vitamin K", "SIMPLE_CHEMICAL", 169, 178], ["vitamin K", "SIMPLE_CHEMICAL", 208, 217], ["vitamin K1", "SIMPLE_CHEMICAL", 325, 335], ["K2", "SIMPLE_CHEMICAL", 340, 342], ["blood", "TEST", 17, 22], ["EDTA plasma", "TEST", 60, 71], ["serum", "TEST", 76, 81], ["retrospective analysis", "TEST", 107, 129], ["blood vitamin K", "TEST", 163, 178], ["vitamin K status", "TEST", 208, 224], ["vitamin K1 and K2)", "TREATMENT", 325, 343]]], ["Additionally, the intake of vitamin K2 is too low to measure accurately.", [["vitamin K2", "CHEMICAL", 28, 38], ["vitamin K2", "CHEMICAL", 28, 38], ["vitamin K2", "SIMPLE_CHEMICAL", 28, 38], ["vitamin K2", "TREATMENT", 28, 38]]], ["Measuring inactive levels of vitamin K-dependent protein in the circulation is a valuable method to quantify the combined deficit of vitamin K1 and K2.", [["vitamin", "CHEMICAL", 29, 36], ["vitamin K1", "CHEMICAL", 133, 143], ["vitamin K-dependent", "CHEMICAL", 29, 48], ["vitamin K1 and K2", "CHEMICAL", 133, 150], ["vitamin", "SIMPLE_CHEMICAL", 29, 36], ["vitamin K1", "SIMPLE_CHEMICAL", 133, 143], ["K2", "SIMPLE_CHEMICAL", 148, 150], ["vitamin K-dependent protein", "PROTEIN", 29, 56], ["vitamin K-dependent protein", "TEST", 29, 56], ["vitamin K1", "TREATMENT", 133, 143], ["K2", "TREATMENT", 148, 150], ["circulation", "ANATOMY", 64, 75]]], ["Desphospho-uncarboxylated (dp-uc)MGP (inactive MGP) is an appropriate indirect marker of extrahepatic vitamin K status [19, 20] .", [["extrahepatic", "ANATOMY", 89, 101], ["Desphospho-uncarboxylated", "CHEMICAL", 0, 25], ["vitamin K", "CHEMICAL", 102, 111], ["Desphospho", "CHEMICAL", 0, 10], ["vitamin K", "CHEMICAL", 102, 111], ["Desphospho", "SIMPLE_CHEMICAL", 0, 10], ["dp-uc)MGP", "GENE_OR_GENE_PRODUCT", 27, 36], ["MGP", "GENE_OR_GENE_PRODUCT", 47, 50], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 89, 111], ["Desphospho-uncarboxylated (dp-uc)MGP", "PROTEIN", 0, 36], ["inactive MGP", "PROTEIN", 38, 50], ["Desphospho", "TEST", 0, 10], ["MGP (inactive MGP", "PROBLEM", 33, 50], ["extrahepatic vitamin K status", "TEST", 89, 118], ["extrahepatic", "ANATOMY", 89, 101]]], ["Subjects with high dp-ucMGP levels have low extrahepatic vitamin K status and vice versa.Dp-ucMGPCirculating dp-ucMGP levels were determined in EDTA plasma using the commercially available IVD chemiluminescent InaKif MGP assay on the IDS-iSYS system (IDS, Boldon, UK) as previously described [21] .", [["extrahepatic", "ANATOMY", 44, 56], ["EDTA plasma", "ANATOMY", 144, 155], ["vitamin K", "CHEMICAL", 57, 66], ["vitamin K", "CHEMICAL", 57, 66], ["EDTA", "CHEMICAL", 144, 148], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 19, 27], ["vitamin K", "SIMPLE_CHEMICAL", 57, 66], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 109, 117], ["EDTA", "ORGANISM_SUBSTANCE", 144, 148], ["plasma", "ORGANISM_SUBSTANCE", 149, 155], ["ucMGP", "DNA", 112, 117], ["MGP", "PROTEIN", 217, 220], ["ucMGP levels", "TEST", 22, 34], ["low extrahepatic vitamin K status", "PROBLEM", 40, 73], ["Dp-ucMGPCirculating dp", "TEST", 89, 111], ["ucMGP levels", "TEST", 112, 124], ["EDTA plasma", "TEST", 144, 155], ["IVD chemiluminescent", "TEST", 189, 209], ["extrahepatic", "ANATOMY", 44, 56]]], ["The within-run and total precision of this assay were 0.8-6.2% and 3.0-8.2%, respectively.Dp-ucMGPThe assay measuring range is between 200-12,000pmol/L and was found to be linear up to 11,651pmol/L. Dp-ucMGP values <300pmol/L are in the normal healthy range and values >500pmol/L reflect vitamin K deficiency [22] .PIVKA-IIProtein induced by vitamin K absence (PIVKA)-II was used to assess hepatic vitamin K status.", [["hepatic", "ANATOMY", 390, 397], ["vitamin K", "CHEMICAL", 288, 297], ["PIVKA-IIProtein", "CHEMICAL", 315, 330], ["vitamin K", "CHEMICAL", 342, 351], ["vitamin K", "CHEMICAL", 398, 407], ["vitamin K", "CHEMICAL", 288, 297], ["vitamin K", "CHEMICAL", 342, 351], ["vitamin K", "CHEMICAL", 398, 407], ["ucMGP", "GENE_OR_GENE_PRODUCT", 202, 207], ["vitamin K", "SIMPLE_CHEMICAL", 288, 297], ["PIVKA-IIProtein", "GENE_OR_GENE_PRODUCT", 315, 330], ["vitamin K", "SIMPLE_CHEMICAL", 342, 351], ["vitamin K", "SIMPLE_CHEMICAL", 398, 407], ["PIVKA", "PROTEIN", 315, 320], ["IIProtein", "PROTEIN", 321, 330], ["this assay", "TEST", 38, 48], ["Dp-ucMGPThe assay", "TEST", 90, 107], ["Dp-ucMGP values", "TEST", 199, 214], ["300pmol", "TEST", 216, 223], ["values", "TEST", 262, 268], ["vitamin K deficiency", "PROBLEM", 288, 308], ["PIVKA", "TEST", 315, 320], ["IIProtein", "TREATMENT", 321, 330], ["vitamin K absence", "TREATMENT", 342, 359], ["healthy range", "OBSERVATION_MODIFIER", 244, 257], ["hepatic", "ANATOMY", 390, 397]]], ["Subjects with high PIVKA-II levels have low hepatic vitamin K status and vice versa.", [["hepatic", "ANATOMY", 44, 51], ["vitamin K", "CHEMICAL", 52, 61], ["vitamin K", "CHEMICAL", 52, 61], ["PIVKA-II", "GENE_OR_GENE_PRODUCT", 19, 27], ["hepatic", "ORGAN", 44, 51], ["vitamin K", "SIMPLE_CHEMICAL", 52, 61], ["PIVKA", "PROTEIN", 19, 24], ["low hepatic vitamin K status", "PROBLEM", 40, 68], ["hepatic", "ANATOMY", 44, 51]]], ["Circulating PIVKA-II levels were measured in serum using a conformation-specific monoclonal antibody in an ELISA-based assay as previously described [23] .", [["serum", "ANATOMY", 45, 50], ["PIVKA-II", "CHEMICAL", 12, 20], ["PIVKA-II", "GENE_OR_GENE_PRODUCT", 12, 20], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["PIVKA", "PROTEIN", 12, 17], ["monoclonal antibody", "PROTEIN", 81, 100], ["Circulating PIVKA-II levels", "TEST", 0, 27], ["a conformation", "TEST", 57, 71], ["specific monoclonal antibody", "TEST", 72, 100], ["an ELISA", "TEST", 104, 112], ["monoclonal antibody", "OBSERVATION", 81, 100]]], ["The detection limit, as well as upper limit of normal, was 0.15AU/mL [23] .PIVKA-IIA c c e p t e d M a n u s c r i p t 7 Desmosine Plasma (p)desmosine and isodesmosine (DES) levels were used as a marker for the rate of elastic fiber degradation [24] .", [["elastic fiber", "ANATOMY", 219, 232], ["desmosine", "CHEMICAL", 141, 150], ["isodesmosine", "CHEMICAL", 155, 167], ["DES", "CHEMICAL", 169, 172], ["desmosine", "CHEMICAL", 141, 150], ["isodesmosine", "CHEMICAL", 155, 167], ["DES", "CHEMICAL", 169, 172], ["Plasma (p)desmosine", "SIMPLE_CHEMICAL", 131, 150], ["isodesmosine", "SIMPLE_CHEMICAL", 155, 167], ["DES", "SIMPLE_CHEMICAL", 169, 172], ["The detection limit", "TEST", 0, 19], ["PIVKA", "TEST", 75, 80], ["a n u s", "TEST", 101, 108], ["r i", "TEST", 111, 114], ["t", "TEST", 117, 118], ["Desmosine Plasma", "TEST", 121, 137], ["desmosine and isodesmosine (DES) levels", "TREATMENT", 141, 180], ["elastic fiber degradation", "TREATMENT", 219, 244], ["upper limit", "OBSERVATION_MODIFIER", 32, 43], ["normal", "OBSERVATION", 47, 53], ["elastic fiber", "OBSERVATION", 219, 232]]], ["DES are formed during the cross-linking of tropo-elastin polymers and are released in the bloodstream after degradation of elastic fibers [24] . pDES directly reflects the rate of systemic elastic fiber degradation.PIVKA-IIDES fractions were measured using liquid chromatography-tandem mass spectrometry as previously described [18, 24] .", [["bloodstream", "ANATOMY", 90, 101], ["elastic fibers", "ANATOMY", 123, 137], ["elastic fiber", "ANATOMY", 189, 202], ["DES", "CHEMICAL", 0, 3], ["DES", "CHEMICAL", 0, 3], ["DES", "SIMPLE_CHEMICAL", 0, 3], ["tropo-elastin polymers", "SIMPLE_CHEMICAL", 43, 65], ["pDES", "SIMPLE_CHEMICAL", 145, 149], ["PIVKA", "SIMPLE_CHEMICAL", 215, 220], ["pDES", "PROTEIN", 145, 149], ["DES", "TREATMENT", 0, 3], ["the cross-linking of tropo-elastin polymers", "TREATMENT", 22, 65], ["pDES", "TEST", 145, 149], ["systemic elastic fiber degradation", "TREATMENT", 180, 214], ["liquid chromatography", "TEST", 257, 278], ["tandem mass spectrometry", "PROBLEM", 279, 303], ["bloodstream", "ANATOMY", 90, 101], ["systemic elastic", "OBSERVATION", 180, 196], ["fiber degradation", "OBSERVATION", 197, 214]]], ["Coefficient of variations of intra-and inter-assay imprecision were <8.2%, lower limit of quantification of 140ng/L, and assay linearity up to 210,000ng/L.CT assessmentThin slice CT scans were acquired by using a Philips Ingenuity multi-detector row scanner (Philips Healthcare).", [["Thin slice", "MULTI-TISSUE_STRUCTURE", 168, 178], ["intra-and inter-assay imprecision", "TEST", 29, 62], ["quantification", "TEST", 90, 104], ["assay linearity", "TEST", 121, 136], ["L.CT assessment", "TEST", 153, 168], ["Thin slice CT scans", "TEST", 168, 187]]], ["CT images of 1-mm thickness were reconstructed by using iterative model-based reconstruction in the axial plane.CT assessmentQuantitative measurements of the volume of ground glass and consolidation were undertaken using the Intellispace Portal (COPD package, Intellispace version 10, Philips Healthcare).", [["CT images", "TEST", 0, 9], ["iterative model-based reconstruction in the axial plane", "TREATMENT", 56, 111], ["CT assessment", "TEST", 112, 125], ["ground glass", "PROBLEM", 168, 180], ["consolidation", "PROBLEM", 185, 198], ["the Intellispace Portal (COPD package", "TREATMENT", 221, 258], ["Intellispace version", "TREATMENT", 260, 280], ["volume", "OBSERVATION_MODIFIER", 158, 164], ["ground glass", "OBSERVATION", 168, 180], ["consolidation", "OBSERVATION", 185, 198], ["Portal", "ANATOMY", 238, 244]]], ["In the software, first the lungs were segmented from the chest wall and major vessels and main bronchi.", [["lungs", "ANATOMY", 27, 32], ["chest wall", "ANATOMY", 57, 67], ["vessels", "ANATOMY", 78, 85], ["bronchi", "ANATOMY", 95, 102], ["lungs", "ORGAN", 27, 32], ["chest wall", "MULTI-TISSUE_STRUCTURE", 57, 67], ["vessels", "MULTI-TISSUE_STRUCTURE", 78, 85], ["bronchi", "MULTI-TISSUE_STRUCTURE", 95, 102], ["lungs", "ANATOMY", 27, 32], ["segmented", "OBSERVATION", 38, 47], ["chest", "ANATOMY", 57, 62], ["wall", "ANATOMY_MODIFIER", 63, 67], ["major vessels", "ANATOMY", 72, 85], ["main", "ANATOMY_MODIFIER", 90, 94], ["bronchi", "ANATOMY", 95, 102]]], ["Manual adjustments were implemented where required by a board-certified chest radiologist.", [["chest", "ORGAN", 72, 77], ["Manual adjustments", "TREATMENT", 0, 18], ["chest", "ANATOMY", 72, 77]]], ["Subsequently, the lung voxels were counted to derive a total lung volume in milliliters.", [["lung voxels", "ANATOMY", 18, 29], ["lung", "ANATOMY", 61, 65], ["lung", "ORGAN", 18, 22], ["lung", "ORGAN", 61, 65], ["the lung voxels", "TEST", 14, 29], ["a total lung volume in milliliters", "TREATMENT", 53, 87], ["lung", "ANATOMY", 18, 22], ["lung", "ANATOMY", 61, 65], ["volume", "OBSERVATION", 66, 72]]], ["Diseased lung tissue was defined as those voxels with an attenuation of Hounsfield Units (HU) > -700 as previously defined.CT assessmentThe abnormal voxels were expressed as a percentage diseased lung of the total volume.", [["lung tissue", "ANATOMY", 9, 20], ["lung", "ANATOMY", 196, 200], ["lung tissue", "TISSUE", 9, 20], ["lung", "ORGAN", 196, 200], ["Diseased lung tissue", "PROBLEM", 0, 20], ["HU", "TEST", 90, 92], ["CT assessment", "TEST", 123, 136], ["The abnormal voxels", "PROBLEM", 136, 155], ["a percentage diseased lung of the total volume", "PROBLEM", 174, 220], ["lung", "ANATOMY", 9, 13], ["tissue", "OBSERVATION", 14, 20], ["attenuation", "OBSERVATION_MODIFIER", 57, 68], ["Hounsfield Units", "OBSERVATION_MODIFIER", 72, 88], ["abnormal voxels", "OBSERVATION", 140, 155], ["percentage", "OBSERVATION_MODIFIER", 176, 186], ["diseased", "OBSERVATION", 187, 195], ["lung", "ANATOMY", 196, 200], ["total volume", "OBSERVATION_MODIFIER", 208, 220]]], ["HU value at the 85th percentile was used [25, 26] .CT assessmentCoronary and thoracic aortic calcification (CAC and TAC, respectively) were also quantified in the Intellispace Portal (Heartbeat CS package).", [["Coronary", "ANATOMY", 64, 72], ["thoracic aortic", "ANATOMY", 77, 92], ["Coronary and thoracic aortic calcification", "DISEASE", 64, 106], ["Coronary", "MULTI-TISSUE_STRUCTURE", 64, 72], ["thoracic aortic", "MULTI-TISSUE_STRUCTURE", 77, 92], ["HU value", "TEST", 0, 8], [".CT assessment", "TEST", 50, 64], ["Coronary and thoracic aortic calcification", "PROBLEM", 64, 106], ["CAC", "TEST", 108, 111], ["Coronary", "ANATOMY", 64, 72], ["thoracic aortic", "ANATOMY", 77, 92], ["calcification", "OBSERVATION", 93, 106], ["Intellispace", "ANATOMY_MODIFIER", 163, 175], ["Portal", "ANATOMY", 176, 182]]], ["Calcifications were defined as areas with a HU of 130 and higher.", [["Calcifications", "DISEASE", 0, 14], ["Calcifications", "PROBLEM", 0, 14], ["a HU", "TEST", 42, 46], ["HU", "OBSERVATION_MODIFIER", 44, 46], ["higher", "OBSERVATION_MODIFIER", 58, 64]]], ["The calcifications were visually localized up to the arterial wall by a board-certified chest A c c e p t e d M a n u s c r i p t 8 radiologist and semi-automatically segmented.", [["arterial wall", "ANATOMY", 53, 66], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 53, 66], ["The calcifications", "PROBLEM", 0, 18], ["a n u s", "TEST", 112, 119], ["calcifications", "OBSERVATION", 4, 18], ["arterial", "ANATOMY", 53, 61], ["wall", "ANATOMY_MODIFIER", 62, 66], ["chest", "ANATOMY", 88, 93]]], ["The volume was used as a measure of calcification burden.Statistical analysisStatistical analyses were performed using SPSS (version 24, IBM, Chicago, IL, USA).", [["calcification", "DISEASE", 36, 49], ["calcification burden", "PROBLEM", 36, 56], ["Statistical analysisStatistical analyses", "TEST", 57, 97], ["SPSS (version", "TEST", 119, 132], ["IBM", "TEST", 137, 140], ["calcification", "OBSERVATION", 36, 49]]], ["Analysis of variance (ANOVA) was used to compare dp-ucMGP, pDES and radiological scores between groups.Statistical analysisAnalysis of covariance (ANCOVA) was used to perform aforementioned analyses: dp-ucMGP, CAC and TAC adjusted for age, sex, and use of VKA, and pDES adjusted for age.Statistical analysisFor each pDES measurement in a COVID-19 patient, virtual age-matched pDES values were calculated using published pDES equations for never and (ex-)smokers [24] . pDES is strongly dialyzed (R. Janssen, unpublished data), and patients receiving dialysis at baseline were excluded from pDES analyses.Statistical analysisSpearman's correlation coefficient was used to test the association of closest time-matched dp-ucMGP with pDES and radiological scores.Statistical analysisFor PIVKA-II, patients were categorized as follows: normal <0.15AU/mL, mildly elevated 0.15-0.5AUmL, moderately elevated 0.5-2.0AU/mL and severely elevated >2.0AU/mL.", [["TAC", "CHEMICAL", 218, 221], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 200, 208], ["patient", "ORGANISM", 347, 354], ["patients", "ORGANISM", 531, 539], ["patients", "ORGANISM", 793, 801], ["pDES", "DNA", 316, 320], ["dp", "DNA", 716, 718], ["ucMGP", "DNA", 719, 724], ["patient", "SPECIES", 347, 354], ["patients", "SPECIES", 531, 539], ["patients", "SPECIES", 793, 801], ["dp", "TEST", 49, 51], ["Statistical analysis", "TEST", 103, 123], ["covariance (ANCOVA)", "TEST", 135, 154], ["aforementioned analyses", "TEST", 175, 198], ["dp", "TEST", 200, 202], ["CAC", "TEST", 210, 213], ["TAC", "TREATMENT", 218, 221], ["VKA", "TREATMENT", 256, 259], ["Statistical analysis", "TEST", 287, 307], ["each pDES measurement", "TEST", 311, 332], ["a COVID", "TEST", 336, 343], ["pDES values", "TEST", 376, 387], ["published pDES equations", "TEST", 410, 434], ["dialysis", "TREATMENT", 550, 558], ["pDES analyses", "TEST", 590, 603], ["Statistical analysisSpearman's correlation", "TEST", 604, 646], ["radiological scores", "TEST", 739, 758], ["Statistical analysis", "TEST", 759, 779], ["PIVKA", "TEST", 783, 788], ["mildly elevated", "PROBLEM", 850, 865], ["AUmL", "TEST", 874, 878], ["moderately elevated", "PROBLEM", 880, 899], ["severely elevated", "PROBLEM", 917, 934], ["VKA", "OBSERVATION", 256, 259], ["strongly", "OBSERVATION_MODIFIER", 477, 485], ["dialyzed", "OBSERVATION", 486, 494], ["mildly", "OBSERVATION_MODIFIER", 850, 856], ["elevated", "OBSERVATION", 857, 865], ["moderately", "OBSERVATION_MODIFIER", 880, 890], ["elevated", "OBSERVATION", 891, 899], ["elevated", "OBSERVATION", 926, 934]]], ["Dp-ucMGP, pDES, and radiological scores had a log-normal distribution and were therefore natural log-transformed prior to analyses.", [["Dp-ucMGP", "TEST", 0, 8], ["pDES", "TEST", 10, 14], ["radiological scores", "TEST", 20, 39], ["analyses", "TEST", 122, 130], ["normal", "OBSERVATION", 50, 56]]], ["Since CAC and TAC scores included values equal to zero, these values were transformed using Ln(CAC+1) and Ln(TAC+1), respectively.", [["Ln(TAC+1", "CHEMICAL", 106, 114], ["CAC", "TEST", 6, 9], ["TAC scores", "TEST", 14, 24], ["values", "TEST", 34, 40], ["these values", "TEST", 56, 68], ["Ln", "TEST", 92, 94], ["CAC", "TEST", 95, 98], ["Ln(TAC", "TEST", 106, 112], ["Ln", "ANATOMY", 106, 108]]], ["The mean difference and 95% Confidence Interval (CI) of log-transformed values was back-transformed to the mean fold change.", [["The mean difference", "PROBLEM", 0, 19], ["CI", "TEST", 49, 51], ["the mean fold change", "PROBLEM", 103, 123], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["mean fold", "OBSERVATION", 107, 116]]], ["Normally distributed continuous variables are presented as mean \u00b1 standard deviation (SD), whereas continuous variables with a natural-log distribution were presented as back-transformed mean and 95% CI.", [["standard deviation (SD)", "PROBLEM", 66, 89]]], ["A P-value of <0.05 was used as threshold for statistical significance.Statistical analysisA c c e p t e d M a n u s c r i p tResultsThe mean age of COVID-19 patients was 68\u00b112 years, 93 (69%) were male, and 12 (8.9%) used VKA.ResultsOf the historical controls, 85 (46%) were male, 3 subjects (1.6%) were taking VKA, and mean age was 61\u00b16.5 years.", [["VKA", "CHEMICAL", 222, 225], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["A P-value", "TEST", 0, 9], ["a n u s", "TEST", 108, 115], ["tResults", "TEST", 124, 132], ["COVID", "TEST", 148, 153], ["VKA", "TREATMENT", 222, 225], ["VKA", "TREATMENT", 311, 314]]], ["Patient and control characteristics are shown in Table 1 .Dp-ucMGPDp-ucMGP was measured in all available samples.", [["samples", "ANATOMY", 105, 112], ["ucMGP", "DNA", 69, 74], ["Patient", "SPECIES", 0, 7]]], ["Maximum dp-ucMGP levels were significantly higher in COVID-19 patients (1476pmol/L, 95% CI, 1341 to 1625) compared to healthy controls (471pmol/L, 95% CI, 434 to 511, mean fold change 3.14, 95% CI, 2.76 to 3.56, p<0.001, figure 3A ), which remained significant after adjustment for age, sex, and use of VKAs (p<0.001).", [["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 8, 16], ["patients", "ORGANISM", 62, 70], ["ucMGP", "PROTEIN", 11, 16], ["patients", "SPECIES", 62, 70], ["Maximum dp", "TEST", 0, 10], ["ucMGP levels", "TEST", 11, 23], ["COVID", "TEST", 53, 58], ["pmol", "TEST", 76, 80], ["CI", "TEST", 88, 90], ["pmol", "TEST", 139, 143], ["CI", "TEST", 151, 153], ["mean fold change", "TEST", 167, 183], ["CI", "TEST", 194, 196], ["p", "TEST", 212, 213], ["VKAs", "TREATMENT", 303, 307], ["significant", "OBSERVATION_MODIFIER", 249, 260]]], ["Dp-ucMGP levels were significantly higher in COVID-19 patients with poor outcome (1998pmol/L, 95% CI, 1737 to 2296) compared to those with good outcome (1157pmol/L, 95% CI, 1022 to 1312, mean fold change 1.73, 95% CI, 1.43 to 2.08, p<0.001; figure 3A), and significance was maintained after adjustments (p<0.001).PIVKA-IIPIVKA-II was measured in the first available sample after admission.", [["PIVKA-IIPIVKA-II", "CHEMICAL", 313, 329], ["Dp-ucMGP", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 54, 62], ["PIVKA-IIPIVKA-II", "GENE_OR_GENE_PRODUCT", 313, 329], ["ucMGP", "PROTEIN", 3, 8], ["PIVKA-IIPIVKA-II", "DNA", 313, 329], ["patients", "SPECIES", 54, 62], ["Dp-ucMGP levels", "TEST", 0, 15], ["COVID", "TEST", 45, 50], ["CI", "TEST", 98, 100], ["CI", "TEST", 169, 171], ["mean fold change", "PROBLEM", 187, 203], ["CI", "TEST", 214, 216], ["p", "TEST", 232, 233], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["higher", "OBSERVATION_MODIFIER", 35, 41]]], ["Levels were normal in 82.1%, mildly elevated in 13.0%, moderately in 4.1% and severely in 0.8% of COVID-19 patients not using VKA ( figure 3B ).", [["VKA", "CHEMICAL", 126, 129], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["Levels", "TEST", 0, 6], ["mildly elevated", "PROBLEM", 29, 44], ["COVID", "TEST", 98, 103], ["VKA", "TREATMENT", 126, 129], ["mildly", "OBSERVATION_MODIFIER", 29, 35], ["elevated", "OBSERVATION_MODIFIER", 36, 44]]], ["PIVKA-II distribution was comparable between patients with good (78.6%, 15.7%, 4.3% and 1.4%, respectively) and poor outcomes (86.8%, 9.4%, 3.8% and 0%, respectively).", [["PIVKA-II", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 45, 53], ["PIVKA", "PROTEIN", 0, 5], ["patients", "SPECIES", 45, 53]]], ["PIVKA-II levels were severely elevated in 100% of COVID-19 patients using VKA.PIVKA-IIA c c e p t e d M a n u s c r i p t Desmosine Sufficient plasma for pDES measurements was available for 127 patients and measured in the first available sample after admission.", [["plasma", "ANATOMY", 143, 149], ["PIVKA-II", "CHEMICAL", 0, 8], ["VKA", "CHEMICAL", 74, 77], ["Desmosine", "CHEMICAL", 122, 131], ["PIVKA-II", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 59, 67], ["plasma", "ORGANISM_SUBSTANCE", 143, 149], ["patients", "ORGANISM", 194, 202], ["PIVKA", "PROTEIN", 0, 5], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 194, 202], ["PIVKA", "TEST", 0, 5], ["II levels", "TEST", 6, 15], ["severely elevated", "PROBLEM", 21, 38], ["COVID", "TEST", 50, 55], ["VKA", "TREATMENT", 74, 77], ["a n u s", "TEST", 104, 111], ["pDES measurements", "TEST", 154, 171], ["severely", "OBSERVATION_MODIFIER", 21, 29], ["elevated", "OBSERVATION_MODIFIER", 30, 38]]], ["Three dialysis-dependent patients were excluded from the analysis. pDES levels were significantly higher in COVID-19 patients (380ng/L, 95% CI, 355 to 405) compared to age-dependent reference values of never-smokers (243ng/L, 95% CI, 228 to 260; mean fold change 1.56, 95% CI, 1.42 to 1.71, p<0.001) and former or current smokers (278ng/L, 95% CI, 260 to 296, mean fold change 1.37, 95% CI 1.25 to 1.50, p<0.001; figure 4A ) [24] . pDES levels, corrected for age, were significantly higher in COVID-19 patients with poor (430ng/L, 95% CI 384 to 481) compared to good outcomes (342ng/L, 95% CI 310 to 379; mean fold change 1.25, 95% CI, 1.07 to 1.47, p=0.004).", [["patients", "ORGANISM", 25, 33], ["pDES", "SIMPLE_CHEMICAL", 67, 71], ["patients", "ORGANISM", 117, 125], ["pDES", "SIMPLE_CHEMICAL", 432, 436], ["patients", "ORGANISM", 502, 510], ["pDES", "PROTEIN", 67, 71], ["pDES", "PROTEIN", 432, 436], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 502, 510], ["Three dialysis-dependent patients", "TREATMENT", 0, 33], ["the analysis", "TEST", 53, 65], ["pDES levels", "TEST", 67, 78], ["COVID", "TEST", 108, 113], ["CI", "TEST", 140, 142], ["CI", "TEST", 230, 232], ["mean fold change", "TEST", 246, 262], ["CI", "TEST", 273, 275], ["p", "TEST", 291, 292], ["CI", "TEST", 344, 346], ["mean fold change", "TEST", 360, 376], ["CI", "TEST", 387, 389], ["p", "TEST", 404, 405], ["pDES levels", "TEST", 432, 443], ["COVID", "TEST", 493, 498], ["CI", "TEST", 535, 537], ["CI", "TEST", 590, 592], ["mean fold change", "TEST", 605, 621], ["CI", "TEST", 632, 634], ["p", "TEST", 650, 651], ["significantly", "OBSERVATION_MODIFIER", 84, 97], ["higher", "OBSERVATION_MODIFIER", 98, 104]]], ["Dp-ucMGP levels significantly correlated with pDES (n=124, r=0.47, p<0.001; figure 4B ).CT assessmentCT scans were available for 109 patients, and CAC and TAC scores were successfully determined for 107 of these patients.", [["Dp-ucMGP", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 212, 220], ["ucMGP", "PROTEIN", 3, 8], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 212, 220], ["Dp-ucMGP levels", "TEST", 0, 15], ["pDES", "TEST", 46, 50], ["r", "TEST", 59, 60], ["p", "TEST", 67, 68], ["CT assessmentCT scans", "TEST", 88, 109], ["CAC", "TEST", 147, 150], ["TAC scores", "TEST", 155, 165]]], ["TAC and CAC scores were significantly higher in COVID-19 patients with poor outcome compared to those with good outcome, however, both lost significance after adjustments (supplementary data).", [["TAC", "CHEMICAL", 0, 3], ["TAC", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["TAC", "TEST", 0, 3], ["CAC scores", "TEST", 8, 18], ["COVID", "TEST", 48, 53], ["poor outcome", "PROBLEM", 71, 83], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["higher", "OBSERVATION_MODIFIER", 38, 44]]], ["The association between pulmonary involvement on CT and time-matched dp-ucMGP levels was not significant (n=109; r=0.18; p=0.06).", [["pulmonary", "ANATOMY", 24, 33], ["pulmonary", "ORGAN", 24, 33], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 69, 77], ["ucMGP", "PROTEIN", 72, 77], ["pulmonary involvement", "PROBLEM", 24, 45], ["CT", "TEST", 49, 51], ["dp-ucMGP levels", "TEST", 69, 84], ["r", "TEST", 113, 114], ["p", "TEST", 121, 122], ["pulmonary", "ANATOMY", 24, 33], ["involvement", "OBSERVATION", 34, 45]]], ["Dp-ucMGP was significantly associated with TAC scores (n=107; r=0.36; p<0.001) and CAC scores (n=107; r=0.30; p=0.002).CT assessmentA c c e p t e d M a n u s c r i p t Discussion Dp-ucMGP, which indirectly indicates extrahepatic vitamin K insufficiency, was severely elevated in hospitalized COVID-19 patients.", [["extrahepatic", "ANATOMY", 216, 228], ["vitamin K", "CHEMICAL", 229, 238], ["vitamin K", "CHEMICAL", 229, 238], ["Dp-ucMGP", "GENE_OR_GENE_PRODUCT", 0, 8], ["Dp-ucMGP", "SIMPLE_CHEMICAL", 179, 187], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 216, 238], ["patients", "ORGANISM", 301, 309], ["Dp", "DNA", 0, 2], ["ucMGP", "DNA", 3, 8], ["Dp", "DNA", 179, 181], ["ucMGP", "DNA", 182, 187], ["patients", "SPECIES", 301, 309], ["Dp", "TEST", 0, 2], ["TAC scores", "TEST", 43, 53], ["r", "TEST", 62, 63], ["p", "TEST", 70, 71], ["CAC scores", "TEST", 83, 93], ["r", "TEST", 102, 103], ["p", "TEST", 110, 111], ["CT assessmentA", "TEST", 119, 133], ["a n u s", "TEST", 150, 157], ["Dp-ucMGP", "TEST", 179, 187], ["extrahepatic vitamin K insufficiency", "PROBLEM", 216, 252], ["severely elevated", "PROBLEM", 258, 275], ["extrahepatic", "ANATOMY", 216, 228], ["vitamin K insufficiency", "OBSERVATION", 229, 252], ["severely", "OBSERVATION_MODIFIER", 258, 266], ["elevated", "OBSERVATION_MODIFIER", 267, 275]]], ["Impaired MGP activation associated with poor outcome and accelerated elastic fiber degradation.", [["elastic fiber", "ANATOMY", 69, 82], ["MGP", "GENE_OR_GENE_PRODUCT", 9, 12], ["elastic fiber", "CELLULAR_COMPONENT", 69, 82], ["MGP", "PROTEIN", 9, 12], ["Impaired MGP activation", "PROBLEM", 0, 23], ["poor outcome", "PROBLEM", 40, 52], ["accelerated elastic fiber degradation", "PROBLEM", 57, 94], ["MGP activation", "OBSERVATION", 9, 23], ["elastic fiber degradation", "OBSERVATION", 69, 94]]], ["In contrast, procoagulant FII activity remained preserved.CT assessmentDp-ucMGP as measure of extrahepatic vitamin K status is a relevant parameter given its close association with mortality [22] .", [["extrahepatic", "ANATOMY", 94, 106], ["vitamin K", "CHEMICAL", 107, 116], ["vitamin K", "CHEMICAL", 107, 116], ["procoagulant FII", "GENE_OR_GENE_PRODUCT", 13, 29], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 94, 116], ["FII", "PROTEIN", 26, 29], ["procoagulant FII activity", "TEST", 13, 38], ["CT assessmentDp-ucMGP", "TEST", 58, 79], ["extrahepatic vitamin K status", "PROBLEM", 94, 123], ["extrahepatic", "ANATOMY", 94, 106]]], ["Low dietary vitamin K intake and VKA use are evident causes of elevated dp-ucMGP [15, 22] .", [["vitamin K", "CHEMICAL", 12, 21], ["VKA", "CHEMICAL", 33, 36], ["vitamin K", "CHEMICAL", 12, 21], ["dp-ucMGP", "CHEMICAL", 72, 80], ["vitamin K", "SIMPLE_CHEMICAL", 12, 21], ["VKA", "SIMPLE_CHEMICAL", 33, 36], ["Low dietary vitamin K intake", "TREATMENT", 0, 28], ["VKA", "TREATMENT", 33, 36], ["elevated dp", "PROBLEM", 63, 74], ["elevated", "OBSERVATION_MODIFIER", 63, 71]]], ["Pathological processes leading to upregulation of vitamin K-dependent protein production and resulting in accelerated utilization of vitamin K for carboxylation may be another important reason for severe extrahepatic vitamin K insufficiency in COVID-19.", [["extrahepatic", "ANATOMY", 204, 216], ["vitamin", "CHEMICAL", 50, 57], ["vitamin K", "CHEMICAL", 133, 142], ["vitamin K", "CHEMICAL", 217, 226], ["vitamin K-dependent", "CHEMICAL", 50, 69], ["vitamin K", "CHEMICAL", 133, 142], ["vitamin K", "CHEMICAL", 217, 226], ["COVID-19", "CHEMICAL", 244, 252], ["vitamin", "SIMPLE_CHEMICAL", 50, 57], ["vitamin K", "SIMPLE_CHEMICAL", 133, 142], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 204, 226], ["vitamin K-dependent protein", "PROTEIN", 50, 77], ["Pathological processes", "PROBLEM", 0, 22], ["vitamin K-dependent protein production", "TREATMENT", 50, 88], ["vitamin K", "TREATMENT", 133, 142], ["carboxylation", "TREATMENT", 147, 160], ["severe extrahepatic vitamin K insufficiency", "PROBLEM", 197, 240], ["COVID", "TEST", 244, 249], ["extrahepatic", "ANATOMY", 204, 216]]], ["Vitamin K supplementation reduced dp-ucMGP in various cohorts [22, 27] , with favorable effects on clinically relevant outcome measurements [27] .", [["Vitamin K", "CHEMICAL", 0, 9], ["dp-ucMGP", "CHEMICAL", 34, 42], ["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "SIMPLE_CHEMICAL", 0, 9], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 34, 42], ["Vitamin K supplementation", "TREATMENT", 0, 25], ["dp", "TEST", 34, 36]]], ["It is reasonable to assume that vitamin K administration reduces dp-ucMGP in COVID-19.", [["vitamin K", "CHEMICAL", 32, 41], ["dp-ucMGP", "CHEMICAL", 65, 73], ["vitamin K", "CHEMICAL", 32, 41], ["vitamin K", "SIMPLE_CHEMICAL", 32, 41], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 65, 73], ["dp", "DNA", 65, 67], ["ucMGP", "DNA", 68, 73], ["vitamin K administration", "TREATMENT", 32, 56], ["dp", "TEST", 65, 67], ["COVID", "TEST", 77, 82]]], ["Whether improving dp-ucMGP results in better outcome of COVID-19 remains to be evaluated.CT assessmentIntriguingly, many comorbid conditions related to poor COVID-19 clinical outcomes are associated with compromised vitamin K status [1, 7, 18] .", [["vitamin K", "CHEMICAL", 216, 225], ["COVID-19", "CHEMICAL", 56, 64], ["vitamin K", "CHEMICAL", 216, 225], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 18, 26], ["vitamin K", "SIMPLE_CHEMICAL", 216, 225], ["dp", "DNA", 18, 20], ["ucMGP", "DNA", 21, 26], ["COVID", "TEST", 56, 61], ["CT assessment", "TEST", 89, 102], ["many comorbid conditions", "PROBLEM", 116, 140], ["poor COVID", "PROBLEM", 152, 162], ["compromised vitamin K status", "PROBLEM", 204, 232]]], ["Elastic fiber calcification and degradation are closely related processes [11, 12] .", [["fiber", "ANATOMY", 8, 13], ["calcification", "DISEASE", 14, 27], ["Elastic fiber calcification", "PROBLEM", 0, 27], ["fiber", "OBSERVATION_MODIFIER", 8, 13], ["calcification", "OBSERVATION", 14, 27]]], ["There seems to be an association between vascular mineralization and lung pathologies [28] [29] [30] .", [["vascular", "ANATOMY", 41, 49], ["lung", "ANATOMY", 69, 73], ["lung pathologies", "DISEASE", 69, 85], ["vascular", "MULTI-TISSUE_STRUCTURE", 41, 49], ["lung", "ORGAN", 69, 73], ["an association between vascular mineralization", "PROBLEM", 18, 64], ["lung pathologies", "PROBLEM", 69, 85], ["seems to be", "UNCERTAINTY", 6, 17], ["vascular", "ANATOMY", 41, 49], ["mineralization", "OBSERVATION", 50, 64], ["lung", "ANATOMY", 69, 73], ["pathologies", "OBSERVATION", 74, 85]]], ["We demonstrated accelerated elastic fiber degradation and arterial calcification correlating with dp-ucMGP, suggesting interrelationships between vitamin K shortage, insufficient MGP carboxylation and elastic fiber pathologies in COVID-19.Although significance was lost after adjustment for age, sex, and VKA use, we found enhanced TAC and CAC in patients with poor prognosis.", [["elastic fiber", "ANATOMY", 28, 41], ["arterial", "ANATOMY", 58, 66], ["elastic fiber", "ANATOMY", 201, 214], ["calcification", "DISEASE", 67, 80], ["vitamin K", "CHEMICAL", 146, 155], ["TAC", "CHEMICAL", 332, 335], ["CAC", "CHEMICAL", 340, 343], ["vitamin K", "CHEMICAL", 146, 155], ["TAC", "CHEMICAL", 332, 335], ["elastic fiber", "CELLULAR_COMPONENT", 28, 41], ["arterial", "MULTI-TISSUE_STRUCTURE", 58, 66], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 98, 106], ["vitamin K", "SIMPLE_CHEMICAL", 146, 155], ["MGP", "GENE_OR_GENE_PRODUCT", 179, 182], ["TAC", "SIMPLE_CHEMICAL", 332, 335], ["patients", "ORGANISM", 347, 355], ["ucMGP", "PROTEIN", 101, 106], ["MGP", "PROTEIN", 179, 182], ["patients", "SPECIES", 347, 355], ["accelerated elastic fiber degradation", "PROBLEM", 16, 53], ["arterial calcification", "PROBLEM", 58, 80], ["dp-ucMGP", "TEST", 98, 106], ["vitamin K shortage", "TREATMENT", 146, 164], ["insufficient MGP carboxylation", "TREATMENT", 166, 196], ["elastic fiber pathologies", "PROBLEM", 201, 226], ["COVID", "TEST", 230, 235], ["accelerated", "OBSERVATION_MODIFIER", 16, 27], ["elastic", "OBSERVATION_MODIFIER", 28, 35], ["fiber degradation", "OBSERVATION", 36, 53], ["arterial", "ANATOMY", 58, 66], ["calcification", "OBSERVATION", 67, 80], ["elastic fiber pathologies", "OBSERVATION", 201, 226]]], ["Hypertension, diabetes, cardiovascular disease, and older age are associated with remodeling of elastic tissues [7] .", [["cardiovascular", "ANATOMY", 24, 38], ["elastic tissues", "ANATOMY", 96, 111], ["Hypertension", "DISEASE", 0, 12], ["diabetes", "DISEASE", 14, 22], ["cardiovascular disease", "DISEASE", 24, 46], ["elastic tissues", "TISSUE", 96, 111], ["Hypertension", "PROBLEM", 0, 12], ["diabetes", "PROBLEM", 14, 22], ["cardiovascular disease", "PROBLEM", 24, 46], ["remodeling of elastic tissues", "PROBLEM", 82, 111], ["diabetes", "OBSERVATION", 14, 22], ["cardiovascular", "ANATOMY", 24, 38], ["disease", "OBSERVATION", 39, 46], ["remodeling", "OBSERVATION", 82, 92], ["elastic tissues", "OBSERVATION", 96, 111]]], ["These damaged and calcified elastic fibers are more prone to further degradation than intact fibers [11] .", [["elastic fibers", "ANATOMY", 28, 42], ["fibers", "ANATOMY", 93, 99], ["elastic fibers", "MULTI-TISSUE_STRUCTURE", 28, 42], ["calcified elastic fibers", "PROBLEM", 18, 42], ["calcified", "OBSERVATION_MODIFIER", 18, 27], ["elastic", "OBSERVATION_MODIFIER", 28, 35], ["fibers", "OBSERVATION_MODIFIER", 36, 42], ["more prone", "OBSERVATION_MODIFIER", 47, 57]]], ["We speculate that this pre-existing A c c e p t e d M a n u s c r i p t elastic fiber dysfunction renders them more susceptible to degradation following enhanced proteolytic activity during COVID-19 [14] .19.We did not find a significant correlation between dp-ucMGP and pneumonia severity.", [["pneumonia", "DISEASE", 271, 280], ["COVID-19", "CHEMICAL", 190, 198], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 258, 266], ["a n u s", "TEST", 54, 61], ["t elastic fiber dysfunction", "PROBLEM", 70, 97], ["enhanced proteolytic activity", "PROBLEM", 153, 182], ["COVID", "TEST", 190, 195], ["dp", "TEST", 258, 260], ["pneumonia severity", "PROBLEM", 271, 289], ["fiber dysfunction", "OBSERVATION", 80, 97], ["pneumonia", "OBSERVATION", 271, 280]]], ["It is possible that the correlation is confounded by the fact that those with pre-existing conditions are predisposed to both higher dp-ucMGP and the development of respiratory failure with less pulmonary involvement.", [["respiratory", "ANATOMY", 165, 176], ["pulmonary", "ANATOMY", 195, 204], ["respiratory failure", "DISEASE", 165, 184], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 133, 141], ["pulmonary", "ORGAN", 195, 204], ["pre-existing conditions", "PROBLEM", 78, 101], ["respiratory failure", "PROBLEM", 165, 184], ["less pulmonary involvement", "PROBLEM", 190, 216], ["respiratory failure", "OBSERVATION", 165, 184], ["less", "OBSERVATION_MODIFIER", 190, 194], ["pulmonary", "ANATOMY", 195, 204], ["involvement", "OBSERVATION", 205, 216]]], ["Furthermore, CT severity is a dynamic process that may change rapidly [31] .19.A clinical trial in which change of both vitamin K status and CT severity are simultaneously assessed before and after vitamin K supplementation would be a more suitable analysis.19.Vitamin K1, the main source of vitamin K in The Netherlands, is preferentially transported to the liver, implying that the grade of carboxylation is usually higher for hepatic than extrahepatic vitamin K-dependent proteins (figure 1) [3, 4, 32] .", [["liver", "ANATOMY", 359, 364], ["hepatic", "ANATOMY", 429, 436], ["vitamin K", "CHEMICAL", 120, 129], ["vitamin K", "CHEMICAL", 198, 207], ["Vitamin K1", "CHEMICAL", 261, 271], ["vitamin K", "CHEMICAL", 292, 301], ["vitamin K-", "CHEMICAL", 455, 465], ["vitamin K", "CHEMICAL", 120, 129], ["vitamin K", "CHEMICAL", 198, 207], ["Vitamin K1", "CHEMICAL", 261, 271], ["vitamin K", "CHEMICAL", 292, 301], ["vitamin K-", "CHEMICAL", 455, 465], ["vitamin K", "SIMPLE_CHEMICAL", 120, 129], ["vitamin K", "SIMPLE_CHEMICAL", 198, 207], ["Vitamin K1", "SIMPLE_CHEMICAL", 261, 271], ["vitamin K", "SIMPLE_CHEMICAL", 292, 301], ["liver", "ORGAN", 359, 364], ["hepatic", "ORGAN", 429, 436], ["extrahepatic vitamin K-", "SIMPLE_CHEMICAL", 442, 465], ["extrahepatic vitamin K-dependent proteins", "PROTEIN", 442, 483], ["CT severity", "TEST", 13, 24], ["A clinical trial", "TEST", 79, 95], ["both vitamin K status", "TREATMENT", 115, 136], ["CT severity", "TEST", 141, 152], ["vitamin K supplementation", "TREATMENT", 198, 223], ["Vitamin K1", "TREATMENT", 261, 271], ["vitamin K", "TREATMENT", 292, 301], ["the grade of carboxylation", "PROBLEM", 380, 406], ["hepatic than extrahepatic vitamin K-dependent proteins", "PROBLEM", 429, 483], ["vitamin K", "OBSERVATION", 292, 301], ["liver", "ANATOMY", 359, 364], ["hepatic", "ANATOMY", 429, 436], ["extrahepatic", "ANATOMY", 442, 454]]], ["This likely explains why dp-ucMGP was severely elevated, while PIVKA-II was normal in the majority of patients.", [["PIVKA-II", "CHEMICAL", 63, 71], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 25, 33], ["PIVKA-II", "GENE_OR_GENE_PRODUCT", 63, 71], ["patients", "ORGANISM", 102, 110], ["dp", "DNA", 25, 27], ["ucMGP", "PROTEIN", 28, 33], ["PIVKA", "PROTEIN", 63, 68], ["patients", "SPECIES", 102, 110], ["dp-ucMGP", "TEST", 25, 33], ["severely elevated", "PROBLEM", 38, 55], ["PIVKA", "TEST", 63, 68], ["likely explains", "UNCERTAINTY", 5, 20], ["severely", "OBSERVATION_MODIFIER", 38, 46], ["elevated", "OBSERVATION", 47, 55], ["normal", "OBSERVATION", 76, 82]]], ["Similar to MGP, the activation of endothelial protein S is disproportionally impacted in times of vitamin K deficiency.", [["endothelial", "ANATOMY", 34, 45], ["vitamin K", "CHEMICAL", 98, 107], ["vitamin K", "CHEMICAL", 98, 107], ["MGP", "GENE_OR_GENE_PRODUCT", 11, 14], ["endothelial protein S", "GENE_OR_GENE_PRODUCT", 34, 55], ["vitamin K", "SIMPLE_CHEMICAL", 98, 107], ["MGP", "PROTEIN", 11, 14], ["endothelial protein S", "PROTEIN", 34, 55], ["endothelial protein S", "PROBLEM", 34, 55], ["vitamin K deficiency", "PROBLEM", 98, 118], ["endothelial", "ANATOMY", 34, 45], ["disproportionally", "OBSERVATION_MODIFIER", 59, 76], ["impacted", "OBSERVATION_MODIFIER", 77, 85]]], ["Theoretically, these observations could be compatible with enhanced thrombogenicity in COVID-19 [2] , where autopsies revealed bilateral deep venous leg thrombosis in all thromboembolic cases, and thrombosis of the prostatic venous plexus in the majority of men who died [33] .", [["venous leg", "ANATOMY", 142, 152], ["prostatic venous plexus", "ANATOMY", 215, 238], ["venous leg thrombosis", "DISEASE", 142, 163], ["thromboembolic", "DISEASE", 171, 185], ["thrombosis", "DISEASE", 197, 207], ["venous leg", "ORGANISM_SUBDIVISION", 142, 152], ["prostatic venous plexus", "MULTI-TISSUE_STRUCTURE", 215, 238], ["men", "ORGANISM", 258, 261], ["men", "SPECIES", 258, 261], ["enhanced thrombogenicity", "PROBLEM", 59, 83], ["COVID", "TEST", 87, 92], ["autopsies", "TEST", 108, 117], ["bilateral deep venous leg thrombosis", "PROBLEM", 127, 163], ["all thromboembolic cases", "PROBLEM", 167, 191], ["thrombosis of the prostatic venous plexus", "PROBLEM", 197, 238], ["could be compatible with", "UNCERTAINTY", 34, 58], ["enhanced", "OBSERVATION_MODIFIER", 59, 67], ["thrombogenicity", "OBSERVATION", 68, 83], ["bilateral", "ANATOMY_MODIFIER", 127, 136], ["deep", "ANATOMY_MODIFIER", 137, 141], ["venous leg", "ANATOMY", 142, 152], ["thrombosis", "OBSERVATION", 153, 163], ["all", "OBSERVATION_MODIFIER", 167, 170], ["thromboembolic cases", "OBSERVATION", 171, 191], ["thrombosis", "OBSERVATION", 197, 207], ["prostatic venous plexus", "ANATOMY", 215, 238]]], ["Future research should investigate this, however, there is currently no readily available assay to measure carboxylated (active) versus uncarboxylated (inactive) protein S. Enhanced thrombosis in a state of vitamin K deficiency has previously been described in calciphylaxis [5] .", [["carboxylated", "CHEMICAL", 107, 119], ["thrombosis", "DISEASE", 182, 192], ["vitamin K", "CHEMICAL", 207, 216], ["calciphylaxis", "DISEASE", 261, 274], ["vitamin K", "CHEMICAL", 207, 216], ["uncarboxylated", "SIMPLE_CHEMICAL", 136, 150], ["vitamin K", "SIMPLE_CHEMICAL", 207, 216], ["carboxylated (active) versus uncarboxylated (inactive) protein S.", "PROBLEM", 107, 172], ["Enhanced thrombosis", "PROBLEM", 173, 192], ["vitamin K deficiency", "PROBLEM", 207, 227], ["calciphylaxis", "PROBLEM", 261, 274], ["Enhanced", "OBSERVATION_MODIFIER", 173, 181], ["thrombosis", "OBSERVATION", 182, 192], ["calciphylaxis", "OBSERVATION", 261, 274]]], ["Calciphylaxis is characterized by cutaneous blood vessel occlusion due to calcification, leading to ischemic skin infarction [5] .", [["cutaneous blood vessel", "ANATOMY", 34, 56], ["skin", "ANATOMY", 109, 113], ["Calciphylaxis", "DISEASE", 0, 13], ["blood vessel occlusion", "DISEASE", 44, 66], ["calcification", "DISEASE", 74, 87], ["ischemic skin infarction", "DISEASE", 100, 124], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 44, 56], ["skin", "ORGAN", 109, 113], ["Calciphylaxis", "PROBLEM", 0, 13], ["cutaneous blood vessel occlusion", "PROBLEM", 34, 66], ["calcification", "PROBLEM", 74, 87], ["ischemic skin infarction", "PROBLEM", 100, 124], ["cutaneous blood vessel occlusion", "OBSERVATION", 34, 66], ["calcification", "OBSERVATION", 74, 87], ["ischemic", "OBSERVATION_MODIFIER", 100, 108], ["skin", "ANATOMY", 109, 113], ["infarction", "OBSERVATION", 114, 124]]], ["Increased levels of inactive MGP are found in skin tissues and the circulation of calciphylaxis patients [5] .", [["skin tissues", "ANATOMY", 46, 58], ["calciphylaxis", "DISEASE", 82, 95], ["MGP", "GENE_OR_GENE_PRODUCT", 29, 32], ["skin tissues", "TISSUE", 46, 58], ["patients", "ORGANISM", 96, 104], ["MGP", "PROTEIN", 29, 32], ["patients", "SPECIES", 96, 104], ["Increased levels of inactive MGP", "PROBLEM", 0, 32], ["calciphylaxis", "PROBLEM", 82, 95], ["inactive MGP", "OBSERVATION", 20, 32], ["skin tissues", "ANATOMY", 46, 58], ["circulation", "OBSERVATION_MODIFIER", 67, 78], ["calciphylaxis", "OBSERVATION", 82, 95]]], ["It may be speculated that, analogous to calciphylaxis, impaired local anticoagulant activity due to vitamin K insufficiency is responsible for microvessel thrombosis in COVID-19 [34] .19.The major strength of our study is the use of robust biomarkers and quantitative CT assessment.", [["microvessel", "ANATOMY", 143, 154], ["calciphylaxis", "DISEASE", 40, 53], ["vitamin K", "CHEMICAL", 100, 109], ["thrombosis", "DISEASE", 155, 165], ["vitamin K", "CHEMICAL", 100, 109], ["vitamin K", "SIMPLE_CHEMICAL", 100, 109], ["microvessel", "TISSUE", 143, 154], ["calciphylaxis", "PROBLEM", 40, 53], ["impaired local anticoagulant activity", "TREATMENT", 55, 92], ["vitamin K insufficiency", "PROBLEM", 100, 123], ["microvessel thrombosis", "PROBLEM", 143, 165], ["COVID", "TEST", 169, 174], ["our study", "TEST", 209, 218], ["robust biomarkers", "TEST", 233, 250], ["quantitative CT assessment", "TEST", 255, 281], ["calciphylaxis", "OBSERVATION", 40, 53], ["responsible for", "UNCERTAINTY", 127, 142], ["microvessel thrombosis", "OBSERVATION", 143, 165]]], ["Our findings are limited by the fact that it is impossible to determine which proportion of circulating dp-A c c e p t e d M a n u s c r i p t 13 ucMGP and DES levels originated from the lungs, as both biomarkers are not tissue specific.19.Therefore, there is urgent need for experimental data to better link vitamin K insufficiency specifically with COVID-19-related lung pathologies.19.As low vitamin K levels are found in comorbidities that are related to poor outcome of COVID-19 [1, 7] , we were unable formally to determine whether vitamin K insufficiency truly predisposes patients to the development of severe COVID-19 or whether it is merely an epiphenomenon.", [["lungs", "ANATOMY", 187, 192], ["tissue", "ANATOMY", 221, 227], ["lung", "ANATOMY", 368, 372], ["DES", "CHEMICAL", 156, 159], ["vitamin K", "CHEMICAL", 309, 318], ["COVID-19", "CHEMICAL", 351, 359], ["lung pathologies", "DISEASE", 368, 384], ["vitamin K", "CHEMICAL", 395, 404], ["vitamin K", "CHEMICAL", 538, 547], ["COVID", "DISEASE", 618, 623], ["DES", "CHEMICAL", 156, 159], ["vitamin K", "CHEMICAL", 309, 318], ["vitamin K", "CHEMICAL", 395, 404], ["COVID-19", "CHEMICAL", 475, 483], ["vitamin K", "CHEMICAL", 538, 547], ["COVID-19", "CHEMICAL", 618, 626], ["ucMGP", "GENE_OR_GENE_PRODUCT", 146, 151], ["DES", "SIMPLE_CHEMICAL", 156, 159], ["lungs", "ORGAN", 187, 192], ["tissue", "TISSUE", 221, 227], ["vitamin K", "SIMPLE_CHEMICAL", 309, 318], ["COVID-19", "GENE_OR_GENE_PRODUCT", 351, 359], ["lung", "ORGAN", 368, 372], ["vitamin K", "SIMPLE_CHEMICAL", 395, 404], ["vitamin K", "SIMPLE_CHEMICAL", 538, 547], ["patients", "ORGANISM", 580, 588], ["patients", "SPECIES", 580, 588], ["circulating dp", "TEST", 92, 106], ["a n u s", "TEST", 125, 132], ["r i", "TEST", 135, 138], ["ucMGP", "TEST", 146, 151], ["DES levels", "TEST", 156, 166], ["experimental data", "TEST", 276, 293], ["vitamin K insufficiency", "PROBLEM", 309, 332], ["COVID", "TEST", 351, 356], ["lung pathologies", "PROBLEM", 368, 384], ["low vitamin K levels", "PROBLEM", 391, 411], ["comorbidities", "PROBLEM", 425, 438], ["COVID", "TEST", 475, 480], ["vitamin K insufficiency", "PROBLEM", 538, 561], ["severe COVID", "PROBLEM", 611, 623], ["an epiphenomenon", "PROBLEM", 651, 667], ["lungs", "ANATOMY", 187, 192], ["lung", "ANATOMY", 368, 372], ["pathologies", "OBSERVATION", 373, 384], ["severe", "OBSERVATION_MODIFIER", 611, 617], ["epiphenomenon", "OBSERVATION", 654, 667]]], ["However, the latter seems highly unlikely given the extreme elevation of dp-ucMGP levels in COVID-19 patients, which was much more pronounced than in hypertensive, diabetic, cardiovascular and COPD patients without COVID-19 (supplementary table 1 ).", [["cardiovascular", "ANATOMY", 174, 188], ["hypertensive", "DISEASE", 150, 162], ["diabetic", "DISEASE", 164, 172], ["COPD", "DISEASE", 193, 197], ["COVID-19", "CHEMICAL", 215, 223], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 73, 81], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 198, 206], ["ucMGP", "PROTEIN", 76, 81], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 198, 206], ["the extreme elevation of dp-ucMGP levels", "PROBLEM", 48, 88], ["COVID", "TEST", 92, 97], ["diabetic", "PROBLEM", 164, 172], ["COVID", "TEST", 215, 220], ["seems highly unlikely", "UNCERTAINTY", 20, 41], ["extreme", "OBSERVATION_MODIFIER", 52, 59], ["elevation", "OBSERVATION", 60, 69], ["more pronounced", "OBSERVATION_MODIFIER", 126, 141], ["diabetic", "OBSERVATION", 164, 172], ["COPD", "OBSERVATION", 193, 197]]], ["The strong correlation that we found between vitamin K status and the rate of elastic fiber degradation also suggests causality.19.We had to make use of a historical control group, due to the implementation of quarantines and social distancing practices to contain SARS-CoV-2.", [["elastic fiber", "ANATOMY", 78, 91], ["vitamin K", "CHEMICAL", 45, 54], ["SARS", "DISEASE", 265, 269], ["vitamin K", "CHEMICAL", 45, 54], ["vitamin K", "SIMPLE_CHEMICAL", 45, 54], ["elastic fiber", "CELLULAR_COMPONENT", 78, 91], ["SARS-CoV", "SPECIES", 265, 273], ["vitamin K status", "TREATMENT", 45, 61], ["elastic fiber degradation", "TREATMENT", 78, 103], ["a historical control group", "TREATMENT", 153, 179], ["quarantines", "TREATMENT", 210, 221], ["social distancing practices", "TREATMENT", 226, 253], ["elastic", "OBSERVATION", 78, 85], ["fiber degradation", "OBSERVATION", 86, 103]]], ["We do not consider this to be a significant problem, however, as dp-ucMGP levels of our historical controls were higher than previously reported in large groups of controls (supplementary table 2 ).", [["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 65, 73], ["ucMGP", "PROTEIN", 68, 73], ["a significant problem", "PROBLEM", 30, 51], ["dp-ucMGP levels", "TEST", 65, 80], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["problem", "OBSERVATION", 44, 51]]], ["Furthermore, differences in dp-ucMGP levels between COVID-19 patients and controls were of such a magnitude that loss of significance when comparing to a matched control group would be highly unlikely.19.In conclusion, dp-ucMGP was strongly elevated in hospitalized COVID-19 patients, which indirectly indicates extrahepatic vitamin K insufficiency.", [["extrahepatic", "ANATOMY", 312, 324], ["vitamin K", "CHEMICAL", 325, 334], ["vitamin K", "CHEMICAL", 325, 334], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 28, 36], ["patients", "ORGANISM", 61, 69], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 219, 227], ["patients", "ORGANISM", 275, 283], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 312, 334], ["dp", "DNA", 28, 30], ["ucMGP", "PROTEIN", 31, 36], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 275, 283], ["dp-ucMGP levels", "TEST", 28, 43], ["COVID", "TEST", 52, 57], ["a matched control group", "TREATMENT", 152, 175], ["dp-ucMGP", "TEST", 219, 227], ["strongly elevated", "PROBLEM", 232, 249], ["extrahepatic vitamin K insufficiency", "PROBLEM", 312, 348], ["elevated", "OBSERVATION", 241, 249], ["extrahepatic", "ANATOMY", 312, 324], ["vitamin K insufficiency", "OBSERVATION", 325, 348]]], ["Impaired MGP activation was associated with poor outcomes.", [["MGP", "GENE_OR_GENE_PRODUCT", 9, 12], ["MGP", "PROTEIN", 9, 12], ["Impaired MGP activation", "PROBLEM", 0, 23], ["poor outcomes", "PROBLEM", 44, 57], ["MGP activation", "OBSERVATION", 9, 23]]], ["COVID-19 patients with premorbid elastic fiber pathologies appeared, in particular, to be at increased risk of complicated disease course.", [["elastic fiber", "ANATOMY", 33, 46], ["elastic fiber pathologies", "DISEASE", 33, 58], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["premorbid elastic fiber pathologies", "PROBLEM", 23, 58], ["complicated disease course", "PROBLEM", 111, 137], ["elastic fiber pathologies", "OBSERVATION", 33, 58], ["complicated", "OBSERVATION_MODIFIER", 111, 122], ["disease", "OBSERVATION", 123, 130]]], ["Despite extrahepatic vitamin K deficiency, hepatic prothrombin activation remained preserved.", [["hepatic", "ANATOMY", 43, 50], ["vitamin K", "CHEMICAL", 21, 30], ["vitamin K", "CHEMICAL", 21, 30], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 8, 30], ["hepatic", "ORGAN", 43, 50], ["prothrombin", "GENE_OR_GENE_PRODUCT", 51, 62], ["prothrombin", "PROTEIN", 51, 62], ["extrahepatic vitamin K deficiency", "PROBLEM", 8, 41], ["hepatic prothrombin activation", "PROBLEM", 43, 73], ["extrahepatic", "ANATOMY", 8, 20], ["vitamin K deficiency", "OBSERVATION", 21, 41], ["hepatic", "ANATOMY", 43, 50], ["prothrombin", "OBSERVATION", 51, 62]]], ["Taken together these data suggest a mechanism of pneumonia-induced extrahepatic vitamin K depletion leading to accelerated elastic fiber degradation and thrombosis formation.", [["extrahepatic", "ANATOMY", 67, 79], ["elastic fiber", "ANATOMY", 123, 136], ["pneumonia", "DISEASE", 49, 58], ["vitamin K", "CHEMICAL", 80, 89], ["thrombosis", "DISEASE", 153, 163], ["vitamin K", "CHEMICAL", 80, 89], ["extrahepatic vitamin K", "SIMPLE_CHEMICAL", 67, 89], ["elastic fiber", "CELLULAR_COMPONENT", 123, 136], ["pneumonia", "PROBLEM", 49, 58], ["extrahepatic vitamin K depletion", "TREATMENT", 67, 99], ["accelerated elastic fiber degradation", "PROBLEM", 111, 148], ["thrombosis formation", "PROBLEM", 153, 173], ["pneumonia", "OBSERVATION", 49, 58], ["extrahepatic", "ANATOMY", 67, 79], ["vitamin K depletion", "OBSERVATION", 80, 99], ["accelerated", "OBSERVATION_MODIFIER", 111, 122], ["elastic fiber degradation", "OBSERVATION", 123, 148], ["thrombosis", "OBSERVATION", 153, 163]]], ["An intervention trial is now needed to assess whether vitamin K administration improves outcome in patients with COVID-19 by increasing pulmonary MGP and endothelial protein S activation.19.A c c e p t e d M a n u s c r i p t M a n u s c r i p t synthesis is upregulated in an attempt to protect elastic fibers from calcification and degradation, (8a) which means that need for vitamin K to activate additional MGP increases.", [["pulmonary", "ANATOMY", 136, 145], ["endothelial", "ANATOMY", 154, 165], ["elastic fibers", "ANATOMY", 296, 310], ["vitamin K", "CHEMICAL", 54, 63], ["COVID-19", "CHEMICAL", 113, 121], ["calcification", "DISEASE", 316, 329], ["vitamin K", "CHEMICAL", 378, 387], ["vitamin K", "CHEMICAL", 54, 63], ["COVID-19", "CHEMICAL", 113, 121], ["vitamin K", "CHEMICAL", 378, 387], ["vitamin K", "SIMPLE_CHEMICAL", 54, 63], ["patients", "ORGANISM", 99, 107], ["pulmonary", "ORGAN", 136, 145], ["MGP", "GENE_OR_GENE_PRODUCT", 146, 149], ["endothelial protein S", "GENE_OR_GENE_PRODUCT", 154, 175], ["elastic fibers", "TISSUE", 296, 310], ["vitamin K", "SIMPLE_CHEMICAL", 378, 387], ["MGP", "GENE_OR_GENE_PRODUCT", 411, 414], ["pulmonary MGP", "PROTEIN", 136, 149], ["endothelial protein S", "PROTEIN", 154, 175], ["MGP", "PROTEIN", 411, 414], ["patients", "SPECIES", 99, 107], ["An intervention trial", "TREATMENT", 0, 21], ["vitamin K administration", "TREATMENT", 54, 78], ["COVID", "TEST", 113, 118], ["increasing pulmonary MGP", "PROBLEM", 125, 149], ["endothelial protein S activation", "TREATMENT", 154, 186], ["u s", "TEST", 212, 215], ["u s", "TEST", 232, 235], ["t synthesis", "TREATMENT", 244, 255], ["calcification", "PROBLEM", 316, 329], ["vitamin K", "TREATMENT", 378, 387], ["additional MGP", "PROBLEM", 400, 414], ["pulmonary", "ANATOMY", 136, 145], ["MGP", "OBSERVATION", 146, 149], ["endothelial protein", "OBSERVATION", 154, 173], ["elastic fibers", "OBSERVATION", 296, 310], ["calcification", "OBSERVATION", 316, 329]]], ["(8b) This increased utilization of vitamin K may induce vitamin K insufficiency, (9) in which case increased production of MGP in a state of vitamin K insufficiency leads to increased desphospho-uncarboxylated (dp-uc)MGP in lungs and blood.19.A c c e p t e d M a n u s c r i p t 21 Figure 3 : Circulating dp-ucMGP and PIVKA-II in COVID-19 patients.", [["lungs", "ANATOMY", 224, 229], ["blood", "ANATOMY", 234, 239], ["vitamin K", "CHEMICAL", 35, 44], ["vitamin K", "CHEMICAL", 56, 65], ["vitamin K", "CHEMICAL", 141, 150], ["vitamin K", "CHEMICAL", 35, 44], ["vitamin K", "CHEMICAL", 56, 65], ["vitamin K", "CHEMICAL", 141, 150], ["desphospho-uncarboxylated", "CHEMICAL", 184, 209], ["vitamin K", "SIMPLE_CHEMICAL", 35, 44], ["vitamin K", "SIMPLE_CHEMICAL", 56, 65], ["MGP", "GENE_OR_GENE_PRODUCT", 123, 126], ["vitamin K", "SIMPLE_CHEMICAL", 141, 150], ["dp-uc)MGP", "GENE_OR_GENE_PRODUCT", 211, 220], ["lungs", "ORGAN", 224, 229], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 305, 313], ["PIVKA-II", "GENE_OR_GENE_PRODUCT", 318, 326], ["patients", "ORGANISM", 339, 347], ["MGP", "PROTEIN", 123, 126], ["desphospho-uncarboxylated (dp-uc)MGP", "PROTEIN", 184, 220], ["Circulating dp-ucMGP and PIVKA-II", "DNA", 293, 326], ["patients", "SPECIES", 339, 347], ["vitamin K", "TREATMENT", 35, 44], ["vitamin K insufficiency", "PROBLEM", 56, 79], ["increased production of MGP", "PROBLEM", 99, 126], ["vitamin K insufficiency", "PROBLEM", 141, 164], ["increased desphospho-uncarboxylated", "PROBLEM", 174, 209], ["MGP in lungs and blood", "PROBLEM", 217, 239], ["u s", "TEST", 265, 268], ["t", "TEST", 277, 278], ["Figure", "TEST", 282, 288], ["Circulating dp", "TEST", 293, 307], ["ucMGP", "TEST", 308, 313], ["PIVKA", "TEST", 318, 323], ["COVID", "TEST", 330, 335], ["increased", "OBSERVATION_MODIFIER", 174, 183], ["uc", "OBSERVATION", 214, 216], ["lungs", "ANATOMY", 224, 229], ["blood", "ANATOMY", 234, 239]]], ["(A) Dp-ucMGP was measured in plasma of COVID-19 patients with a good outcome (discharge without invasive ventilation, n=75, orange) or poor outcome (invasive ventilation and/or death, n=60, red), compared to a cohort of controls.", [["plasma", "ANATOMY", 29, 35], ["death", "DISEASE", 177, 182], ["(A) Dp-ucMGP", "CHEMICAL", 0, 12], ["Dp-ucMGP", "GENE_OR_GENE_PRODUCT", 4, 12], ["plasma", "ORGANISM_SUBSTANCE", 29, 35], ["patients", "ORGANISM", 48, 56], ["Dp-ucMGP", "PROTEIN", 4, 12], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 39, 44], ["invasive ventilation", "TREATMENT", 96, 116], ["poor outcome", "PROBLEM", 135, 147], ["invasive ventilation", "TREATMENT", 149, 169], ["death", "PROBLEM", 177, 182]]], ["Subjects with high dp-ucMGP have low extrahepatic vitamin K status and vice versa.", [["extrahepatic", "ANATOMY", 37, 49], ["vitamin K", "CHEMICAL", 50, 59], ["vitamin K", "CHEMICAL", 50, 59], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 19, 27], ["vitamin K", "SIMPLE_CHEMICAL", 50, 59], ["high dp-ucMGP", "PROBLEM", 14, 27], ["low extrahepatic vitamin K status", "PROBLEM", 33, 66], ["extrahepatic", "ANATOMY", 37, 49]]], ["The maximal dp-ucMGP measured during the study is shown, with open circles representing those patients using VKA at admission.", [["VKA", "CHEMICAL", 109, 112], ["dp-ucMGP", "GENE_OR_GENE_PRODUCT", 12, 20], ["patients", "ORGANISM", 94, 102], ["dp", "DNA", 12, 14], ["ucMGP", "DNA", 15, 20], ["patients", "SPECIES", 94, 102], ["The maximal dp-ucMGP", "TEST", 0, 20], ["the study", "TEST", 37, 46], ["open circles", "TREATMENT", 62, 74], ["VKA", "TREATMENT", 109, 112], ["maximal", "OBSERVATION_MODIFIER", 4, 11], ["dp", "OBSERVATION_MODIFIER", 12, 14]]], ["(B) PIVKA-II was measured in plasma at baseline in those patients not using VKA (n=122).", [["plasma", "ANATOMY", 29, 35], ["PIVKA-II", "CHEMICAL", 4, 12], ["VKA", "CHEMICAL", 76, 79], ["PIVKA-II", "GENE_OR_GENE_PRODUCT", 4, 12], ["plasma", "ORGANISM_SUBSTANCE", 29, 35], ["patients", "ORGANISM", 57, 65], ["PIVKA-II", "PROTEIN", 4, 12], ["patients", "SPECIES", 57, 65], ["VKA", "TREATMENT", 76, 79]]], ["The detection threshold and normal range for healthy controls is shown in gray.", [["The detection threshold", "TEST", 0, 23]]], ["A single patient not using VKAs had a severely elevated PIVKA-II outside the detection range and is not shown in the figure.", [["PIVKA-II", "CHEMICAL", 56, 64], ["patient", "ORGANISM", 9, 16], ["PIVKA-II", "PROTEIN", 56, 64], ["patient", "SPECIES", 9, 16], ["VKAs", "TREATMENT", 27, 31], ["a severely elevated PIVKA", "PROBLEM", 36, 61], ["severely", "OBSERVATION_MODIFIER", 38, 46], ["elevated", "OBSERVATION", 47, 55]]]], "c7aa6180e9f2df08b1b07b8705a17bcc526aee11": [["IntroductionRNA viruses represent the largest class of existing and emerging human pathogens.", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["IntroductionRNA viruses", "PROBLEM", 0, 23], ["emerging human pathogens", "PROBLEM", 68, 92], ["largest", "OBSERVATION_MODIFIER", 38, 45], ["human pathogens", "OBSERVATION", 77, 92]]], ["Few vaccines have been licensed to prevent RNA virus infections, and only one broad-spectrum antiviral (ribavirin) has been licensed to treat RNA virus infections in humans.", [["infections", "DISEASE", 53, 63], ["ribavirin", "CHEMICAL", 104, 113], ["RNA virus infections", "DISEASE", 142, 162], ["ribavirin", "CHEMICAL", 104, 113], ["ribavirin", "SIMPLE_CHEMICAL", 104, 113], ["humans", "ORGANISM", 166, 172], ["humans", "SPECIES", 166, 172], ["humans", "SPECIES", 166, 172], ["Few vaccines", "TREATMENT", 0, 12], ["RNA virus infections", "PROBLEM", 43, 63], ["one broad-spectrum antiviral (ribavirin)", "TREATMENT", 74, 114], ["RNA virus infections in humans", "PROBLEM", 142, 172], ["RNA virus infections", "OBSERVATION", 43, 63], ["RNA virus infections", "OBSERVATION", 142, 162]]], ["Unfortunately, this single antiviral agent is not effective against all RNA viruses [1] .", [["this single antiviral agent", "TREATMENT", 15, 42], ["all RNA viruses", "PROBLEM", 68, 83]]], ["Replication of the RNA virus genome is catalyzed by the virus-encoded RNA-dependent RNA polymerase (RdRp) [2] .", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 70, 98], ["RNA virus genome", "DNA", 19, 35], ["virus-encoded RNA-dependent RNA polymerase", "PROTEIN", 56, 98], ["RdRp", "PROTEIN", 100, 104], ["the RNA virus genome", "TREATMENT", 15, 35], ["RNA virus genome", "OBSERVATION", 19, 35]]], ["Like other viral polymerases, the RdRp is an important target for the development of antiviral therapeutics.", [["RdRp", "GENE_OR_GENE_PRODUCT", 34, 38], ["viral polymerases", "PROTEIN", 11, 28], ["RdRp", "PROTEIN", 34, 38], ["other viral polymerases", "PROBLEM", 5, 28], ["the RdRp", "TREATMENT", 30, 38], ["antiviral therapeutics", "TREATMENT", 85, 107], ["viral polymerases", "OBSERVATION", 11, 28], ["antiviral therapeutics", "OBSERVATION", 85, 107]]], ["Rational design of RdRp-specific, nucleotide-based inhibitors and/or substrates would benefit from the knowledge of how catalytic efficiency and nucleotide specificity are engineered into the active site of the enzyme.", [["nucleotide", "CHEMICAL", 34, 44], ["nucleotide", "CHEMICAL", 145, 155], ["nucleotide", "CHEMICAL", 34, 44], ["nucleotide", "CHEMICAL", 145, 155], ["nucleotide", "SIMPLE_CHEMICAL", 34, 44], ["RdRp", "PROTEIN", 19, 23], ["enzyme", "PROTEIN", 211, 217], ["RdRp", "PROBLEM", 19, 23], ["nucleotide-based inhibitors", "TREATMENT", 34, 61], ["how catalytic efficiency", "PROBLEM", 116, 140], ["nucleotide specificity", "TEST", 145, 167], ["the enzyme", "TEST", 207, 217]]], ["Addressing these very fundamental issues regarding polymerase function is among the most active areas of polymerase enzymology.", [["these very fundamental issues", "PROBLEM", 11, 40], ["polymerase function", "PROBLEM", 51, 70], ["polymerase enzymology", "TEST", 105, 126]]], ["Herein we review some of the most recent studies of RdRp structure and function.", [["RdRp structure", "OBSERVATION", 52, 66]]], ["We conclude that existing gaps in our ability to connect RdRp structure to RdRp function may require investigations into RdRp dynamics.IntroductionStructures of the RdRp are unable to explain the reduced catalytic efficiency of antiviral nucleoside triphosphatesIntroductionRdRps have a semi-classical structural organization that is often compared to a right hand (Figure 1a) .", [["right hand", "ANATOMY", 354, 364], ["nucleoside triphosphates", "CHEMICAL", 238, 262], ["nucleoside triphosphates", "CHEMICAL", 238, 262], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 238, 262], ["hand", "ORGANISM_SUBDIVISION", 360, 364], ["RdRp", "PROTEIN", 165, 169], ["RdRp dynamics", "TEST", 121, 134], ["the RdRp", "PROBLEM", 161, 169], ["the reduced catalytic efficiency", "PROBLEM", 192, 224], ["antiviral nucleoside triphosphates", "TREATMENT", 228, 262], ["a semi-classical structural organization", "PROBLEM", 285, 325], ["antiviral nucleoside triphosphates", "OBSERVATION", 228, 262], ["structural organization", "OBSERVATION", 302, 325], ["right", "ANATOMY_MODIFIER", 354, 359], ["hand", "ANATOMY", 360, 364]]], ["The enzyme not only has the fingers, palm, and thumb subdomains found in other classes of nucleic acid polymerases but also has a fingertips subdomain that leads to the formation of a completely encircled active site.", [["nucleic acid", "CHEMICAL", 90, 102], ["fingers", "ORGANISM_SUBDIVISION", 28, 35], ["palm", "ORGANISM_SUBDIVISION", 37, 41], ["fingers, palm, and thumb subdomains", "PROTEIN", 28, 63], ["nucleic acid polymerases", "PROTEIN", 90, 114], ["fingertips subdomain", "PROTEIN", 130, 150], ["The enzyme", "TEST", 0, 10], ["palm", "TEST", 37, 41], ["thumb subdomains", "PROBLEM", 47, 63], ["nucleic acid polymerases", "PROBLEM", 90, 114], ["a fingertips subdomain", "PROBLEM", 128, 150], ["fingers", "ANATOMY", 28, 35], ["palm", "ANATOMY", 37, 41], ["thumb", "ANATOMY", 47, 52], ["nucleic acid polymerases", "OBSERVATION", 90, 114], ["fingertips subdomain", "OBSERVATION", 130, 150], ["completely", "OBSERVATION_MODIFIER", 184, 194], ["encircled", "OBSERVATION_MODIFIER", 195, 204], ["active", "OBSERVATION_MODIFIER", 205, 211], ["site", "OBSERVATION", 212, 216]]], ["Seven conserved structural elements, termed motifs A-G, exist.", [["A-G", "GENE_OR_GENE_PRODUCT", 51, 54], ["conserved structural elements", "DNA", 6, 35], ["structural elements", "OBSERVATION", 16, 35]]], ["Motifs A-E are located in the palm subdomain and contribute to aspects of nucleotide and nucleic acid binding, as well as catalysis.", [["nucleotide", "CHEMICAL", 74, 84], ["nucleic acid", "CHEMICAL", 89, 101], ["nucleotide", "CHEMICAL", 74, 84], ["A-E", "GENE_OR_GENE_PRODUCT", 7, 10], ["nucleotide", "SIMPLE_CHEMICAL", 74, 84], ["nucleic acid", "SIMPLE_CHEMICAL", 89, 101], ["palm subdomain", "PROTEIN", 30, 44], ["nucleotide and nucleic acid binding", "PROBLEM", 74, 109]]], ["Motif C is the most well known motif as it contains the GDD sequence that is a hallmark of viral RdRps.", [["Motif C", "GENE_OR_GENE_PRODUCT", 0, 7], ["GDD", "GENE_OR_GENE_PRODUCT", 56, 59], ["RdRps", "GENE_OR_GENE_PRODUCT", 97, 102], ["GDD sequence", "DNA", 56, 68], ["viral RdRps", "PROTEIN", 91, 102], ["Motif C", "PROBLEM", 0, 7], ["the GDD sequence", "TEST", 52, 68], ["viral RdRps", "TREATMENT", 91, 102], ["viral RdRps", "OBSERVATION", 91, 102]]], ["The function of motif D is only now becoming clear and will be discussed below.", [["clear", "OBSERVATION", 45, 50]]], ["Motifs F and G are located in the fingertips and fingers subdomains, respectively.", [["fingertips", "ANATOMY", 34, 44], ["Motifs F and G", "GENE_OR_GENE_PRODUCT", 0, 14], ["fingertips", "ORGANISM_SUBDIVISION", 34, 44], ["fingertips and fingers subdomains", "DNA", 34, 67], ["fingertips", "ANATOMY", 34, 44], ["fingers", "ANATOMY", 49, 56], ["subdomains", "ANATOMY_MODIFIER", 57, 67]]], ["Motif F contains basic amino acid residues that appear to be responsible for ground-state binding of the triphosphate moiety of the incoming nucleotide [2] .", [["amino acid", "CHEMICAL", 23, 33], ["triphosphate", "CHEMICAL", 105, 117], ["nucleotide", "CHEMICAL", 141, 151], ["amino acid", "CHEMICAL", 23, 33], ["triphosphate", "CHEMICAL", 105, 117], ["nucleotide", "CHEMICAL", 141, 151], ["Motif F", "GENE_OR_GENE_PRODUCT", 0, 7], ["amino acid", "AMINO_ACID", 23, 33], ["triphosphate", "SIMPLE_CHEMICAL", 105, 117], ["Motif F", "PROTEIN", 0, 7], ["basic amino acid residues", "TREATMENT", 17, 42], ["the triphosphate moiety", "TREATMENT", 101, 124]]], ["The function of motif G is not absolutely clear, although substitutions of residues in this motif inhibit polymerase activity [3] .IntroductionRdRps have often been characterized as error-prone polymerases.", [["motif G", "PROTEIN", 16, 23], ["error-prone polymerases", "PROTEIN", 182, 205], ["motif G", "PROBLEM", 16, 23], ["substitutions of residues", "PROBLEM", 58, 83], ["this motif inhibit polymerase activity", "PROBLEM", 87, 125], ["IntroductionRdRps", "TREATMENT", 131, 148]]], ["However, it is now clear that the low fidelity is primarily due to the absence of proofreading exonuclease activity [4] .", [["exonuclease", "PROTEIN", 95, 106], ["the low fidelity", "PROBLEM", 30, 46], ["proofreading exonuclease activity", "PROBLEM", 82, 115], ["low fidelity", "OBSERVATION_MODIFIER", 34, 46]]], ["RNA viruses with genomes longer than 10 000 nt, coronaviruses, for example, may encode a proofreading activity [5 ] .", [["RNA viruses", "PROBLEM", 0, 11], ["coronaviruses", "PROBLEM", 48, 61], ["viruses", "OBSERVATION", 4, 11]]], ["Transition mutations do occur with a frequency of 1 in 10 000, primarily due to GMP misincorporation opposite uridine (Figure 1b) .", [["GMP", "CHEMICAL", 80, 83], ["uridine", "CHEMICAL", 110, 117], ["GMP", "CHEMICAL", 80, 83], ["uridine", "CHEMICAL", 110, 117], ["GMP", "SIMPLE_CHEMICAL", 80, 83], ["uridine", "SIMPLE_CHEMICAL", 110, 117], ["Transition mutations", "PROBLEM", 0, 20], ["GMP misincorporation opposite uridine", "TREATMENT", 80, 117]]], ["RdRps do not distinguish correct nucleotides from incorrect nucleotides or nucleotide analogs, such as ribavirin triphosphate (RTP), at the binding step as the apparent dissociation constants (K d,app ) for all nucleotides are quite similar (Figure 1b) , consistent with motif F interactions with the triphosphate governing nucleotide binding [4] .", [["nucleotide", "CHEMICAL", 75, 85], ["ribavirin triphosphate", "CHEMICAL", 103, 125], ["RTP", "CHEMICAL", 127, 130], ["triphosphate", "CHEMICAL", 301, 313], ["nucleotide", "CHEMICAL", 324, 334], ["nucleotides", "CHEMICAL", 33, 44], ["nucleotides", "CHEMICAL", 60, 71], ["nucleotide", "CHEMICAL", 75, 85], ["ribavirin triphosphate", "CHEMICAL", 103, 125], ["RTP", "CHEMICAL", 127, 130], ["nucleotides", "CHEMICAL", 211, 222], ["triphosphate", "CHEMICAL", 301, 313], ["nucleotide", "CHEMICAL", 324, 334], ["RdRps", "GENE_OR_GENE_PRODUCT", 0, 5], ["ribavirin triphosphate", "SIMPLE_CHEMICAL", 103, 125], ["RTP", "SIMPLE_CHEMICAL", 127, 130], ["triphosphate", "SIMPLE_CHEMICAL", 301, 313], ["nucleotide", "SIMPLE_CHEMICAL", 324, 334], ["RdRps", "PROTEIN", 0, 5], ["incorrect nucleotides", "TREATMENT", 50, 71], ["nucleotide analogs", "TREATMENT", 75, 93], ["ribavirin triphosphate (RTP", "TREATMENT", 103, 130], ["the apparent dissociation constants", "PROBLEM", 156, 191], ["K d,app", "TEST", 193, 200], ["all nucleotides", "PROBLEM", 207, 222], ["the triphosphate governing nucleotide binding", "TREATMENT", 297, 342]]], ["The primary fidelity checkpoint for the RdRp occurs after binding and represents a conformational change that has been attributed to the reorientation of the triphosphate into a position for efficient catalysis [4, 6] .", [["triphosphate", "CHEMICAL", 158, 170], ["triphosphate", "CHEMICAL", 158, 170], ["triphosphate", "SIMPLE_CHEMICAL", 158, 170], ["RdRp", "PROTEIN", 40, 44], ["the RdRp", "PROBLEM", 36, 44], ["a conformational change", "PROBLEM", 81, 104], ["the triphosphate", "TREATMENT", 154, 170]]], ["Changes in the equilibrium constant for this conformational-change step manifest as a change in the maximal rate constant for nucleotide addition (k pol ) ( Figure 1b) .IntroductionOne of the most exciting advances in the field of RdRp enzymology recently was the solution of structures for the RdRp from foot-and-mouth disease virus (FMDV) in complex with primed template and various correct nucleotides and RTP [7, 8 ] .", [["nucleotide", "CHEMICAL", 126, 136], ["nucleotide", "CHEMICAL", 126, 136], ["nucleotides", "CHEMICAL", 393, 404], ["foot-and-mouth disease virus", "ORGANISM", 305, 333], ["FMDV", "ORGANISM", 335, 339], ["RdRp", "PROTEIN", 295, 299], ["foot-and-mouth disease virus", "SPECIES", 305, 333], ["FMDV", "SPECIES", 335, 339], ["foot-and-mouth disease virus", "SPECIES", 305, 333], ["FMDV", "SPECIES", 335, 339], ["the maximal rate", "TEST", 96, 112], ["nucleotide addition (k pol", "TREATMENT", 126, 152], ["RdRp enzymology", "TREATMENT", 231, 246], ["the RdRp from foot", "TEST", 291, 309], ["mouth disease virus", "PROBLEM", 314, 333], ["primed template", "TREATMENT", 357, 372], ["various correct nucleotides", "TREATMENT", 377, 404], ["RTP", "TEST", 409, 412], ["foot", "ANATOMY", 305, 309], ["mouth", "ANATOMY", 314, 319]]], ["Because the fingertips of the RdRp constrain movement of the fingers subdomain relative to the thumb subdomain, reorganization of these subdomains did not occur as observed in polymerases that lack a fingertips subdomain [8 ] .", [["thumb subdomain", "ANATOMY", 95, 110], ["RdRp", "GENE_OR_GENE_PRODUCT", 30, 34], ["RdRp", "PROTEIN", 30, 34], ["fingers subdomain", "PROTEIN", 61, 78], ["thumb subdomain", "PROTEIN", 95, 110], ["polymerases", "PROTEIN", 176, 187], ["these subdomains", "PROBLEM", 130, 146], ["fingertips", "ANATOMY_MODIFIER", 12, 22], ["RdRp", "OBSERVATION", 30, 34], ["movement", "OBSERVATION_MODIFIER", 45, 53], ["fingers", "ANATOMY", 61, 68], ["thumb", "ANATOMY", 95, 100]]], ["This observation suggests that subdomain movements are not responsible for rate-limiting, conformational-change steps observed by kinetic analysis of the single-nucleotide-addition cycle.", [["nucleotide", "CHEMICAL", 161, 171], ["nucleotide", "CHEMICAL", 161, 171], ["This observation", "TEST", 0, 16], ["subdomain movements", "PROBLEM", 31, 50], ["kinetic analysis", "TEST", 130, 146], ["subdomain movements", "OBSERVATION", 31, 50]]], ["The most substantial difference between a complex with a correct nucleotide (UTP in Figure 1c ) relative to a complex with an inefficiently incorporated nucleotide analog (RTP in Figure 1c ) was the position of residues, such as Lys-369, on motif D. The complexes are essentially superimposable when atoms involved in catalysis are interrogated ( Figure 1d ).", [["nucleotide", "CHEMICAL", 65, 75], ["UTP", "CHEMICAL", 77, 80], ["nucleotide", "CHEMICAL", 153, 163], ["Lys-369", "CHEMICAL", 229, 236], ["nucleotide", "CHEMICAL", 65, 75], ["UTP", "CHEMICAL", 77, 80], ["nucleotide", "CHEMICAL", 153, 163], ["Lys", "CHEMICAL", 229, 232], ["UTP", "SIMPLE_CHEMICAL", 77, 80], ["Lys-369", "SIMPLE_CHEMICAL", 229, 236], ["a correct nucleotide (UTP", "TREATMENT", 55, 80], ["nucleotide analog", "TREATMENT", 153, 170], ["Lys", "TEST", 229, 232], ["most", "OBSERVATION_MODIFIER", 4, 8], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["difference", "OBSERVATION", 21, 31]]], ["As discussed below, Lys-369 (Lys-359 in poliovirus (PV) RdRp) of motif D is a dynamic element that influences the rate of catalysis.", [["Lys-369", "CHEMICAL", 20, 27], ["Lys-359", "CHEMICAL", 29, 36], ["Lys", "CHEMICAL", 20, 23], ["Lys", "CHEMICAL", 29, 32], ["Lys-369", "SIMPLE_CHEMICAL", 20, 27], ["Lys-359", "AMINO_ACID", 29, 36], ["poliovirus (PV) RdRp", "ORGANISM", 40, 60], ["poliovirus (PV) RdRp", "PROTEIN", 40, 60], ["PV", "SPECIES", 52, 54], ["Lys", "TEST", 20, 23], ["Lys", "TEST", 29, 32], ["poliovirus", "PROBLEM", 40, 50], ["a dynamic element", "PROBLEM", 76, 93], ["dynamic element", "OBSERVATION", 78, 93]]], ["Structural studies may fail to identify the basis of fidelity because they are unable to capture the trajectory of motif D during a catalytic cycle.Remote sites control active site, fidelity checkpointsSeveral surprises regarding the mechanistic basis for RdRp fidelity came from studies of PV that were aimed at identifying a high-fidelity polymerase by selecting for PV mutants that exhibit reduced sensitivity to ribavirin [9, 10] .", [["sites", "ANATOMY", 155, 160], ["site", "ANATOMY", 176, 180], ["ribavirin", "CHEMICAL", 416, 425], ["ribavirin", "CHEMICAL", 416, 425], ["PV", "GENE_OR_GENE_PRODUCT", 369, 371], ["ribavirin", "SIMPLE_CHEMICAL", 416, 425], ["motif D", "PROTEIN", 115, 122], ["high-fidelity polymerase", "PROTEIN", 327, 351], ["PV mutants", "PROTEIN", 369, 379], ["Structural studies", "TEST", 0, 18], ["a catalytic cycle", "TREATMENT", 130, 147], ["Remote sites control active site", "PROBLEM", 148, 180], ["RdRp fidelity", "PROBLEM", 256, 269], ["a high-fidelity polymerase", "PROBLEM", 325, 351], ["PV mutants", "PROBLEM", 369, 379], ["reduced sensitivity", "PROBLEM", 393, 412], ["ribavirin", "TREATMENT", 416, 425], ["active", "OBSERVATION_MODIFIER", 169, 175]]], ["The first surprise was that a site remote from the catalytic center controlled fidelity.", [["a site", "PROBLEM", 28, 34]]], ["Gly-64 of the PV RdRp, a residue in the fingers subdomain, was changed to Ser.", [["Gly-64", "CHEMICAL", 0, 6], ["Gly-64", "CHEMICAL", 0, 6], ["Gly-64", "AMINO_ACID", 0, 6], ["PV RdRp", "ORGANISM", 14, 21], ["PV RdRp", "PROTEIN", 14, 21], ["fingers subdomain", "PROTEIN", 40, 57], ["Gly", "TEST", 0, 3], ["the PV RdRp", "TREATMENT", 10, 21], ["a residue in the fingers subdomain", "PROBLEM", 23, 57], ["PV RdRp", "OBSERVATION", 14, 21], ["fingers", "ANATOMY", 40, 47]]], ["Gly-64 has an indirect connection to motif A in the active site; this motif contributes to interactions in the ribose-binding site and coordination of Mg 2+ ions required for catalysis [9] .", [["Gly-64", "CHEMICAL", 0, 6], ["ribose", "CHEMICAL", 111, 117], ["Mg", "CHEMICAL", 151, 153], ["Gly-64", "CHEMICAL", 0, 6], ["ribose", "CHEMICAL", 111, 117], ["Mg 2+", "CHEMICAL", 151, 156], ["Gly-64", "AMINO_ACID", 0, 6], ["ribose", "SIMPLE_CHEMICAL", 111, 117], ["Mg 2+ ions", "SIMPLE_CHEMICAL", 151, 161], ["ribose-binding site", "PROTEIN", 111, 130], ["Gly", "TEST", 0, 3], ["an indirect connection to motif A in the active site", "PROBLEM", 11, 63], ["the ribose-binding site", "TREATMENT", 107, 130], ["Mg", "TREATMENT", 151, 153], ["catalysis", "PROBLEM", 175, 184], ["active site", "OBSERVATION", 52, 63]]], ["A second surprise was that this same mutant was isolated independently by two different laboratories, suggesting that few solutions may exist to development of resistance to this class of antiviral nucleosides, a distinct contrast to other classes of nucleosidebased RdRp inhibitors [11] .", [["nucleosides", "CHEMICAL", 198, 209], ["antiviral nucleosides", "TREATMENT", 188, 209], ["nucleosidebased RdRp inhibitors", "TREATMENT", 251, 282]]], ["Limited flexibility observed of the RdRp during the catalytic cycle.", [["RdRp", "PROTEIN", 36, 40], ["the RdRp", "PROBLEM", 32, 40], ["RdRp", "OBSERVATION", 36, 40]]], ["RdRp from foot-and-mouth disease virus (FMDV) is employed here but is a representative for most viral RdRps [8 ] .", [["foot-and-mouth disease virus", "ORGANISM", 10, 38], ["FMDV", "ORGANISM", 40, 44], ["foot-and-mouth disease virus", "SPECIES", 10, 38], ["FMDV", "SPECIES", 40, 44], ["foot-and-mouth disease virus", "SPECIES", 10, 38], ["FMDV", "SPECIES", 40, 44], ["RdRp from foot", "PROBLEM", 0, 14], ["mouth disease virus", "PROBLEM", 19, 38], ["foot", "ANATOMY", 10, 14], ["mouth", "ANATOMY", 19, 24]]], ["Mechanistic studies of the PV G64S polymerase revealed that this substitution decreased the equilibrium constant for the conformational-change step (K 2 ) preceding chemistry ( Figure 2a ) [9] .", [["PV G64S polymerase", "PROTEIN", 27, 45], ["PV", "SPECIES", 27, 29], ["Mechanistic studies", "TEST", 0, 19], ["the PV G64S polymerase", "TEST", 23, 45], ["this substitution", "PROBLEM", 60, 77]]], ["The more difficult it is for the enzyme to achieve the catalytically competent conformation, the more faithful the nucleotide-addition cycle will be.", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["the enzyme", "TEST", 29, 39]]], ["Structural studies of the G64S polymerase in complex with substrates have not been completed, but the structure of the unliganded enzyme provided no insight into changes in the organization of motif A as might have been predicted (Figure 2b ).", [["G64S polymerase", "GENE_OR_GENE_PRODUCT", 26, 41], ["A", "GENE_OR_GENE_PRODUCT", 199, 200], ["G64S polymerase", "PROTEIN", 26, 41], ["unliganded enzyme", "PROTEIN", 119, 136], ["motif A", "PROTEIN", 193, 200], ["Structural studies", "TEST", 0, 18], ["the G64S polymerase", "TEST", 22, 41], ["the unliganded enzyme", "TEST", 115, 136]]], ["Because conformational changes appear to be altered by the G64S substitution, analysis of the dynamics during the nucleotide-addition cycle may be most insightful.Remote sites control active site, fidelity checkpointsBiological studies of PV encoding the G64S substitution have shown that the fidelity of the PV RdRp appears to be important for pathogenesis.", [["sites", "ANATOMY", 170, 175], ["site", "ANATOMY", 191, 195], ["nucleotide", "CHEMICAL", 114, 124], ["nucleotide", "CHEMICAL", 114, 124], ["PV", "GENE_OR_GENE_PRODUCT", 239, 241], ["G64S", "GENE_OR_GENE_PRODUCT", 255, 259], ["PV RdRp", "ORGANISM", 309, 316], ["G64S", "DNA", 255, 259], ["PV RdRp", "PROTEIN", 309, 316], ["PV", "SPECIES", 309, 311], ["conformational changes", "PROBLEM", 8, 30], ["the G64S substitution", "TREATMENT", 55, 76], ["the nucleotide", "TEST", 110, 124], ["Remote sites control active site", "PROBLEM", 163, 195], ["Biological studies", "TEST", 217, 235], ["the G64S substitution", "TREATMENT", 251, 272], ["the PV RdRp", "TREATMENT", 305, 316], ["pathogenesis", "PROBLEM", 345, 357], ["active", "OBSERVATION_MODIFIER", 184, 190], ["PV RdRp", "OBSERVATION", 309, 316], ["appears to be important for", "UNCERTAINTY", 317, 344]]], ["The ability for G64S PV to cause disease was attenuated in a very permissive mouse model [12 ,13 ] .", [["G64S PV", "GENE_OR_GENE_PRODUCT", 16, 23], ["mouse", "ORGANISM", 77, 82], ["G64S PV", "PROTEIN", 16, 23], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 77, 82], ["disease", "PROBLEM", 33, 40], ["attenuated", "PROBLEM", 45, 55]]], ["The attenuated phenotype was shown to be a reflection of the reduced population diversity produced by a high-fidelity polymerase by using chemical mutagenesis to restore virulence to the G64S PV population [13 ] .", [["high-fidelity polymerase", "PROTEIN", 104, 128], ["The attenuated phenotype", "PROBLEM", 0, 24], ["the reduced population diversity", "PROBLEM", 57, 89], ["a high-fidelity polymerase", "PROBLEM", 102, 128], ["chemical mutagenesis", "TREATMENT", 138, 158], ["reduced", "OBSERVATION_MODIFIER", 61, 68], ["population", "OBSERVATION", 69, 79]]], ["Importantly, G64S PV and related mutants confer long-term protection of mice from a lethal challenge with wild-type PV [14 ] .", [["G64S PV", "GENE_OR_GENE_PRODUCT", 13, 20], ["mice", "ORGANISM", 72, 76], ["G64S PV", "PROTEIN", 13, 20], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["long-term protection of mice", "TREATMENT", 48, 76], ["a lethal challenge", "TREATMENT", 82, 100]]], ["Therefore, an understanding of how fidelity is engineered into the RdRp structure has practical implication for the development of vaccines.Remote sites control active site, fidelity checkpointsA determinant of nucleotide incorporation efficiency resides on a highly mobile structural element in all nucleic acid polymerases Nucleic acid polymerases employ a two-metal-ion mechanism for catalysis [15] .", [["sites", "ANATOMY", 147, 152], ["site", "ANATOMY", 168, 172], ["nucleotide", "CHEMICAL", 211, 221], ["nucleic acid", "CHEMICAL", 300, 312], ["nucleotide", "CHEMICAL", 211, 221], ["nucleotide", "SIMPLE_CHEMICAL", 211, 221], ["RdRp structure", "PROTEIN", 67, 81], ["nucleic acid polymerases", "PROTEIN", 300, 324], ["Nucleic acid polymerases", "PROTEIN", 325, 349], ["vaccines", "TREATMENT", 131, 139], ["Remote sites control active site", "PROBLEM", 140, 172], ["nucleotide incorporation efficiency", "PROBLEM", 211, 246], ["all nucleic acid polymerases", "TREATMENT", 296, 324], ["Nucleic acid polymerases", "TREATMENT", 325, 349], ["a two-metal-ion mechanism", "TREATMENT", 357, 382], ["active", "OBSERVATION_MODIFIER", 161, 167], ["incorporation efficiency", "OBSERVATION", 222, 246]]], ["One metal (B in Figure 3a ) enters the active site with the nucleotide; the other (A in Figure 3a ) enters after the nucleotide.", [["nucleotide", "CHEMICAL", 60, 70], ["nucleotide", "CHEMICAL", 117, 127], ["nucleotide", "CHEMICAL", 60, 70], ["nucleotide", "CHEMICAL", 117, 127], ["the nucleotide", "TREATMENT", 56, 70], ["the nucleotide", "TREATMENT", 113, 127], ["metal", "OBSERVATION_MODIFIER", 4, 9], ["active", "OBSERVATION", 39, 45]]], ["Metal B likely influences organization of the triphosphate in the active site.", [["Metal B", "CHEMICAL", 0, 7], ["triphosphate", "CHEMICAL", 46, 58], ["Metal B", "CHEMICAL", 0, 7], ["triphosphate", "CHEMICAL", 46, 58], ["Metal B", "GENE_OR_GENE_PRODUCT", 0, 7], ["triphosphate", "SIMPLE_CHEMICAL", 46, 58], ["Metal B", "PROTEIN", 0, 7], ["the triphosphate in the active site", "PROBLEM", 42, 77], ["active", "OBSERVATION_MODIFIER", 66, 72], ["site", "OBSERVATION_MODIFIER", 73, 77]]], ["However, metal A lowers the pK a value for the 3 0 -OH of the primer and contributes to charge neutralization that forms during the transition state.", [["3 0 -OH", "CHEMICAL", 47, 54], ["metal A", "SIMPLE_CHEMICAL", 9, 16], ["the primer", "TREATMENT", 58, 68], ["charge neutralization", "PROBLEM", 88, 109], ["neutralization", "OBSERVATION", 95, 109]]], ["The acceptor for the proton from the primer 3 0 -OH is not known.", [["3 0 -OH", "CHEMICAL", 44, 51], ["0 -OH", "SIMPLE_CHEMICAL", 46, 51], ["the proton from the primer", "TREATMENT", 17, 43]]], ["Recent studies of the nucleotidyl transfer reaction catalyzed by the RdRp and other polymerases have made the unexpected observation that two protons are transferred during the reaction, not just one proton [16] .", [["nucleotidyl", "CHEMICAL", 22, 33], ["protons", "SIMPLE_CHEMICAL", 142, 149], ["RdRp", "PROTEIN", 69, 73], ["polymerases", "PROTEIN", 84, 95], ["Recent studies", "TEST", 0, 14], ["the nucleotidyl transfer reaction", "PROBLEM", 18, 51]]], ["Moreover, it is now clear that the second proton derives from a basic amino acid (general acid) of the polymerase and is transferred to the pyrophosphate leaving group (Figure 3a ) [17 ] .", [["amino acid", "CHEMICAL", 70, 80], ["pyrophosphate", "CHEMICAL", 140, 153], ["amino acid", "CHEMICAL", 70, 80], ["pyrophosphate", "CHEMICAL", 140, 153], ["amino acid", "AMINO_ACID", 70, 80], ["pyrophosphate", "SIMPLE_CHEMICAL", 140, 153], ["polymerase", "PROTEIN", 103, 113], ["a basic amino acid (general acid) of the polymerase", "TREATMENT", 62, 113], ["clear", "OBSERVATION", 20, 25]]], ["Protonation of the pyrophosphate leaving group is not absolutely essential but contributes 50-fold to 1000fold to the rate constant for nucleotide addition.", [["pyrophosphate", "CHEMICAL", 19, 32], ["nucleotide", "CHEMICAL", 136, 146], ["pyrophosphate", "CHEMICAL", 19, 32], ["nucleotide", "CHEMICAL", 136, 146], ["pyrophosphate", "SIMPLE_CHEMICAL", 19, 32], ["nucleotide", "SIMPLE_CHEMICAL", 136, 146], ["the rate", "TEST", 114, 122], ["nucleotide addition", "TREATMENT", 136, 155]]], ["The general acid is located on motif D of RdRps and reverse transcriptases (RTs), on helix O of A-family polymerases (e.g. T7 RNA polymerase), helix P of B-family polymerases (e.g. RB69 DNA polymerase) and the trigger loop of multisubunit RNA polymerases (Figure 3a ) [17 ] .Remote sites control active site, fidelity checkpointsThe general acid is Lys-359 in PV RdRp, Lys-369 in FMDV RdRp, and Lys-220 in the RT from human immunodeficiency virus (HIV).", [["sites", "ANATOMY", 282, 287], ["site", "ANATOMY", 303, 307], ["Lys-359", "CHEMICAL", 349, 356], ["Lys-369", "CHEMICAL", 369, 376], ["Lys-220", "CHEMICAL", 395, 402], ["human immunodeficiency virus (HIV)", "DISEASE", 418, 452], ["Lys", "CHEMICAL", 349, 352], ["Lys", "CHEMICAL", 369, 372], ["Lys", "CHEMICAL", 395, 398], ["RdRps", "GENE_OR_GENE_PRODUCT", 42, 47], ["A-family polymerases", "GENE_OR_GENE_PRODUCT", 96, 116], ["B-family polymerases", "GENE_OR_GENE_PRODUCT", 154, 174], ["RB69", "GENE_OR_GENE_PRODUCT", 181, 185], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["Lys-359", "AMINO_ACID", 349, 356], ["PV RdRp", "ORGANISM", 360, 367], ["Lys-369", "AMINO_ACID", 369, 376], ["FMDV RdRp", "ORGANISM", 380, 389], ["Lys-220", "GENE_OR_GENE_PRODUCT", 395, 402], ["human immunodeficiency virus", "ORGANISM", 418, 446], ["HIV", "ORGANISM", 448, 451], ["RdRps", "PROTEIN", 42, 47], ["reverse transcriptases", "PROTEIN", 52, 74], ["RTs", "PROTEIN", 76, 79], ["helix O", "PROTEIN", 85, 92], ["A-family polymerases", "PROTEIN", 96, 116], ["T7 RNA polymerase", "PROTEIN", 123, 140], ["helix P of B-family polymerases", "PROTEIN", 143, 174], ["RB69 DNA polymerase", "PROTEIN", 181, 200], ["trigger loop", "PROTEIN", 210, 222], ["multisubunit RNA polymerases", "PROTEIN", 226, 254], ["FMDV RdRp", "PROTEIN", 380, 389], ["FMDV", "SPECIES", 380, 384], ["human", "SPECIES", 418, 423], ["immunodeficiency virus", "SPECIES", 424, 446], ["HIV", "SPECIES", 448, 451], ["FMDV RdRp", "SPECIES", 380, 389], ["human immunodeficiency virus", "SPECIES", 418, 446], ["HIV", "SPECIES", 448, 451], ["RdRps", "TREATMENT", 42, 47], ["A-family polymerases", "TREATMENT", 96, 116], ["B-family polymerases", "TREATMENT", 154, 174], ["DNA polymerase", "TEST", 186, 200], ["the trigger loop of multisubunit RNA polymerases", "TREATMENT", 206, 254], ["Remote sites control active site", "PROBLEM", 275, 307], ["Lys", "TEST", 349, 352], ["PV RdRp", "TEST", 360, 367], ["Lys", "TEST", 369, 372], ["FMDV RdRp", "TREATMENT", 380, 389], ["Lys", "TEST", 395, 398], ["human immunodeficiency virus", "PROBLEM", 418, 446], ["active", "OBSERVATION_MODIFIER", 296, 302]]], ["This residue is absolutely conserved in all RdRps and RTs.", [["RdRps", "GENE_OR_GENE_PRODUCT", 44, 49], ["RdRps", "PROTEIN", 44, 49]]], ["Motif D is the most dynamic structural element of RdRps and RTs ( Figure 3b) .", [["Motif D", "GENE_OR_GENE_PRODUCT", 0, 7], ["RdRps", "GENE_OR_GENE_PRODUCT", 50, 55], ["RdRps", "DNA", 50, 55], ["RTs", "DNA", 60, 63]]], ["Surprisingly, none of the structures available for RdRps or RTs, presumably poised for catalysis, reveal a conformation that is consistent with the ability of this residue to function as a general acid.", [["RdRps", "GENE_OR_GENE_PRODUCT", 51, 56], ["RdRps", "PROTEIN", 51, 56], ["RTs", "TEST", 60, 63], ["catalysis", "TEST", 87, 96], ["a general acid", "TREATMENT", 187, 201], ["consistent with", "UNCERTAINTY", 128, 143]]], ["The general acid (Lys-374) of the RdRp from a Norovirus (NV) comes the closest (Figure 3b ).Remote sites control active site, fidelity checkpointsIt is not at all clear why the FMDV RdRp and HIV RT structural studies have not succeeded in capturing the general acid and motif D in its active conformation.", [["sites", "ANATOMY", 99, 104], ["site", "ANATOMY", 120, 124], ["Lys-374", "CHEMICAL", 18, 25], ["Norovirus", "DISEASE", 46, 55], ["Lys-374", "CHEMICAL", 18, 25], ["Lys-374", "AMINO_ACID", 18, 25], ["FMDV RdRp", "ORGANISM", 177, 186], ["RdRp", "PROTEIN", 34, 38], ["FMDV RdRp", "PROTEIN", 177, 186], ["general acid and motif D", "PROTEIN", 253, 277], ["FMDV", "SPECIES", 177, 181], ["FMDV", "SPECIES", 177, 181], ["HIV", "SPECIES", 191, 194], ["The general acid (Lys", "TEST", 0, 21], ["the RdRp", "PROBLEM", 30, 38], ["a Norovirus", "PROBLEM", 44, 55], ["Remote sites control active site", "PROBLEM", 92, 124], ["the FMDV RdRp", "TREATMENT", 173, 186], ["HIV RT structural studies", "TEST", 191, 216], ["Norovirus", "OBSERVATION", 46, 55], ["active", "OBSERVATION_MODIFIER", 113, 119], ["FMDV", "OBSERVATION", 177, 181]]], ["Studies of the other polymerases have successfully captured the general acid in the active conformation (Figure 3c ).", [["the other polymerases", "TEST", 11, 32]]], ["Interestingly, all of the structural elements that contain the general acid undergo substantial changes in conformation after nucleotide binding (Figure 3c ).", [["nucleotide", "CHEMICAL", 126, 136], ["nucleotide", "CHEMICAL", 126, 136], ["substantial changes in conformation", "PROBLEM", 84, 119], ["nucleotide binding", "PROBLEM", 126, 144], ["substantial", "OBSERVATION_MODIFIER", 84, 95], ["changes", "OBSERVATION", 96, 103]]], ["This conformational change may be related to the rate-limiting step (K 2 ) that is used for the fidelity of nucleotide addition.", [["nucleotide", "CHEMICAL", 108, 118], ["nucleotide", "CHEMICAL", 108, 118], ["nucleotide", "SIMPLE_CHEMICAL", 108, 118], ["This conformational change", "PROBLEM", 0, 26], ["the rate", "TEST", 45, 53], ["nucleotide addition", "TREATMENT", 108, 127]]], ["Consistent with this possibility, amino acid substitutions in helix O of A-family polymerases and the trigger loop of multisubunit RNA polymerases contribute to fidelity [18] [19] [20] [21] [22] 23 ] .", [["amino acid", "CHEMICAL", 34, 44], ["amino acid", "CHEMICAL", 34, 44], ["amino acid", "AMINO_ACID", 34, 44], ["A-family polymerases", "GENE_OR_GENE_PRODUCT", 73, 93], ["[18] [19] [20] [21] [22] 23", "SIMPLE_CHEMICAL", 170, 197], ["helix O", "PROTEIN", 62, 69], ["A-family polymerases", "PROTEIN", 73, 93], ["multisubunit RNA polymerases", "PROTEIN", 118, 146], ["amino acid substitutions", "TREATMENT", 34, 58], ["A-family polymerases", "TREATMENT", 73, 93], ["the trigger loop of multisubunit RNA polymerases", "TREATMENT", 98, 146], ["with this possibility", "UNCERTAINTY", 11, 32]]], ["If this Structure is unable to reveal the basis for RdRp fidelity. (a) The conformational-change step (K 2 ) is used to alter fidelity of G64S PV RdRp [9] . (b) Crystal structure of the high-fidelity mutant G64S in PV-3Dpol is essentially identical to the WT (rmsd of 0.33 \u00c5 ) [26 ] . function.", [["K", "CHEMICAL", 103, 104], ["PV-3Dpol", "CHEMICAL", 215, 223], ["PV-3Dpol", "SIMPLE_CHEMICAL", 215, 223], ["high-fidelity mutant G64S", "PROTEIN", 186, 211], ["PV", "PROTEIN", 215, 217], ["3Dpol", "PROTEIN", 218, 223], ["RdRp fidelity", "PROBLEM", 52, 65], ["PV RdRp", "TEST", 143, 150], ["Crystal structure", "TEST", 161, 178], ["rmsd", "TEST", 260, 264]]], ["We suggest that motif D dynamics may hold the key to our understanding of RdRp fidelity and our ability to tune RdRp fidelity for applications such as vaccine development.Remote sites control active site, fidelity checkpointsStructure of an RdRp precursor cannot explain the absence of polymerase activity Picornaviruses produce a single polyprotein that is posttranslationally processed by viral proteases to produce a variety of incompletely and terminally processed products.", [["sites", "ANATOMY", 178, 183], ["site", "ANATOMY", 199, 203], ["RdRp precursor", "PROTEIN", 241, 255], ["Picornaviruses", "PROTEIN", 306, 320], ["viral proteases", "PROTEIN", 391, 406], ["motif D dynamics", "TREATMENT", 16, 32], ["RdRp fidelity", "PROBLEM", 74, 87], ["vaccine development", "TREATMENT", 151, 170], ["Remote sites control active site", "PROBLEM", 171, 203], ["an RdRp precursor", "PROBLEM", 238, 255], ["polymerase activity Picornaviruses", "PROBLEM", 286, 320], ["a single polyprotein", "PROBLEM", 329, 349], ["viral proteases", "PROBLEM", 391, 406], ["active", "OBSERVATION_MODIFIER", 192, 198], ["RdRp", "OBSERVATION", 241, 245], ["cannot explain", "UNCERTAINTY", 256, 270], ["viral proteases", "OBSERVATION", 391, 406], ["variety", "OBSERVATION_MODIFIER", 420, 427]]], ["For example, in addition to the 3C protease and 3D RdRp, a 3C-3D fusion protein (3CD) is also made.", [["3C protease", "PROTEIN", 32, 43], ["3D RdRp", "PROTEIN", 48, 55], ["3C-3D fusion protein", "PROTEIN", 59, 79], ["3CD", "PROTEIN", 81, 84], ["the 3C protease", "TREATMENT", 28, 43], ["3D RdRp", "TREATMENT", 48, 55], ["a 3C-3D fusion protein", "TREATMENT", 57, 79]]], ["Like 3C, 3CD has protease activity, but unlike 3D, 3CD lacks RdRp activity.", [["3CD", "SIMPLE_CHEMICAL", 9, 12], ["RdRp", "GENE_OR_GENE_PRODUCT", 61, 65], ["3CD", "PROTEIN", 9, 12], ["protease", "PROTEIN", 17, 25], ["3CD", "PROTEIN", 51, 54], ["RdRp", "PROTEIN", 61, 65], ["protease activity", "TREATMENT", 17, 34], ["RdRp activity", "OBSERVATION", 61, 74]]], ["The molecular basis for this difference has been of great interest to picornavirologists.", [["picornavirologists", "CANCER", 70, 88]]], ["A recent suggestion was that the fingers subdomain of 3D was derived from a 'chameleon' sequence [25] .", [["3D", "PROTEIN", 54, 56], ["a 'chameleon' sequence", "TREATMENT", 74, 96]]], ["As long as the amino terminus of 3D is free to bury itself into the fingers subdomain, then the fingers subdomain would fold into conformation suitable for RdRp function [25] .", [["amino", "CHEMICAL", 15, 20], ["amino terminus", "PROTEIN", 15, 29], ["3D", "PROTEIN", 33, 35], ["fingers subdomain", "PROTEIN", 68, 85], ["fingers subdomain", "PROTEIN", 96, 113], ["the amino terminus of 3D", "TREATMENT", 11, 35], ["RdRp function", "TEST", 156, 169], ["fingers", "ANATOMY", 68, 75], ["fingers", "ANATOMY", 96, 103]]], ["When the amino terminus of 3D is fused to 3C, however, a new conformation that is inconsistent with RdRp function would be realized.", [["amino", "CHEMICAL", 9, 14], ["amino", "AMINO_ACID", 9, 14], ["amino terminus", "PROTEIN", 9, 23], ["3D", "PROTEIN", 27, 29], ["RdRp", "PROTEIN", 100, 104], ["the amino terminus", "TREATMENT", 5, 23], ["RdRp function", "TREATMENT", 100, 113], ["new", "OBSERVATION_MODIFIER", 57, 60]]], ["The first structure of a picornaviral 3CD protein was solved recently [26 ] .", [["picornaviral 3CD protein", "PROTEIN", 25, 49], ["a picornaviral 3CD protein", "TREATMENT", 23, 49]]], ["As shown in Figure 4 , 3CD is a composite of 3C and 3D.", [["3CD", "SIMPLE_CHEMICAL", 23, 26]]], ["The only hypothesis that could be put forward to explain the absence of RdRp activity in 3CD was that the dynamics of the 3D domain of 3CD may be negatively impacted [26 ] .Remote sites control active site, fidelity checkpointsProcessing intermediates have the ability to expand the viral proteome, potentially creating new functions or, as described here, inactivating some functions.", [["sites", "ANATOMY", 180, 185], ["site", "ANATOMY", 201, 205], ["RdRp", "PROTEIN", 72, 76], ["3D domain", "PROTEIN", 122, 131], ["3CD", "PROTEIN", 135, 138], ["RdRp activity", "PROBLEM", 72, 85], ["Remote sites control active site", "PROBLEM", 173, 205], ["RdRp activity", "OBSERVATION", 72, 85], ["active", "OBSERVATION_MODIFIER", 194, 200], ["viral proteome", "OBSERVATION", 283, 297]]], ["Moreover, a single amino acid change of a residue that influences protein dynamics can be sufficient to alter the global dynamics of a protein and potentially its function [27] .", [["amino acid", "CHEMICAL", 19, 29], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "AMINO_ACID", 19, 29], ["a single amino acid change", "PROBLEM", 10, 36], ["a residue", "PROBLEM", 40, 49]]], ["If this is the case, then the combination of a viral quasispecies and variable extents of polyprotein processing creates unlimited possibilities for the acquisition and evolution of function by a virus with limited coding capacity.Future directions: exploiting RdRp structures for the discovery of dynamics-function relationshipsIn spite of all of the structural information now available for the RdRp (see Supplementary Table 1 ), many gaps exist in our understanding of RdRp function.", [["RdRp", "GENE_OR_GENE_PRODUCT", 472, 476], ["RdRp", "PROTEIN", 397, 401], ["RdRp", "PROTEIN", 472, 476], ["a viral quasispecies", "PROBLEM", 45, 65], ["polyprotein processing", "PROBLEM", 90, 112], ["the acquisition", "TEST", 149, 164], ["a virus", "PROBLEM", 194, 201], ["limited coding capacity", "PROBLEM", 207, 230], ["exploiting RdRp structures", "PROBLEM", 250, 276], ["viral quasispecies", "OBSERVATION", 47, 65]]], ["We would like to suggest that dynamics may represent the missing link to our complete understanding of RdRp function ( Figure 5 ).", [["RdRp", "PROTEIN", 103, 107]]], ["Given the numerous high-resolution structures available for the RdRp in the same and different families, it should be possible to use molecular dynamics (MD) simulations to determine the extent to which dynamics coevolves with structure and function.", [["RdRp", "PROTEIN", 64, 68], ["the RdRp", "TREATMENT", 60, 68]]], ["In addition, the impact of mutations or fusions on dynamics should be tractable by using MD.", [["mutations or fusions", "TREATMENT", 27, 47]]], ["A recent study on HIV RT reported the use of a 360 ns simulation to explain the impact of a non-nucleoside RT inhibitor on HIV RT dynamics [29 ] .", [["HIV", "ORGANISM", 18, 21], ["HIV", "ORGANISM", 123, 126], ["HIV", "SPECIES", 18, 21], ["HIV", "SPECIES", 123, 126], ["HIV", "SPECIES", 18, 21], ["HIV", "SPECIES", 123, 126], ["A recent study", "TEST", 0, 14], ["HIV RT", "TREATMENT", 18, 24], ["a 360 ns simulation", "TREATMENT", 45, 64], ["a non-nucleoside RT inhibitor", "TREATMENT", 90, 119], ["HIV RT dynamics", "TREATMENT", 123, 138]]], ["It should also be possible to Structure is unable to reveal the basis for the absence of activity for polymerase precursors.", [["polymerase precursors", "PROBLEM", 102, 123], ["should also be possible", "UNCERTAINTY", 3, 26]]], ["The polymerase precursor 3CD (pdb 2IJD) is a composite of 3C (pdb 1L1N, pink) and 3Dpol (pdb 1RA6, light blue) [26 ] .Figure 5Dynamics: the missing link to a complete understanding of RdRp function.Figure 5use hydrogen-deuterium exchange mass spectrometry (HDXMS) to evaluate RdRp dynamics.", [["hydrogen-deuterium", "CHEMICAL", 210, 228], ["hydrogen-deuterium", "CHEMICAL", 210, 228], ["pdb 1L1N", "GENE_OR_GENE_PRODUCT", 62, 70], ["polymerase precursor 3CD", "PROTEIN", 4, 28], ["pdb 2IJD", "PROTEIN", 30, 38], ["3C", "PROTEIN", 58, 60], ["pdb 1L1N", "PROTEIN", 62, 70], ["pink", "PROTEIN", 72, 76], ["3Dpol", "PROTEIN", 82, 87], ["pdb 1RA6", "PROTEIN", 89, 97], ["RdRp", "PROTEIN", 184, 188], ["The polymerase precursor 3CD (pdb 2IJD)", "TREATMENT", 0, 39], ["a composite of 3C (pdb 1L1N", "TREATMENT", 43, 70], ["3Dpol (pdb 1RA6", "TREATMENT", 82, 97], ["hydrogen-deuterium exchange mass spectrometry", "TREATMENT", 210, 255], ["HDXMS", "TEST", 257, 262], ["RdRp dynamics", "TEST", 276, 289]]], ["HDXMS should permit analysis of RdRp dynamics in complex with substrates, as well as when fused to other proteins.", [["RdRp", "PROTEIN", 32, 36], ["RdRp dynamics", "PROBLEM", 32, 45], ["RdRp", "OBSERVATION", 32, 36]]], ["Again, HDXMS studies of HIV RT have recently been used to identify regions of RT that change conformation in the absence of substrates [30 ] .", [["HIV", "ORGANISM", 24, 27], ["HIV", "SPECIES", 24, 27], ["HIV", "SPECIES", 24, 27], ["HDXMS studies", "TEST", 7, 20], ["HIV RT", "PROBLEM", 24, 30]]], ["Finally, the molecular weight of most viral RdRps is in the 50-65 kDa range.", [["RdRps", "GENE_OR_GENE_PRODUCT", 44, 49], ["viral RdRps", "PROTEIN", 38, 49]]], ["Enzymes in this size range can now be studied by using nuclear magnetic resonance spectroscopy, which offers an empirical approach to the evaluation of dynamics on the widest range of timescales.ConclusionRdRp fidelity may be a tractable target for viral attenuation and vaccine development.", [["Enzymes", "TEST", 0, 7], ["nuclear magnetic resonance spectroscopy", "TEST", 55, 94], ["an empirical approach", "TEST", 109, 130], ["the evaluation", "TEST", 134, 148], ["viral attenuation", "PROBLEM", 249, 266], ["may be", "UNCERTAINTY", 219, 225], ["viral attenuation", "OBSERVATION", 249, 266]]], ["Our current understanding of the basis of RdRp fidelity is incomplete even with the availability of multiple crystal structures.", [["RdRp fidelity", "PROBLEM", 42, 55], ["RdRp fidelity", "OBSERVATION", 42, 55]]], ["Computational and empirical studies of RdRp dynamics may complete our understanding of RdRp function.", [["RdRp", "GENE_OR_GENE_PRODUCT", 87, 91], ["RdRp", "PROTEIN", 87, 91], ["empirical studies", "TEST", 18, 35], ["RdRp dynamics", "PROBLEM", 39, 52]]]], "b6eab1b98d221709f5e86d431c04e275e8fb07ee": [["IntroductionThe novel coronavirus (COVID-19) was first identified in Wuhan City, Hubei province of China, towards the end of 2019 [1] .", [["coronavirus", "ORGANISM", 22, 33], ["COVID-19", "ORGANISM", 35, 43], ["COVID", "TEST", 35, 40]]], ["The COVID-19 pandemic is currently causing widespread infection and deaths around the world; with growing concern in the medical community [2] .IntroductionGlobally, the number of confirmed cases has exceeded 5 million with hundreds of thousands of death [2] .", [["infection", "DISEASE", 54, 63], ["deaths", "DISEASE", 68, 74], ["death", "DISEASE", 249, 254], ["COVID-19", "SPECIES", 4, 12], ["The COVID", "TEST", 0, 9], ["widespread infection", "PROBLEM", 43, 63], ["widespread", "OBSERVATION_MODIFIER", 43, 53], ["infection", "OBSERVATION", 54, 63]]], ["The confirmatory test for and 10 in 1 and 5 minutes, respectively.", [["The confirmatory test", "TEST", 0, 21]]], ["Intraoperative oxygen saturation was maintained at a minimum of 98%, intraoperative infusion volume was 1000mL and estimated blood loss was 600mL.Patient and observationShe had prophylactic intravenous tranexamic acid 1g and carbetocin 100\u03bcg.", [["blood", "ANATOMY", 125, 130], ["intravenous", "ANATOMY", 190, 201], ["oxygen", "CHEMICAL", 15, 21], ["blood loss", "DISEASE", 125, 135], ["tranexamic acid", "CHEMICAL", 202, 217], ["carbetocin", "CHEMICAL", 225, 235], ["oxygen", "CHEMICAL", 15, 21], ["tranexamic acid", "CHEMICAL", 202, 217], ["carbetocin", "CHEMICAL", 225, 235], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 201], ["tranexamic acid", "SIMPLE_CHEMICAL", 202, 217], ["carbetocin", "SIMPLE_CHEMICAL", 225, 235], ["Patient", "SPECIES", 146, 153], ["Intraoperative oxygen saturation", "TEST", 0, 32], ["intraoperative infusion volume", "TREATMENT", 69, 99], ["estimated blood loss", "PROBLEM", 115, 135], ["prophylactic intravenous tranexamic acid", "TREATMENT", 177, 217], ["carbetocin", "TREATMENT", 225, 235]]], ["The mother and baby were nursed in the recovery room of the operating theatre and the immediate postnatal period was uneventful.Patient and observationThe newborn was commenced on breast milk substitute until the mother was able to breastfeed the baby on demand.", [["breast milk", "ANATOMY", 180, 191], ["baby", "ORGANISM", 15, 19], ["breast milk", "ORGANISM_SUBSTANCE", 180, 191], ["Patient", "SPECIES", 128, 135], ["breast milk substitute", "TREATMENT", 180, 202], ["newborn", "OBSERVATION_MODIFIER", 155, 162]]], ["On day 3 after delivery, the mother and her newborn were transferred back to the isolation ward.", [["delivery", "TREATMENT", 15, 23]]], ["The nasopharyngeal swabs collected from the neonate (at birth and 48 hours after birth) were all negative for COVID-19Patient and observationinfection.", [["nasopharyngeal swabs", "ANATOMY", 4, 24], ["nasopharyngeal swabs", "CANCER", 4, 24], ["neonate", "ORGANISM", 44, 51], ["The nasopharyngeal swabs", "TEST", 0, 24], ["observationinfection", "PROBLEM", 130, 150], ["nasopharyngeal", "ANATOMY", 4, 18], ["swabs", "OBSERVATION", 19, 24]]], ["Both mother and baby remained asymptomatic during the postpartum period.", [["baby", "ORGANISM", 16, 20], ["asymptomatic", "PROBLEM", 30, 42], ["asymptomatic", "OBSERVATION", 30, 42]]], ["On day 15 after delivery, the mother met the criteria for discharge because she had remained asymptomatic for more than 14 days after her initial positive result [4].", [["delivery", "TREATMENT", 16, 24], ["asymptomatic", "PROBLEM", 93, 105]]]], "PMC7086545": [["Papers appeared describing progressively better techniques for specimen processing, as the transmission electron microscope became easier to use and more widely available.", [["specimen", "ANATOMY", 63, 71], ["specimen processing", "TEST", 63, 82], ["the transmission electron microscope", "TEST", 87, 123]]], ["The transmission electron microscope employs a fine electron beam, created by a high-voltage, electric current-heated tungsten filament, focused by magnetic lenses.", [["tungsten", "CHEMICAL", 118, 126], ["heated tungsten filament", "TREATMENT", 111, 135], ["magnetic lenses", "OBSERVATION", 148, 163]]], ["The electron beam passes through an ultrathin plastic section whose tissue and cellular components have been post-fixed in osmium and impregnated with the heavy metals uranyl and lead, which impede the beam in proportion to their respective degrees of electron density.", [["tissue", "ANATOMY", 68, 74], ["cellular", "ANATOMY", 79, 87], ["osmium", "CHEMICAL", 123, 129], ["uranyl", "CHEMICAL", 168, 174], ["osmium", "CHEMICAL", 123, 129], ["uranyl", "CHEMICAL", 168, 174], ["electron", "SIMPLE_CHEMICAL", 4, 12], ["tissue", "TISSUE", 68, 74], ["cellular", "CELL", 79, 87], ["osmium", "SIMPLE_CHEMICAL", 123, 129], ["heavy metals uranyl", "SIMPLE_CHEMICAL", 155, 174], ["electron", "SIMPLE_CHEMICAL", 252, 260], ["The electron beam passes", "TREATMENT", 0, 24], ["an ultrathin plastic section", "TREATMENT", 33, 61], ["osmium", "TREATMENT", 123, 129], ["the heavy metals uranyl", "TREATMENT", 151, 174], ["electron density", "PROBLEM", 252, 268], ["electron density", "OBSERVATION", 252, 268]]], ["The differential transmission of the electrons creates an image that is captured on a fluorescent screen, where it is viewed through a binocular microscope.", [["an image", "TEST", 55, 63], ["a fluorescent screen", "TEST", 84, 104], ["a binocular microscope", "TEST", 133, 155]]], ["Once the image is finally focused with the magnetic lenses, the film is exposed or the image is captured with a digital camera.The transmission electron microscope ::: IntroductionTEM continues to play a critical role in discovering and describing new organisms, especially viruses, and rendering viral diagnosis in, for example, diarrheal diseases.", [["diarrheal diseases", "DISEASE", 330, 348], ["the image", "TEST", 5, 14], ["the film", "TEST", 60, 68], ["a digital camera", "TEST", 110, 126], ["IntroductionTEM", "TREATMENT", 168, 183], ["new organisms", "PROBLEM", 248, 261], ["viruses", "PROBLEM", 274, 281], ["diarrheal diseases", "PROBLEM", 330, 348]]], ["It has provided an understanding of the structure and organization of the components of tissue, cells and organisms.", [["tissue", "ANATOMY", 88, 94], ["cells", "ANATOMY", 96, 101], ["tissue", "TISSUE", 88, 94], ["cells", "CELL", 96, 101], ["organisms", "PROBLEM", 106, 115], ["tissue", "ANATOMY", 88, 94]]], ["The morphology of organelles, some of their functions and their relationships to one another have been derived from ultrastructural studies11,12,13.", [["organelles", "ANATOMY", 18, 28], ["organelles", "CELLULAR_COMPONENT", 18, 28], ["ultrastructural studies", "TEST", 116, 139]]], ["Employing electron microscopic immunocytochemistry using ferritin, peroxidase and colloidal gold beads as markers for example, immunoglobulins, hormones, enzymes, filaments, bacteria and viruses have been identified and described in tissues and cells14.", [["filaments", "ANATOMY", 163, 172], ["tissues", "ANATOMY", 233, 240], ["cells", "ANATOMY", 245, 250], ["ferritin", "GENE_OR_GENE_PRODUCT", 57, 65], ["peroxidase", "GENE_OR_GENE_PRODUCT", 67, 77], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 127, 142], ["filaments", "CELLULAR_COMPONENT", 163, 172], ["tissues", "TISSUE", 233, 240], ["cells", "CELL", 245, 250], ["ferritin", "PROTEIN", 57, 65], ["peroxidase", "PROTEIN", 67, 77], ["immunoglobulins", "PROTEIN", 127, 142], ["enzymes", "PROTEIN", 154, 161], ["electron microscopic immunocytochemistry", "TEST", 10, 50], ["ferritin", "TEST", 57, 65], ["peroxidase", "TEST", 67, 77], ["colloidal gold beads", "TREATMENT", 82, 102], ["immunoglobulins", "TEST", 127, 142], ["enzymes", "TEST", 154, 161], ["bacteria", "PROBLEM", 174, 182], ["viruses", "PROBLEM", 187, 194]]], ["TEM is also used to visualize chromatin and DNA in its various forms, while freeze-fracture techniques have been used to image cell surfaces and also the contents of cellular organelles.The transmission electron microscope ::: IntroductionTEM has been critical in HIV/AIDS research, particularly in the area of the morphogenesis and the natural history of the virus, tissue changes in the disease, and the identification and characteristics of a plethora of opportunistic pathogens15,16.", [["chromatin", "ANATOMY", 30, 39], ["cell surfaces", "ANATOMY", 127, 140], ["cellular organelles", "ANATOMY", 166, 185], ["tissue", "ANATOMY", 367, 373], ["HIV/AIDS", "DISEASE", 264, 272], ["opportunistic pathogens", "DISEASE", 458, 481], ["chromatin", "CELLULAR_COMPONENT", 30, 39], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["cell surfaces", "CELL", 127, 140], ["cellular organelles", "CELLULAR_COMPONENT", 166, 185], ["tissue", "TISSUE", 367, 373], ["chromatin", "DNA", 30, 39], ["HIV", "SPECIES", 264, 267], ["TEM", "TEST", 0, 3], ["DNA", "PROBLEM", 44, 47], ["fracture techniques", "PROBLEM", 83, 102], ["HIV/AIDS research", "PROBLEM", 264, 281], ["the virus", "PROBLEM", 356, 365], ["tissue changes in the disease", "PROBLEM", 367, 396], ["opportunistic pathogens", "PROBLEM", 458, 481], ["fracture", "OBSERVATION", 83, 91], ["cellular organelles", "OBSERVATION", 166, 185], ["virus", "OBSERVATION", 360, 365], ["disease", "OBSERVATION", 389, 396], ["opportunistic", "OBSERVATION_MODIFIER", 458, 471]]], ["Some laboratories, such as ours, have submitted a portion of virtually all biopsy and resection specimens from HIV/AIDS patients for ultrastructural study.", [["specimens", "ANATOMY", 96, 105], ["HIV/AIDS", "DISEASE", 111, 119], ["biopsy", "TISSUE", 75, 81], ["resection specimens", "CANCER", 86, 105], ["HIV", "ORGANISM", 111, 114], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["HIV", "SPECIES", 111, 114], ["Some laboratories", "TEST", 0, 17], ["all biopsy", "TEST", 71, 81], ["resection specimens", "TEST", 86, 105], ["ultrastructural study", "TEST", 133, 154], ["resection", "OBSERVATION", 86, 95]]], ["As a result, new genera and species of pathogens have been discovered, and knowledge of the ultrastructure of these pathogens has been acquired, rendering their diagnosis at the light microscopic level easier; for example, several new microsporidia were identified and their morphogenesis was revealed17,18,19,20,21,22.", [["new genera and species of pathogens", "PROBLEM", 13, 48], ["these pathogens", "PROBLEM", 110, 125], ["several new microsporidia", "PROBLEM", 223, 248], ["new", "OBSERVATION_MODIFIER", 231, 234], ["microsporidia", "OBSERVATION", 235, 248]]], ["The persistence of infectious HIV particles associated with follicular dendritic cells in the germinal centers of hyperplastic lymph nodes from HIV/AIDS patients was an important observation made by TEM, and confirmed by immunohistochemistry (IHC) and in situ hybridization.", [["follicular dendritic cells", "ANATOMY", 60, 86], ["germinal centers", "ANATOMY", 94, 110], ["hyperplastic lymph nodes", "ANATOMY", 114, 138], ["HIV/AIDS", "DISEASE", 144, 152], ["HIV", "ORGANISM", 30, 33], ["follicular dendritic cells", "CELL", 60, 86], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 94, 110], ["hyperplastic lymph nodes", "MULTI-TISSUE_STRUCTURE", 114, 138], ["HIV", "ORGANISM", 144, 147], ["patients", "ORGANISM", 153, 161], ["follicular dendritic cells", "CELL_TYPE", 60, 86], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 144, 147], ["patients", "SPECIES", 153, 161], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 144, 147], ["infectious HIV particles", "PROBLEM", 19, 43], ["follicular dendritic cells", "PROBLEM", 60, 86], ["hyperplastic lymph nodes", "PROBLEM", 114, 138], ["HIV/AIDS", "PROBLEM", 144, 152], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["HIV particles", "OBSERVATION", 30, 43], ["follicular dendritic cells", "OBSERVATION", 60, 86], ["germinal", "ANATOMY", 94, 102], ["hyperplastic", "OBSERVATION_MODIFIER", 114, 126], ["lymph nodes", "OBSERVATION", 127, 138]]], ["The pathology and diagnostic characteristics associated with viruses such as adenovirus, cytomegalovirus and papovavirus have been elucidated using TEM23,24.", [["adenovirus, cytomegalovirus and papovavirus", "DISEASE", 77, 120], ["adenovirus", "ORGANISM", 77, 87], ["cytomegalovirus", "ORGANISM", 89, 104], ["papovavirus", "CANCER", 109, 120], ["The pathology", "TEST", 0, 13], ["viruses", "PROBLEM", 61, 68], ["adenovirus", "PROBLEM", 77, 87], ["cytomegalovirus", "PROBLEM", 89, 104], ["papovavirus", "PROBLEM", 109, 120], ["viruses", "OBSERVATION", 61, 68], ["cytomegalovirus", "OBSERVATION", 89, 104]]], ["The human herpesvirus 8 or Kaposi's sarcoma herpesvirus associated with Kaposi's sarcoma (KS) and multicentric Castleman's disease was successfully visualized in Kaposi's sarcoma specimens25.The transmission electron microscope ::: IntroductionMore recently, TEM has been instrumental in identifying the coronavirus that causes SARS; a new respiratory virus, NL-63, that infects children; and an antigen-positive intracytoplasmic inclusion in the ciliated bronchial epithelium of children with Kawasaki disease26,27,28.", [["Kaposi's sarcoma", "ANATOMY", 72, 88], ["KS", "ANATOMY", 90, 92], ["Kaposi's sarcoma specimens", "ANATOMY", 162, 188], ["bronchial epithelium", "ANATOMY", 456, 476], ["Kaposi's sarcoma herpesvirus", "DISEASE", 27, 55], ["Kaposi's sarcoma", "DISEASE", 72, 88], ["KS", "DISEASE", 90, 92], ["Castleman's disease", "DISEASE", 111, 130], ["Kaposi's sarcoma", "DISEASE", 162, 178], ["coronavirus", "DISEASE", 304, 315], ["SARS", "DISEASE", 328, 332], ["respiratory virus", "DISEASE", 340, 357], ["NL-63", "CHEMICAL", 359, 364], ["Kawasaki disease", "DISEASE", 494, 510], ["human herpesvirus 8", "ORGANISM", 4, 23], ["Kaposi's sarcoma herpesvirus", "ORGANISM", 27, 55], ["Kaposi's sarcoma", "CANCER", 72, 88], ["KS", "CANCER", 90, 92], ["Castleman's disease", "CANCER", 111, 130], ["Kaposi's sarcoma specimens", "CANCER", 162, 188], ["coronavirus", "ORGANISM", 304, 315], ["respiratory virus", "ORGANISM", 340, 357], ["NL-63", "ORGANISM", 359, 364], ["children", "ORGANISM", 379, 387], ["ciliated bronchial epithelium", "TISSUE", 447, 476], ["children", "ORGANISM", 480, 488], ["human", "SPECIES", 4, 9], ["Kaposi's sarcoma herpesvirus", "SPECIES", 27, 55], ["children", "SPECIES", 379, 387], ["children", "SPECIES", 480, 488], ["human herpesvirus", "SPECIES", 4, 21], ["Kaposi's sarcoma herpesvirus", "SPECIES", 27, 55], ["Kaposi's sarcoma (KS)", "SPECIES", 72, 93], ["NL-63", "SPECIES", 359, 364], ["The human herpesvirus", "TEST", 0, 21], ["Kaposi's sarcoma herpesvirus", "PROBLEM", 27, 55], ["Kaposi's sarcoma", "PROBLEM", 72, 88], ["multicentric Castleman's disease", "PROBLEM", 98, 130], ["Kaposi's sarcoma specimens", "TEST", 162, 188], ["the coronavirus", "PROBLEM", 300, 315], ["SARS", "PROBLEM", 328, 332], ["a new respiratory virus", "PROBLEM", 334, 357], ["an antigen", "TEST", 393, 403], ["positive intracytoplasmic inclusion", "PROBLEM", 404, 439], ["Kawasaki disease", "PROBLEM", 494, 510], ["human herpesvirus", "ANATOMY", 4, 21], ["Kaposi", "OBSERVATION_MODIFIER", 27, 33], ["sarcoma herpesvirus", "OBSERVATION", 36, 55], ["Kaposi", "OBSERVATION_MODIFIER", 72, 78], ["sarcoma", "OBSERVATION", 81, 88], ["multicentric", "OBSERVATION_MODIFIER", 98, 110], ["Castleman", "OBSERVATION", 111, 120], ["Kaposi", "OBSERVATION_MODIFIER", 162, 168], ["sarcoma", "OBSERVATION", 171, 178], ["new", "OBSERVATION_MODIFIER", 336, 339], ["respiratory virus", "OBSERVATION", 340, 357], ["positive", "OBSERVATION_MODIFIER", 404, 412], ["intracytoplasmic inclusion", "OBSERVATION", 413, 439], ["ciliated", "ANATOMY_MODIFIER", 447, 455], ["bronchial epithelium", "ANATOMY", 456, 476], ["Kawasaki disease", "OBSERVATION", 494, 510]]], ["Looking to the future, we predict that TEM will be very helpful in stem cell research for identifying cellular differentiation.Applications of TEM in pathology ::: IntroductionAlthough some pathologists claim that TEM has passed its heyday, when, for example, it was a routine part of the practice of anatomic pathology and an integral part of pathology research, this has surely not been our experience.", [["stem cell", "ANATOMY", 67, 76], ["cellular", "ANATOMY", 102, 110], ["stem cell", "CELL", 67, 76], ["cellular", "CELL", 102, 110], ["anatomic pathology", "TEST", 301, 319], ["stem cell", "OBSERVATION", 67, 76], ["cellular differentiation", "OBSERVATION", 102, 126]]], ["At one time, virtually every academic pathology department had a TEM laboratory where every possible tumor was subjected to ultrastructural characterization and diagnoses were routinely made29,30,31,32,33,34,35.Applications of TEM in pathology ::: IntroductionThe ultrastructural findings of TEM add immensely to the pathologist's understanding of the light microscopic images that are the mainstay of anatomic pathology.", [["tumor", "ANATOMY", 101, 106], ["tumor", "DISEASE", 101, 106], ["tumor", "CANCER", 101, 106], ["tumor", "PROBLEM", 101, 106], ["ultrastructural characterization", "TEST", 124, 156], ["the light microscopic images", "TEST", 348, 376], ["anatomic pathology", "TEST", 402, 420], ["possible", "UNCERTAINTY", 92, 100], ["tumor", "OBSERVATION", 101, 106]]], ["For example, both the pathologist and the nephrologists still depend on TEM for interpreting renal biopsies.", [["renal biopsies", "ANATOMY", 93, 107], ["renal biopsies", "MULTI-TISSUE_STRUCTURE", 93, 107], ["interpreting renal biopsies", "TEST", 80, 107], ["renal", "ANATOMY", 93, 98], ["biopsies", "OBSERVATION", 99, 107]]], ["TEM is irreplaceable for diagnosing and categorizing ciliary, storage and neuromuscular diseases.", [["ciliary", "ANATOMY", 53, 60], ["neuromuscular", "ANATOMY", 74, 87], ["ciliary, storage and neuromuscular diseases", "DISEASE", 53, 96], ["ciliary", "MULTI-TISSUE_STRUCTURE", 53, 60], ["diagnosing", "TEST", 25, 35], ["neuromuscular diseases", "PROBLEM", 74, 96], ["neuromuscular", "ANATOMY", 74, 87], ["diseases", "OBSERVATION", 88, 96]]], ["It plays a therapeutic role in determining the source of a metastasis from an unknown primary tumor.", [["primary tumor", "ANATOMY", 86, 99], ["metastasis", "DISEASE", 59, 69], ["tumor", "DISEASE", 94, 99], ["tumor", "CANCER", 94, 99], ["a metastasis", "PROBLEM", 57, 69], ["an unknown primary tumor", "PROBLEM", 75, 99], ["metastasis", "OBSERVATION", 59, 69], ["primary", "OBSERVATION_MODIFIER", 86, 93], ["tumor", "OBSERVATION", 94, 99]]], ["TEM provides diagnostic criteria: for example, the long, wavy, villous processes of mesothelial cells in mesotheliomas; desmosomes and bundles of cytokeratin of squamous cells in squamous cell carcinoma; the microvillous-lined lumina of adenocarcinomas; the inclusion of the alveolar soft parts sarcoma; pre-melanosomes in amelanotic melanomas; Weibel\u2013Palade bodies of endothelial cells in vascular tumors; Reincke crystals of Leydig cell tumors; dense core granules of neuroendocrine tumors; prominent core rootlets of alimentary tract tumors, especially of the colorectum; mitochondria of oncocytomas; and the small clear vesicles of chromophobe tumors of the kidney.Applications of TEM in pathology ::: IntroductionAlthough TEM is limited by the size of a specimen that can be actually examined, the fine details that can be discerned, even from single cells, often compensates for the size limitation.", [["villous", "ANATOMY", 63, 70], ["mesothelial cells", "ANATOMY", 84, 101], ["mesotheliomas", "ANATOMY", 105, 118], ["desmosomes", "ANATOMY", 120, 130], ["bundles", "ANATOMY", 135, 142], ["squamous cells", "ANATOMY", 161, 175], ["squamous cell carcinoma", "ANATOMY", 179, 202], ["microvillous-lined lumina", "ANATOMY", 208, 233], ["adenocarcinomas", "ANATOMY", 237, 252], ["alveolar soft parts sarcoma", "ANATOMY", 275, 302], ["pre-melanosomes", "ANATOMY", 304, 319], ["amelanotic melanomas", "ANATOMY", 323, 343], ["Weibel\u2013Palade bodies", "ANATOMY", 345, 365], ["endothelial cells", "ANATOMY", 369, 386], ["vascular tumors", "ANATOMY", 390, 405], ["Leydig cell tumors", "ANATOMY", 427, 445], ["granules", "ANATOMY", 458, 466], ["neuroendocrine tumors", "ANATOMY", 470, 491], ["rootlets", "ANATOMY", 508, 516], ["alimentary tract tumors", "ANATOMY", 520, 543], ["colorectum", "ANATOMY", 563, 573], ["mitochondria", "ANATOMY", 575, 587], ["oncocytomas", "ANATOMY", 591, 602], ["vesicles", "ANATOMY", 624, 632], ["chromophobe tumors", "ANATOMY", 636, 654], ["kidney", "ANATOMY", 662, 668], ["cells", "ANATOMY", 856, 861], ["mesotheliomas", "DISEASE", 105, 118], ["squamous cell carcinoma", "DISEASE", 179, 202], ["adenocarcinomas", "DISEASE", 237, 252], ["sarcoma", "DISEASE", 295, 302], ["amelanotic melanomas", "DISEASE", 323, 343], ["vascular tumors", "DISEASE", 390, 405], ["Leydig cell tumors", "DISEASE", 427, 445], ["neuroendocrine tumors", "DISEASE", 470, 491], ["alimentary tract tumors", "DISEASE", 520, 543], ["chromophobe tumors", "DISEASE", 636, 654], ["mesothelial cells", "CELL", 84, 101], ["mesotheliomas", "CANCER", 105, 118], ["desmosomes", "CELLULAR_COMPONENT", 120, 130], ["bundles", "CELLULAR_COMPONENT", 135, 142], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 146, 157], ["squamous cells", "CELL", 161, 175], ["squamous cell carcinoma", "CANCER", 179, 202], ["microvillous-lined lumina", "TISSUE", 208, 233], ["adenocarcinomas", "CANCER", 237, 252], ["alveolar soft parts sarcoma", "CANCER", 275, 302], ["amelanotic melanomas", "CANCER", 323, 343], ["Weibel\u2013Palade bodies", "CELL", 345, 365], ["endothelial cells", "CELL", 369, 386], ["vascular tumors", "CANCER", 390, 405], ["Leydig cell tumors", "CANCER", 427, 445], ["granules", "ORGANISM_SUBSTANCE", 458, 466], ["neuroendocrine tumors", "CANCER", 470, 491], ["alimentary tract tumors", "CANCER", 520, 543], ["colorectum", "ORGAN", 563, 573], ["mitochondria", "CELLULAR_COMPONENT", 575, 587], ["oncocytomas", "CANCER", 591, 602], ["vesicles", "CELLULAR_COMPONENT", 624, 632], ["chromophobe tumors", "CANCER", 636, 654], ["kidney", "ORGAN", 662, 668], ["cells", "CELL", 856, 861], ["mesothelial cells", "CELL_TYPE", 84, 101], ["cytokeratin", "PROTEIN", 146, 157], ["squamous cells", "CELL_TYPE", 161, 175], ["endothelial cells", "CELL_TYPE", 369, 386], ["the long, wavy, villous processes of mesothelial cells", "PROBLEM", 47, 101], ["mesotheliomas", "PROBLEM", 105, 118], ["squamous cells", "PROBLEM", 161, 175], ["squamous cell carcinoma", "PROBLEM", 179, 202], ["the microvillous-lined lumina of adenocarcinomas", "PROBLEM", 204, 252], ["the alveolar soft parts sarcoma", "PROBLEM", 271, 302], ["pre-melanosomes", "PROBLEM", 304, 319], ["amelanotic melanomas", "PROBLEM", 323, 343], ["endothelial cells", "PROBLEM", 369, 386], ["vascular tumors", "PROBLEM", 390, 405], ["Leydig cell tumors", "PROBLEM", 427, 445], ["dense core granules of neuroendocrine tumors", "PROBLEM", 447, 491], ["alimentary tract tumors", "PROBLEM", 520, 543], ["oncocytomas", "PROBLEM", 591, 602], ["the small clear vesicles of chromophobe tumors of the kidney", "PROBLEM", 608, 668], ["villous", "OBSERVATION", 63, 70], ["mesothelial cells", "OBSERVATION", 84, 101], ["mesotheliomas", "OBSERVATION", 105, 118], ["bundles", "OBSERVATION_MODIFIER", 135, 142], ["squamous cells", "OBSERVATION", 161, 175], ["squamous cell carcinoma", "OBSERVATION", 179, 202], ["microvillous", "OBSERVATION_MODIFIER", 208, 220], ["lined", "OBSERVATION_MODIFIER", 221, 226], ["lumina", "OBSERVATION_MODIFIER", 227, 233], ["adenocarcinomas", "OBSERVATION", 237, 252], ["alveolar", "ANATOMY_MODIFIER", 275, 283], ["soft parts", "ANATOMY", 284, 294], ["sarcoma", "OBSERVATION", 295, 302], ["amelanotic melanomas", "OBSERVATION", 323, 343], ["endothelial cells", "OBSERVATION", 369, 386], ["vascular", "ANATOMY", 390, 398], ["tumors", "OBSERVATION", 399, 405], ["crystals", "OBSERVATION_MODIFIER", 415, 423], ["Leydig cell tumors", "OBSERVATION", 427, 445], ["dense", "OBSERVATION_MODIFIER", 447, 452], ["core", "OBSERVATION_MODIFIER", 453, 457], ["granules", "OBSERVATION_MODIFIER", 458, 466], ["neuroendocrine tumors", "OBSERVATION", 470, 491], ["prominent", "OBSERVATION_MODIFIER", 493, 502], ["core", "OBSERVATION_MODIFIER", 503, 507], ["rootlets", "OBSERVATION_MODIFIER", 508, 516], ["alimentary tract", "ANATOMY", 520, 536], ["tumors", "OBSERVATION", 537, 543], ["colorectum", "ANATOMY", 563, 573], ["oncocytomas", "OBSERVATION", 591, 602], ["small", "OBSERVATION_MODIFIER", 612, 617], ["clear", "OBSERVATION_MODIFIER", 618, 623], ["vesicles", "OBSERVATION_MODIFIER", 624, 632], ["chromophobe tumors", "OBSERVATION", 636, 654], ["kidney", "ANATOMY", 662, 668], ["size", "OBSERVATION_MODIFIER", 749, 753], ["size", "OBSERVATION_MODIFIER", 889, 893]]], ["Standard light microscopy (LM) and even IHC may only reveal the tip of an iceberg.Applications of TEM in pathology ::: IntroductionWhen submitting a tissue specimen for TEM, in addition to receiving ultrastructural information, LM of a semi-thin plastic section is also performed, which is often more than adequate for LM diagnosis.", [["tissue specimen", "ANATOMY", 149, 164], ["tissue specimen", "TISSUE", 149, 164], ["Standard light microscopy", "TEST", 0, 25], ["IHC", "TEST", 40, 43], ["a tissue specimen", "TEST", 147, 164], ["a semi-thin plastic section", "TREATMENT", 234, 261], ["tip", "OBSERVATION_MODIFIER", 64, 67], ["iceberg", "OBSERVATION", 74, 81]]], ["Thus, a large amount of information can be obtained from a small sample.", [["large", "OBSERVATION_MODIFIER", 8, 13], ["amount", "OBSERVATION_MODIFIER", 14, 20]]], ["In our opinion, it is the patient who potentially suffers most, when TEM is not available to the pathologist.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33]]], ["It is also a missed opportunity when researchers do not consider the potential of TEM in their work on cells, tissues and organisms.Applications of TEM in pathology ::: IntroductionTEM actually complements the newer research techniques.", [["cells", "ANATOMY", 103, 108], ["tissues", "ANATOMY", 110, 117], ["cells", "CELL", 103, 108], ["tissues", "TISSUE", 110, 117]]], ["Confocal (light) microscopy provides a three-dimensional view, with the ability to mark different components, in color.", [["Confocal (light) microscopy", "TEST", 0, 27], ["a three-dimensional view", "TEST", 37, 61]]], ["Scanning electron microscopy and its variants provide a three-dimensional view of surfaces.", [["Scanning electron microscopy", "TEST", 0, 28]]], ["High-voltage TEM, which has a limited availability, allows the use of thicker sections to provide more of a three-dimensional view.Applications of TEM in pathology ::: IntroductionOnly time will tell what impact molecular techniques will have on TEM and IHC.", [["sections", "ANATOMY", 78, 86], ["High-voltage TEM", "PROBLEM", 0, 16], ["thicker sections", "TREATMENT", 70, 86], ["voltage TEM", "OBSERVATION_MODIFIER", 5, 16]]], ["In our opinion, all these techniques will ultimately have a complementary future in both diagnostic and research pathology.Applications of TEM in pathology ::: IntroductionAs more and more antibodies have become available, IHC has all but replaced TEM in many surgical pathology departments.", [["antibodies", "PROTEIN", 189, 199], ["research pathology", "TEST", 104, 122], ["IntroductionAs", "TREATMENT", 160, 174]]], ["In some cases, this has been unfortunate, as markers that have purported to be specific for certain cell types/tumors, in time, turn out to have only a nonspecific association.", [["cell", "ANATOMY", 100, 104], ["tumors", "ANATOMY", 111, 117], ["tumors", "DISEASE", 111, 117], ["cell", "CELL", 100, 104], ["tumors", "CANCER", 111, 117], ["tumors", "PROBLEM", 111, 117], ["tumors", "OBSERVATION", 111, 117]]], ["A prime example is the antibody for neuron-specific enolase, which was heralded as specific for neuroendocrine tumors and is now referred to as 'nonspecific enolase'.", [["neuron", "ANATOMY", 36, 42], ["neuroendocrine tumors", "ANATOMY", 96, 117], ["neuroendocrine tumors", "DISEASE", 96, 117], ["neuron-specific enolase", "GENE_OR_GENE_PRODUCT", 36, 59], ["neuroendocrine tumors", "CANCER", 96, 117], ["enolase", "GENE_OR_GENE_PRODUCT", 157, 164], ["neuron-specific enolase", "PROTEIN", 36, 59], ["enolase", "PROTEIN", 157, 164], ["the antibody", "TEST", 19, 31], ["neuroendocrine tumors", "PROBLEM", 96, 117], ["tumors", "OBSERVATION", 111, 117]]], ["As in many cases, one antibody, like neuron-specific enolase, has been replaced by a panel of antibodies, to create statistically more specific diagnostic results.", [["neuron-specific enolase", "GENE_OR_GENE_PRODUCT", 37, 60], ["neuron-specific enolase", "PROTEIN", 37, 60], ["antibodies", "PROTEIN", 94, 104], ["one antibody", "TEST", 18, 30]]], ["On the other hand, the transmission electron microscope is an excellent tool for identifying the few and the many diagnostic dense core granules in the range of neuroendocrine tumors from small cell to carcinoid, respectively.", [["granules", "ANATOMY", 136, 144], ["neuroendocrine tumors", "ANATOMY", 161, 182], ["cell", "ANATOMY", 194, 198], ["carcinoid", "ANATOMY", 202, 211], ["tumors", "DISEASE", 176, 182], ["carcinoid", "DISEASE", 202, 211], ["granules", "ORGANISM_SUBSTANCE", 136, 144], ["neuroendocrine tumors", "CANCER", 161, 182], ["small cell", "CELL", 188, 198], ["carcinoid", "CANCER", 202, 211], ["the transmission electron microscope", "TEST", 19, 55], ["the many diagnostic dense core granules", "PROBLEM", 105, 144], ["neuroendocrine tumors", "PROBLEM", 161, 182], ["small cell to carcinoid", "PROBLEM", 188, 211], ["dense", "OBSERVATION_MODIFIER", 125, 130], ["core", "OBSERVATION_MODIFIER", 131, 135], ["granules", "OBSERVATION", 136, 144], ["neuroendocrine tumors", "OBSERVATION", 161, 182], ["small cell", "OBSERVATION", 188, 198], ["carcinoid", "OBSERVATION", 202, 211]]], ["With increased use of IHC, it has become apparent that there are few magic IHC 'bullets' and panels of IHC stains typically must be used.", [["IHC", "TREATMENT", 22, 25], ["IHC stains", "TEST", 103, 113], ["increased", "OBSERVATION_MODIFIER", 5, 14]]], ["Interestingly, compared to a panel of IHC stains, TEM often is not only at least as specific, but is also a more economical approach in solving a diagnostic problem.", [["IHC stains", "TEST", 38, 48]]], ["Ultrastructural study can readily determine the type of a poorly or 'undifferentiated' carcinoma and even indicate the primary site of a metastasis.Applications of TEM in pathology ::: IntroductionTEM also has an important role in cytopathology.", [["undifferentiated' carcinoma", "ANATOMY", 69, 96], ["carcinoma", "DISEASE", 87, 96], ["metastasis", "DISEASE", 137, 147], ["carcinoma", "CANCER", 87, 96], ["Ultrastructural study", "TEST", 0, 21], ["a poorly or 'undifferentiated' carcinoma", "PROBLEM", 56, 96], ["a metastasis", "PROBLEM", 135, 147], ["carcinoma", "OBSERVATION", 87, 96], ["metastasis", "OBSERVATION", 137, 147], ["cytopathology", "OBSERVATION", 231, 244]]], ["Cells in effusions, like cells in culture, can be readily prepared for TEM.", [["Cells", "ANATOMY", 0, 5], ["effusions", "ANATOMY", 9, 18], ["cells", "ANATOMY", 25, 30], ["effusions", "DISEASE", 9, 18], ["Cells", "CELL", 0, 5], ["cells", "CELL", 25, 30], ["effusions", "PROBLEM", 9, 18], ["like cells", "PROBLEM", 20, 30], ["culture", "TEST", 34, 41], ["effusions", "OBSERVATION", 9, 18]]], ["Epithelial cells are easily distinguishable from mesothelial cells.", [["Epithelial cells", "ANATOMY", 0, 16], ["mesothelial cells", "ANATOMY", 49, 66], ["Epithelial cells", "CELL", 0, 16], ["mesothelial cells", "CELL", 49, 66], ["Epithelial cells", "CELL_TYPE", 0, 16], ["mesothelial cells", "CELL_TYPE", 49, 66], ["Epithelial cells", "PROBLEM", 0, 16], ["mesothelial cells", "PROBLEM", 49, 66], ["cells", "OBSERVATION", 11, 16], ["mesothelial cells", "OBSERVATION", 49, 66]]], ["Needle biopsies are particularly good specimens for TEM.", [["specimens", "ANATOMY", 38, 47], ["Needle biopsies", "CANCER", 0, 15], ["Needle biopsies", "TEST", 0, 15]]], ["Radiographic guidance assures obtaining lesional tissue, minimizes elapsed time between the procedure and immersion in fixative and guarantees optimal preservation.", [["lesional tissue", "ANATOMY", 40, 55], ["lesional tissue", "TISSUE", 40, 55], ["Radiographic guidance", "TEST", 0, 21], ["lesional tissue", "PROBLEM", 40, 55], ["the procedure", "TREATMENT", 88, 101], ["immersion in fixative", "TREATMENT", 106, 127], ["lesional tissue", "OBSERVATION_MODIFIER", 40, 55]]], ["Likewise, fine-needle aspirates (FNAs) are ideal for TEM.", [["FNAs", "ANATOMY", 33, 37], ["needle aspirates", "MULTI-TISSUE_STRUCTURE", 15, 31]]], ["They can be optimally fixed by being injected directly into glutaraldehyde and treated as a cell suspension.", [["cell", "ANATOMY", 92, 96], ["glutaraldehyde", "CHEMICAL", 60, 74], ["glutaraldehyde", "CHEMICAL", 60, 74], ["glutaraldehyde", "SIMPLE_CHEMICAL", 60, 74], ["cell", "CELL", 92, 96], ["glutaraldehyde", "TREATMENT", 60, 74], ["a cell suspension", "TREATMENT", 90, 107], ["cell suspension", "OBSERVATION", 92, 107]]], ["Of course, if there are fragments of tissue present, they can also be routinely processed.Limitations of TEM ::: IntroductionWhen considering using TEM as a diagnostic or research tool, one must appreciate its limitations.", [["tissue", "ANATOMY", 37, 43], ["tissue", "TISSUE", 37, 43], ["fragments of tissue", "PROBLEM", 24, 43]]], ["Although one can see the cytologic features of malignancy, for example, prominent heterochromatin and nucleoli, pleomorphic nuclei, mitotic figures and cell pleomorphism, TEM is basically not employed for distinguishing benign from malignant tumors.", [["malignancy", "ANATOMY", 47, 57], ["heterochromatin", "ANATOMY", 82, 97], ["nucleoli", "ANATOMY", 102, 110], ["pleomorphic nuclei", "ANATOMY", 112, 130], ["cell", "ANATOMY", 152, 156], ["benign", "ANATOMY", 220, 226], ["malignant tumors", "ANATOMY", 232, 248], ["malignancy", "DISEASE", 47, 57], ["malignant tumors", "DISEASE", 232, 248], ["malignancy", "CANCER", 47, 57], ["heterochromatin", "CELLULAR_COMPONENT", 82, 97], ["nucleoli", "CELLULAR_COMPONENT", 102, 110], ["pleomorphic nuclei", "CELLULAR_COMPONENT", 112, 130], ["cell", "CELL", 152, 156], ["malignant tumors", "CANCER", 232, 248], ["malignancy", "PROBLEM", 47, 57], ["prominent heterochromatin and nucleoli", "PROBLEM", 72, 110], ["pleomorphic nuclei", "PROBLEM", 112, 130], ["mitotic figures", "PROBLEM", 132, 147], ["cell pleomorphism", "PROBLEM", 152, 169], ["malignant tumors", "PROBLEM", 232, 248], ["malignancy", "OBSERVATION", 47, 57], ["prominent", "OBSERVATION_MODIFIER", 72, 81], ["heterochromatin", "OBSERVATION", 82, 97], ["nucleoli", "OBSERVATION_MODIFIER", 102, 110], ["pleomorphic nuclei", "OBSERVATION", 112, 130], ["mitotic figures", "OBSERVATION", 132, 147], ["cell pleomorphism", "OBSERVATION", 152, 169], ["malignant", "OBSERVATION_MODIFIER", 232, 241], ["tumors", "OBSERVATION", 242, 248]]], ["This should be left to a light microscopist, who visualizes the cytology as well as the critical cell behavior, for example, tissue invasion by the tumor cells.Reagents ::: Materials", [["cell", "ANATOMY", 97, 101], ["tissue", "ANATOMY", 125, 131], ["tumor cells", "ANATOMY", 148, 159], ["tumor", "DISEASE", 148, 153], ["cell", "CELL", 97, 101], ["tissue", "TISSUE", 125, 131], ["tumor cells", "CELL", 148, 159], ["tumor cells", "CELL_TYPE", 148, 159], ["the cytology", "TEST", 60, 72], ["tissue invasion", "PROBLEM", 125, 140], ["the tumor cells", "PROBLEM", 144, 159], ["invasion", "OBSERVATION", 132, 140], ["tumor cells", "OBSERVATION", 148, 159]]]], "b5f185fcc710eacf01c0f7ff954be7b3d9770249": [["Results:The mean age of 131 enrolled patients was 51.2 years (standard deviation [SD]: 16.1 years), and 70 (53.4%) patients were male.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 115, 123]]], ["A total of 76 patients developed liver injury (mild, 40.5%; moderate, 15.3%; severe, 2.3%) with a median occurrence time of 10.0 days.", [["liver", "ANATOMY", 33, 38], ["liver injury", "DISEASE", 33, 45], ["patients", "ORGANISM", 14, 22], ["liver", "ORGAN", 33, 38], ["patients", "SPECIES", 14, 22], ["liver injury", "PROBLEM", 33, 45], ["liver", "ANATOMY", 33, 38], ["injury", "OBSERVATION", 39, 45], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["moderate", "OBSERVATION_MODIFIER", 60, 68]]], ["Critically ill patients had higher and earlier occurrence (81.5 vs. 51.9%, 12.0 vs. 5.0 days; p < 0.001), greater injury severity (p < 0.001), and slower recovery (50.0 vs. 61.1%) of liver function than non-critically ill patients.", [["liver", "ANATOMY", 183, 188], ["Critically ill", "DISEASE", 0, 14], ["non-critically ill", "DISEASE", 203, 221], ["patients", "ORGANISM", 15, 23], ["liver", "ORGAN", 183, 188], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 222, 230], ["Critically ill", "PROBLEM", 0, 14], ["greater injury severity", "PROBLEM", 106, 129], ["liver function", "TEST", 183, 197], ["liver", "ANATOMY", 183, 188]]], ["Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05-1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44-9.52) were risk factors for liver injury in non-critically ill patients.", [["liver", "ANATOMY", 257, 262], ["lopinavir/ritonavir", "CHEMICAL", 173, 192], ["arbidol", "CHEMICAL", 197, 204], ["liver injury", "DISEASE", 257, 269], ["non-critically ill", "DISEASE", 273, 291], ["lopinavir", "CHEMICAL", 173, 182], ["ritonavir", "CHEMICAL", 183, 192], ["arbidol", "CHEMICAL", 197, 204], ["lopinavir", "SIMPLE_CHEMICAL", 173, 182], ["ritonavir", "SIMPLE_CHEMICAL", 183, 192], ["arbidol", "SIMPLE_CHEMICAL", 197, 204], ["liver", "ORGAN", 257, 262], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["Multivariable regression", "TEST", 0, 24], ["concomitant medications", "TREATMENT", 51, 74], ["CI", "TEST", 124, 126], ["lopinavir", "TREATMENT", 173, 182], ["ritonavir", "TREATMENT", 183, 192], ["arbidol", "TREATMENT", 197, 204], ["CI", "TEST", 220, 222], ["liver injury", "PROBLEM", 257, 269], ["liver", "ANATOMY", 257, 262], ["injury", "OBSERVATION", 263, 269]]], ["The metabolism of arbidol can be significantly inhibited by lopinavir/ritonavir in vitro (p < 0.005), which may be the underlying cause of drug-related liver injury.", [["liver", "ANATOMY", 152, 157], ["arbidol", "CHEMICAL", 18, 25], ["lopinavir/ritonavir", "CHEMICAL", 60, 79], ["liver injury", "DISEASE", 152, 164], ["arbidol", "CHEMICAL", 18, 25], ["lopinavir", "CHEMICAL", 60, 69], ["ritonavir", "CHEMICAL", 70, 79], ["arbidol", "SIMPLE_CHEMICAL", 18, 25], ["lopinavir", "SIMPLE_CHEMICAL", 60, 69], ["ritonavir", "SIMPLE_CHEMICAL", 70, 79], ["liver", "ORGAN", 152, 157], ["arbidol", "TREATMENT", 18, 25], ["lopinavir", "TREATMENT", 60, 69], ["ritonavir", "TREATMENT", 70, 79], ["liver injury", "PROBLEM", 152, 164], ["drug", "OBSERVATION", 139, 143], ["liver", "ANATOMY", 152, 157], ["injury", "OBSERVATION", 158, 164]]], ["Liver injury was related to increased length of hospital stay (mean difference [MD]: 3.2, 95% CI: 1.3-5.2) and viral shedding duration (MD: 3.0, 95% CI: 1.0-4.9).INTRODUCTIONSince December 2019, a newly recognized acute respiratory illness, now officially named coronavirus disease-19 (COVID- 19) , has become widespread globally and accounts for considerable human morbidity and mortality over 200 countries, areas, and territories worldwide (1) (2) (3) (4) .", [["Liver", "ANATOMY", 0, 5], ["respiratory", "ANATOMY", 220, 231], ["Liver injury", "DISEASE", 0, 12], ["acute respiratory illness", "DISEASE", 214, 239], ["coronavirus disease", "DISEASE", 262, 281], ["COVID- 19", "CHEMICAL", 286, 295], ["Liver", "ORGAN", 0, 5], ["coronavirus disease-19", "ORGANISM", 262, 284], ["human", "ORGANISM", 360, 365], ["human", "SPECIES", 360, 365], ["human", "SPECIES", 360, 365], ["Liver injury", "PROBLEM", 0, 12], ["CI", "TEST", 94, 96], ["CI", "TEST", 149, 151], ["acute respiratory illness", "PROBLEM", 214, 239], ["coronavirus disease", "PROBLEM", 262, 281], ["COVID", "TEST", 286, 291], ["considerable human morbidity", "PROBLEM", 347, 375], ["injury", "OBSERVATION", 6, 12], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["length", "OBSERVATION_MODIFIER", 38, 44], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory illness", "OBSERVATION", 220, 239], ["coronavirus disease", "OBSERVATION", 262, 281], ["widespread", "OBSERVATION_MODIFIER", 310, 320]]], ["The novel coronavirus is identified and designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (5) by the International Committee on Taxonomy of Viruses.", [["acute respiratory syndrome coronavirus", "DISEASE", 61, 99], ["coronavirus", "ORGANISM", 10, 21], ["SARS-CoV-2", "ORGANISM", 103, 113], ["coronavirus", "SPECIES", 10, 21], ["severe acute respiratory syndrome coronavirus", "SPECIES", 54, 99], ["SARS-CoV-2", "SPECIES", 103, 113], ["The novel coronavirus", "PROBLEM", 0, 21], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 54, 99], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["coronavirus", "OBSERVATION", 10, 21], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["respiratory syndrome", "OBSERVATION", 67, 87], ["Viruses", "OBSERVATION", 165, 172]]], ["As of May 30, 2020, more than five million COVID-19 cases had been diagnosed worldwide, and almost 360,000 deaths had been reported (2) .", [["deaths", "DISEASE", 107, 113]]], ["COVID-19 has been officially declared a pandemic by the World Health Organization (6) due to the ongoing outbreak globally.INTRODUCTIONThe common clinical manifestations of COVID-19 include fever, cough, and shortness of breath (4, 7, 8) .", [["COVID-19", "CHEMICAL", 0, 8], ["fever", "DISEASE", 190, 195], ["cough", "DISEASE", 197, 202], ["shortness of breath", "DISEASE", 208, 227], ["COVID", "TEST", 173, 178], ["fever", "PROBLEM", 190, 195], ["cough", "PROBLEM", 197, 202], ["shortness of breath", "PROBLEM", 208, 227], ["cough", "OBSERVATION", 197, 202]]], ["According to the latest epidemiological studies, \u223c16-53% of patients with COVID-19 experienced different degrees of liver injury (4, (7) (8) (9) (10) (11) (12) (13) , and some patients have developed severe liver injury.", [["liver", "ANATOMY", 116, 121], ["liver", "ANATOMY", 207, 212], ["liver injury", "DISEASE", 116, 128], ["liver injury", "DISEASE", 207, 219], ["patients", "ORGANISM", 60, 68], ["liver", "ORGAN", 116, 121], ["patients", "ORGANISM", 176, 184], ["liver", "ORGAN", 207, 212], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 176, 184], ["\u223c", "TEST", 49, 50], ["COVID", "TEST", 74, 79], ["liver injury", "PROBLEM", 116, 128], ["severe liver injury", "PROBLEM", 200, 219], ["different degrees", "OBSERVATION_MODIFIER", 95, 112], ["liver", "ANATOMY", 116, 121], ["injury", "OBSERVATION", 122, 128], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["liver", "ANATOMY", 207, 212], ["injury", "OBSERVATION", 213, 219]]], ["The coagulant function abnormality induced by liver injury may cause serious bleeding, especially in critically ill patients who are receiving continuous renal replacement or extracorporeal membrane oxygenation.", [["liver", "ANATOMY", 46, 51], ["renal", "ANATOMY", 154, 159], ["extracorporeal membrane", "ANATOMY", 175, 198], ["liver injury", "DISEASE", 46, 58], ["bleeding", "DISEASE", 77, 85], ["critically ill", "DISEASE", 101, 115], ["liver", "ORGAN", 46, 51], ["patients", "ORGANISM", 116, 124], ["renal", "ORGAN", 154, 159], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 175, 198], ["patients", "SPECIES", 116, 124], ["The coagulant function abnormality", "PROBLEM", 0, 34], ["liver injury", "PROBLEM", 46, 58], ["serious bleeding", "PROBLEM", 69, 85], ["continuous renal replacement", "TREATMENT", 143, 171], ["extracorporeal membrane oxygenation", "TREATMENT", 175, 210], ["liver", "ANATOMY", 46, 51], ["injury", "OBSERVATION", 52, 58], ["may cause", "UNCERTAINTY", 59, 68], ["serious", "OBSERVATION_MODIFIER", 69, 76], ["bleeding", "OBSERVATION", 77, 85], ["renal", "ANATOMY", 154, 159], ["replacement", "OBSERVATION", 160, 171], ["extracorporeal membrane oxygenation", "OBSERVATION", 175, 210]]], ["Liver function deterioration can lead to liver failure and even death.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 41, 46], ["liver failure", "DISEASE", 41, 54], ["death", "DISEASE", 64, 69], ["Liver", "ORGAN", 0, 5], ["liver", "ORGAN", 41, 46], ["Liver function deterioration", "PROBLEM", 0, 28], ["liver failure", "PROBLEM", 41, 54], ["even death", "PROBLEM", 59, 69], ["deterioration", "OBSERVATION", 15, 28], ["liver", "ANATOMY", 41, 46], ["failure", "OBSERVATION", 47, 54]]], ["Therefore, liver injury in patients with COVID-19 needs close attention.", [["liver", "ANATOMY", 11, 16], ["liver injury", "DISEASE", 11, 23], ["COVID-19", "CHEMICAL", 41, 49], ["COVID-19", "CHEMICAL", 41, 49], ["liver", "ORGAN", 11, 16], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["liver injury", "PROBLEM", 11, 23], ["COVID", "TEST", 41, 46], ["liver", "ANATOMY", 11, 16], ["injury", "OBSERVATION", 17, 23]]], ["Although some studies have reported the incidence of liver injury in patients with COVID-19 (8, 14, 15) , there are limited data describing the course of liver injury occurrence, such as liver injury onset, progression, and recovery, during an entire hospitalization period, particularly in patients with different disease severity.INTRODUCTIONStudies on the causes and risk factors of liver injury during SARS-CoV-2 infection are still limited and controversial.", [["liver", "ANATOMY", 53, 58], ["liver", "ANATOMY", 154, 159], ["liver", "ANATOMY", 187, 192], ["liver", "ANATOMY", 386, 391], ["liver injury", "DISEASE", 53, 65], ["liver injury", "DISEASE", 154, 166], ["liver injury", "DISEASE", 187, 199], ["liver injury", "DISEASE", 386, 398], ["infection", "DISEASE", 417, 426], ["COVID-19", "CHEMICAL", 83, 91], ["liver", "ORGAN", 53, 58], ["patients", "ORGANISM", 69, 77], ["liver", "ORGAN", 154, 159], ["liver", "ORGAN", 187, 192], ["patients", "ORGANISM", 291, 299], ["liver", "ORGAN", 386, 391], ["SARS-CoV-2", "ORGANISM", 406, 416], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 291, 299], ["SARS-CoV", "SPECIES", 406, 414], ["some studies", "TEST", 9, 21], ["liver injury", "PROBLEM", 53, 65], ["COVID", "TEST", 83, 88], ["liver injury occurrence", "PROBLEM", 154, 177], ["liver injury onset", "PROBLEM", 187, 205], ["different disease severity", "PROBLEM", 305, 331], ["liver injury", "PROBLEM", 386, 398], ["SARS", "PROBLEM", 406, 410], ["CoV-2 infection", "PROBLEM", 411, 426], ["liver", "ANATOMY", 53, 58], ["injury", "OBSERVATION", 59, 65], ["liver", "ANATOMY", 154, 159], ["injury", "OBSERVATION", 160, 166], ["liver", "ANATOMY", 187, 192], ["injury", "OBSERVATION", 193, 199], ["progression", "OBSERVATION_MODIFIER", 207, 218], ["different", "OBSERVATION_MODIFIER", 305, 314], ["disease", "OBSERVATION", 315, 322], ["liver", "ANATOMY", 386, 391], ["injury", "OBSERVATION", 392, 398], ["infection", "OBSERVATION", 417, 426]]], ["According to current research, liver injury in COVID-19 is associated with several main factors, such as SARS-CoV-2 infection, treatment with potentially hepatotoxic drugs, virally induced cytotoxic T cells, and dysregulated innate immune response (16) .", [["liver", "ANATOMY", 31, 36], ["cytotoxic T cells", "ANATOMY", 189, 206], ["liver injury", "DISEASE", 31, 43], ["COVID-19", "CHEMICAL", 47, 55], ["infection", "DISEASE", 116, 125], ["liver", "ORGAN", 31, 36], ["COVID-19", "CELL", 47, 55], ["SARS-CoV-2", "ORGANISM", 105, 115], ["cytotoxic T cells", "CELL", 189, 206], ["virally induced cytotoxic T cells", "CELL_TYPE", 173, 206], ["liver injury", "PROBLEM", 31, 43], ["COVID", "TEST", 47, 52], ["SARS", "PROBLEM", 105, 109], ["CoV-2 infection", "PROBLEM", 110, 125], ["treatment", "TREATMENT", 127, 136], ["hepatotoxic drugs", "TREATMENT", 154, 171], ["virally induced cytotoxic T cells", "PROBLEM", 173, 206], ["liver", "ANATOMY", 31, 36], ["injury", "OBSERVATION", 37, 43], ["infection", "OBSERVATION", 116, 125], ["cytotoxic T cells", "OBSERVATION", 189, 206]]], ["Moderate microvesicular steatosis and mild lobular activity are observed in the liver tissue of patients with COVID-19 (17) .", [["microvesicular", "ANATOMY", 9, 23], ["lobular", "ANATOMY", 43, 50], ["liver tissue", "ANATOMY", 80, 92], ["steatosis", "DISEASE", 24, 33], ["COVID-19", "CHEMICAL", 110, 118], ["COVID-19", "CHEMICAL", 110, 118], ["lobular", "CANCER", 43, 50], ["liver tissue", "TISSUE", 80, 92], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Moderate microvesicular steatosis", "PROBLEM", 0, 33], ["mild lobular activity", "PROBLEM", 38, 59], ["COVID", "TEST", 110, 115], ["microvesicular", "OBSERVATION_MODIFIER", 9, 23], ["steatosis", "OBSERVATION", 24, 33], ["mild", "OBSERVATION_MODIFIER", 38, 42], ["lobular activity", "OBSERVATION", 43, 59], ["liver", "ANATOMY", 80, 85], ["tissue", "ANATOMY_MODIFIER", 86, 92]]], ["A preliminary study indicates that SARS-CoV-2 may directly bind to ACE2-positive cholangiocytes to dysregulate liver function.", [["cholangiocytes", "ANATOMY", 81, 95], ["liver", "ANATOMY", 111, 116], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 35, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["liver", "ORGAN", 111, 116], ["ACE2", "PROTEIN", 67, 71], ["SARS-CoV", "SPECIES", 35, 43], ["A preliminary study", "TEST", 0, 19], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43], ["ACE2", "TEST", 67, 71], ["positive cholangiocytes", "PROBLEM", 72, 95], ["liver function", "TEST", 111, 125], ["positive cholangiocytes", "OBSERVATION", 72, 95], ["liver", "ANATOMY", 111, 116]]], ["However, systematic study of the causes and the Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe acute respiratory syndrome coronaviruses 2; DILI, Drug-induced liver injury; RUCAM, A Roussel Uclaf Causality Assessment Method; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ALP, Alkaline phosphatase; TBL, Total bilirubin. risk factors of liver injury in specific populations, such as critically ill and non-critically ill patients with COVID-19, is still lacking.", [["liver", "ANATOMY", 181, 186], ["liver", "ANATOMY", 376, 381], ["Coronavirus disease", "DISEASE", 73, 92], ["SARS-CoV", "DISEASE", 99, 107], ["acute respiratory syndrome coronaviruses", "DISEASE", 118, 158], ["DILI", "DISEASE", 162, 166], ["Drug-induced liver injury", "DISEASE", 168, 193], ["Alanine", "CHEMICAL", 252, 259], ["Aspartate", "CHEMICAL", 283, 292], ["bilirubin", "CHEMICAL", 349, 358], ["liver injury", "DISEASE", 376, 388], ["critically ill", "DISEASE", 422, 436], ["non-critically ill", "DISEASE", 441, 459], ["Alanine", "CHEMICAL", 252, 259], ["Aspartate", "CHEMICAL", 283, 292], ["bilirubin", "CHEMICAL", 349, 358], ["SARS-CoV-2", "ORGANISM", 99, 109], ["liver", "ORGAN", 181, 186], ["ALT", "SIMPLE_CHEMICAL", 247, 250], ["Alanine aminotransferase", "SIMPLE_CHEMICAL", 252, 276], ["AST", "SIMPLE_CHEMICAL", 278, 281], ["Aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 283, 309], ["ALP", "SIMPLE_CHEMICAL", 311, 314], ["Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 316, 336], ["bilirubin", "SIMPLE_CHEMICAL", 349, 358], ["liver", "ORGAN", 376, 381], ["patients", "ORGANISM", 460, 468], ["ALT", "PROTEIN", 247, 250], ["Alanine aminotransferase", "PROTEIN", 252, 276], ["AST", "PROTEIN", 278, 281], ["Aspartate aminotransferase", "PROTEIN", 283, 309], ["ALP", "PROTEIN", 311, 314], ["Alkaline phosphatase", "PROTEIN", 316, 336], ["TBL", "PROTEIN", 338, 341], ["patients", "SPECIES", 460, 468], ["SARS-CoV", "SPECIES", 99, 107], ["Severe acute respiratory syndrome coronaviruses", "SPECIES", 111, 158], ["systematic study", "TEST", 9, 25], ["COVID", "TEST", 63, 68], ["Coronavirus disease", "PROBLEM", 73, 92], ["SARS", "TEST", 99, 103], ["CoV", "TEST", 104, 107], ["Severe acute respiratory syndrome coronaviruses 2", "PROBLEM", 111, 160], ["DILI", "PROBLEM", 162, 166], ["liver injury", "PROBLEM", 181, 193], ["Assessment", "TEST", 228, 238], ["Method", "TEST", 239, 245], ["ALT", "TEST", 247, 250], ["Alanine aminotransferase", "TEST", 252, 276], ["AST", "TEST", 278, 281], ["Aspartate aminotransferase", "TEST", 283, 309], ["ALP", "TEST", 311, 314], ["Alkaline phosphatase", "TEST", 316, 336], ["TBL", "TEST", 338, 341], ["Total bilirubin", "TEST", 343, 358], ["liver injury", "PROBLEM", 376, 388], ["critically ill", "PROBLEM", 422, 436], ["COVID", "TEST", 474, 479], ["Severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome", "OBSERVATION", 124, 144], ["liver", "ANATOMY", 181, 186], ["injury", "OBSERVATION", 187, 193], ["liver", "ANATOMY", 376, 381], ["injury", "OBSERVATION", 382, 388]]], ["Additionally, little is known about the correlations between liver injury and some important clinical outcomes, such as length of hospital stay and duration of SARS-CoV-2 shedding.", [["liver", "ANATOMY", 61, 66], ["liver injury", "DISEASE", 61, 73], ["SARS", "DISEASE", 160, 164], ["liver", "ORGAN", 61, 66], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 160, 170], ["liver injury", "PROBLEM", 61, 73], ["SARS", "PROBLEM", 160, 164], ["CoV", "TEST", 165, 168], ["liver", "ANATOMY", 61, 66], ["injury", "OBSERVATION", 67, 73]]], ["Therefore, a further in-depth study is needed.INTRODUCTIONHere, we conducted a multicenter, retrospective, observational study to explore liver injury in critically ill and non-critically ill patients with COVID-19 in Zhejiang Province, China.", [["liver", "ANATOMY", 138, 143], ["liver injury", "DISEASE", 138, 150], ["critically ill", "DISEASE", 154, 168], ["non-critically ill", "DISEASE", 173, 191], ["COVID-19", "CHEMICAL", 206, 214], ["liver", "ORGAN", 138, 143], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["a further in-depth study", "TEST", 11, 35], ["observational study", "TEST", 107, 126], ["liver injury", "PROBLEM", 138, 150], ["COVID", "TEST", 206, 211], ["liver", "ANATOMY", 138, 143], ["injury", "OBSERVATION", 144, 150]]], ["This study aims to reveal the course of occurrence, risk factors, and correlations with clinical outcome of liver injury in specific COVID-19 populations.", [["liver", "ANATOMY", 108, 113], ["liver injury", "DISEASE", 108, 120], ["liver", "ORGAN", 108, 113], ["This study", "TEST", 0, 10], ["risk factors", "PROBLEM", 52, 64], ["liver injury", "PROBLEM", 108, 120], ["liver", "ANATOMY", 108, 113], ["injury", "OBSERVATION", 114, 120]]], ["Our study may be helpful in understanding the pathogenesis of liver injury in patients with COVID-19, preventing liver injury, and optimizing individual therapeutic treatment.Study Design and ParticipantsThis retrospective observational study was conducted in three tertiary hospitals designated to treat patients with COVID-19 in Zhejiang Province, China.", [["liver", "ANATOMY", 62, 67], ["liver", "ANATOMY", 113, 118], ["liver injury", "DISEASE", 62, 74], ["COVID-19", "CHEMICAL", 92, 100], ["liver injury", "DISEASE", 113, 125], ["COVID-19", "CHEMICAL", 319, 327], ["liver", "ORGAN", 62, 67], ["patients", "ORGANISM", 78, 86], ["liver", "ORGAN", 113, 118], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 78, 86], ["Participants", "SPECIES", 192, 204], ["patients", "SPECIES", 305, 313], ["Our study", "TEST", 0, 9], ["liver injury", "PROBLEM", 62, 74], ["COVID", "TEST", 92, 97], ["liver injury", "PROBLEM", 113, 125], ["individual therapeutic treatment", "TREATMENT", 142, 174], ["This retrospective observational study", "TEST", 204, 242], ["COVID", "TREATMENT", 319, 324], ["liver", "ANATOMY", 62, 67], ["injury", "OBSERVATION", 68, 74], ["liver", "ANATOMY", 113, 118], ["injury", "OBSERVATION", 119, 125]]], ["The study was launch by the First Affiliated Hospital of Zhejiang University, which is a university-affiliated tertiary hospital with 2m500 beds and over 100,000 discharged patients per year.", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["The study", "TEST", 0, 9]]], ["SARS-CoV-2 infection was confirmed using real-time polymerase chain reaction (4, 7) by the local designated hospitals.", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 11, 20]]], ["From January 19, 2020, to February 20, 2020, patients diagnosed with COVID-19 were enrolled in this study.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["COVID", "TEST", 69, 74], ["this study", "TEST", 95, 105]]], ["Patients were excluded on the basis of the following criteria: (1) pregnancy in women, (2)Data CollectionThe clinical electronic medical records were reviewed, and epidemiological, clinical, demographic, laboratory, and outcome data were collected for all included patients.", [["Patients", "ORGANISM", 0, 8], ["women", "ORGANISM", 80, 85], ["patients", "ORGANISM", 265, 273], ["Patients", "SPECIES", 0, 8], ["women", "SPECIES", 80, 85], ["patients", "SPECIES", 265, 273], ["Data Collection", "TEST", 90, 105], ["outcome data", "TEST", 220, 232]]], ["A standard case report form was used to record data, including sex, age, chronic medical illness, laboratory data, systemic antiviral agents (i.e., lopinavir/ritonavir, arbidol, fapilavir, and darunavir/cobicistat), potentially hepatotoxic concomitant drugs (18-21) (i.e., corticosteroids, quinolones, statins, immunosuppressive drugs, and non-steroidal anti-inflammatory drugs [NSAIDs]), number of concomitant drugs, length of hospital stay, and duration of viral shedding.", [["non-steroidal", "ANATOMY", 340, 353], ["chronic medical illness", "DISEASE", 73, 96], ["lopinavir/ritonavir", "CHEMICAL", 148, 167], ["arbidol", "CHEMICAL", 169, 176], ["fapilavir", "CHEMICAL", 178, 187], ["darunavir", "CHEMICAL", 193, 202], ["cobicistat", "CHEMICAL", 203, 213], ["hepatotoxic", "DISEASE", 228, 239], ["quinolones", "CHEMICAL", 290, 300], ["statins", "CHEMICAL", 302, 309], ["lopinavir", "CHEMICAL", 148, 157], ["ritonavir", "CHEMICAL", 158, 167], ["arbidol", "CHEMICAL", 169, 176], ["fapilavir", "CHEMICAL", 178, 187], ["darunavir", "CHEMICAL", 193, 202], ["cobicistat", "CHEMICAL", 203, 213], ["corticosteroids", "CHEMICAL", 273, 288], ["quinolones", "CHEMICAL", 290, 300], ["statins", "CHEMICAL", 302, 309], ["lopinavir", "SIMPLE_CHEMICAL", 148, 157], ["ritonavir", "SIMPLE_CHEMICAL", 158, 167], ["arbidol", "SIMPLE_CHEMICAL", 169, 176], ["fapilavir", "SIMPLE_CHEMICAL", 178, 187], ["darunavir", "SIMPLE_CHEMICAL", 193, 202], ["cobicistat", "SIMPLE_CHEMICAL", 203, 213], ["quinolones", "SIMPLE_CHEMICAL", 290, 300], ["statins", "SIMPLE_CHEMICAL", 302, 309], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 340, 377], ["NSAIDs", "SIMPLE_CHEMICAL", 379, 385], ["chronic medical illness", "PROBLEM", 73, 96], ["laboratory data", "TEST", 98, 113], ["systemic antiviral agents", "TREATMENT", 115, 140], ["lopinavir", "TREATMENT", 148, 157], ["ritonavir", "TREATMENT", 158, 167], ["arbidol", "TREATMENT", 169, 176], ["fapilavir", "TREATMENT", 178, 187], ["darunavir", "TREATMENT", 193, 202], ["cobicistat", "TREATMENT", 203, 213], ["hepatotoxic concomitant drugs", "TREATMENT", 228, 257], ["corticosteroids", "TREATMENT", 273, 288], ["quinolones", "TREATMENT", 290, 300], ["statins", "TREATMENT", 302, 309], ["immunosuppressive drugs", "TREATMENT", 311, 334], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 340, 377], ["NSAIDs", "TREATMENT", 379, 385], ["concomitant drugs", "TREATMENT", 399, 416], ["viral shedding", "PROBLEM", 459, 473]]], ["Clinical data were followed up until March 10, 2020.", [["Clinical data", "TEST", 0, 13]]], ["Topical drugs were not included in concomitant medications.", [["Topical drugs", "TREATMENT", 0, 13], ["concomitant medications", "TREATMENT", 35, 58]]], ["Missing data were obtained by direct communication with doctors responsible for the treatment of the patient and their families.", [["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["the treatment", "TREATMENT", 80, 93]]], ["All data were verified by three researchers.DefinitionsThe severity of COVID-19 was defined as non-severe (mild or moderate pneumonia), severe (severe pneumonia), and critically ill during admission in accordance with the diagnostic and treatment guidelines for SARS-CoV-2 pneumonia of the Chinese National Health Committee (version 6) (22) .", [["pneumonia", "DISEASE", 124, 133], ["pneumonia", "DISEASE", 151, 160], ["critically ill", "DISEASE", 167, 181], ["SARS", "DISEASE", 262, 266], ["pneumonia", "DISEASE", 273, 282], ["All data", "TEST", 0, 8], ["COVID", "TEST", 71, 76], ["non-severe (mild or moderate pneumonia)", "PROBLEM", 95, 134], ["severe (severe pneumonia)", "PROBLEM", 136, 161], ["treatment guidelines", "TREATMENT", 237, 257], ["SARS", "PROBLEM", 262, 266], ["CoV", "PROBLEM", 267, 270], ["pneumonia", "PROBLEM", 273, 282], ["mild", "OBSERVATION_MODIFIER", 107, 111], ["moderate", "OBSERVATION_MODIFIER", 115, 123], ["pneumonia", "OBSERVATION", 124, 133], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["pneumonia", "OBSERVATION", 151, 160], ["pneumonia", "OBSERVATION", 273, 282]]], ["In accordance with the severity of COVID-19, the patients were divided into non-critically ill (non-severe and severe disease severity) and critically ill groups.", [["non-critically ill", "DISEASE", 76, 94], ["critically ill", "DISEASE", 140, 154], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["COVID", "TEST", 35, 40], ["non-critically ill (non-severe and severe disease severity)", "PROBLEM", 76, 135], ["critically ill groups", "PROBLEM", 140, 161], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["disease", "OBSERVATION", 118, 125]]], ["Non-severe cases included patients with mild and moderate COVID-19.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["Non-severe cases", "PROBLEM", 0, 16], ["mild and moderate COVID", "PROBLEM", 40, 63], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["moderate", "OBSERVATION_MODIFIER", 49, 57]]], ["The clinical symptoms of mild cases were mild, and there was no sign of pneumonia on imaging.", [["pneumonia", "DISEASE", 72, 81], ["The clinical symptoms", "PROBLEM", 0, 21], ["mild cases", "PROBLEM", 25, 35], ["pneumonia", "PROBLEM", 72, 81], ["imaging", "TEST", 85, 92], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["no sign of", "UNCERTAINTY", 61, 71], ["pneumonia", "OBSERVATION", 72, 81]]], ["Moderate COVID-19 refers to fever and respiratory symptoms with radiological findings of pneumonia.", [["respiratory", "ANATOMY", 38, 49], ["fever", "DISEASE", 28, 33], ["respiratory symptoms", "DISEASE", 38, 58], ["pneumonia", "DISEASE", 89, 98], ["COVID-19", "DNA", 9, 17], ["Moderate COVID", "PROBLEM", 0, 14], ["fever", "PROBLEM", 28, 33], ["respiratory symptoms", "PROBLEM", 38, 58], ["radiological findings", "TEST", 64, 85], ["pneumonia", "PROBLEM", 89, 98], ["pneumonia", "OBSERVATION", 89, 98]]], ["Severe COVID-19 refers to cases meeting any of the following criteria: (1) respiratory distress, (2) oxygen saturation, and (3) arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) \u2266300 mmHg or cases with chest imaging that showed obvious lesion progression within 24-48 h >50%.", [["respiratory", "ANATOMY", 75, 86], ["arterial", "ANATOMY", 128, 136], ["chest", "ANATOMY", 230, 235], ["lesion", "ANATOMY", 264, 270], ["respiratory distress", "DISEASE", 75, 95], ["oxygen", "CHEMICAL", 101, 107], ["oxygen", "CHEMICAL", 157, 163], ["oxygen", "CHEMICAL", 192, 198], ["oxygen", "CHEMICAL", 101, 107], ["oxygen", "CHEMICAL", 157, 163], ["oxygen", "CHEMICAL", 192, 198], ["FiO2", "CHEMICAL", 200, 204], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["arterial", "MULTI-TISSUE_STRUCTURE", 128, 136], ["oxygen", "SIMPLE_CHEMICAL", 157, 163], ["PaO2", "SIMPLE_CHEMICAL", 165, 169], ["oxygen", "SIMPLE_CHEMICAL", 192, 198], ["FiO2", "SIMPLE_CHEMICAL", 200, 204], ["Severe COVID", "PROBLEM", 0, 12], ["respiratory distress", "PROBLEM", 75, 95], ["oxygen saturation", "TEST", 101, 118], ["arterial partial pressure of oxygen", "TREATMENT", 128, 163], ["PaO2", "TEST", 165, 169], ["inspired oxygen (FiO2", "TREATMENT", 183, 204], ["chest imaging", "TEST", 230, 243], ["obvious lesion progression", "PROBLEM", 256, 282], ["respiratory", "ANATOMY", 75, 86], ["distress", "OBSERVATION", 87, 95], ["pressure", "OBSERVATION_MODIFIER", 145, 153], ["chest", "ANATOMY", 230, 235], ["obvious", "OBSERVATION_MODIFIER", 256, 263], ["lesion", "OBSERVATION", 264, 270]]], ["Critically ill refers to cases meeting any of the following criteria: (1) respiratory failure necessitating mechanical ventilation, (2) shock, and (3) combination with organ failure and admission to an intensive care unit.DefinitionsLiver injury was defined as any increase above the normal range for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin (TBL).", [["respiratory", "ANATOMY", 74, 85], ["organ", "ANATOMY", 168, 173], ["Liver", "ANATOMY", 233, 238], ["Critically ill", "DISEASE", 0, 14], ["respiratory failure", "DISEASE", 74, 93], ["shock", "DISEASE", 136, 141], ["organ failure", "DISEASE", 168, 181], ["Liver injury", "DISEASE", 233, 245], ["alanine", "CHEMICAL", 301, 308], ["aspartate", "CHEMICAL", 333, 342], ["bilirubin", "CHEMICAL", 404, 413], ["alanine", "CHEMICAL", 301, 308], ["aspartate", "CHEMICAL", 333, 342], ["bilirubin", "CHEMICAL", 404, 413], ["organ", "ORGAN", 168, 173], ["Liver", "ORGAN", 233, 238], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 301, 325], ["ALT", "SIMPLE_CHEMICAL", 327, 330], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 333, 359], ["AST", "SIMPLE_CHEMICAL", 361, 364], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 367, 387], ["ALP", "GENE_OR_GENE_PRODUCT", 389, 392], ["bilirubin", "GENE_OR_GENE_PRODUCT", 404, 413], ["alanine aminotransferase", "PROTEIN", 301, 325], ["ALT", "PROTEIN", 327, 330], ["aspartate aminotransferase", "PROTEIN", 333, 359], ["AST", "PROTEIN", 361, 364], ["alkaline phosphatase", "PROTEIN", 367, 387], ["ALP", "PROTEIN", 389, 392], ["Critically ill", "PROBLEM", 0, 14], ["respiratory failure", "PROBLEM", 74, 93], ["mechanical ventilation", "TREATMENT", 108, 130], ["shock", "PROBLEM", 136, 141], ["organ failure", "PROBLEM", 168, 181], ["Liver injury", "PROBLEM", 233, 245], ["alanine aminotransferase", "TEST", 301, 325], ["ALT", "TEST", 327, 330], ["aspartate aminotransferase", "TEST", 333, 359], ["AST", "TEST", 361, 364], ["alkaline phosphatase", "TEST", 367, 387], ["ALP", "TEST", 389, 392], ["total bilirubin", "TEST", 398, 413], ["respiratory", "ANATOMY", 74, 85], ["failure", "OBSERVATION", 86, 93], ["mechanical ventilation", "OBSERVATION", 108, 130], ["failure", "OBSERVATION", 174, 181], ["Liver", "ANATOMY", 233, 238], ["injury", "OBSERVATION", 239, 245]]], ["The degree of liver injury was classified as mild, moderate, or severe ( Table 1) in accordance with the Common Terminology Criteria for Adverse Events (version 5) (23).", [["liver", "ANATOMY", 14, 19], ["liver injury", "DISEASE", 14, 26], ["liver", "ORGAN", 14, 19], ["liver injury", "PROBLEM", 14, 26], ["mild, moderate, or severe ( Table 1", "PROBLEM", 45, 80], ["Adverse Events", "PROBLEM", 137, 151], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["liver", "ANATOMY", 14, 19], ["injury", "OBSERVATION", 20, 26], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["moderate", "OBSERVATION_MODIFIER", 51, 59], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["Mild, moderate, and severe liver injuries were defined as the occurrence of adverse event grades 1, 2, and 3 (i.e., the increase in ALT, AST, ALP, or TBL, Table 1 ), respectively.", [["liver", "ANATOMY", 27, 32], ["liver injuries", "DISEASE", 27, 41], ["liver", "ORGAN", 27, 32], ["ALT", "SIMPLE_CHEMICAL", 132, 135], ["AST", "SIMPLE_CHEMICAL", 137, 140], ["ALP", "GENE_OR_GENE_PRODUCT", 142, 145], ["ALT", "PROTEIN", 132, 135], ["AST", "PROTEIN", 137, 140], ["ALP", "PROTEIN", 142, 145], ["Mild, moderate, and severe liver injuries", "PROBLEM", 0, 41], ["ALT", "TEST", 132, 135], ["AST", "TEST", 137, 140], ["ALP", "TEST", 142, 145], ["TBL", "TEST", 150, 153], ["moderate", "OBSERVATION_MODIFIER", 6, 14], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["liver", "ANATOMY", 27, 32], ["injuries", "OBSERVATION", 33, 41], ["adverse", "OBSERVATION_MODIFIER", 76, 83], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["ALT", "ANATOMY", 132, 135]]], ["The recovery rate of liver function was defined as the decrease in the number of patients with liver injury at discharge divided by the number of patients with liver injury during treatment.DefinitionsViral clearance was defined as the presence of two consecutive negative results with qPCR detection over an interval of 24 h.Metabolic Interactions Between Lopinavir/Ritonavir and Arbidol in vitroThe metabolic interactions between lopinavir/ritonavir and arbidol was tested in human hepatic microsomes.", [["liver", "ANATOMY", 21, 26], ["liver", "ANATOMY", 95, 100], ["liver", "ANATOMY", 160, 165], ["hepatic microsomes", "ANATOMY", 484, 502], ["liver injury", "DISEASE", 95, 107], ["liver injury", "DISEASE", 160, 172], ["Lopinavir", "CHEMICAL", 357, 366], ["Ritonavir", "CHEMICAL", 367, 376], ["Arbidol", "CHEMICAL", 381, 388], ["lopinavir/ritonavir", "CHEMICAL", 432, 451], ["arbidol", "CHEMICAL", 456, 463], ["Lopinavir", "CHEMICAL", 357, 366], ["Ritonavir", "CHEMICAL", 367, 376], ["Arbidol", "CHEMICAL", 381, 388], ["lopinavir", "CHEMICAL", 432, 441], ["ritonavir", "CHEMICAL", 442, 451], ["arbidol", "CHEMICAL", 456, 463], ["liver", "ORGAN", 21, 26], ["patients", "ORGANISM", 81, 89], ["liver", "ORGAN", 95, 100], ["patients", "ORGANISM", 146, 154], ["liver", "ORGAN", 160, 165], ["Viral", "ORGANISM", 201, 206], ["Lopinavir", "SIMPLE_CHEMICAL", 357, 366], ["Ritonavir", "SIMPLE_CHEMICAL", 367, 376], ["Arbidol", "SIMPLE_CHEMICAL", 381, 388], ["lopinavir", "SIMPLE_CHEMICAL", 432, 441], ["ritonavir", "SIMPLE_CHEMICAL", 442, 451], ["arbidol", "SIMPLE_CHEMICAL", 456, 463], ["human", "ORGANISM", 478, 483], ["hepatic microsomes", "TISSUE", 484, 502], ["human hepatic microsomes", "CELL_TYPE", 478, 502], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 146, 154], ["human", "SPECIES", 478, 483], ["human", "SPECIES", 478, 483], ["liver injury", "PROBLEM", 95, 107], ["liver injury", "PROBLEM", 160, 172], ["treatment", "TREATMENT", 180, 189], ["Viral clearance", "TEST", 201, 216], ["qPCR detection", "TEST", 286, 300], ["Lopinavir", "TREATMENT", 357, 366], ["Ritonavir", "TREATMENT", 367, 376], ["Arbidol in vitro", "TREATMENT", 381, 397], ["lopinavir", "TREATMENT", 432, 441], ["ritonavir", "TREATMENT", 442, 451], ["arbidol", "TREATMENT", 456, 463], ["liver", "ANATOMY", 21, 26], ["decrease", "OBSERVATION_MODIFIER", 55, 63], ["liver", "ANATOMY", 95, 100], ["injury", "OBSERVATION", 101, 107], ["liver", "ANATOMY", 160, 165], ["injury", "OBSERVATION", 166, 172], ["metabolic interactions", "OBSERVATION", 401, 423], ["hepatic", "ANATOMY", 484, 491]]], ["The metabolic reaction was performed in 0.1 ml incubation mixture containing 0.5 mg microsome protein.", [["The metabolic reaction", "PROBLEM", 0, 22], ["metabolic reaction", "OBSERVATION", 4, 22]]], ["The reaction was started by adding 1 mM nicotinamide adenine dinucleotide phosphate andStatistical AnalysisStatistical tests were performed using SPSS19.0 (www.spss.com) and R 3.5.1 (R Core team, www.r-project.org).", [["nicotinamide adenine dinucleotide phosphate", "CHEMICAL", 40, 83], ["nicotinamide adenine dinucleotide phosphate", "CHEMICAL", 40, 83], ["nicotinamide adenine dinucleotide phosphate", "SIMPLE_CHEMICAL", 40, 83], ["The reaction", "PROBLEM", 0, 12], ["1 mM nicotinamide adenine dinucleotide phosphate", "TREATMENT", 35, 83], ["Statistical AnalysisStatistical tests", "TEST", 87, 124]]], ["Continuous variables were presented as mean (standard deviation [SD]) or median (interquartile range [IQR] ) and compared between and within non-critically ill and critically ill groups by using the Student's t-tests or the Mann-Whitney U-test, as appropriate.", [["critically ill", "DISEASE", 164, 178], ["the Student's t-tests", "TEST", 195, 216]]], ["Categorical variables were presented as frequency (percentage) and assessed using the Pearson \u03c7 2 or Fisher's exact test (cell size < 5).Statistical AnalysisThe occurrence time of liver injury was defined from the time a patient was admitted to hospital until liver injury occurred.", [["cell", "ANATOMY", 122, 126], ["liver", "ANATOMY", 180, 185], ["liver", "ANATOMY", 260, 265], ["liver injury", "DISEASE", 180, 192], ["liver injury", "DISEASE", 260, 272], ["cell", "CELL", 122, 126], ["liver", "ORGAN", 180, 185], ["patient", "ORGANISM", 221, 228], ["liver", "ORGAN", 260, 265], ["patient", "SPECIES", 221, 228], ["Categorical variables", "TEST", 0, 21], ["Fisher's exact test", "TEST", 101, 120], ["Statistical Analysis", "TEST", 137, 157], ["liver injury", "PROBLEM", 180, 192], ["liver injury", "PROBLEM", 260, 272], ["liver", "ANATOMY", 180, 185], ["injury", "OBSERVATION", 186, 192], ["liver", "ANATOMY", 260, 265], ["injury", "OBSERVATION", 266, 272]]], ["The occurrence time of liver injury was portrayed by the Kaplan-Meier plot and compared between patients in critically ill and non-critically ill groups with a log-rank test.", [["liver", "ANATOMY", 23, 28], ["liver injury", "DISEASE", 23, 35], ["critically ill", "DISEASE", 108, 122], ["non-critically ill", "DISEASE", 127, 145], ["liver", "ORGAN", 23, 28], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["liver injury", "PROBLEM", 23, 35], ["a log-rank test", "TEST", 158, 173], ["liver", "ANATOMY", 23, 28], ["injury", "OBSERVATION", 29, 35]]], ["Liver injury after admission and at discharge, abnormal liver function indicators, and recovery rate of liver function were compared between the critically ill and non-critically ill groups.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 56, 61], ["liver", "ANATOMY", 104, 109], ["Liver injury", "DISEASE", 0, 12], ["critically ill", "DISEASE", 145, 159], ["non-critically ill", "DISEASE", 164, 182], ["Liver", "ORGAN", 0, 5], ["liver", "ORGAN", 56, 61], ["liver", "ORGAN", 104, 109], ["Liver injury", "PROBLEM", 0, 12], ["abnormal liver function indicators", "PROBLEM", 47, 81], ["injury", "OBSERVATION", 6, 12], ["liver", "ANATOMY", 56, 61], ["liver", "ANATOMY", 104, 109]]], ["Univariable and multivariable logistic regression models were used to explore the risk factors for liver injury.", [["liver", "ANATOMY", 99, 104], ["liver injury", "DISEASE", 99, 111], ["liver", "ORGAN", 99, 104], ["multivariable logistic regression models", "TREATMENT", 16, 56], ["liver injury", "PROBLEM", 99, 111], ["liver", "ANATOMY", 99, 104], ["injury", "OBSERVATION", 105, 111]]], ["Demographic data, laboratory test indicators, disease severity, antiviral agents, and potentially hepatotoxic concomitant drugs were investigated.", [["hepatotoxic", "DISEASE", 98, 109], ["Demographic data", "TEST", 0, 16], ["laboratory test", "TEST", 18, 33], ["disease severity", "PROBLEM", 46, 62], ["antiviral agents", "TREATMENT", 64, 80], ["hepatotoxic concomitant drugs", "TREATMENT", 98, 127], ["hepatotoxic", "OBSERVATION_MODIFIER", 98, 109]]], ["The factors that showed a significant association (95% confidence interval [CI]: does not include one) after univariate logistic regression analysis were entered into the multivariable logistic regression analysis.", [["univariate logistic regression analysis", "TEST", 109, 148], ["the multivariable logistic regression analysis", "TEST", 167, 213], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["Clinical outcomes (i.e., length of hospital stay and duration of viral clearance) were compared between patients with or without liver injury within each group. p < 0.05 was considered statistically significant.Demographic and Clinical CharacteristicsThe demographic and clinical characteristics of the patients are shown in Table 2 .", [["liver", "ANATOMY", 129, 134], ["liver injury", "DISEASE", 129, 141], ["patients", "ORGANISM", 104, 112], ["liver", "ORGAN", 129, 134], ["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 303, 311], ["viral clearance", "TEST", 65, 80], ["liver injury", "PROBLEM", 129, 141], ["liver", "ANATOMY", 129, 134], ["injury", "OBSERVATION", 135, 141]]], ["Nineteen ineligible patients were excluded, and the clinical data of 131 patients with confirmed COVID-19 were collected (Figure 1) .", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 73, 81], ["the clinical data", "TEST", 48, 65], ["COVID", "TEST", 97, 102]]], ["The sample sizes of included The baseline characteristics of patients in critically ill and noncritically ill groups were significantly different (p < 0.05) for the parameters age, prevalence of cardiovascular and cerebrovascular diseases, laboratory data (i.e., leucocytes, neutrophils, albumin, serum creatinine, and C-reactive protein), and treatments (i.e., number of concomitant medications and use of glucocorticoids and antiviral agents).Incidence and Characteristics of Liver InjuryThe incidence of liver injury over the study period is shown in Figure 2 .", [["cardiovascular", "ANATOMY", 195, 209], ["cerebrovascular", "ANATOMY", 214, 229], ["leucocytes", "ANATOMY", 263, 273], ["neutrophils", "ANATOMY", 275, 286], ["serum", "ANATOMY", 297, 302], ["Liver", "ANATOMY", 478, 483], ["liver", "ANATOMY", 507, 512], ["critically ill", "DISEASE", 73, 87], ["cardiovascular and cerebrovascular diseases", "DISEASE", 195, 238], ["creatinine", "CHEMICAL", 303, 313], ["glucocorticoids", "CHEMICAL", 407, 422], ["Liver Injury", "DISEASE", 478, 490], ["liver injury", "DISEASE", 507, 519], ["creatinine", "CHEMICAL", 303, 313], ["patients", "ORGANISM", 61, 69], ["cardiovascular", "ANATOMICAL_SYSTEM", 195, 209], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 214, 229], ["leucocytes", "CELL", 263, 273], ["neutrophils", "CELL", 275, 286], ["albumin", "GENE_OR_GENE_PRODUCT", 288, 295], ["serum", "ORGANISM_SUBSTANCE", 297, 302], ["creatinine", "SIMPLE_CHEMICAL", 303, 313], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 319, 337], ["Liver", "ORGAN", 478, 483], ["liver", "ORGAN", 507, 512], ["leucocytes", "CELL_TYPE", 263, 273], ["neutrophils", "CELL_TYPE", 275, 286], ["albumin", "PROTEIN", 288, 295], ["C-reactive protein", "PROTEIN", 319, 337], ["patients", "SPECIES", 61, 69], ["noncritically ill groups", "PROBLEM", 92, 116], ["cardiovascular and cerebrovascular diseases", "PROBLEM", 195, 238], ["laboratory data", "TEST", 240, 255], ["leucocytes", "TEST", 263, 273], ["neutrophils", "TEST", 275, 286], ["albumin", "TEST", 288, 295], ["serum creatinine", "TEST", 297, 313], ["C", "TEST", 319, 320], ["treatments", "TREATMENT", 344, 354], ["concomitant medications", "TREATMENT", 372, 395], ["glucocorticoids", "TREATMENT", 407, 422], ["antiviral agents", "TREATMENT", 427, 443], ["Liver Injury", "PROBLEM", 478, 490], ["liver injury", "PROBLEM", 507, 519], ["the study", "TEST", 525, 534], ["sizes", "OBSERVATION_MODIFIER", 11, 16], ["cardiovascular", "ANATOMY", 195, 209], ["cerebrovascular", "ANATOMY", 214, 229], ["diseases", "OBSERVATION", 230, 238], ["Liver", "ANATOMY", 478, 483], ["Injury", "OBSERVATION", 484, 490], ["liver", "ANATOMY", 507, 512], ["injury", "OBSERVATION", 513, 519]]], ["During the treatment, 76 patients (58.0%) had liver injury (mild, 40.5%; moderate, 15.3%; severe, 2.3%, Table 3 ).", [["liver", "ANATOMY", 46, 51], ["liver injury", "DISEASE", 46, 58], ["patients", "ORGANISM", 25, 33], ["liver", "ORGAN", 46, 51], ["patients", "SPECIES", 25, 33], ["the treatment", "TREATMENT", 7, 20], ["liver injury", "PROBLEM", 46, 58], ["liver", "ANATOMY", 46, 51], ["injury", "OBSERVATION", 52, 58], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["moderate", "OBSERVATION_MODIFIER", 73, 81]]], ["The median occurrence time of liver injury was 10.0 days.", [["liver", "ANATOMY", 30, 35], ["liver injury", "DISEASE", 30, 42], ["liver", "ORGAN", 30, 35], ["liver injury", "PROBLEM", 30, 42], ["median", "OBSERVATION_MODIFIER", 4, 10], ["liver", "ANATOMY", 30, 35], ["injury", "OBSERVATION", 36, 42]]], ["The percentage of liver injury was reduced to 24.4% at discharge, and liver function returned to normal levels in 57.9% of patients with liver injury.", [["liver", "ANATOMY", 18, 23], ["liver", "ANATOMY", 70, 75], ["liver", "ANATOMY", 137, 142], ["liver injury", "DISEASE", 18, 30], ["liver injury", "DISEASE", 137, 149], ["liver", "ORGAN", 18, 23], ["liver", "ORGAN", 70, 75], ["patients", "ORGANISM", 123, 131], ["liver", "ORGAN", 137, 142], ["patients", "SPECIES", 123, 131], ["liver injury", "PROBLEM", 18, 30], ["liver function", "TEST", 70, 84], ["liver injury", "PROBLEM", 137, 149], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["liver", "ANATOMY", 18, 23], ["injury", "OBSERVATION", 24, 30], ["liver", "ANATOMY", 70, 75], ["liver", "ANATOMY", 137, 142], ["injury", "OBSERVATION", 143, 149]]], ["However, none patients with severe liver injury returned to the normal liver function at discharge ( Table 3) .Incidence and Characteristics of Liver InjuryThe Kaplan-Meier survival curves for liver injury in different groups are presented in Figure 2 .", [["liver", "ANATOMY", 35, 40], ["liver", "ANATOMY", 71, 76], ["Liver", "ANATOMY", 144, 149], ["liver", "ANATOMY", 193, 198], ["liver injury", "DISEASE", 35, 47], ["Liver Injury", "DISEASE", 144, 156], ["liver injury", "DISEASE", 193, 205], ["patients", "ORGANISM", 14, 22], ["liver", "ORGAN", 35, 40], ["liver", "ORGAN", 71, 76], ["Liver", "ORGAN", 144, 149], ["liver", "ORGAN", 193, 198], ["patients", "SPECIES", 14, 22], ["severe liver injury", "PROBLEM", 28, 47], ["Liver Injury", "PROBLEM", 144, 156], ["liver injury", "PROBLEM", 193, 205], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["liver", "ANATOMY", 35, 40], ["injury", "OBSERVATION", 41, 47], ["liver", "ANATOMY", 71, 76], ["Liver", "ANATOMY", 144, 149], ["Injury", "OBSERVATION", 150, 156], ["liver", "ANATOMY", 193, 198], ["injury", "OBSERVATION", 199, 205]]], ["The incidence of liver injury was significantly different between patients in critically ill and non-critically ill groups (Figure 2 , median: 12.0 day vs. 5.0 days, p < 0.001) over the study period.", [["liver", "ANATOMY", 17, 22], ["liver injury", "DISEASE", 17, 29], ["critically ill", "DISEASE", 78, 92], ["non-critically ill", "DISEASE", 97, 115], ["liver", "ORGAN", 17, 22], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["liver injury", "PROBLEM", 17, 29], ["the study", "TEST", 182, 191], ["liver", "ANATOMY", 17, 22], ["injury", "OBSERVATION", 23, 29], ["significantly different", "OBSERVATION_MODIFIER", 34, 57]]], ["As shown in Table 3 , 81.5% of the patients in the critically ill group developed liver injury, compared with 51.9% in the non-critically ill group.", [["liver", "ANATOMY", 82, 87], ["critically ill", "DISEASE", 51, 65], ["liver injury", "DISEASE", 82, 94], ["non-critically ill", "DISEASE", 123, 141], ["patients", "ORGANISM", 35, 43], ["liver", "ORGAN", 82, 87], ["patients", "SPECIES", 35, 43], ["liver injury", "PROBLEM", 82, 94], ["liver", "ANATOMY", 82, 87], ["injury", "OBSERVATION", 88, 94]]], ["The severity of liver injury in the critically ill group was greater (p < 0.001) than that in the non-critically ill group.", [["liver", "ANATOMY", 16, 21], ["liver injury", "DISEASE", 16, 28], ["critically ill", "DISEASE", 36, 50], ["liver", "ORGAN", 16, 21], ["liver injury", "PROBLEM", 16, 28], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["liver", "ANATOMY", 16, 21], ["injury", "OBSERVATION", 22, 28]]], ["ALT and AST levels were more commonly elevated in critically ill patients (p < 0.05) than in the non-critically ill group, whereas no statistical difference was observed in the abnormal ALP and TBL levels ( Table 3) .", [["critically ill", "DISEASE", 50, 64], ["non-critically ill", "DISEASE", 97, 115], ["ALT", "GENE_OR_GENE_PRODUCT", 0, 3], ["AST", "SIMPLE_CHEMICAL", 8, 11], ["patients", "ORGANISM", 65, 73], ["ALP", "GENE_OR_GENE_PRODUCT", 186, 189], ["ALT", "PROTEIN", 0, 3], ["AST", "PROTEIN", 8, 11], ["ALP", "PROTEIN", 186, 189], ["TBL", "PROTEIN", 194, 197], ["patients", "SPECIES", 65, 73], ["ALT", "TEST", 0, 3], ["AST levels", "TEST", 8, 18], ["statistical difference", "PROBLEM", 134, 156], ["the abnormal ALP", "PROBLEM", 173, 189], ["TBL levels", "TEST", 194, 204]]], ["The recovery rate of liver function in the non-critically ill group was higher than that in the critically ill group (61.1 vs. 50.0%).Risk Factors for Liver InjuryUnivariable and multivariable logistic regression models were used to explore the risk factors for liver injury in the critically ill and non-critically ill groups.", [["liver", "ANATOMY", 21, 26], ["Liver", "ANATOMY", 151, 156], ["liver", "ANATOMY", 262, 267], ["non-critically ill", "DISEASE", 43, 61], ["critically ill", "DISEASE", 96, 110], ["liver injury", "DISEASE", 262, 274], ["critically ill", "DISEASE", 282, 296], ["non-critically ill", "DISEASE", 301, 319], ["liver", "ORGAN", 21, 26], ["Liver", "ORGAN", 151, 156], ["liver", "ORGAN", 262, 267], ["liver function", "TEST", 21, 35], ["Risk Factors", "PROBLEM", 134, 146], ["Liver InjuryUnivariable", "TREATMENT", 151, 174], ["multivariable logistic regression models", "TREATMENT", 179, 219], ["the risk factors", "PROBLEM", 241, 257], ["liver injury", "PROBLEM", 262, 274], ["liver", "ANATOMY", 21, 26], ["Liver", "ANATOMY", 151, 156], ["liver", "ANATOMY", 262, 267], ["injury", "OBSERVATION", 268, 274]]], ["However, given the limited sample size in the critically ill group, the statistical power was insufficient, and the multivariable logistic regression model was not conducted in this group.", [["critically ill", "DISEASE", 46, 60], ["the multivariable logistic regression model", "TEST", 112, 155], ["size", "OBSERVATION_MODIFIER", 34, 38]]], ["The comparison between patients with or without liver injury in the critically ill group showed that the patients with liver injury had lower lymphocyte numbers, received more concomitant medications, and had higher serum creatinine levels on admission, but the differences were not statistically different (Supplementary Table S1 ).Risk Factors for Liver InjuryIn the non-critically ill group, the univariate logistic analyses showed that the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were significantly associated with liver injury ( Table 4) .Risk Factors for Liver InjuryAfter the multivariable regression analysis, the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were determined to be independent risk factors for liver injury.", [["liver", "ANATOMY", 48, 53], ["liver", "ANATOMY", 119, 124], ["lymphocyte", "ANATOMY", 142, 152], ["serum", "ANATOMY", 216, 221], ["Liver", "ANATOMY", 350, 355], ["liver", "ANATOMY", 578, 583], ["Liver", "ANATOMY", 620, 625], ["liver", "ANATOMY", 831, 836], ["liver injury", "DISEASE", 48, 60], ["critically ill", "DISEASE", 68, 82], ["liver injury", "DISEASE", 119, 131], ["creatinine", "CHEMICAL", 222, 232], ["Liver Injury", "DISEASE", 350, 362], ["non-critically ill", "DISEASE", 369, 387], ["lopinavir/ritonavir", "CHEMICAL", 469, 488], ["arbidol", "CHEMICAL", 493, 500], ["liver injury", "DISEASE", 578, 590], ["lopinavir/ritonavir", "CHEMICAL", 706, 725], ["arbidol", "CHEMICAL", 730, 737], ["liver injury", "DISEASE", 831, 843], ["creatinine", "CHEMICAL", 222, 232], ["lopinavir", "CHEMICAL", 469, 478], ["ritonavir", "CHEMICAL", 479, 488], ["arbidol", "CHEMICAL", 493, 500], ["lopinavir", "CHEMICAL", 706, 715], ["ritonavir", "CHEMICAL", 716, 725], ["arbidol", "CHEMICAL", 730, 737], ["patients", "ORGANISM", 23, 31], ["liver", "ORGAN", 48, 53], ["patients", "ORGANISM", 105, 113], ["liver", "ORGAN", 119, 124], ["lymphocyte", "CELL", 142, 152], ["serum", "ORGANISM_SUBSTANCE", 216, 221], ["creatinine", "SIMPLE_CHEMICAL", 222, 232], ["Liver", "ORGAN", 350, 355], ["lopinavir", "SIMPLE_CHEMICAL", 469, 478], ["ritonavir", "SIMPLE_CHEMICAL", 479, 488], ["arbidol", "SIMPLE_CHEMICAL", 493, 500], ["liver", "ORGAN", 578, 583], ["Liver", "ORGAN", 620, 625], ["lopinavir", "SIMPLE_CHEMICAL", 706, 715], ["ritonavir", "SIMPLE_CHEMICAL", 716, 725], ["arbidol", "SIMPLE_CHEMICAL", 730, 737], ["liver", "ORGAN", 831, 836], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 105, 113], ["liver injury", "PROBLEM", 48, 60], ["liver injury", "PROBLEM", 119, 131], ["lower lymphocyte numbers", "PROBLEM", 136, 160], ["concomitant medications", "TREATMENT", 176, 199], ["higher serum creatinine levels", "PROBLEM", 209, 239], ["Risk Factors", "PROBLEM", 333, 345], ["Liver Injury", "PROBLEM", 350, 362], ["the univariate logistic analyses", "TEST", 395, 427], ["lopinavir", "TREATMENT", 469, 478], ["ritonavir", "TREATMENT", 479, 488], ["arbidol", "TREATMENT", 493, 500], ["concomitant medications", "TREATMENT", 519, 542], ["liver injury", "PROBLEM", 578, 590], ["Liver InjuryAfter", "PROBLEM", 620, 637], ["lopinavir", "TREATMENT", 706, 715], ["ritonavir", "TREATMENT", 716, 725], ["arbidol", "TREATMENT", 730, 737], ["concomitant medications", "TREATMENT", 756, 779], ["liver injury", "PROBLEM", 831, 843], ["liver", "ANATOMY", 48, 53], ["injury", "OBSERVATION", 54, 60], ["liver", "ANATOMY", 119, 124], ["injury", "OBSERVATION", 125, 131], ["lower lymphocyte", "OBSERVATION", 136, 152], ["Liver", "ANATOMY", 350, 355], ["Injury", "OBSERVATION", 356, 362], ["liver", "ANATOMY", 578, 583], ["injury", "OBSERVATION", 584, 590], ["Liver", "ANATOMY", 620, 625], ["liver", "ANATOMY", 831, 836], ["injury", "OBSERVATION", 837, 843]]], ["The patients who received the combination treatment of lopinavir/ritonavir and arbidol had 3.58 times the odds (95% CI: 1.44-9.52) of liver injury than patients who did not receive the aforementioned treatment.", [["liver", "ANATOMY", 134, 139], ["lopinavir/ritonavir", "CHEMICAL", 55, 74], ["arbidol", "CHEMICAL", 79, 86], ["liver injury", "DISEASE", 134, 146], ["lopinavir", "CHEMICAL", 55, 64], ["ritonavir", "CHEMICAL", 65, 74], ["arbidol", "CHEMICAL", 79, 86], ["patients", "ORGANISM", 4, 12], ["lopinavir", "SIMPLE_CHEMICAL", 55, 64], ["ritonavir", "SIMPLE_CHEMICAL", 65, 74], ["arbidol", "SIMPLE_CHEMICAL", 79, 86], ["liver", "ORGAN", 134, 139], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 152, 160], ["lopinavir", "TREATMENT", 55, 64], ["ritonavir", "TREATMENT", 65, 74], ["arbidol", "TREATMENT", 79, 86], ["CI", "TEST", 116, 118], ["liver injury", "PROBLEM", 134, 146], ["the aforementioned treatment", "TREATMENT", 181, 209], ["liver", "ANATOMY", 134, 139], ["injury", "OBSERVATION", 140, 146]]], ["For every increase in concomitant medication, the odds of liver injury increased by 12.1% (95% CI: 4.9%\u221221.2%, Table 3 ).Metabolic Interactions Between Lopinavir/Ritonavir and Arbidol in vitroLopinavir/ritonavir combined with arbidol was shown to be a risk factor of liver injury.", [["liver", "ANATOMY", 58, 63], ["liver", "ANATOMY", 267, 272], ["liver injury", "DISEASE", 58, 70], ["Lopinavir", "CHEMICAL", 152, 161], ["Ritonavir", "CHEMICAL", 162, 171], ["Arbidol", "CHEMICAL", 176, 183], ["vitroLopinavir", "CHEMICAL", 187, 201], ["ritonavir", "CHEMICAL", 202, 211], ["arbidol", "CHEMICAL", 226, 233], ["liver injury", "DISEASE", 267, 279], ["Lopinavir", "CHEMICAL", 152, 161], ["Ritonavir", "CHEMICAL", 162, 171], ["Arbidol", "CHEMICAL", 176, 183], ["vitroLopinavir", "CHEMICAL", 187, 201], ["ritonavir", "CHEMICAL", 202, 211], ["arbidol", "CHEMICAL", 226, 233], ["liver", "ORGAN", 58, 63], ["Lopinavir", "SIMPLE_CHEMICAL", 152, 161], ["Ritonavir", "SIMPLE_CHEMICAL", 162, 171], ["Arbidol", "SIMPLE_CHEMICAL", 176, 183], ["vitroLopinavir", "SIMPLE_CHEMICAL", 187, 201], ["ritonavir", "SIMPLE_CHEMICAL", 202, 211], ["arbidol", "SIMPLE_CHEMICAL", 226, 233], ["liver", "ORGAN", 267, 272], ["concomitant medication", "TREATMENT", 22, 44], ["liver injury", "PROBLEM", 58, 70], ["CI", "TEST", 95, 97], ["Metabolic Interactions", "PROBLEM", 121, 143], ["Lopinavir", "TREATMENT", 152, 161], ["Ritonavir", "TREATMENT", 162, 171], ["Arbidol", "TREATMENT", 176, 183], ["vitroLopinavir", "TREATMENT", 187, 201], ["ritonavir", "TREATMENT", 202, 211], ["arbidol", "TREATMENT", 226, 233], ["liver injury", "PROBLEM", 267, 279], ["liver", "ANATOMY", 58, 63], ["injury", "OBSERVATION", 64, 70], ["liver", "ANATOMY", 267, 272], ["injury", "OBSERVATION", 273, 279]]], ["We inferred that the metabolic interaction between arbidol and lopinavir/ritonavir may increase drug concentrations and may thus lead to a higher risk of liver injury.", [["liver", "ANATOMY", 154, 159], ["arbidol", "CHEMICAL", 51, 58], ["lopinavir", "CHEMICAL", 63, 72], ["ritonavir", "CHEMICAL", 73, 82], ["liver injury", "DISEASE", 154, 166], ["arbidol", "CHEMICAL", 51, 58], ["lopinavir", "CHEMICAL", 63, 72], ["ritonavir", "CHEMICAL", 73, 82], ["arbidol", "SIMPLE_CHEMICAL", 51, 58], ["lopinavir", "SIMPLE_CHEMICAL", 63, 72], ["ritonavir", "SIMPLE_CHEMICAL", 73, 82], ["liver", "ORGAN", 154, 159], ["arbidol", "TREATMENT", 51, 58], ["lopinavir", "TREATMENT", 63, 72], ["ritonavir", "TREATMENT", 73, 82], ["drug concentrations", "TREATMENT", 96, 115], ["liver injury", "PROBLEM", 154, 166], ["metabolic interaction", "OBSERVATION", 21, 42], ["liver", "ANATOMY", 154, 159], ["injury", "OBSERVATION", 160, 166]]], ["The metabolic interactions were tested in human hepatic microsomes in vitro, and the results showed that the metabolism of arbidol can be significantly inhibited after exposure to different concentrations of lopinavir/ritonavir (p < 0.005, Figure 3) , whereas arbidol had no effect on the metabolism of lopinavir/ritonavir (p > 0.05, Figure 3 ).Correlations Between Liver Injury and Clinical OutcomesThe average length of hospital stay was 16.6 (SD: 5.7) days and was statistically longer in patients with liver injury than in patients without liver injury (MD: 3.2, 95% CI: 1.3-5.2).", [["hepatic microsomes", "ANATOMY", 48, 66], ["Liver", "ANATOMY", 366, 371], ["liver", "ANATOMY", 506, 511], ["liver", "ANATOMY", 544, 549], ["arbidol", "CHEMICAL", 123, 130], ["lopinavir/ritonavir", "CHEMICAL", 208, 227], ["arbidol", "CHEMICAL", 260, 267], ["lopinavir/ritonavir", "CHEMICAL", 303, 322], ["Liver Injury", "DISEASE", 366, 378], ["liver injury", "DISEASE", 506, 518], ["liver injury", "DISEASE", 544, 556], ["arbidol", "CHEMICAL", 123, 130], ["lopinavir", "CHEMICAL", 208, 217], ["ritonavir", "CHEMICAL", 218, 227], ["arbidol", "CHEMICAL", 260, 267], ["lopinavir", "CHEMICAL", 303, 312], ["ritonavir", "CHEMICAL", 313, 322], ["human", "ORGANISM", 42, 47], ["hepatic microsomes", "TISSUE", 48, 66], ["arbidol", "SIMPLE_CHEMICAL", 123, 130], ["lopinavir", "SIMPLE_CHEMICAL", 208, 217], ["ritonavir", "SIMPLE_CHEMICAL", 218, 227], ["arbidol", "SIMPLE_CHEMICAL", 260, 267], ["lopinavir", "SIMPLE_CHEMICAL", 303, 312], ["ritonavir", "SIMPLE_CHEMICAL", 313, 322], ["Liver", "ORGAN", 366, 371], ["patients", "ORGANISM", 492, 500], ["liver", "ORGAN", 506, 511], ["patients", "ORGANISM", 527, 535], ["liver", "ORGAN", 544, 549], ["human hepatic microsomes", "CELL_TYPE", 42, 66], ["human", "SPECIES", 42, 47], ["patients", "SPECIES", 492, 500], ["patients", "SPECIES", 527, 535], ["human", "SPECIES", 42, 47], ["arbidol", "TREATMENT", 123, 130], ["lopinavir", "TREATMENT", 208, 217], ["ritonavir", "TREATMENT", 218, 227], ["lopinavir", "TREATMENT", 303, 312], ["ritonavir", "TREATMENT", 313, 322], ["Liver Injury", "PROBLEM", 366, 378], ["liver injury", "PROBLEM", 506, 518], ["liver injury", "PROBLEM", 544, 556], ["CI", "TEST", 571, 573], ["metabolic interactions", "OBSERVATION", 4, 26], ["hepatic", "ANATOMY", 48, 55], ["Liver", "ANATOMY", 366, 371], ["Injury", "OBSERVATION", 372, 378], ["average", "OBSERVATION_MODIFIER", 404, 411], ["length", "OBSERVATION_MODIFIER", 412, 418], ["liver", "ANATOMY", 506, 511], ["injury", "OBSERVATION", 512, 518], ["without", "UNCERTAINTY", 536, 543], ["liver", "ANATOMY", 544, 549], ["injury", "OBSERVATION", 550, 556]]], ["The mean duration of viral clearance in patients with liver injury was 13.6 days, which was 3 days longer than that in patients with normal liver function (95% CI:1.0-4.9).", [["liver", "ANATOMY", 54, 59], ["liver", "ANATOMY", 140, 145], ["liver injury", "DISEASE", 54, 66], ["patients", "ORGANISM", 40, 48], ["liver", "ORGAN", 54, 59], ["patients", "ORGANISM", 119, 127], ["liver", "ORGAN", 140, 145], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 119, 127], ["viral clearance", "PROBLEM", 21, 36], ["liver injury", "PROBLEM", 54, 66], ["CI", "TEST", 160, 162], ["viral clearance", "OBSERVATION", 21, 36], ["liver", "ANATOMY", 54, 59], ["injury", "OBSERVATION", 60, 66], ["liver", "ANATOMY", 140, 145]]], ["Within the non-critically ill and critically ill groups, the length of hospital stay and duration of viral clearance tended to increase in patients developing liver injury ( Table 5) .DISCUSSIONCOVID-19 is a newly identified illness that has spread around the world and has become a global health crisis (2, 4, 7, 24) .DISCUSSIONEpidemiological studies have demonstrated that liver injury can occur in patients with COVID-19 (7, 8, 10, 12) and may be related to SARS-CoV-2 infection or therapeutic drugs (9, 17) .", [["liver", "ANATOMY", 159, 164], ["liver", "ANATOMY", 376, 381], ["non-critically ill", "DISEASE", 11, 29], ["critically ill", "DISEASE", 34, 48], ["liver injury", "DISEASE", 159, 171], ["liver injury", "DISEASE", 376, 388], ["SARS-CoV-2 infection", "DISEASE", 462, 482], ["COVID-19", "CHEMICAL", 416, 424], ["patients", "ORGANISM", 139, 147], ["liver", "ORGAN", 159, 164], ["liver", "ORGAN", 376, 381], ["patients", "ORGANISM", 402, 410], ["SARS-CoV-2", "ORGANISM", 462, 472], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 402, 410], ["SARS-CoV", "SPECIES", 462, 470], ["viral clearance", "PROBLEM", 101, 116], ["patients developing liver injury", "PROBLEM", 139, 171], ["a newly identified illness", "PROBLEM", 206, 232], ["a global health crisis", "PROBLEM", 281, 303], [".DISCUSSIONEpidemiological studies", "TEST", 318, 352], ["liver injury", "PROBLEM", 376, 388], ["COVID", "TEST", 416, 421], ["SARS", "PROBLEM", 462, 466], ["CoV-2 infection", "PROBLEM", 467, 482], ["therapeutic drugs", "TREATMENT", 486, 503], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["liver", "ANATOMY", 159, 164], ["injury", "OBSERVATION", 165, 171], ["illness", "OBSERVATION", 225, 232], ["global", "OBSERVATION_MODIFIER", 283, 289], ["liver", "ANATOMY", 376, 381], ["injury", "OBSERVATION", 382, 388], ["may be related to", "UNCERTAINTY", 444, 461], ["SARS", "OBSERVATION", 462, 466], ["infection", "OBSERVATION", 473, 482]]], ["Here, the onset, progression, recovery, risk factors, and correlation with clinical outcomes of liver injury in patients with varying severities of COVID-19 were investigated.", [["liver", "ANATOMY", 96, 101], ["liver injury", "DISEASE", 96, 108], ["COVID-19", "CHEMICAL", 148, 156], ["liver", "ORGAN", 96, 101], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["risk factors", "PROBLEM", 40, 52], ["liver injury", "PROBLEM", 96, 108], ["COVID", "TEST", 148, 153], ["progression", "OBSERVATION_MODIFIER", 17, 28], ["liver", "ANATOMY", 96, 101], ["injury", "OBSERVATION", 102, 108]]], ["The results show that the liver injury in critically ill patients with COVID-19 occurred more frequently and earlier, developed more seriously, and recovered more slowly than that in non-critically patients.", [["liver", "ANATOMY", 26, 31], ["liver injury", "DISEASE", 26, 38], ["critically ill", "DISEASE", 42, 56], ["COVID-19", "CHEMICAL", 71, 79], ["COVID-19", "CHEMICAL", 71, 79], ["liver", "ORGAN", 26, 31], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 198, 206], ["the liver injury", "PROBLEM", 22, 38], ["COVID", "TEST", 71, 76], ["liver", "ANATOMY", 26, 31], ["injury", "OBSERVATION", 32, 38]]], ["Drug factors, including the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were independent risk factors for liver injury in non-critically ill patients with COVID-19, which may be due to drug interactions at the metabolic level.", [["liver", "ANATOMY", 161, 166], ["lopinavir/ritonavir", "CHEMICAL", 53, 72], ["arbidol", "CHEMICAL", 77, 84], ["liver injury", "DISEASE", 161, 173], ["non-critically ill", "DISEASE", 177, 195], ["COVID-19", "CHEMICAL", 210, 218], ["lopinavir", "CHEMICAL", 53, 62], ["ritonavir", "CHEMICAL", 63, 72], ["arbidol", "CHEMICAL", 77, 84], ["COVID-19", "CHEMICAL", 210, 218], ["lopinavir", "SIMPLE_CHEMICAL", 53, 62], ["ritonavir", "SIMPLE_CHEMICAL", 63, 72], ["arbidol", "SIMPLE_CHEMICAL", 77, 84], ["liver", "ORGAN", 161, 166], ["patients", "ORGANISM", 196, 204], ["Drug factors", "PROTEIN", 0, 12], ["patients", "SPECIES", 196, 204], ["Drug factors", "PROBLEM", 0, 12], ["lopinavir", "TREATMENT", 53, 62], ["ritonavir", "TREATMENT", 63, 72], ["arbidol", "TREATMENT", 77, 84], ["concomitant medications", "TREATMENT", 103, 126], ["liver injury", "PROBLEM", 161, 173], ["COVID", "TEST", 210, 215], ["drug interactions", "PROBLEM", 240, 257], ["liver", "ANATOMY", 161, 166], ["injury", "OBSERVATION", 167, 173], ["may be due to", "UNCERTAINTY", 226, 239]]], ["Liver injury was found to be related to prolonged hospital stay and delayed virus eradication in all enrolled patients.", [["Liver", "ANATOMY", 0, 5], ["Liver injury", "DISEASE", 0, 12], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["Liver injury", "PROBLEM", 0, 12], ["delayed virus eradication", "PROBLEM", 68, 93], ["injury", "OBSERVATION", 6, 12]]], ["Consistent with previous studies (7, 8, 25) , this study has found that the high incidence of liver injury in patients with COVID-19 is related to disease severity.", [["liver", "ANATOMY", 94, 99], ["liver injury", "DISEASE", 94, 106], ["COVID-19", "CHEMICAL", 124, 132], ["COVID-19", "CHEMICAL", 124, 132], ["liver", "ORGAN", 94, 99], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["previous studies", "TEST", 16, 32], ["this study", "TEST", 46, 56], ["liver injury", "PROBLEM", 94, 106], ["COVID", "TEST", 124, 129], ["disease severity", "PROBLEM", 147, 163], ["high", "OBSERVATION_MODIFIER", 76, 80], ["liver", "ANATOMY", 94, 99], ["injury", "OBSERVATION", 100, 106], ["disease", "OBSERVATION", 147, 154]]], ["Additionally, the progression and the recovery process of liver injury during the entire hospital stay were investigated.", [["liver", "ANATOMY", 58, 63], ["liver injury", "DISEASE", 58, 70], ["liver", "ORGAN", 58, 63], ["liver injury", "PROBLEM", 58, 70], ["progression", "OBSERVATION_MODIFIER", 18, 29], ["liver", "ANATOMY", 58, 63], ["injury", "OBSERVATION", 64, 70]]], ["Our results indicated that the liver injury in critically ill patients with COVID-19 happened earlier and recovered more slowly than that in non-critically ill patients.", [["liver", "ANATOMY", 31, 36], ["liver injury", "DISEASE", 31, 43], ["critically ill", "DISEASE", 47, 61], ["non-critically ill", "DISEASE", 141, 159], ["COVID-19", "CHEMICAL", 76, 84], ["liver", "ORGAN", 31, 36], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 160, 168], ["the liver injury", "PROBLEM", 27, 43], ["COVID", "TEST", 76, 81], ["liver", "ANATOMY", 31, 36], ["injury", "OBSERVATION", 37, 43]]], ["A higher rate of liver injury was presented in critically ill patients over the study period.", [["liver", "ANATOMY", 17, 22], ["liver injury", "DISEASE", 17, 29], ["critically ill", "DISEASE", 47, 61], ["liver", "ORGAN", 17, 22], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["A higher rate of liver injury", "PROBLEM", 0, 29], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["liver", "ANATOMY", 17, 22], ["injury", "OBSERVATION", 23, 29]]], ["Our further data showed that the severity of liver injury was also related to COVID-19 disease severity.", [["liver", "ANATOMY", 45, 50], ["liver injury", "DISEASE", 45, 57], ["liver", "ORGAN", 45, 50], ["Our further data", "TEST", 0, 16], ["liver injury", "PROBLEM", 45, 57], ["COVID-19 disease severity", "PROBLEM", 78, 103], ["liver", "ANATOMY", 45, 50], ["injury", "OBSERVATION", 51, 57], ["disease", "OBSERVATION", 87, 94]]], ["The incidences of mild liver injury were similar in different groups, whereas moderate and severe liver injuries occurred more frequently in critically ill patients than in noncritically ill patients.", [["liver", "ANATOMY", 23, 28], ["liver", "ANATOMY", 98, 103], ["liver injury", "DISEASE", 23, 35], ["liver injuries", "DISEASE", 98, 112], ["critically ill", "DISEASE", 141, 155], ["noncritically ill", "DISEASE", 173, 190], ["liver", "ORGAN", 23, 28], ["liver", "ORGAN", 98, 103], ["patients", "ORGANISM", 156, 164], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 191, 199], ["mild liver injury", "PROBLEM", 18, 35], ["moderate and severe liver injuries", "PROBLEM", 78, 112], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["liver", "ANATOMY", 23, 28], ["injury", "OBSERVATION", 29, 35], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["liver", "ANATOMY", 98, 103], ["injuries", "OBSERVATION", 104, 112]]], ["SARS-CoV-2 may directly dysregulate liver function by binding to ACE2-positive cholangiocytes (26) .", [["liver", "ANATOMY", 36, 41], ["cholangiocytes", "ANATOMY", 79, 93], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["liver", "ORGAN", 36, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACE2", "PROTEIN", 65, 69], ["SARS-CoV", "SPECIES", 0, 8], ["ACE2", "TEST", 65, 69], ["liver", "ANATOMY", 36, 41], ["cholangiocytes", "ANATOMY", 79, 93]]], ["Our results demonstrated that rather than TBL, ALT and AST were the most elevated indicators in critically ill patients with COVID-19.", [["critically ill", "DISEASE", 96, 110], ["COVID-19", "CHEMICAL", 125, 133], ["ALT", "SIMPLE_CHEMICAL", 47, 50], ["AST", "SIMPLE_CHEMICAL", 55, 58], ["patients", "ORGANISM", 111, 119], ["ALT", "PROTEIN", 47, 50], ["AST", "PROTEIN", 55, 58], ["patients", "SPECIES", 111, 119], ["TBL", "TEST", 42, 45], ["ALT", "TEST", 47, 50], ["AST", "TEST", 55, 58], ["COVID", "TEST", 125, 130]]], ["Hepatocyte injury can be caused by immune interactions that involve virally induced cytotoxic T and Kupffer cells (16) .", [["Hepatocyte", "ANATOMY", 0, 10], ["Kupffer cells", "ANATOMY", 100, 113], ["Hepatocyte injury", "DISEASE", 0, 17], ["Hepatocyte", "MULTI-TISSUE_STRUCTURE", 0, 10], ["T", "CELL", 94, 95], ["Kupffer cells", "CELL", 100, 113], ["cytotoxic T and Kupffer cells", "CELL_TYPE", 84, 113], ["Hepatocyte injury", "PROBLEM", 0, 17], ["immune interactions", "PROBLEM", 35, 54], ["Kupffer cells", "TEST", 100, 113], ["injury", "OBSERVATION", 11, 17]]], ["We speculated that besides the direct damage by SARS-CoV-2, virus-induced cytokine storm may also play an important role in critically ill patients with liver injury.DISCUSSIONParticularly, unlike other studies, this study has found that drug factors rather than disease severity may play a more important role in the liver injury of non-critically ill patients with COVID-19.", [["liver", "ANATOMY", 153, 158], ["liver", "ANATOMY", 318, 323], ["SARS", "DISEASE", 48, 52], ["critically ill", "DISEASE", 124, 138], ["liver injury", "DISEASE", 153, 165], ["liver injury", "DISEASE", 318, 330], ["non-critically ill", "DISEASE", 334, 352], ["COVID-19", "CHEMICAL", 367, 375], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "ORGANISM", 139, 147], ["liver", "ORGAN", 153, 158], ["liver", "ORGAN", 318, 323], ["patients", "ORGANISM", 353, 361], ["cytokine", "PROTEIN", 74, 82], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 353, 361], ["SARS-CoV", "SPECIES", 48, 56], ["the direct damage", "PROBLEM", 27, 44], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["virus", "PROBLEM", 60, 65], ["liver injury", "PROBLEM", 153, 165], ["other studies", "TEST", 197, 210], ["this study", "TEST", 212, 222], ["drug factors", "PROBLEM", 238, 250], ["disease severity", "PROBLEM", 263, 279], ["COVID", "TEST", 367, 372], ["liver", "ANATOMY", 153, 158], ["injury", "OBSERVATION", 159, 165], ["liver", "ANATOMY", 318, 323], ["injury", "OBSERVATION", 324, 330]]], ["The combination treatment of lopinavir/ritonavir and arbidol was an independent risk factor.", [["lopinavir/ritonavir", "CHEMICAL", 29, 48], ["arbidol", "CHEMICAL", 53, 60], ["lopinavir", "CHEMICAL", 29, 38], ["ritonavir", "CHEMICAL", 39, 48], ["arbidol", "CHEMICAL", 53, 60], ["lopinavir", "SIMPLE_CHEMICAL", 29, 38], ["ritonavir", "SIMPLE_CHEMICAL", 39, 48], ["arbidol", "SIMPLE_CHEMICAL", 53, 60], ["lopinavir", "TREATMENT", 29, 38], ["ritonavir", "TREATMENT", 39, 48], ["arbidol", "TREATMENT", 53, 60], ["an independent risk factor", "PROBLEM", 65, 91]]], ["Lopinavir/ritonavir and arbidol are recommended as potential drugs for SARS-CoV-2 infection by the Chinese National Health Committee.", [["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["arbidol", "CHEMICAL", 24, 31], ["SARS-CoV-2 infection", "DISEASE", 71, 91], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["arbidol", "CHEMICAL", 24, 31], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 10, 19], ["arbidol", "SIMPLE_CHEMICAL", 24, 31], ["SARS-CoV-2", "ORGANISM", 71, 81], ["SARS-CoV-2", "SPECIES", 71, 81], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir", "TREATMENT", 10, 19], ["arbidol", "TREATMENT", 24, 31], ["SARS", "PROBLEM", 71, 75], ["CoV-2 infection", "PROBLEM", 76, 91]]], ["Existing evidence shows that elevated serum aminotransferase and jaundice occur in patients receiving lopinavir/ritonavir containing antiretroviral regimens (18) and that arbidol may induce an increase in transaminase (27).", [["serum", "ANATOMY", 38, 43], ["jaundice", "DISEASE", 65, 73], ["lopinavir/ritonavir", "CHEMICAL", 102, 121], ["arbidol", "CHEMICAL", 171, 178], ["lopinavir", "CHEMICAL", 102, 111], ["ritonavir", "CHEMICAL", 112, 121], ["arbidol", "CHEMICAL", 171, 178], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["aminotransferase", "SIMPLE_CHEMICAL", 44, 60], ["patients", "ORGANISM", 83, 91], ["lopinavir", "SIMPLE_CHEMICAL", 102, 111], ["ritonavir", "SIMPLE_CHEMICAL", 112, 121], ["arbidol", "SIMPLE_CHEMICAL", 171, 178], ["patients", "SPECIES", 83, 91], ["elevated serum aminotransferase", "PROBLEM", 29, 60], ["jaundice", "PROBLEM", 65, 73], ["lopinavir", "TREATMENT", 102, 111], ["ritonavir", "TREATMENT", 112, 121], ["antiretroviral regimens", "TREATMENT", 133, 156], ["arbidol", "TREATMENT", 171, 178], ["transaminase", "TEST", 205, 217], ["elevated", "OBSERVATION_MODIFIER", 29, 37], ["serum aminotransferase", "OBSERVATION", 38, 60], ["jaundice", "OBSERVATION", 65, 73], ["increase", "OBSERVATION_MODIFIER", 193, 201]]], ["Lopinavir and arbidol are mainly metabolized by cytochrome P3A (CYP3A) (28) .", [["Lopinavir", "CHEMICAL", 0, 9], ["arbidol", "CHEMICAL", 14, 21], ["Lopinavir", "CHEMICAL", 0, 9], ["arbidol", "CHEMICAL", 14, 21], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["arbidol", "SIMPLE_CHEMICAL", 14, 21], ["cytochrome P3A", "GENE_OR_GENE_PRODUCT", 48, 62], ["CYP3A", "GENE_OR_GENE_PRODUCT", 64, 69], ["cytochrome P3A", "PROTEIN", 48, 62], ["CYP3A", "PROTEIN", 64, 69], ["Lopinavir", "TREATMENT", 0, 9], ["arbidol", "TREATMENT", 14, 21]]], ["Ritonavir is a potent CYP3A inhibitor.", [["Ritonavir", "CHEMICAL", 0, 9], ["Ritonavir", "CHEMICAL", 0, 9], ["Ritonavir", "SIMPLE_CHEMICAL", 0, 9], ["CYP3A", "GENE_OR_GENE_PRODUCT", 22, 27], ["Ritonavir", "TREATMENT", 0, 9], ["a potent CYP3A inhibitor", "TREATMENT", 13, 37]]], ["Our results demonstrated that lopinavir/ritonavir can significantly inhibit the metabolism of arbidol, thereby leading to increased arbidol serum concentration.", [["serum", "ANATOMY", 140, 145], ["lopinavir", "CHEMICAL", 30, 39], ["ritonavir", "CHEMICAL", 40, 49], ["arbidol", "CHEMICAL", 94, 101], ["arbidol", "CHEMICAL", 132, 139], ["lopinavir", "CHEMICAL", 30, 39], ["ritonavir", "CHEMICAL", 40, 49], ["arbidol", "CHEMICAL", 94, 101], ["arbidol", "CHEMICAL", 132, 139], ["lopinavir", "SIMPLE_CHEMICAL", 30, 39], ["ritonavir", "SIMPLE_CHEMICAL", 40, 49], ["arbidol", "SIMPLE_CHEMICAL", 94, 101], ["arbidol", "SIMPLE_CHEMICAL", 132, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["lopinavir/ritonavir", "TREATMENT", 30, 49], ["arbidol", "TREATMENT", 94, 101], ["increased arbidol serum concentration", "TREATMENT", 122, 159]]], ["In addition, TBL was the major elevated indicator in non-critically ill patients, indicating that arbidol may have novel adverse reactions in jaundice.", [["non-critically ill", "DISEASE", 53, 71], ["arbidol", "CHEMICAL", 98, 105], ["jaundice", "DISEASE", 142, 150], ["arbidol", "CHEMICAL", 98, 105], ["patients", "ORGANISM", 72, 80], ["arbidol", "SIMPLE_CHEMICAL", 98, 105], ["patients", "SPECIES", 72, 80], ["arbidol", "TREATMENT", 98, 105], ["novel adverse reactions", "PROBLEM", 115, 138], ["jaundice", "PROBLEM", 142, 150], ["jaundice", "OBSERVATION", 142, 150]]], ["Therapeutic drug monitoring may be useful in optimizing the regimens in COVID-19 patients receiving the combination treatment of lopinavir/ritonavir and arbidol.", [["lopinavir/ritonavir", "CHEMICAL", 129, 148], ["arbidol", "CHEMICAL", 153, 160], ["lopinavir", "CHEMICAL", 129, 138], ["ritonavir", "CHEMICAL", 139, 148], ["arbidol", "CHEMICAL", 153, 160], ["patients", "ORGANISM", 81, 89], ["lopinavir", "SIMPLE_CHEMICAL", 129, 138], ["ritonavir", "SIMPLE_CHEMICAL", 139, 148], ["arbidol", "SIMPLE_CHEMICAL", 153, 160], ["patients", "SPECIES", 81, 89], ["Therapeutic drug monitoring", "TEST", 0, 27], ["the regimens", "TREATMENT", 56, 68], ["COVID", "TREATMENT", 72, 77], ["the combination treatment", "TREATMENT", 100, 125], ["lopinavir", "TREATMENT", 129, 138], ["ritonavir", "TREATMENT", 139, 148], ["arbidol", "TREATMENT", 153, 160]]], ["The number of concomitant medications was another independent predictor of liver injury.", [["liver", "ANATOMY", 75, 80], ["liver injury", "DISEASE", 75, 87], ["liver", "ORGAN", 75, 80], ["concomitant medications", "TREATMENT", 14, 37], ["liver injury", "PROBLEM", 75, 87], ["liver", "ANATOMY", 75, 80], ["injury", "OBSERVATION", 81, 87]]], ["Concomitant drugs can affect the metabolism of other drugs through induction, inhibition, or substrate competition (20) .", [["Concomitant drugs", "TREATMENT", 0, 17], ["drugs", "OBSERVATION", 12, 17]]], ["We considered that an increased number of concomitant drugs may lead to complex drug interactions and can increase the risk of liver injury.DISCUSSIONOur study also found that the liver injury in patients with COVID-19 was related to prolonged viral shedding and hospital stay durations.", [["liver", "ANATOMY", 127, 132], ["liver", "ANATOMY", 180, 185], ["liver injury", "DISEASE", 127, 139], ["liver injury", "DISEASE", 180, 192], ["COVID-19", "CHEMICAL", 210, 218], ["COVID-19", "CHEMICAL", 210, 218], ["liver", "ORGAN", 127, 132], ["liver", "ORGAN", 180, 185], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["concomitant drugs", "TREATMENT", 42, 59], ["complex drug interactions", "PROBLEM", 72, 97], ["liver injury", "PROBLEM", 127, 139], ["DISCUSSIONOur study", "TEST", 140, 159], ["the liver injury", "PROBLEM", 176, 192], ["COVID", "TEST", 210, 215], ["prolonged viral shedding", "PROBLEM", 234, 258], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["liver", "ANATOMY", 127, 132], ["injury", "OBSERVATION", 133, 139], ["liver", "ANATOMY", 180, 185], ["injury", "OBSERVATION", 186, 192], ["prolonged", "OBSERVATION_MODIFIER", 234, 243], ["viral", "OBSERVATION", 244, 249]]], ["We inferred that liver injury would lead to immune dysfunction, thereby causing a delay in virus clearance.", [["liver", "ANATOMY", 17, 22], ["liver injury", "DISEASE", 17, 29], ["immune dysfunction", "DISEASE", 44, 62], ["liver", "ORGAN", 17, 22], ["liver injury", "PROBLEM", 17, 29], ["immune dysfunction", "PROBLEM", 44, 62], ["a delay in virus clearance", "PROBLEM", 80, 106], ["liver", "ANATOMY", 17, 22], ["injury", "OBSERVATION", 23, 29]]], ["The prolonged hospital stay can be explained by the need for increased time for liver function recovery or the failure of virus eradication.", [["liver", "ANATOMY", 80, 85], ["liver", "ORGAN", 80, 85], ["liver function recovery", "TREATMENT", 80, 103], ["virus eradication", "TREATMENT", 122, 139], ["liver", "ANATOMY", 80, 85]]], ["In the critically ill group, the length of hospital stay and the duration of viral shedding in patients with liver injury were only numerically but not statistically higher than those in patients without liver injury.", [["liver", "ANATOMY", 109, 114], ["liver", "ANATOMY", 204, 209], ["critically ill", "DISEASE", 7, 21], ["liver injury", "DISEASE", 109, 121], ["liver injury", "DISEASE", 204, 216], ["patients", "ORGANISM", 95, 103], ["liver", "ORGAN", 109, 114], ["patients", "ORGANISM", 187, 195], ["liver", "ORGAN", 204, 209], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 187, 195], ["viral shedding", "PROBLEM", 77, 91], ["liver injury", "PROBLEM", 109, 121], ["liver injury", "PROBLEM", 204, 216], ["liver", "ANATOMY", 109, 114], ["injury", "OBSERVATION", 115, 121], ["liver", "ANATOMY", 204, 209], ["injury", "OBSERVATION", 210, 216]]], ["We speculated that the durations of hospital stay and viral shedding should be influenced by complex factors in critically ill patients with COVID-19, and liver injury may not be the only factor affecting the clinical outcomes.DISCUSSIONOur study has some limitations.", [["liver", "ANATOMY", 155, 160], ["critically ill", "DISEASE", 112, 126], ["liver injury", "DISEASE", 155, 167], ["patients", "ORGANISM", 127, 135], ["liver", "ORGAN", 155, 160], ["complex factors", "PROTEIN", 93, 108], ["patients", "SPECIES", 127, 135], ["viral shedding", "PROBLEM", 54, 68], ["COVID", "TEST", 141, 146], ["liver injury", "PROBLEM", 155, 167], ["DISCUSSIONOur study", "TEST", 227, 246], ["liver", "ANATOMY", 155, 160], ["injury", "OBSERVATION", 161, 167]]], ["First, this study is a retrospective, non-randomized clinical observational trial.", [["this study", "TEST", 7, 17], ["non-randomized clinical observational trial", "TREATMENT", 38, 81]]], ["Our cohort is a convenience sample of patients with COVID-19 admitted to three hospitals in Zhejiang, China.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["However, this study reflects real-world clinical practices and provides relevant data about liver injury in patients with COVID-19.", [["liver", "ANATOMY", 92, 97], ["liver injury", "DISEASE", 92, 104], ["COVID-19", "CHEMICAL", 122, 130], ["liver", "ORGAN", 92, 97], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["this study", "TEST", 9, 19], ["liver injury", "PROBLEM", 92, 104], ["COVID", "TEST", 122, 127], ["liver", "ANATOMY", 92, 97], ["injury", "OBSERVATION", 98, 104]]], ["Second, the treatments among the three centers were highly consistent because all patients were from Zhejiang province.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["the treatments", "TREATMENT", 8, 22]]], ["Antiviral agents were administered to all patients with COVID-19 but limited to a few kinds (e.g., lopinavir/ritonavir and arbidol).", [["COVID-19", "CHEMICAL", 56, 64], ["lopinavir/ritonavir", "CHEMICAL", 99, 118], ["arbidol", "CHEMICAL", 123, 130], ["lopinavir", "CHEMICAL", 99, 108], ["ritonavir", "CHEMICAL", 109, 118], ["arbidol", "CHEMICAL", 123, 130], ["patients", "ORGANISM", 42, 50], ["lopinavir", "SIMPLE_CHEMICAL", 99, 108], ["ritonavir", "SIMPLE_CHEMICAL", 109, 118], ["arbidol", "SIMPLE_CHEMICAL", 123, 130], ["patients", "SPECIES", 42, 50], ["Antiviral agents", "TREATMENT", 0, 16], ["COVID", "TEST", 56, 61], ["lopinavir", "TREATMENT", 99, 108], ["ritonavir", "TREATMENT", 109, 118], ["arbidol", "TREATMENT", 123, 130]]], ["Therefore, our results cannot be extrapolated to antiviral agents that are not involved in this study, and large controlled studies are necessary to explore the potential risks of liver injury by other antivirals.", [["liver", "ANATOMY", 180, 185], ["liver injury", "DISEASE", 180, 192], ["liver", "ORGAN", 180, 185], ["antiviral agents", "TREATMENT", 49, 65], ["this study", "TEST", 91, 101], ["large controlled studies", "TEST", 107, 131], ["liver injury", "PROBLEM", 180, 192], ["other antivirals", "TREATMENT", 196, 212], ["liver", "ANATOMY", 180, 185], ["injury", "OBSERVATION", 186, 192]]], ["Finally, univariable and multivariable logistic regression models were planned to be used to explore the risk factors for liver injury in the critically ill and non-critically ill groups.", [["liver", "ANATOMY", 122, 127], ["liver injury", "DISEASE", 122, 134], ["critically ill", "DISEASE", 142, 156], ["non-critically ill", "DISEASE", 161, 179], ["liver", "ORGAN", 122, 127], ["multivariable logistic regression models", "TREATMENT", 25, 65], ["the risk factors", "PROBLEM", 101, 117], ["liver injury", "PROBLEM", 122, 134], ["liver", "ANATOMY", 122, 127], ["injury", "OBSERVATION", 128, 134]]], ["However, considering the limited sample size in the critically ill group, the statistical power was insufficient, and the multivariable logistic regression model was not conducted in this group.", [["critically ill", "DISEASE", 52, 66], ["the multivariable logistic regression model", "TEST", 118, 161], ["size", "OBSERVATION_MODIFIER", 40, 44]]], ["Focusing on such a population with an expanded sample size would be challenging but would be interesting future research.CONCLUSIONLiver injury has occurred widely in patients with COVID-19.", [["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["an expanded sample size", "TREATMENT", 35, 58], ["CONCLUSIONLiver injury", "PROBLEM", 121, 143], ["COVID", "TEST", 181, 186], ["injury", "OBSERVATION", 137, 143], ["widely", "OBSERVATION_MODIFIER", 157, 163]]], ["Critically ill patients suffered higher incidence, earlier occurrence, greater injury severity, and slower recovery from liver injury.", [["liver", "ANATOMY", 121, 126], ["Critically ill", "DISEASE", 0, 14], ["liver injury", "DISEASE", 121, 133], ["patients", "ORGANISM", 15, 23], ["liver", "ORGAN", 121, 126], ["patients", "SPECIES", 15, 23], ["Critically ill", "PROBLEM", 0, 14], ["greater injury severity", "PROBLEM", 71, 94], ["liver injury", "PROBLEM", 121, 133], ["higher incidence", "OBSERVATION_MODIFIER", 33, 49], ["greater", "OBSERVATION_MODIFIER", 71, 78], ["injury", "OBSERVATION", 79, 85], ["slower", "OBSERVATION_MODIFIER", 100, 106], ["recovery", "OBSERVATION_MODIFIER", 107, 115], ["liver", "ANATOMY", 121, 126], ["injury", "OBSERVATION", 127, 133]]], ["Drug factors were independent risk factors for liver injury of non-critically ill patients, and drug interaction based on the CYP450 enzymes and concomitant drugs should be closely monitored.", [["liver", "ANATOMY", 47, 52], ["liver injury", "DISEASE", 47, 59], ["non-critically ill", "DISEASE", 63, 81], ["Drug factors", "GENE_OR_GENE_PRODUCT", 0, 12], ["liver", "ORGAN", 47, 52], ["patients", "ORGANISM", 82, 90], ["CYP450 enzymes", "GENE_OR_GENE_PRODUCT", 126, 140], ["Drug factors", "PROTEIN", 0, 12], ["CYP450 enzymes", "PROTEIN", 126, 140], ["patients", "SPECIES", 82, 90], ["Drug factors", "PROBLEM", 0, 12], ["liver injury", "PROBLEM", 47, 59], ["drug interaction", "PROBLEM", 96, 112], ["the CYP450 enzymes", "TEST", 122, 140], ["concomitant drugs", "TREATMENT", 145, 162], ["liver", "ANATOMY", 47, 52], ["injury", "OBSERVATION", 53, 59]]], ["Liver injury was related to prolonged hospital stay and viral shedding duration in patients with COVID-19.", [["Liver", "ANATOMY", 0, 5], ["Liver injury", "DISEASE", 0, 12], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Liver injury", "PROBLEM", 0, 12], ["viral shedding duration", "PROBLEM", 56, 79], ["COVID", "TEST", 97, 102], ["injury", "OBSERVATION", 6, 12]]], ["Therefore, special attention to liver injury during SARS-CoV-2 infection is recommended.", [["liver", "ANATOMY", 32, 37], ["liver injury", "DISEASE", 32, 44], ["SARS", "DISEASE", 52, 56], ["infection", "DISEASE", 63, 72], ["liver", "ORGAN", 32, 37], ["SARS-CoV-2", "ORGANISM", 52, 62], ["SARS-CoV", "SPECIES", 52, 60], ["liver injury", "PROBLEM", 32, 44], ["SARS", "PROBLEM", 52, 56], ["CoV-2 infection", "PROBLEM", 57, 72], ["liver", "ANATOMY", 32, 37], ["injury", "OBSERVATION", 38, 44], ["infection", "OBSERVATION", 63, 72]]], ["Healthcare workers should closely monitor the medications used during hospitalization and adjust and optimize the drug treatment in a timely manner.DATA AVAILABILITY STATEMENTAll datasets presented in this study are included in the article/Supplementary Material.ETHICS STATEMENTThe studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (Reference Number: 2020IIT[71]).", [["human", "ORGANISM", 301, 306], ["human", "SPECIES", 301, 306], ["participants", "SPECIES", 307, 319], ["human", "SPECIES", 301, 306], ["the medications", "TREATMENT", 42, 57], ["the drug treatment", "TREATMENT", 110, 128], ["this study", "TEST", 201, 211], ["The studies", "TEST", 279, 290]]], ["Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.", [["this study", "TEST", 64, 74]]], ["This study followed the statement of Strengthening the Reporting of Observational Studies in Epidemiology.AUTHOR CONTRIBUTIONSTL, YQ, and XL participated in the conception and design of this study.", [["This study", "TEST", 0, 10], ["Observational Studies", "TEST", 68, 89], ["this study", "TEST", 186, 196]]], ["SJ and XL were the project managers and coordinated patient recruitment.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["SJ and XL", "TREATMENT", 0, 9], ["XL", "ANATOMY", 7, 9], ["recruitment", "OBSERVATION_MODIFIER", 60, 71]]], ["DH, LL, RW, RR, YR, JM, NC, XW, ZY, and MZ coordinated all analyses in the project.", [["MZ", "CHEMICAL", 40, 42], ["RR", "TEST", 12, 14], ["NC", "TREATMENT", 24, 26], ["ZY", "TREATMENT", 32, 34], ["LL", "ANATOMY", 4, 6], ["NC", "ANATOMY", 24, 26]]], ["SJ, LL, RW, and DH were involved in the acquisition, analysis, or interpretation of data.", [["the acquisition", "TEST", 36, 51], ["analysis", "TEST", 53, 61], ["interpretation of data", "TEST", 66, 88], ["LL", "ANATOMY", 4, 6]]], ["MZ and YH conducted the in vitro experiments on drug interaction.", [["MZ", "CHEMICAL", 0, 2]]], ["Data analysis was done by DH, JM, ZY, and NC.", [["Data analysis", "TEST", 0, 13], ["NC", "TREATMENT", 42, 44], ["NC", "ANATOMY", 42, 44]]]]}